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Adeno-associated virus (AAV) is a small, ssDNA virus with a unique 
biphasic life cycle in which productive replication is dependent on both helper 
virus and host cellular factors. Unable to replicate autonomously, infection by 
AAV alone leads to the establishment of latency through either integration of 
the viral genome, or long-term episomal persistence. The complex AAV life 
cycle is orchestrated almost entirely by four isoforms of a single 
multifunctional viral nonstructural replication (Rep) protein. While it is known 
that Rep must interact with a multitude of host factors in order to complete 
the AAV life cycle, little is yet known about the nature of such interactions 
with respect to AAV gene regulation and the establishment of latency.  Here, 
we used a screening method called BioID to identify new interaction partners 
for the Rep proteins, resulting in the identification of a number of interesting 
candidates involved in gene regulation, including the transcriptional 
corepressor KAP1. We show that KAP1 binds the latent AAV2 genome at the 
rep ORF, leading to trimethylation of AAV2-associated H3K9. We present 
evidence that helper viruses target KAP1 for degradation and demonstrate 
that antagonism of PP1α by Rep52/Rep78 further counteracts KAP1-
mediated repression by enhancing nuclear levels of phosphorylated KAP1-
S824, and that this interaction is essential for AAV2 transcription and 
replication. This work challenges the currently held model for AAV latency, 
and introduces not only a new viral mechanism for the counteraction of KAP1 
repression, but also the notion that KAP1 targeting represents a conserved 
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CHAPTER 1: INTRODUCTION 
 
1.1 ADENO-ASSOCIATED VIRUS 
 
1.1.1 A History of AAV Discovery 
Adeno-associated virus (AAV) was originally discovered 50 years ago 
as a contaminant of both human and simian adenovirus preparations 
(Atchison et al., 1965; Hoggan et al., 1966). It was initially debated whether 
the observed hexagonal particles approximately 24 nm in diameter were 
representative of internal components from mature adenoviral particles shed 
in vitro (Mayor et al., 1965), or an independent virus. The latter hypothesis 
was substantiated through studies into the biological and immunological 
properties of these particles, which demonstrated that AAV was distinct from 
adenovirus in thermal stability and serological profile. These studies also 
revealed the defective nature of AAV by demonstrating that infection with 
AAV alone elicited no cytopathic effect, and furthermore that it was 
dependent on heterologous adenovirus for replication (Atchison et al., 1965; 
Hoggan et al., 1966). The observation that infection with adenovirus of 
African green monkey kidney cells as well as certain primary cultures of 
human embryonic kidney cells resulted in the rescue of infectious AAV later 
led to the discovery that, in the absence of adenovirus infection, AAV 
establishes a persistent latent infection through integration (Cheung et al., 
1980; Hoggan et al., 1972).  
Initial studies into the composition of the AAV genome yielded 
conflicting results. Biochemical and hydrodynamic analysis of extracted DNA 
was consistent with a double-stranded configuration with a molecular weight 
of 3 x 106 bases (Rose et al., 1966), while acridine orange staining of purified 
virions suggested a single-stranded secondary structure (Mayor and Melnick, 
1966). A detailed comparison of the DNA composition and packaging 
capacity of AAV with the Minute Virus of Mice (MVM) led to the suggestion 
that AAV genomes were individually packaged as positive and negative 
single-stranded DNA molecules that annealed to form duplex structures upon 
extraction (Crawford et al., 1969). Elegant experiments utilizing the density 
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labeling of viral DNA with bromodeoxyuridine (BUdR) revealed that a mixture 
of BUdR-substituted (heavy) and unsubstituted (light) extracted DNA resulted 
in the formation of DNA density hybrids, strongly supporting this hypothesis 
(Rose et al., 1969). Confirmation was provided upon the subsequent isolation 
of the individual genomes, representing the first documented instance of the 
separation of complementary strands of DNA of an animal virus (Berns and 
Rose, 1970). Base compositional analysis of isolated genomes then revealed 
that only the negative sense DNA strand served as a template for 
transcription (Carter et al., 1972; Rose and Koczot, 1971). 
Building upon this work, the observation that isolated single-stranded 
AAV genomes eluted from hydroxylapatite as if double-stranded led to the 
deduction that a small region of the genome was partially self complementary 
(Figure 2, pg. 27) (Carter et al., 1972). This was confirmed when beautiful 
electron micrographs of single-stranded AAV DNA revealed the presence of 
various linear and circular DNA concatamers, consistent with the self-
annealing of complementary sequences at or near the ends of plus or minus 
strands of AAV DNA (Koczot et al., 1973). These regions of complementary 
DNA were later shown by restriction enzyme (RE) digestion to exist both in a 
linear conformation and as a cruciform structure (Carter et al., 1975; 
Denhardt et al., 1976), and more detailed studies utilizing RE digest 
combined with [3H]thymidine pulse-labeling of AAV DNA demonstrated that 
these regions served as the origin for viral replication (Ori) through a unique 
mechanism in which DNA synthesis was initiated by the self-priming of these 
terminal sequences (Hauswirth and Berns, 1978; Straus et al., 1976). 
Sequencing of these regions, subsequently termed inverted terminal repeats 
(ITR), determined that they were 145 nucleotides in length, and that the first 
125 nucleotides were palindromic (Lusby et al., 1980).  
Work by Cathy Laughlin (Laughlin et al., 1979b) and Carol Marcus-
Sekura (Marcus et al., 1981) was instrumental in the discovery of the basic 
transcriptional map for AAV. Together, these studies established the 
existence of three overlapping mRNA families transcribed from promoters at 
map units 5, 19, and 40 (p5, p19, and p40), which existed in both spliced and 
unspliced forms. Furthermore, these studies showed that the smaller 2.3 kb 
mRNA transcribed from p40 was translated to yield the structural capsid 
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proteins, VP1, VP2, and VP3 (Jay et al., 1981; Lubeck et al., 1979), which 
had been described several years previously (Johnson et al., 1972; Rose et 
al., 1971). It was still unknown at this time what gene products resulted from 
the p5- and p19-driven transcripts. The existence of a virally encoded protein 
necessary for replication was made apparent through studies into the 
replication dynamics of fully infectious AAV particles and naturally occurring 
defective interfering (DI) AAV particles, which contain aberrant genomes in 
which an essential gene is deleted and are therefore inherently non-
infectious. The observation that AAV DI particle replication could be rescued 
in the presence of fully functional AAV led the field to suspect the existence 
of a nonstructural AAV replication protein, missing in the DI genome 
(Laughlin et al., 1979a). This was confirmed only several years later 
however, after the cloning and sequencing of the AAV genome. 
The nonpathogenic nature of AAV and its ability to establish a 
persistent latent infection in the absence of adenovirus began to draw 
attention to its potential for development as a vector for gene therapy. The 
construction of molecular clones in 1982 (Laughlin et al., 1983; Samulski et 
al., 1982) was crucial to the advent of this movement as it allowed for the 
detailed genetic analysis of the viral genome. Transfection of plasmids 
encoding the full AAV genome into cells infected with adenovirus led to the 
rescue and replication of infectious AAV without the need for prior excision of 
the viral genomes. This demonstrated not only the efficiency of the plasmid 
replication system, but also the fortuitous result that AAV plasmids 
represented a model for the rescue of integrated latent viral genomes 
(Laughlin et al., 1983; Samulski et al., 1982). The observation that clones 
derived from a GC-tailing approach (Samulski et al., 1982) – the majority of 
which lacked intact ITRs due to recombination between the GC tails and GC 
rich regions within the ITR – also gave rise to infectious clones led to the 
characterization of a mechanism for gene recovery by AAV in which duplex 
plasmids containing at least one intact ITR provide the template for 
correction of the defective ITR during replication (Samulski et al., 1983). 
Samulski et al. further made the prescient prediction that the activity of a 
cleavage enzyme would be necessary to recognize and resolve the Holiday 
structures predicted to result from this mechanism (Samulski et al., 1983). It 
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was not however until sequencing of the full AAV genome (Srivastava et al., 
1983) rendered the analysis of mutant replication phenotypes possible that 
the need for at least one nonstructural AAV protein for viral DNA replication 
was clearly demonstrated (Hermonat et al., 1984; Tratschin et al., 1984). The 
Rep proteins were later identified (Mendelson et al., 1986), and their 
purification (Im and Muzyczka, 1992) led to the characterization of the 
remarkable interaction between the Rep proteins and the viral ITRs.  
These mutagenesis studies also paved the way for the development 
of AAV vectors by demonstrating that the ITRs were the only cis-acting 
function necessary for replication (Hermonat et al., 1984; Tratschin et al., 
1984). Both Rep and Cap function could be provided in trans, meaning that 
the entire viral genome could be replaced with a transgene of interest. The 
first recombinant AAV vectors (rAAV) consisted of plasmids in which only the 
capsid gene was replaced with a transgene, meaning the vectors generated 
had a rep+cap- phenotype. Plasmids providing the complementing Rep and 
Cap functions consisted either of the entire wild-type viral sequence, or had 
considerable homology with the AAV vectors. These were transfected in the 
presence of adenovirus to generate rAAV particles, and as a result, all early 
rAAV preparations were contaminated with varying levels of wild type AAV 
(wtAAV) as well as heat-inactivated adenovirus. Nevertheless, these early 
vectors provided a proof-of-concept that rAAV could be generated and used 
to introduce and express foreign transgenes in mammalian cells (Hermonat 
et al., 1984; Tratschin et al., 1984). Further advancements in vector 
production eventually led the generation of rAAV preparations that were free 
from contamination with either wtAAV or adenovirus, leading to the first in 
vivo studies in 1993 (Flotte et al., 1993). This was followed by the first clinical 
trial in patients with cystic fibrosis 10 years later (Flotte et al., 2003). Further 
developments in vector design over the past 20 years have been aimed to 
increase packaging capacity, transduction efficiency, and tissue specificity. 
As a result, AAV gene therapy today is demonstrating great success in 
multiple ongoing clinical trials, highlighting the enormous potential for this 
therapy in the treatment of debilitating monogenic diseases.  
Another aspect of AAV biology that was of intense interest was the 
viral mechanism for latent persistence. It had previously been shown in 
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Detroit 6 cells that infection with AAV in the absence of adenovirus led to the 
establishment of latency through the integration of the viral genome in head-
to-tail concatemer formation (Cheung et al., 1980; Hoggan et al., 1972; 
Laughlin et al., 1986). Similar results were observed in Detroit 6 and KB cells 
that had been transduced with a Rep-expressing neomycin AAV vector 
(McLaughlin et al., 1988), however it was noted that these integration events 
could also have resulted from wtAAV contamination. When sequences 
flanking the viral-cellular junctions of wtAAV integrants in Detroit 6 cells were 
used to screen various cell types containing integrated wtAAV or rAAV DNA, 
it was discovered that most integration events had occurred at a defined 
region of human chromosome 19, subsequently termed AAVS1 (Kotin et al., 
1990). We now know however that integration of Rep-deficient rAAV 
genomes occurs only infrequently and without specificity (Kearns et al., 
1996), as integration is dependent on the origin binding and endonuclease 
activities of the large Rep proteins (Im and Muzyczka, 1990a; Linden et al., 
1996b; Weitzman et al., 1994), and that the persistence of rAAV genomes 
occurs mostly in the form of episomal head-to-tail concatemers (Kearns et 
al., 1996; Schnepp et al., 2003). The advent of additional techniques has 
since led to the detailed molecular characterization of wtAAV integration into 
AAVS1 (Giraud et al., 1994; Henckaerts et al., 2009; Kotin et al., 1990, 1991; 
Linden et al., 1996b). 
The wealth of knowledge with respect to AAV biology has grown 
exponentially with the emerging development of AAV vector gene therapy. 
As a result however, the focus has been mostly on improving vector design, 
and not necessarily on the dissection of basic AAV biology. Various 
challenges remain in bringing AAV vectors more widely into the clinics. In 
particular, high doses are currently necessary to effectively target large 
human organ systems. This presents a real challenge at the level of vector 
production, and also increases the ordinarily low risk of complications related 
to vector immunogenicity. As a result, there is a strong drive to establish 
methods both for the scaling-up of vector production, as well as for the 
design of vectors with greater bioactivity. Significant enhancements in AAV 
vector design have previously been derived from an enhanced understanding 
of basic AAV biology, however there are many aspects of AAV biology that 
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still remain elusive. Of particular relevance to AAV vectors, whose biology 
may mimic that of latent viral genomes, little is known about the mechanisms 
involved in the regulation of, and release from, AAV latency. Understanding 
the changes that occur at the level of viral chromatin and the protein 
interactions involved will be instrumental not only in laying the foundation for 
improved vector design, but also in shedding light on the fascinating interplay 
between AAV, its helper virus, and a host with which it appears to have so 
perfectly coevolved. 
 
1.1.2 AAV – the virus 
1.1.2.1 The Taxonomy 
 AAV belongs to a family of small, icosahedral, and non-enveloped 
DNA viruses called Parvoviridae, whose common characteristics include 
linear ssDNA genomes terminating in hairpins that render the genome self-
priming. The history of this family began in 1959 with the isolation of Kilham 
rat virus (KRV) from lysates of experimental rat tumors (Kilham and Olivier, 
1959). Over the next 10 years, various other similar particles were isolated 
as contaminants of laboratory tumors, cell cultures, and viral stocks (Atchison 
et al., 1965; Hoggan et al., 1966; Kilham and Olivier, 1959; Toolan, 1961), 
each causing variable levels of pathology when injected into rodents. 
Isolation of another physically similar virus from the larvae of the greater wax 
moth led to the discovery that these viruses might not be confined to 
vertebrate hosts. Based on this, the Parvoviridae family was first divided into 
the subfamilies Densovirinae, which target insects and other arthropods, and 
Parvovirinae, which target vertebrates. The Parvovirinae family is further 
subdivided based on the combination of characteristics such as the ability to 
autonomously replicate, the packaging of single sense strands of DNA, and 
the number of promoters in the genome. The resulting genera are the 
Parvovirses, Erythroviruses, Amdoviruses, Bocaviruses, and 
Dependoviruses, of which AAV is a member.  
Dependoviruses, so named for their dependency on a helper virus for 
replication, were originally comprised only of the AAVs. Phylogenetic 
analysis however has now placed the autonomously replicating goose and 
duck parvoviruses within this genus, where they cluster with avian AAV 
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(Tattersall, 2006). Additionally, 9 serotypes of AAV (AAV1-9) have been 
isolated from various hosts and are classified as different species within the 
genus. While not all members of the dependovirus family share the 
characteristic of helper dependency, shared characteristics include the 
packaging of equal numbers of plus and minus strands of DNA 4.7-5.1 kb in 
length, the use of three promoters at positions 5, 19, and 40, and the use of 
functional polyadenylation signals at the right hand end of the genome 
(Tattersall, 2006).  
 
                  
 
Figure 1. Phylogeny of the subfamily Parvovirinae 
Phylogenetic relationship between the nonstructural genes of members of the subfamily 
Parvovirinae. Adapted from Peter Tattersall, 2006. The evolution of parvovirus taxonomy. In: 





1.1.2.2 The Genome 
 The AAV genome consists of a 4.7 kb ssDNA molecule flanked by two 
inverted terminal repeats (ITRs), which are packaged separately as positive 
or negative sense strands into preformed capsids (Berns and Rose, 1970; 
King et al., 2001). The negative sense strand alone serves as a template for 
transcription and is comprised of only two major open reading frames (ORFs) 
(Rose and Koczot, 1971; Srivastava et al., 1983). The left ORF codes for the 
nonstructural replication (Rep) proteins, termed Rep40, Rep52, Rep68, and 
Rep78 based on their apparent molecular weight. These are generated 
through the use of two different promoters, p5 and p19, and alternative 
splicing (reviewed in section 1.1.3.6), resulting in four structurally related 
proteins that together orchestrate virtually every aspect of the viral life cycle. 
The p40 promoter in the right ORF drives the expression of the three 
structural capsid proteins – VP1, VP2, and VP3 – which are derived through 
the use of alternative start codons as well as alternative splicing, and which 
together form the viral capsid. Additionally, a nested, alternative ORF within 
the cap gene has been described, resulting in the expression of an 
assembly-activating protein (AAP) necessary for efficient capsid assembly 
(Sonntag et al., 2010). The AAV genome is flanked by two ITRs comprised of 
imperfect palindromes that self-anneal to form hairpin-like secondary 
structures (Lusby et al., 1981). Within the ITRs are two sequences, the Rep 
binding site (RBS) and terminal resolution site (TRS), which represent the 
only cis-acting signals necessary for viral replication (Samulski et al., 1989). 
The RBS specifically recruits the large Rep proteins to the origin of 
replication (McCarty et al., 1994), after which Rep endonuclease activity 
introduces a nick at the nearby TRS necessary for the resolution of 5’ 
hairpins during replication (Im and Muzyczka, 1990a). 
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Figure 2. AAV genome, transcriptional units, and gene products 
Shown is a schematic representation of the AAV genome, including the various ORFs, as 
well as the resulting AAV transcripts. Straight right-facing arrows (top of figure) depict the 
two major AAV ORFs, rep and cap, which code for the nonstructural replication proteins and 
the structural VP proteins, respectively, as well as the cryptic ORF, AAP. The ssDNA AAV 
genome is shown below in black, flanked by two ITRs. Small, bent arrows stemming from 
the genome represent the three AAV promoters, p5, p19, and p40.  Transcripts arising from 
p5, p19, and p40 are shown in red, pink, and blue, respectively, and the cryptic ORF product 
is shown in green.   
 
 
1.1.2.3 The Capsid 
The AAV genome is enclosed within a non-enveloped protein coat 
whose role in the viral life cycle includes not only the protection of the viral 
genome, but also the mediation of host cell recognition, nuclear trafficking, 
release of the viral genome upon arrival at the nucleus, and egress from the 
host cell (Agbandje-McKenna and Kleinschmidt, 2011).  Interestingly, recent 
work with various capsid mutants has also revealed a transcriptional role for 
the capsid proteins (Aydemir et al., 2016; Salganik et al., 2014). The AAV 
capsid is ~20-25 nm in size and is composed of 60 protein subunits arranged 
into a lattice with T = 1 icosahedral symmetry. The three capsid proteins – 
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VP1, VP2, and VP3 – are 87, 73, and 62 kDa in size, respectively, and are 
transcribed from the p40 promoter. The use of both alternative splicing and 
alternative start codons results in three VP proteins that share an identical C-
terminal domain, with VP2 and VP3 containing successive amino-terminal 
truncations. Additionally, translation of VP2 from a weak, unconventional 
ACG start codon, and VP3 from an internal AUG, supports expression of the 
capsid proteins in the correct stoichiometry of 1:1:10 (Becerra et al., 1988).  
Newly synthesized capsid proteins are targeted to the cell nucleolus 
by the AAV protein AAP, after which capsid morphogenesis is facilitated by 
AAP through an unknown mechanism (Sonntag et al., 2010). Preformed 
capsids are then transported to the nucleoplasm in a Rep-dependent manner 
for the process of viral genome encapsidation (Wistuba et al., 1997). Several 
basic regions (BR) within the capsid proteins have been shown to be 
essential for viral infectivity and propagation. BR1-3, located at the N-
terminus of VP1 and VP2, resemble classical nuclear localization signals 
(NLS) (Grieger et al., 2006; Sonntag et al., 2006). The contribution of each of 
these BR to nuclear localization remains to be determined, however 
mutational analysis suggests a stronger contribution of BR3 to the nuclear 
transport capacity of VP1/VP2 N-termini (Popa-Wagner et al. 2012). BR4, 
shared by all three capsid proteins, is thought to be essential for virion 
assembly in the nucleus (Grieger et al., 2006), and a small basic region at 
the C-terminus of the capsid proteins, BR5, has yet to be analyzed for AAV. 
More recent work suggests that AAP also contains a redundant, multipartite 
NLS and nucleolar localization signal (NoLS), and that it plays a critical role 
in transporting VP3 to the nucleolus for assembly (Earley et al., 2015). In 
addition, VP1 contains a conserved N-terminal phospholipase A2 (PLA2) 
domain, which is exposed upon acidification of endosomes after uptake and 
is essential for endosomal escape of incoming viral particles (Girod et al., 
2002; Stahnke et al., 2011).  
X-ray crystallography resolution of the capsid structures for AAV 
serotypes 1 through 9 (DiMattia et al., 2012; Lerch et al., 2010; Miller et al., 
2006; Nam et al., 2007; Ng et al., 2010; Padron et al., 2005; Quesada et al., 
2007; Walters et al., 2004; Xie et al., 2002) has led to a more profound 
understanding of the molecular basis for certain variable characteristics of 
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AAV, such as serotype tropism, capsid stability, and immunogenicity. While 
all three capsid proteins contribute to the overall structure, VP3 alone 
appears to constitute the majority of the observable capsid surface. The N-
termini of VP1 and VP2 have been described to form globules within the 
internal capsid at the twofold axis of symmetry, which are externalized upon 
heat shock or acidification through pores located at the fivefold axes of 
symmetry (Kronenberg et al., 2005; Sonntag et al., 2006), exposing the 
putative NLSs and the essential VP1-specific PLA2 domain. The structure of 
the capsid appears to be mainly formed from a highly conserved region of 
VP3, consisting of an eight-stranded β-barrel core (Agbandje-McKenna and 
Kleinschmidt, 2011). These β-barrel cores however are connected by long 
hypervariable loop structures that intimately interact with those of 
neighboring VP3 subunits, forming 3-fold peaks that cluster around a 
depression at the threefold axis of symmetry (Xie et al., 2002), and which 
account for variability between the serotypes in receptor binding and tissue 
tropism as well as immunogenicity (Drouin and Agbandje-McKenna, 2013).  
 
                      
 
Figure 3. AAV2 capsid structure 
Shown is a radially depth-cued surface representation of the AAV2 capsid viewed along the 





1.1.3 The Life Cycle 
1.1.3.1 An overview 
 Studies in tissue culture suggest that AAV has evolved a unique, 
biphasic life cycle in which replication is dependent on both host and helper 
virus. AAV enters the host cell via endocytosis, after which it is trafficked to 
the nucleus via the endosomal pathway and enters the nucleus as an intact 
particle, whereupon the genome is released. In the presence of helper virus 
coinfection, the AAV genome undergoes several rounds of replication before 
packaging into preformed capsids and release via cell lysis. In the absence 
of coinfection, AAV establishes latency either through long-term persistence 
as an episome, or through preferential integration into specific sites of the 
host genome. AAV can then be rescued from this latent state through 
subsequent superinfection by helper virus. 
 
                        
 
Figure 4. The AAV life cycle 
AAV infection can result in either a productive infection in the presence of helper virus 
(adenovirus pictured here, not to scale) or a latent infection in its absence. The AAV particle 
enters the cells by receptor-mediated endocytosis (I) and is trafficked to the nucleus through 
the endosomal system (II) to the nuclear membrane (III). After tanslocation into the nucleus, 
viral DNA is released (IV) and undergoes several rounds of replication (V) before being 
packaged into preformed capsids (VI) and released from the cell (VII). In the absence of 
helper virus, the AAV particle reaches the nucleus where it can establish latency by forming 
a stable extrachromosomal episome (1) or by integrating into particular sites in the host 
genome (2). From here, latent AAV can be rescued by superinfection with a helper virus (3). 
! 31!
1.1.3.2 AAV infection in humans 
 From the very earliest discovery of AAV, it was noted that infection 
with AAV alone caused no cytopathic effect in various cell types in tissue 
culture or pathology when inoculated into newborn mice or hamsters 
(Atchison et al., 1965). It has since become accepted that AAV infection in 
humans is also non-pathogenic, and no convincing correlation has yet been 
made between the widespread infection of the human population by AAV and 
any known disease. AAV DNA has been extracted from various human 
tissues, including oral, gastrointestinal, and genital tissues (Bantel-Schaal 
and Hausen, 1984; Blacklow et al., 1967), and seroepidemiological studies 
have shown that approximately 80% of the human population has detectable 
levels of antibodies against various AAV serotypes (Blacklow et al., 1968, 
1971; Calcedo et al., 2009; Georg-Fries et al., 1984; Mayor et al., 1976; 
Rosenbaum et al., 1971). By 10 years of age, more than 60% of the 
population presents with neutralizing antibodies to AAV serotypes 1-3, which 
generally persist into adulthood. The lack of any detectable pathology 
associated with AAV infection however presents a real obstacle to the study 
of the relationship between AAV and its host. 
 Despite the lack of pathology, certain interesting clinical correlations 
have been made with respect to a potential protective effect of AAV infection 
against cervical cancer, although this has not been conclusively established. 
Epidemiological studies found that 85% of women with normal cervical 
cytology were seropositive for AAV, as compared to only 14% of women with 
cervical cancer (Mayor et al., 1976). In addition, it was found that antibody 
titers were 3-fold higher in healthy women than in women with cervical 
cancer and that the risk of cervical cancer was inversely correlated with titers 
of anti-AAV2 IgG in serum (Georg-Fries et al., 1984; Smith et al., 2001).  This 
putative protective effect is posited to result from the helper-dependent life 
cycle of AAV, in which AAV replication ensures the specific lysis of cells 
infected with deleterious viruses, such as adeno-, herpes-, and papilloma-
virus. This question remains unresolved however, as several other studies 
have failed to find any correlation between AAV seropositivity and cervical 
cancer (Odunsi et al., 2000; Strickler et al., 1999).  
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 The lack of a correlation between AAV infection and any pathology 
has also hindered the study of the viral life cycle in vivo. Several groups have 
attempted to identify target tissues in humans. While AAV has been readily 
detected in adenovirus isolates from respiratory and gastrointestinal tissues 
(Blacklow et al., 1967), as well as in the genital tracts of HSV-infected 
women (Friedman-Einat et al., 1997), these routes of infection likely 
represent only the productive, helper-assisted phase of the AAV life cycle. 
Determining the potential reservoir tissue for latent AAV has proven much 
more difficult. So far, the only tissue found to have high frequencies of AAV is 
muscle, where 17% of random biopsies tested positive (Tezak et al., 2000). It 
is also still unclear in what form (i.e. integrated or episomal) AAV establishes 
latency in vivo. Although there is compelling evidence from studies in tissue 
culture that AAV integrates in a site-specific manner into AAVS1 in human 
chromosome 19, one study attempting to characterize genomes isolated 
from human tissues found that the majority of AAV DNA existed as circular 
double-stranded episomes (Schnepp et al., 2005).  
 In agreement with its nonpathogenic nature, AAV is also associated 
with relatively mild immune toxicity, characterized mostly by a humoral 
response (Chirmule et al., 1999) initiated via the complement pathway (Zaiss 
et al., 2008). While the relevance of this response for wtAAV infection is 
unknown, the high seroprevalence for AAV antibodies in the human 
population does have implications for AAV gene therapy. A study concerning 
the prevalence of pre-existing neutralizing antibodies (nAb) to various AAV 
serotypes showed a high prevalence of nAb to AAV2, followed by AAV1 
(Calcedo et al., 2009). This presents an obvious problem for AAV gene 
therapy in patients who have pre-existing NAB, or alternatively those who 
may need more than one treatment. Additionally, in one clinical trial, in which 
liver-directed AAV vectors expressing human Factor IX (AAV-hFIX) were 
used to treat Hemophilia B, CD8+ T cell responses to AAV capsid in one 
patient who had received a high dose of vector led to transient and self-
limited liver transaminitis and an associated decline in hFIX levels (Manno et 
al., 2006; Mingozzi et al., 2007). These results highlight the importance of 
intensifying our efforts to further elucidate the biology and immunology of 
AAV infection so as to enable the continued development of AAV vectors 
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with increased bioactivity, which could translate to therapeutic doses low 
enough as to greatly reduce or even avoid immunological responses. 
 
1.1.3.3 Entry and Trafficking 
 Much of our current understanding of AAV entry and trafficking is 
derived from studies using rAAV vectors of various serotypes. As a result, 
there remains a degree of ambiguity with respect to the particular receptors 
and trafficking pathways used by wtAAV during the natural infection process. 
In addition, studies have been performed with tissue culture adapted strains 
of rAAV, whose capsids have often undergone changes in order to more 
efficiently target the particular receptors expressed on immortalized tissue 
culture cell lines. This notion is supported by the finding that tissue culture 
adapted rAAV2 readily binds heparan sulfate proteoglycans (HSPG), while 
isolates extracted from human tonsils do not (Chen et al., 2005). It is highly 
likely that AAV in fact exploits a combination of alternative pathways 
depending on target tissue, serotype, and the presence or absence of helper 
virus.  
 As is the case with many other viruses, AAV uses both a primary 
attachment receptor, generally consisting of carbohydrate moieties such as 
glycoproteins or proteoglycans, as well as a secondary proteinaceous 
receptor for efficient binding and endocytosis. Various attachment receptors 
have been identified. For AAV2 and AAV3, interactions between two arginine 
residues at positions 585 and 588 with the proteoglycan HSPG have been 
shown to mediate cellular attachment (Kern et al., 2003; Opie et al., 2003; 
Summerford and Samulski, 1998; Summerford et al., 1999). Different 
linkages of sialic acids provide the equivalent attachment functions for AAV4 
and AAV5 (Kaludov et al., 2001; Walters et al., 2001; Wu et al., 2006), while 
galactose has been shown to serve as an attachment receptor for AAV9 
(Shen et al., 2011). There is evidence to suggest that these primary 
attachment receptors may also induce conformational changes to the capsid, 
increasing affinity for the secondary entry receptor (Levy et al., 2009).  Entry 
receptors identified so far include fibroblast growth receptor 1 (FGFR-1) and 
αVβ5 integrin for AAV2, platelet derived growth factor receptor (PDGFR) for 
AAV5, and epidermal growth factor receptor (EGFR) for AAV6 (Di Pasquale 
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et al., 2003; Qing et al., 1999; Weller et al., 2010). Recently however, a 
ground-breaking study in which haploid cell lines were used to screen for 
essential proteins in AAV2 infection identified an uncharacterized type I 
transmembrane protein, KIAA0319L, as a universal receptor for AAV (Pillay 
et al., 2016). The investigators were able to show that this protein was not 
only essential for infection of a wide range of mammalian cell types by all 
AAV serotypes tested, but also that KIAA0319L -/- mice were resistant to 
infection by AAV.  This protein has since been termed the AAV receptor 
(AAVR). 
 Following attachment, AAV is internalized in a rapid and efficient 
manner through various mechanisms of endocytosis. Roles for clathrin-
mediated endocytosis, macropinocytosis, and Clathrin-Independent 
Carriers/GPI-Enriched Endocytic Compartment (GLIC/GLEEC) endocytosis 
have been demonstrated in mediating cellular uptake of AAV (Bartlett et al., 
2000; Duan et al., 1999; Nonnenmacher and Weber, 2011; Sanlioglu et al., 
2000). Additionally, multiple pathways appear to occur simultaneously as 
inhibition of both clathrin- and GLIC/GLEEC-mediated pathways was shown 
necessary to fully block viral entry (Nonnenmacher and Weber, 2011). 
Several lines of evidence suggest that these different pathways lead to 
alternative fates for the viral particle, either delivering the virion successfully 
to the nucleus via the infectious pathway, or targeting the virion for 
degradation or export via the non-infectious pathway. Inhibition of clathrin-
mediated endocytosis reduced the uptake of rAAV2 while having no effect on 
transduction, suggesting this pathway in fact represents a dead-end for 
infection (Nonnenmacher and Weber, 2011). It has also been observed that 
certain cell types can efficiently internalize viral particles while being non-
permissive to transduction due to impaired post-entry trafficking (Di Pasquale 
and Chiorini, 2006), and in vivo experiments performed with various rAAV 
serotypes also failed to demonstrate any strict correlation between DNA 
accumulation and transduction (Miao et al., 2000; Zincarelli et al., 2008, 
2010). Perhaps most strikingly, inhibition of transcytosis in polarized cells 
increased transduction by rAAV4 and rAAV5, but not rAAV2 or rAAV6, 
suggesting these cells were redirecting vectors to two independent pathways 
(Di Pasquale and Chiorini, 2006).  
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In contrast to internalization, intracellular trafficking of AAV is 
inefficient, with only a small fraction of viral particles reaching the nucleus 
and the majority accumulating in perinuclear compartments (Bartlett et al., 
2000). Retrograde transport intermediates are also still not entirely clear. 
Studies using various lysosomotropic agents have rigorously demonstrated 
that AAV is transported through the endosomal compartment (Bartlett et al., 
2000; Douar et al., 2001; Sonntag et al., 2006), where acidification triggers 
essential conformational changes to the capsid necessary for downstream 
nuclear trafficking and, ultimately, infection. These include externalization of 
the N-termini of VP1 and VP2, which contain the PLA2 domain necessary for 
endosomal escape, and BR1-4 necessary for nuclear localization (Johnson 
et al., 2010; Nam et al., 2011; Sonntag et al., 2006). Studies using 
fluorescently labeled wtAAV and rAAV have shown that viral particles then 
accumulate at the trans golgi network (TGN) (Bantel-Schaal et al., 2002; 
Johnson et al., 2010), however the significance of this for infection is still 
elusive. The observation that inhibition of endosomal acidification more than 
90 minutes post infection no longer inhibits transduction would suggest that 
infectious particles escape from early endosomes (Bartlett et al., 2000). It is 
possible that the block to transduction observed with inhibition of the TGN 
(Nonnenmacher and Weber, 2011) reflects the role of the TGN in mediating 
endosomal acidification through the provision of hydrolases, rather than the 
need for viral particles to accumulate within it. It is important to note that 
trafficking experiments are necessarily performed in the absence of helper 
virus and using high MOIs of AAV. Only a fraction of AAV is ever truly 
infectious however (Zeltner et al., 2010), meaning that we cannot be sure 
that an observed particle is actually reflective of the infectious pathway. It 
may be that infectious particles escape from early endosomes after 
acidification, and the majority observed to accumulate at the TGN represent 
dead particles.  Furthermore, the lack of helper virus means that these 
pathways may represent mechanisms specific to latent infection.  
AAV nuclear translocation is also still ill defined. Studies using rAAV2 
suggest a role for interactions between the AAV2 capsid proteins and 
importin-β in entry through the nuclear pore complex (NPC), however 
antagonism of this pathway only led to partial inhibition in nuclear 
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translocation (Johnson and Samulski, 2014). Intact AAV particles enter the 
nucleus and initially become sequestered within nucleolar compartments in 
stable form (Johnson and Samulski, 2009). Subsequent mobilization of 
virions to the nucleoplasm leads to uncoating and gene expression or 
genome degradation, the kinetics of which appear to be cell type- and 
serotype-dependent (Johnson and Samulski, 2009).  
 
1.1.3.4 Gene transcription and regulation 
 Adeno-associated viruses exhibit a highly compact, overlapping 
genetic organization in order to maximize the transcriptional potential of their 
small genomes. The AAV2 genome has three different promoters – p5, p19, 
and p40 – all transcripts of which contain a single intron just downstream of 
p40, which uses a 5’ splice donor site at nucleotide 1906 and one of two 
acceptor sites at either nucleotide 2001 (A1) or 2228 (A2) (Carter et al., 
1990; Green and Roeder, 1980; Lusby and Berns, 1982), and a single 
polyadenylation site. Unspliced transcripts of the p5 and p19 promoters 
encode Rep78 and Rep52, respectively, while spliced transcripts encode 
Rep68 and Rep40. Alternative splicing to the acceptors A1 or A2 results in 
the formation of two different isoforms of Rep68 and Rep40, however no 
difference in function between the alternatively spliced forms of Rep68 or of 
Rep40 has ever been reported. Transcripts from the p40 promoter that are 
spliced using the A1 acceptor encode the VP1 capsid protein, while 
transcripts using the A2 acceptor encode both VP2 and VP3 (Trempe and 
Carter, 1988a). VP2 is generated from a non-canonical ACG initiation site, 
and VP3 from read-through to the next available AUG.   
 AAV gene expression must be tightly regulated due to the anti-
proliferative potential of the Rep proteins. This regulation is achieved through 
a complex interplay between host cellular, helper virus, and AAV Rep 
proteins. In addition, Rep binding to the viral RBS can serve to both activate 
and repress transcription (Pereira et al., 1997), depending on the particular 
RBS in question and the presence or absence of helper virus proteins. In the 
absence of helper virus coinfection, three elements within the p5 promoter 
have been shown to be responsible for repression of all three viral promoters 
– a major late transcription factor (MLTF) binding site at position -80, a YY1 
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binding site at position -60, and an RBS at position -20 (Chang et al., 1989; 
Hörer et al., 1995; Kyostio et al., 1995; Kyöstiö et al., 1994; Pereira et al., 
1997). Optimal repression of the p5 promoter is dependent on both Rep 
binding to the p5 RBS as well as the presence of an intact NTP-binding site 
within the Rep ATPase domain (Kyostio et al., 1995; Kyöstiö et al., 1994). 
However, the small Rep proteins, which contain only ATPase and helicase 
activity, are also able to repress both the p5 and p19 promoters (Hörer et al., 
1995; Im and Muzyczka, 1992; Kyostio et al., 1994; Smith and Kotin, 1998).  
In the presence of helper virus coinfection, interactions between the 
helper virus factors Ad E1A or HSV-1 ICP0 with YY1 (Geoffroy et al., 2004a; 
Lee et al., 1995) lead to the activation of p5 transcription by both YY1 and 
MLTF, possibly through the presence of a YY1 responsive initiator site at 
position +1 (Seto et al., 1991). Rep bound to the RBS in the p5 promoter 
continues to have an inhibitory effect on p5 while simultaneously 
transactivating both p19 and p40 (Kyostio et al., 1995; Weger et al., 1997) 
through a common mechanism involving interactions between Rep bound at 
the p5 promoter and the transcription factor Sp1 bound to the p19 and p40 
promoters (Lackner and Muzyczka, 2002; Pereira and Muzyczka, 1997a). 
These interactions lead to the formation of complexes that bring transcription 
factors in the p5 promoter, such as YY1, into close proximity with p19 and 
p40. Additionally, binding of Rep to the RBS in the viral ITR is necessary for 
the transactivation of all three promoters (Weger et al., 1997).  
 Pre-mRNA splicing is also a critical determinant for productive AAV 
infection, which is necessary for regulating the ratio of unspliced to spliced 
p5- and p19-generated transcripts, as well as the temporal order of 
appearance of AAV mRNAs throughout the infection cycle. Efficient splicing 
requires the participation of both the helper virus and the large Rep proteins. 
Coinfection stimulates splicing of p19- and p40-driven transcripts in a manner 
dependent on the adenoviral factors E1A, E1B, E2A, E4, and VA RNA, but 
this is only manifest in the presence of Rep bound to the RBS (Qiu and 
Pintel, 2002). Rep-mediated enhancement of the relative levels of spliced 
RNA is inversely correlated with the distance between the promoter and the 
intron of the affected transcription unit, meaning that p40 transcripts are 
spliced with the most efficiency, and p5 transcripts the least (Qiu and Pintel, 
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2002). There is also a temporal order of appearance for the different AAV 
mRNAs (Labow et al., 1986; Mouw and Pintel, 2000; Trempe and Carter, 
1988b). Unspliced p5 transcripts appear first upon activation of p5, but p19-
generated transcripts ultimately accumulate to levels greater than those from 
p5, creating a negative feedback loop on p5 activity. By late infection 
however, p40 transcripts dominate. Finally, the percentage of each spliced 
mRNA increases by varying degrees during the course of infection (Mouw 
and Pintel, 2002), a phenomenon that might be explained by the 
aforementioned correlation between splicing efficiency and the distance of 
the RBS from the affected intron.  
 
1.1.3.5 Genome replication  
AAV DNA replication occurs via a mechanism often referred to as 
rolling hairpin replication (Straus et al., 1978; Tattersall and Ward, 1976; 
Ward, 2006), a variation of the rolling circle replication (RCR) mechanism 
used by numerous single-stranded phages, eukaryotic viruses, and bacterial 
plasmids (Chandler et al., 2013). Upon release from the viral capsid, self-
annealing of the ITRs provides the heteroduplex structure necessary to prime 
initiation of unidirectional strand synthesis (Figure 5A, B), resulting in a full-
length duplex genome in which one end is in closed hairpin conformation 
(Figure 5C). Binding of the RBS and subsequent nicking at the TRS by the 
large Rep proteins (Figure 5D) generates the new free base-paired 3’-OH 
necessary for replication through the initiating ITR, a process termed terminal 
resolution (Figure 5E). The result is a linear, double-stranded replication 
intermediate, in which the two right ITRs can self-anneal (Figure 5F) to 
initiate another round of replication by strand displacement (Figure 5G).  
Each cycle of replication yields two possible products: a double-stranded full 
length AAV genome containing a closed hairpin, and a single-stranded full-
length displacement product (Figure 5H). In addition, if a new round of 
replication from the 3’ terminus reaches a closed hairpin before it has been 
resolved, duplex dimers in head-to-head or tail-to-tail conformation can 
occur. This mode of replication leads to the inversion of part of the ITR 
sequence during each round of replication, leading to two alternative 
conformations designated flip and flop (Lusby 1980). 
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Figure 5. Rolling hairpin replication of AAV 
The free 3’-OH provided by the self-annealed ITR serves as a primer (A) for DNA replication 
by the cellular replication machinery (B). The right ITR is replicated by strand displacement, 
generating a double stranded molecule covalently linked by the left ITR (C). Rep binds to the 
RBS in the left ITR and generates a nick at the TRS located on the opposite strand (D) to 
allow for terminal resolution of the left ITR (E). The complementary ITRs at the right end of 
the genome refold (F), generating a new 3’-OH that can be used for another round of 
replication by strand displacement (G) that generates a new single stranded AAV genome 
and a double stranded molecule covalently linked by the right ITR (H). These molecules 
could be used for new rounds of replication or alternatively could serve as packaging 
templates. If refolding of the right ITR occurs prior to terminal resolution of the left ITR (I), a 
dimeric replication intermediate can be formed (J).  
 
The biochemical interactions between the Rep proteins and the ITRs 
necessary for replication are extensive. The large Rep proteins contain an 
origin binding domain (OBD) necessary for substrate recognition, which 
recognizes and binds the RBS within the ITR (Chiorini et al., 1995; Davis et 
al., 2000; McCarty et al., 1994; Snyder et al., 1993).  Upon binding, the ATP-
dependent helicase activity of the Rep proteins unwinds the neighboring 
region of the ITR containing the TRS (Brister and Muzyczka, 1999; Davis et 
al., 2000; Im and Muzyczka, 1990a), creating the single-stranded template 
that is necessary for Rep endonuclease activity. Rep proteins then nick the 
TRS in a site- and strand-specific manner (Brister and Muzyczka, 1999; 
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Davis et al., 2000; Im and Muzyczka, 1990a; Smith and Kotin, 2000), 
becoming covalently linked to the 5’ side of the cleavage site in the process 
(Prasad et al., 1997; Wistuba et al., 1997). Evidence suggests that Rep 
proteins remain associated with the viral genome for up to 8 hours and may 
be involved in the encapsidation process, although this is still not entirely 
clear. Rep helicase activity is then again necessary for the unwinding of the 
newly freed 3’ ITR (Brister and Muzyczka, 1999; Davis et al., 2000; Snyder et 
al., 1993). The actual hairpin structure of the ITR itself appears to also be 
important for efficient replication. Hairpins in which regions of the T arms 
were substituted in such a way as to alter the nucleotide sequence without 
affecting formation of the intact hairpin structure were still able to support 
efficient viral replication (Bohenzky and Berns, 1989; Lefebvre et al., 1984). 
As AAV can exploit various rather disparate helper viruses, it is 
thought that, rather than provide specific factors for replication, these helper 
viruses instead create a cellular environment conducive for replication. It has 
been shown in in vitro reconstitution assays that the minimal protein 
complexes necessary for AAV DNA replication are replication factor C (RFC), 
proliferating nuclear antigen (PCNA), the minichromosome maintenance 
(MCM) complex, and the cellular polymerase δ (Nash et al., 2007, 2008). As 
with other viruses, AAV replication occurs in foci, or replication centers (RC), 
which colocalize with an array of cellular and helper virus proteins (Vogel et 
al., 2013). The particular factors involved are altered depending on the 
requirements of the different helper viruses, but also depending on the 
specific function of the RC at a point in time. In the case of herpesvirus, DNA 
replication and genome packaging is localized to the viral RCs, however 
these two functions occur in distinct nuclear compartments during adenovirus 
infection (Vogel et al., 2013).  The site of genome packaging for AAV is still 
not entirely clear, and it may be that AAV RCs temporally and spatially 
evolve over the course of infection in parallel to the changes in Rep and Cap 
protein expression.    
 
1.1.3.6 Helper functions 
 Productive AAV replication is dependent on coinfection of its targeted 
cell by an unrelated helper virus – such as adeno-, herpes-, and papilloma-
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virus (Ad, HSV-1, and HPV) – which provides essential factors necessary to 
both alter the cellular milieu such that it becomes conducive to viral 
replication, as well as to directly support AAV transcription and DNA 
replication. The particular subsets of viral proteins necessary to support AAV 
replication have been extensively studied and defined for the two major AAV 
helper viruses, Ad and HSV-1. The minimal set of Ad proteins necessary for 
AAV replication is comprised of E1A, E1B55K, E2A, E4orf6, and viral 
associated RNA (VA RNA) (Fisher et al., 1996; Samulski and Shenk, 1988). 
Interactions between Ad E1A and YY1 bound to the AAV p5 promoter are 
necessary to relieve repression of p5 and to initiate transcription of the large 
Rep proteins (Chang et al., 1989; Lewis et al., 1995; Shi et al., 1991; 
Weitzman et al., 1996). E1B55K and E4orf6 act as a complex to enhance 
AAV replication through the targeted proteasome-mediated degradation of 
the Mre11/Rad50/Nbs1 (MRN) complex, and DNA ligase IV (Baker et al., 
2007; Stracker et al., 2002). The MRN complex is a primary component of 
the DNA damage and repair pathway, which has been shown to be recruited 
to AAV ITRs, whereupon it inhibits second strand synthesis and promotes 
the concatamerization of replicating genomes (Cervelli et al., 2008; Schwartz 
et al., 2007). E2A encodes a ssDNA binding protein that colocalizes with 
AAV RCs and which stimulates the processivity of AAV replication in vitro, 
possibly by helping to maintain in solution the extensive lengths of displaced 
ssDNA that are inherent to the mechanism of rolling circle replication (Ward 
et al., 1998).  VA RNA is a small, non-coding RNA produced abundantly 
during Ad infection whose role is to enhance the translation of Ad proteins. 
Inhibition of the kinase PKR by competitive binding of VA RNA prevents the 
phosphorylation of the translation initiation factor eIF2α, thereby overcoming 
the shutdown of protein translation often associated with viral infection, and 
thus also allowing for the efficient translation of AAV mRNA (Nayak and 
Pintel, 2007). 
  In contrast to the helper functions of Ad, which predominantly 
modulate AAV gene regulation, helper functions provided by HSV-1 relate 
mostly to DNA replication. The minimal subset of HSV-1 proteins initially 
defined as being sufficient to support AAV replication were UL5, UL8, and 
UL52, which together form a helicase/primase complex, and the ssDNA 
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binding protein ICP8 encoded by the UL29 gene (Stracker et al., 2004; 
Weindler and Heilbronn, 1991), which performs a similar function in AAV 
replication as the ssDNA binding protein of Ad. In the context of AAV latency, 
it was later shown that the proteins ICP0, ICP4, and ICP22 act synergistically 
to stimulate rep expression (Alazard-Dany et al., 2009; Geoffroy et al., 
2004b). In addition, the HSV-1 DNA polymerase complex (UL30/UL42) was 
demonstrated to play a role in the induction of AAV DNA replication (Alazard-
Dany et al., 2009), and the HSV-1 polymerase alone (UL30) was shown to 
replicate the AAV genome efficiently in vitro (Ward et al., 2001), effectively 
replacing cellular replication machinery.  
 
1.1.3.7 Capsid assembly and egress 
 AAV capsid assembly takes place in nucleolar compartments, and so 
the initial challenge of the assembly pathway is in the nuclear translocation of 
newly synthesized capsid proteins. The proposed assembly intermediate 
competent for nuclear transport is a trimer containing VP3 with VP1, VP2, or 
VP1 and VP2, in which the basic residues of the VP1/VP2-specific NLS are 
externalized (Agbandje-McKenna et al., 1998; Lombardo et al., 2000; Xie 
and Chapman, 1996). Once transported into the nucleus, these partially 
assembled VP complexes accumulate within nucleoli (Johnson and 
Samulski, 2009; Wistuba et al., 1997), where the process of capsid formation 
takes place separated from ongoing DNA replication in Rep-containing RCs 
(Weitzman et al., 1996; Wistuba et al., 1997). As infection progresses, Cap 
proteins can be seen mobilizing out of nucleoli and into the nucleoplasm in a 
Rep-dependent manner (Wistuba et al., 1997) where they then colocalize 
with Rep-DNA complexes (Hunter and Samulski, 1992; Weitzman et al., 
1996). 
 Based on a detailed pulse-chase study of AAV2 virion assembly, a 
commonly accepted concept of AAV2 assembly has been established in 
which replicated, ssDNA strand displacement products are packaged into 
preformed capsids (Myers and Carter, 1980). Further observations that Rep 
ATPase activity was essential for efficient packaging (King et al., 2001) and 
that the Rep proteins physically interact with capsid proteins (Dubielzig et al., 
1999; Kube et al., 1997; Prasad and Trempe, 1995; Wistuba et al., 1995) 
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helped to shed more light on the mechanism involved. It is thought that Rep 
proteins covalently bound to the 3’ ITR of replicated and resolved viral 
genomes (Prasad et al., 1997) together with a 20 bp signal in the D region of 
the bound ITR (Wang et al., 1997) acts as a sort of initiation sequence for 
encapsidation by interacting with Rep helicase complexes covalently bound 
to the capsid (Hölscher et al., 1995) and thus guiding the replicated viral 
genome to the capsid pore. The Rep helicase complex then serves as a 
molecular pump to translocate the genome into the capsid in a 3’ to 5’ 
direction (Hölscher et al., 1995; King et al., 2001).  
 The exact mechanism of egress has not been well characterized. It is 
generally assumed that non-enveloped viruses exit the nucleus by 
accumulation and eventual cell lysis. Infectious viral particles can be 
detected in the culture medium prior to the onset of cytopathic effects in the 
host cells however (Vandenberghe, 2010), suggesting an active transport 
mechanism also contributes to particle release.  Indeed, it has been 
demonstrated for the related parvovirus MVM that a phosphopeptide in VP2 
consisting of serines at position 2, 6, and 10 may act as a non-conventional 
nuclear export signal (Carreira et al., 2004; Maroto et al., 2000, 2004), and it 
is possible that a similar mechanism may be relevant to AAV.  
 
1.1.3.8 Latency and site-specific integration 
 The ability of AAV to establish latency through integration in the 
absence of helper virus was recognized soon after its discovery, when 
Detroit 6 cells that had been infected with 250 IU of AAV were found to still 
be positive for AAV up to 100 passages later (Berns et al., 1975; Hoggan et 
al., 1972). Initial southern blot analysis of these cells indicated that viral DNA 
was integrated as head-to-tail concatemers and that the viral ITRs were 
present at the integration site (Cheung et al., 1980). Similar results were later 
observed in numerous other cell types (Handa et al., 1977; Laughlin et al., 
1986). In order to further characterize integrated AAV DNA, two viral-cellular 
junctions obtained from the original Detroit 6 cells were mapped and 
sequenced, revealing that several copies of AAV were integrated in tail-to-tail 
conformation (Kotin and Berns, 1989). The cellular sequences flanking the 
AAV insertion sites were later engineered into probes for southern blot and 
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used to screen a panel of latently infected human cell lines. The results 
indicated that a specific cellular sequence had been disrupted in 78% of 
AAV-infected cells, suggesting that integration had occurred in a site-specific 
manner (Kotin et al., 1990) at a locus which was later sequenced and termed 
AAVS1 (Kotin et al., 1992). 
 The minimal requirements for AAV site-specific integration were 
subsequently identified as the large Rep proteins, a viral RBS, and a cellular 
TRS and RBS located in AAVS1. The role of the Rep proteins was 
demonstrated when transfected plasmids containing a rep gene and a 
selectable marker flanked by the AAV ITRs were shown to integrate site-
specifically into AAVS1 (Shelling and Smith, 1994), and this was definitively 
demonstrated when Rep provided in trans was shown to be sufficient to 
mediate integration of a plasmid containing only a marker flanked by ITRs 
(Surovsky et al., 1997). The only cis-acting signal necessary to mediate site-
specific integration is a viral RBS; transfection of plasmids containing either 
the RBS alone (Surovsky et al., 1997; Young  Jr. and Samulski, 2001) or the 
p5 promoter (Philpott et al., 2002), which contains an RBS (McCarty et al., 
1994), was sufficient to mediate integration of ITR-containing plasmids into 
AAVS1. The presence of critical sequences within the cellular integration site 
was established when AAV infection of cell lines containing stable Epstein-
Barr Virus (EBV)-based episomes into which the AAVS1 pre-integration site 
had been cloned revealed that a 33-nt sequence containing both a TRS and 
RBS were necessary and sufficient to mediate integration (Giraud et al., 
1994; Linden et al., 1996a, 1996b). 
 AAVS1 was initially mapped to the long arm of human chromosome 
19, at position 19q13.42 (Kotin et al., 1991; Samulski et al., 1991). Detailed 
analysis of this region confirmed the existence of both an RBS and a TRS 
within the first 500 bp of AAVS1 (Urecelay et al., 1995; Weitzman et al., 
1994) similar to those found in the AAV genome (Smith et al., 1999; Ward et 
al., 2001), which were shown to support Rep-mediated integration (Linden et 
al., 1996b; Weitzman et al., 1994), 1996). It was later found that these 
signals existed in the 5’ UTR of the PPP1R12C gene, only 17-nt upstream 
from the translation initiation start codon (Tan et al., 2001). This gene codes 
for the protein phosphatase 1 regulatory subunit 12C, also known as Myosin-
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binding subunit 5 (MBS85). The MBS85 gene product is a regulatory subunit 
of myosin light-chain phosphatase and thus plays a prominent role in the 
regulation of actin/myosin assembly and disassembly. Furthermore, MBS85 
is ubiquitously expressed in both human and mouse tissues (Tan et al., 
2001), and is closely linked to three other genes also essential for the 
function of actin, TNN13, TNNT1, and EPS8L1 (Dutheil and Linden, 2006). 
Indeed, the highly gene dense nature of the AAV integration site AAVS1 
initially made it difficult to reconcile the capacity of AAV for latent persistence 
through integration into this region with its apparent lack of pathology.  
Initial PCR-based studies used to specifically locate viral-cellular 
junctions showed that integration was taking place within the first exon and 
intron of the MBS85 gene, and that most junctions were close to the cellular 
TRS/RBS (Huser et al., 2002; Kotin and Berns, 1989; Samulski et al., 1991). 
This observation may not be surprising however as the PCR primers used 
were all specific for this particular region of AAVS1. Analysis of the structure 
of a number of recombinants produced using EBV-based shuttle vectors 
containing AAVS1 pre-integration sites (Giraud et al., 1994) as described 
above revealed several interesting features that would provide a basis for an 
initial integration model – (1) the observation that viral-cellular junctions 
occurred circa 1kb downstream of cellular RBS/TRS sites suggested a role 
for DNA replication in the integration process, (2) evidence for head-to-tail 
arrangement of integrated DNA suggested the involvement of a circular 
replication intermediate of AAV, and (3) rearrangement/inversions of flanking 
cellular sequences implied a series of template strand switches, a major 
feature of Rep-mediated AAV replication. These observations led to an initial 
model for integration through replication in which a double-stranded and 
circular form of AAV is brought into proximity to AAVS1 via the simultaneous 
recognition of cellular and viral RBS by large Rep proteins bound to the viral 
RBS. The linking of viral to cellular DNA by Rep proteins has previously been 
demonstrated in vitro (Weitzman et al., 1994), and circular AAV could result 
from end-to-end joining or recombination between the two ITRs. Rep then 
introduces a nick at the AAVS1 TRS just upstream of the RBS, and DNA 
synthesis is initiated leading to the displacement of a single strand of AAVS1. 
After limited extension, the extent of which determines the location of the 
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viral-cellular junction, the elongating strand undergoes a template switch to 
the displaced strand, resulting in the observed inversion of flanking 
sequences. Upon reaching the end of the displaced strand – where Rep is 
assumed to still be covalently bound at the RBS – the elongating strand 
makes another template switch onto the circular AAV DNA. After replication 
of the AAV template, the elongating strand again reaches the Rep-bound 
RBS and makes a final template strand switch back onto AAVS1. The single-
strand gap created by the inserted AAV sequence is then repaired by cellular 
machinery. This model explains both the rearrangements of flanking 
sequences and the variable location of viral-cellular junctions. It also 
addresses the issue of head-to-tail integrants, as these could only be the 
result of circular AAV.  
Unbiased approaches based on linker-mediated PCR were later used 
to identify junctions of chromosomal DNA with both the left and right viral 
ITRs and to study the molecular organization of AAV integration into AAVS1 
(Henckaerts et al., 2009). In addition to commonly reported hallmarks of viral-
cellular junctions – such as microhomologies or insertions of unknown 
sequences at breakpoints – it was revealed that integration events actually 
occurred at a much greater distance (i.e. >9 kb) from the cellular TRS than 
previously believed, indicating that extensive DNA replication takes place. 
Furthermore, the investigators found that MBS85 sequences at both 
junctions were present in 5’->3’ orientation. Together these observations led 
to the introduction of a new integration model (Figure 6), in which AAV 
integration leads to the partial duplication of MBS85, potentially maintaining 2 
functional copies of the target gene. This study also took advantage of the 
presence of a conserved, homologous AAVS1 site in the mouse genome 
(Dutheil et al., 2004, 2009) to generate latently infected mouse ES cells, 
which were used to study both the molecular organization and the functional 
consequences of AAV integration. The fact that Rep-mediated site-specific 
integration appears to occur without functionally disrupting the target gene 
infers that novel technologies based on this unique ability of wtAAV may be 
safe for the genetic manipulation of stem cells. Further studies with human 
and mouse ES cells harboring a site-specifically integrated rAAV genome 
expressing GFP revealed that these cells maintained their stem cell 
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characteristics and that transgene expression remained robust throughout 
differentiation.  
 
      
 
Figure 6. Model for Rep-mediated integration of AAV DNA 
(A) Rep binds to the cellular RBS and introduces a strand-specific nick at the cellular TRS in 
AAVS1. (B) DNA synthesis is initiated at the nicked TRS, leading to displacement of a single 
strand of AAVS1 (C) The replication switches template onto AAV. (D) Occasional second 
template strand switch back onto AAVS1 generates an inverted repeat. (E) Ligation between 
replicated AAV and displaced strand. (F) Nicking at the bottom strand stimulates repair of 
the non-complimentary strand. (G) AAV site-specific integration results in partial duplication 
of MBS85 sequence. Adapted from (Henckaerts et al., 2009) 
 
Evidence for integration is compelling and has led to the detailed 
characterization of AAV integration into AAVS1. More recently, additional 
clusters of integration sites, characterized by the presence of RBS motifs, 
and in some cases, cryptic TRS motifs, have been found throughout the 
human genome (Hüser et al., 2014; Janovitz et al., 2013; Petri et al., 2015). 
In addition, regions of open chromatin structure were shown to influence 
patterns of AAV integration (Hüser et al., 2014). It is important to note 
however that the majority of observations supporting AAV integration have 
been obtained in tissue culture experiments, and there is very little data 
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available with respect to the molecular characterization of latent AAV in vivo. 
AAV DNA sequences have been detected in a variety of tissues, however 
these studies did not present any data on integration into AAVS1, or other 
integration sites. One study in which sensitive, unbiased PCR techniques 
were used to characterize AAV DNA obtained from 7 AAV-positive tonsil-
adenoid samples showed that the viral genome existed predominantly as a 
circular double-stranded episome in head-to-tail configuration (Schnepp et 
al., 2005). Only one sample was shown to contain AAV integrated into 
chromosome 1. In addition, while it is known for numerous other DNA viruses 
that latency is regulated through the epigenetic modification of viral 
chromatin structure, the potential contribution of such mechanisms on AAV 
latency have yet to be extensively studied. Early evidence that AAV assumes 
a chromatinized configuration shortly after infection would support a role for 
epigenetic modification in the establishment and/or maintenance of AAV 
latency (Marcus-Sekura and Carter, 1983). 
         
1.2 THE AAV2 REP PROTEINS 
 
1.2.1 The Rep proteins and their roles in the AAV life cycle 
The particular genomic organization of the rep ORF generates four 
structurally related replication proteins that together orchestrate virtually 
every aspect of the AAV life cycle. As described in section 1.1.2.2, the use of 
two promoters and alternative splicing yields four structurally related proteins, 
termed Rep78, -68, -52, and -40 after their apparent molecular weight, which 
are comprised of various combinations of three modular domains. The large 
Rep proteins, Rep68 and Rep78, contain an OBD necessary for DNA binding 
and site-specific endonuclease activity, while all four Rep proteins share a 
central ATPase domain containing helicase activity. Additionally, Rep78 and 
Rep52 share a C-terminal zinc finger (ZNF) domain implicated in several 





        
 
Figure 7. The Rep proteins 
Schematic diagram depicting the domain architecture of the four Rep proteins. The OBD, 
containing DNA binding and endonuclease activities is shown in green; the central helicase 
domain shared by all four Rep proteins is shown in blue; the C-terminal ZNF domain shared 
by Rep78 and Rep52 is shown in yellow.  
 
A consequence of this modular structure is that the Rep proteins, in 
particular Rep78 and Rep68, are versatile and multi-functional proteins with 
diverse biological functions. The large Rep proteins are essential for virtually 
every aspect of the AAV life cycle. Binding of the viral RBS by the Rep OBD 
and subsequent nicking at the TRS forms the basis of terminal resolution 
during DNA replication, a process necessary to replicate through initiating 
ITRs and to regenerate 3’-OH groups for new rounds of replication (Ward, 
1996). This activity also forms the basis of AAV integration into AAVS1 as 
well as subsequent rescue of integrated AAV upon helper virus 
superinfection (Dutheil and Linden, 2006). All four of the Rep proteins also 
regulate transcription from the three AAV promoters, as well as helper virus 
promoters, ensuring minute levels of protein expression during latency, and 
optimal regulation of lytic protein expression during coinfection. Regulation of 
certain cellular promoters by the Rep proteins has also been observed and is 
thought to play a role in maintaining a cellular environment conducive to viral 
replication. In addition to their role in transcriptional regulation, the small Rep 
proteins, Rep52 and Rep40, are also essential for the accumulation of single-
stranded genomes and their efficient packaging into preformed capsids 
(King, 2001). Finally, the ZNF domain shared by Rep52 and Rep78 has been 
implicated in several protein interactions with the potential for disrupting the 
cell cycle, and so it is possible that these Rep proteins have additional roles 
in modifying the cellular milieu for viral replication. Numerous other protein 
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interactions not dependent on the ZNF domain have also been identified; 
many of these remain poorly defined however, and it is likely that their 
characterization will illuminate numerous new and significant roles for the 
Rep proteins in AAV propagation.  
 
1.2.2 Rep domains and enzymatic functions 
The OBD is comprised of the first ~200 amino acids shared by the 
large Rep proteins, Rep78 and Rep68, and contains sequence-specific DNA 
binding activity as well as strand- and sequence-specific endonuclease 
activity, conferring upon these proteins the ability to bind and nick DNA 
substrates containing RBS and TRS, respectively (Chiorini et al., 1994; Davis 
et al., 2000; Im and Muzyczka, 1990a; McCarty et al., 1994; Owens et al., 
1993; Yoon et al., 2001). It shares certain essential features with proteins 
known to mediate rolling circle replication (RCR), such as the gene A 
proteins from the bacteriophage ϕX174 and the NS1 proteins of plant 
geminiviruses (Koonin and Ilyina, 1992, 1993). These include the conserved 
HUH motif, involved in metal ion binding, and either one or two tyrosine 
residues shown to be catalytically essential for endonuclease activity (Figure 
8) (van Mansfeld et al., 1986; Odegrip and Haggård-Ljungquist, 2001). In 
addition, the Rep OBD shares structural homology with the DNA-binding 
proteins SV40 T antigen and papillomavirus E1 (Enemark et al., 2000; 
Hickman et al., 2002).  
The central helicase domain (aa 225-536) shared by all four Rep 
proteins consists of a motor domain with motifs required for ATPase and 
helicase activity, as well as a nuclear import signal (Figure 9) (Im and 
Muzyczka, 1990b; Smith and Kotin, 1998; Wonderling et al., 1995). The AAV 
Rep helicase belongs to the superfamily 3 (SF3) of helicases, a family found 
mainly in small DNA and RNA viruses and which includes the helicases of 
papillomaviruses, poliovirus, and SV40. Like other SF3 helicases, the AAV 
Rep proteins couple the energy derived from NTP hydrolysis to DNA 
unwinding in a 3’ to 5’ direction. The signature of this family is a short stretch 
of ~100 aa containing the Walker A and B motifs, which comprise the NTP-
binding site, the B’ box necessary for metal cation binding, and the sensor 1 
site. Structural studies of Rep40, which is equivalent to the minimal helicase 
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domain (Figure 9), and SV40 LTag revealed that these helicases are 
structurally similar to the AAA+ class of cellular proteins (James et al., 2003) 
that couple ATP hydrolysis and DNA unwinding. 
 
 
                           
 
Figure 8. Crystal structure of the AAV5 Rep OBD 
The structure shows the five central anti-parallel strands, with the characteristic HUH motif 
located in the central strand and highlighted in red. This motif is facing the active site 
tyrosine located in one of the α-helices, also highlighted in red.  
 
 
The combined activity of the origin-binding and ATPase domains in 
the large Rep proteins is essential for the processes of genome replication 
and integration. In both cases, Rep binding of the RBS is followed by nicking 
at the TRS. As the endonuclease activity of the Rep proteins is specific for 
ssDNA, this process necessarily occurs in two steps. First, ATP-dependent 
Rep helicase activity unwinds the TRS in a 3’ to 5’ direction, resulting in the 
extrusion of a stem-loop structure and exposing the TRS (Brister and 
Muzyczka, 1999; Davis et al., 2000). The second step is a strand- and 
sequence-specific nicking reaction at the sequence 3’-GCT/TGA-5’, which is 
catalyzed by the active site Tyr-156. Transesterifiation of the T/T 
phosphodiester bonds creates a free 3’ OH for subsequent rounds of 
replication and leaves Rep covalently bound to the 5’ thymidine residue in 
the AAV genome (Brister and Muzyczka, 1999; Smith and Kotin, 2000).  
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Figure 9. Crystal structure of Rep40 (AAA+ domain) 
The structure of Rep40, defined as the minimal helicase domain of AAV Rep, is bi-modular 
and contains an N-terminal small helical bundle (bottom) and an AAA+-like core 
characteristic of SF3 helicases.  
 
 
Both the OBD and ATPase domain are also involved in transcriptional 
regulation by the Rep proteins via two independent mechanisms - (1) OBD-
dependent repression by the large Rep proteins, most likely through steric 
hindrance of the p5 promoter as a result of binding to the RBS (Dutheil et al., 
2014), and (2) ATPase-dependent repression of all three AAV promoters, 
possibly through interactions between the ATPase/helicase domain of the 
Rep proteins and components of the cellular transcriptional machinery. 
Rep68 has also been shown to act as an RNA/DNA helicase (Wonderling et 
al., 1995), which may provide a mechanism for the observed ATPase-
dependent gene regulatory activity of the Rep proteins. Like other AAA+ 
proteins, the helicase domains of the large Rep proteins interact with one 
another to form concentration- and ATP-dependent multimers both in vitro 
and in vivo, preferentially forming hexamers in the presence of AAV-derived 
substrates (Mansilla-Soto et al., 2009; Smith et al., 1997). It is thought that 
these structures are (1) necessary for efficient helicase activity and (2) 
reflective of the multi-functionality of the Rep proteins. Additionally, the 
helicase activity of the small Rep proteins, Rep52/40, is essential for the 
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translocation of full-length, capsid-associated ssDNA AAV genomes into 
preformed capsids during the process of encapsidation (King et al., 2001).  
The C-terminal end of Rep78 (aa 534-607) and Rep52 consists of a 
short zinc finger motif composed of three CXXC and three CXXH sequences 
shown to bind zinc in vitro. Mutation of either of the repeated motifs 
abolished zinc binding, suggesting that both of these repeats act together to 
form a functional ZNF (Hörer et al., 1995). Zinc binding by consecutive 
CXXC/CXXH motifs leads to the formation of a series of stable, finger-like 
protrusions that make tandem contacts with their target molecule. Several 
mammalian proteins involved in chromatin and DNA modification contain 
CXXC zinc finger domains (Frauer et al., 2011), however no interactions 
between the Rep ZNF and DNA have been documented. Rather, the Rep 
ZNF has been implicated in various protein interactions (reviewed in section 
1.3.1) with implications for cell cycle regulation.  For example, binding and 
inhibition of the phosphatase Cdc25 by the Rep ZNF domain prevents 
progression of the cell cycle through the G1 to S checkpoint. Furthermore, 
interactions between the Rep52/Rep78 ZNF and the catalytic subunit of 
protein kinase A (PKAc) and its close homolog PKrX are thought to interfere 
with the transcriptional regulation of several proteins involved in cell cycle 
regulation by interfering with CREB signaling.  
 
1.3 Interactions with the host and helper virus 
 
1.3.1 Rep interactions with cellular proteins 
Given the limited repertoire of AAV proteins, the Rep proteins must 
interact with an array of host cellular factors in order to successfully navigate 
the complex viral life cycle. Indeed, a multitude of factors involved in DNA 
replication, transcription, RNA splicing, and the cellular DNA damage 
response (DDR) have been shown to colocalize with AAV2 replication 
centers, as well as to copurify with Rep (Vogel et al., 2013). For example, 
while both the large Rep proteins have the intrinsic DNA-binding and 
endonuclease activity necessary for terminal resolution and genome 
integration, in vitro assays have shown that binding of both Rep68 and 
Rep78 to the cellular ssDNA binding protein replication protein A (RPA) and 
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nucleophosmin enhances Rep binding to the viral ITR and stimulates 
endonuclease activity (Bevington et al., 2007; Stracker et al., 2004). 
Similarly, binding of Rep78 to the non-histone chromosomal protein high 
mobility group protein 1 (HMG1) stimulates Rep endonuclease activity and 
ATP hydrolysis and promotes the formation of Rep-DNA complexes (Costello 
et al., 1997) through the ability of HMG1 to increase DNA flexibility and 
promote the formation of nucleoprotein complexes.  
In addition to their well-characterized role in AAV DNA replication and 
integration, the Rep proteins both activate and repress transcription from the 
three AAV promoters (Hörer et al., 1995; Kyostio et al., 1995; Pereira and 
Muzyczka, 1997a, 1997b; Pereira et al., 1997). Rep-mediated repression has 
also been observed for various heterologous promoters (Hörer et al., 1995; 
Labow et al., 1986; Needham et al., 2006). Repression by the Rep proteins is 
based on two distinct mechanisms, one relying on direct binding of the large 
Rep proteins to viral (or cellular) RBS, and the other requiring only an intact 
NTP-binding site within the helicase domain shared by all four Rep proteins, 
indicating the possible reliance of this pathway on interactions with cellular 
factors (Dutheil et al., 2014; Kyostio et al., 1995; Kyöstiö et al., 1994). 
Supporting this notion, Rep is known to interact with various transcription 
factors (TF) in a repressive capacity. Interactions between the N-terminal 
domain of Rep78/Rep68 with the transcription factor TATA box binding 
protein, or TBP, were shown to inhibit the adenovirus major late transcription 
factor (Hernonat et al., 1998; Needham et al., 2006). TBP is a core factor 
required for the assembly of the transcription initiation complexes associated 
with RNA polymerases I, II, and III, and may thus represent one of the most 
central proteins in transcription initiation. These studies indicate that Rep 
interaction with TBP may alter the preinitiation complex of RNA pol II, 
resulting in transcriptional repression (Needham et al., 2006). Similarly, 
Rep68/Rep78 were shown to bind to the ssDNA binding domain of the 
transcriptional activator PC4 in an ATP-dependent manner, an interaction 
suggested to be necessary for the inhibition of cellular transformation by the 
adenovirus E1A protein, presumably through repression of the associated 
oncogenes (Weger et al., 1999). Finally, binding of Rep78 to c-Jun 
downregulated transcription from AP-1 dependent promoters (Prasad et al., 
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2003). Certain Rep/TF interactions can also lead to transcriptional activation 
rather than repression. As described earlier, interactions between the large 
Rep proteins bound to the AAV p5 promoter and the transcription factor Sp1 
bound to the p19 and p40 promoters is thought to be necessary for 
transactivation of p19 and p40 (Pereira and Muzyczka, 1997a, 1997b) 
through the formation of a DNA loop that brings essential transcriptional 
machinery into proximity with p19 and p40. 
A number of studies have highlighted the oncosuppressive and 
antiproliferative properties of the AAV Rep proteins (Hermanns et al., 1997; 
Winocour et al., 1988). The oncosuppressive effect is thought to be due to 
the inhibition of tumor-causing viruses by AAV, such as adenoviruses and 
HPV (reviewed in section 1.3.3). However, the large Rep proteins have also 
been observed to interfere independently with cell cycle progression by 
inducing arrest in all cell cycle phases (Saudan et al., 2000) and to induce 
apoptosis (Schmidt et al., 2000). This is thought to occur via several 
converging mechanisms. Both Rep68 and Rep78 arrest cells in G1 and G2 
phases by producing nicks in cellular chromatin and inducing an ATM-
mediated DNA damage response (Berthet et al., 2005; Saudan et al., 2000). 
In addition, it was observed that Rep78 leads to a complete arrest in S 
phase, a response rarely seen after DNA damage. This activity was later 
mapped to the C-terminal ZNF domain present in Rep78, which was shown 
to bind and inhibit the phosphatase Cdc25 (Berthet et al., 2005). The cell 
cycle is driven by a family of proteins called the cyclin-dependent kinases 
(CDKs), which are activated in a sequential manner through the removal of 
inhibitory phosphates by the Cdc25 family of protein phosphatases. This in 
turn inactivates the tumor suppressor retinoblastoma protein (pRb) through 
phosphorylation, releasing the transcription factor E2F1 and thus activating 
expression from E2F1-controlled genes necessary for progression through 
the G1 to S phase restriction point. Rep78 binds Cdc25 as a 
pseudosubstrate, preventing access to its substrates Cdk1 and Cdk2 and 
therefore preventing phosphorylation/inactivation of pRb (Berthet et al., 
2005). This Rep-mediated inhibition of Cdc25 combined with DNA damage 
induced by the intrinsic endonuclease activity of Rep78 leads to a potent 
arrest of DNA replication within S phase, characterized by the accumulation 
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of active, hypophosphorylated pRb (Berthet et al., 2005; Saudan et al., 
2000). The importance of this interaction for AAV is underscored by the 
existence of two supplementary pathways towards the same goal. Rep78 
additionally binds E2F1, stabilizing E2F1-pRb complexes and preventing 
E2F1 release, and interferes directly with expression of E2F1 by binding to 
and repressing the E2F1 promoter (Batchu et al., 2001).  
A number of viruses are known to regulate their gene expression 
through the use of cAMP response elements (CRE) (Flamand and Menezes, 
1996; Kwok et al., 1996; Leib et al., 1991; Nokta and Pollard, 1992). Cellular 
CRE sites are also involved in the regulation of a variety of cellular 
processes, including differentiation, proliferation, and apoptosis. CRE sites 
are regulated by the transcription factor cAMP response element-binding 
(CREB) protein, which becomes activated when phosphorylated by the 
cAMP-mediated activation of the protein kinase A (PKA). Rep78 and Rep52 
were shown by yeast-two-hybrid experiments to interact via their shared C-
terminal ZNF domain with the catalytic subunit of PKA (PKAc), as well as its 
close homolog PKrX, and to inhibit PKA- and PKrX-mediated CREB signaling 
through a protein kinase inhibitor (PKI) like domain in the ZNF domain 
(Chiorini et al., 1998; Di Pasquale and Stacey, 1998). Inhibition of PKA by 
PKI plays a central role in the induction of mitosis, and several proteins 
involved in cell cycle regulation are regulated by CRE in their promoters (Guo 
et al., 1997; Melendez et al., 1995; Wen et al., 1995; Yoshizumi et al., 1997). 
Both AAV and MVM contain CRE elements in their p5 and p4 promoters, 
respectively, and while the function of this site for AAV is unclear, cAMP-
dependent stimulation of the CRE of MVM was shown to have a negative 
regulatory effect (Flotte et al., 1992; Perros et al., 1995). In addition, 
stimulation of the cAMP pathway, which leads to CREB phosphorylation, 
strongly enhances both the transcriptional activation and apoptotic properties 
of the tumor suppressor p53 (Giebler et al., 2000), the cellular accumulation 
of which induces cell cycle arrest or apoptosis in response to a variety of 
cellular stress signals, including DNA damage. Interference of CREB 
signaling by the Rep proteins may thus provide another way to interfere with 
the cellular DDR.  
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Finally, while the contribution of chromatin structure to AAV 
transcription is not yet clear, it is known for various other DNA viruses that 
remodeling of incoming viral genomes must occur in order to create an active 
template for transcription and replication (Knipe et al., 2013). For Ad and 
HSV-1, this is a function provided by the template activating factor I/Set 
oncoprotein (TAF1/Set) complex, a histone chaperone that acts in complex 
with the acidic nuclear proteins 32A and 32B (ANP32A and ANP32B). Rep68 
was shown to interact with ANP32B via its N-terminal domain, subsequently 
recruiting the remaining components of the complex, ANP32B and TAF1/Set 
(Pegoraro et al., 2006). Manipulation of these various components 
demonstrated a requirement for TAF1/Set activity in the replication of both 
WT and recombinant AAV (Pegoraro et al., 2006), suggesting that a 
mechanism similar to what has been demonstrated for Ad and HSV-1 may 
be necessary to prepare the AAV genome for transcription and replication.  
 
1.3.2 Cellular DNA damage response to AAV 
DDR signaling and repair pathways are controlled by the family of 
PI3K-related protein kinases, comprised of ATM, ATR, and DNA-PK (Linn, 
2004). DNA double strand breaks (DSB) in particular represent one of the 
most dangerous forms of DNA damage, and several independent pathways 
are in place to repair DSBs. During cellular S/G2 phase, when sister 
chromatids are easily available, recruitment of ATM to DSBs by the DNA 
sensor complex MRN leads to ATM-mediated phosphorylation of the 
downstream effectors Chk2 and p53, cell cycle arrest, and repair via 
homologous recombination (HR). ATR is recruited to ssDNA coated in 
ssDNA-binding protein RPA, a process which naturally occurs either upon 
ATM-mediated resection of DSBs or at stalled replication forks, whereupon 
the activation of the downstream effector Chk1 also leads to HR pathways. In 
the absence of available homologous DNA however, DNA-PK is recruited to 
DSB by its regulatory proteins Ku70/Ku80, where it mediates repair via non-
homologous end joining (NHEJ) through the recruitment of DNA ligase IV.  
 Both the structure of incoming viral DNA as well as viral replication 
intermediates have been shown to mediate the recruitment of various 
components of the cellular DDR pathway. In the absence of a helper virus, 
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single-stranded AAV DNA has been shown to trigger damage signaling via 
ATR activation resembling the cellular response to a stalled replication fork 
(Jurvansuu et al., 2005). It is also worth noting that expression of the large 
Rep proteins alone can induce a mild activation of ATM and H2AX (Glauser 
et al., 2010; Schwartz et al., 2009). This is believed to result from the nicking, 
DNA-binding, and helicase activities of Rep (Berthet et al., 2005; Glauser et 
al., 2010; Schmidt et al., 2000), however the possibility cannot be excluded 
that interactions between Rep and cellular proteins are involved. Indeed, Rep 
proteins have been shown to interact with various cellular proteins involved in 
the DDR, including RAD50, RPA, γ-H2AX, NBS1, DNA-PKcs, and p53 
(Collaco et al., 2009; Nash et al., 2009; Schwartz et al., 2009). In the context 
of AAV and Ad5 coinfection, AAV replication elicits a robust DDR as 
demonstrated by the phosphorylation of ATM, Chk1, Chk2, RPA32, and 
H2AX (Collaco et al., 2009; Schwartz et al., 2009). Studies using rAAV 
plasmids in the presence of Ad5 and Rep in trans suggested that AAV 
replication is required to induce the DDR (Schwartz et al., 2009). Using 
chemical inhibitors as well as ATM- and DNA-PK-deficient cell lines, the 
investigators were able to demonstrate that DNA-PK is the primary mediator 
of damage signaling in response to AAV replication (Collaco et al., 2009; 
Schwartz et al., 2009). Supporting this, immunofluorescence analysis 
confirmed the recruitment of DNA-PKcs, Ku70, and Ku80 to AAV RCs in both 
Ad and HSV-1 supported AAV RCs (Schwartz et al., 2009; Vogel et al., 
2012). In AAV and HSV-1 coinfected cells however, signaling is mediated by 
both ATM and DNA-PK (Vogel et al., 2012). Furthermore, the changing 
prevalence of the different AAV replication intermediates within AAV RCs is 
likely to affect the composition of signaling proteins involved. 
The consequences of DDR signaling for AAV replication are still under 
debate. Genotoxic agents of various forms have been shown to enhance 
AAV replication, even leading to helper-independent rep expression and 
minimal levels of DNA replication (Nicolas et al., 2012; Yakobson et al., 
1987, 1989; Yalkinoglu et al., 1988), however the exact mechanism for this 
has never been understood. It has been suggested that AAV may need 
repair factors for processing of replicating genomes; it has also been 
suggested that inducing a DDR effectively sequesters these proteins away 
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from AAV RCs, allowing for more efficient replication. In the case of AAV and 
Ad coinfected cells however, depletion of DNA-PK leads to enhanced AAV 
replication (Collaco et al., 2009), presumably because DNA-PK would result 
in the NHEJ-mediated concatamerization of replicating genomes, thus 
simultaneously removing them from the pool of replicating DNA and 
preventing encapsidation. Depletion of ATM or ATR however has the 
opposite effect (Collaco et al., 2009). The reason for this is not clear, and it 
may be that phosphorylation of a downstream target of these kinases plays a 
role in AAV replication. Conversely, studies using self-complementary rAAV 
vectors have shown that DNA-PK is necessary to form the stable episomes 
that lead to long term transgene expression (Cataldi and McCarty, 2010; 
Choi et al., 2006). It is possible that a similar mechanism is true for the 
establishment of stable, circular episomes of latent wtAAV. Furthermore, 
ATM/ATR activation has a deleterious effect on episomes derived from 
single-stranded rAAV vectors (Cataldi and McCarty, 2010). As DNA resection 
is inherent to the ATM/ATR pathway, it is possible that processing of ssDNA 
genomes results in ITRs that can no longer undergo productive 
concatamerization.  
During AAV and Ad coinfection, degradation of the MRN complex, 
which is the principal mediator of ATM activation, is an essential helper 
function for AAV replication. Studies using complementation of these proteins 
as well as Ad E1B55K/E4orf6 mutants showed that degradation of Mre11 
enhances wtAAV replication and rAAV transduction (Cataldi and McCarty, 
2010; Cervelli et al., 2008; Choi et al., 2006; Schwartz et al., 2007). 
Components of the MRN complex are recruited to the viral ITRs in a manner 
dependent on the hairpin structure, where they lead to silencing of the 
genome (Cataldi and McCarty, 2013; Lentz et al., 2015). This effect seems to 
be independent from the activation of downstream effectors, such as ATM, 
and may instead rely on some consequence of the physical interaction (Lentz 
et al., 2015). Interestingly, in HSV-1 supported AAV replication, all 
components of the MRN complex are recruited to AAV RCs without any 
apparent inhibitory effect (Nicolas et al., 2010; Vogel et al., 2012). It has 
been suggested that the utilization of the HSV-1 polymerase for AAV 
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replication may somehow bypass the observed inhibitory effects of the MRN 
complex (Vogel et al., 2013).  
 
1.3.3 AAV interactions with helper virus 
In addition to its effects on the proliferation of the host cell in the 
absence of helper virus, AAV also exerts a profound effect on the replication 
of its helper viruses and on cellular transformation. AAV is dependent on 
various helper factors for its replication (reviewed in section 1.1.3.5), 
however competition for space and resources within the host cell means that 
AAV must limit the replication of its helper virus without affecting the 
synthesis of the helper factors required for AAV replication. It has long been 
observed that AAV interferes with Ad propagation during coinfection, leading 
to up to 100-fold reduction in the production of infectious Ad particles, and up 
to a 10-fold decrease in Ad DNA replication (Carter et al., 1979; Laughlin et 
al., 1979a; Weitzman et al., 1996). Evidence that AAV may regulate Ad 
propagation both at the transcriptional level and by interfering with Ad-
mediated cellular transformation may begin to explain the balance between 
AAV’s requirement for adenoviral early proteins, and the ongoing competition 
for cellular space and resources, as well as helper virus factors.   
Transcriptional regulation of Ad gene expression by AAV has been 
demonstrated on various levels. As described in section 1.3.2, AAV interferes 
with CREB-signaling through the inhibition of the cAMP-responsive kinase 
PKA. CRE sequences regulate the expression of numerous viral genes 
(Gilchrist et al., 1996), and the cAMP response pathway components are 
often used to control switches from early to late or latent to lytic replication 
modes (Leib et al., 1991; Leza and Hearing, 1989; Pei and Berk, 1989; Xia et 
al., 1996). Ad has been shown to be dependent on protein kinase activation 
both for transport into the nucleus, and for E1A-mediated transactivation of 
E1A, E3, and E4, all of which contain PKA-responsive CRE within their 
promoters (Leza and Hearing, 1989; Suomalainen et al., 2001). While 
mutated AAV genomes lacking the PKI-like domain necessary for PKA 
inhibition could replicate efficiently in the presence of Ad helper plasmids, 
these mutant variants were outcompeted in the presence of WT Ad, 
suggesting that this pathway is necessary to preserve AAV replication fitness 
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during Ad coinfection by selectively targeting Ad gene expression (Pasquale 
et al., 1998). This effect was particularly profound at low MOI, indicating PKA 
inhibition may be an absolute necessity in the context of limiting 
concentrations of AAV.  
Several studies demonstrated a role for the Rep proteins in the direct 
transcriptional regulation of Ad gene expression. Cotransfection of HeLa cells 
with Ad-luciferase and AAV rep expressing plasmids showed that Rep78 
could repress expression from all five Ad early gene promoters when in the 
presence of over-expressed E1A, indicating that Rep could interfere with 
E1A-mediated transactivation of E1B, E2, E3, and E4 (Jing et al., 2001). This 
effect could conceivably result from the aforementioned inhibition of CREB 
signaling. All of the Ad early gene promoters also contain TATA or 
noncanonical TATA boxes however. As mentioned in section 1.3.1, Rep has 
been shown to physically interact with the TATA binding protein, TBP, which 
suggests that the promiscuous repression of Ad early gene expression by 
Rep may be a result of Rep-specific interactions with TBP, preventing its 
activation by E1A (Jing et al., 2001).  In addition, both Rep68 and Rep78 
were shown to inhibit E2A expression by directly binding to a sequence 
between the E2A TATA region and mRNA start site that is homologous to the 
RBS’ in the AAV ITR (Casper et al., 2005; Jing et al., 2001; Nada and 
Trempe, 2002). The presence of two binding sites for the transcription factor 
E2F also suggests that interactions between Rep, TBP, and E2F1 (also 
shown to interact with Rep) bound to E2A may serve to stabilize the weak 
Rep-DNA interaction.  
Dose-response and temporal analyses of the effect of AAV on Ad 
replication and gene expression during coinfection revealed that the 
inhibitory effects of Rep are dependent both on the ratio of AAV to Ad, and 
on the particular time-point of infection (Timpe et al., 2006). In the presence 
of low concentrations of AAV (1 IU), E1A expression was in fact enhanced 
when compared to cells infected with Ad alone. Increasing levels of AAV 
resulted in repression of all Ad early promoters. This effect was not 
detectable until 12 h post infection however, correlating with the onset of Ad 
DNA replication. Indeed, Ad transcript levels remained unchanged prior to 
DNA replication even in the presence of overexpressed Rep78 (Timpe et al., 
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2006). These results suggest that a combination of AAV amplification and 
Rep expression are necessary to inhibit Ad gene expression and DNA 
synthesis (Timpe et al., 2006), providing a potential mechanism for how AAV 
is able to repress Ad only after having benefited from the effects of its helper 
functions.  
Independently from its inhibitory effects on Ad gene expression, AAV 
Rep also interferes with Ad by inhibiting Ad-mediated cellular transformation. 
One of the hallmarks of cellular transformation by adenovirus infection is a 
progression through S-phase triggered by the E1A-mediated release of the 
transcription factor E2F1 from pRb complexes, leading to cell proliferation. 
Indeed, this is a mechanism common to several other DNA tumor viruses, 
such as SV40 and HPV (Chellappan et al., 1992; Paganon et al., 1992). Ad 
also requires E2F1 for the transactivation of E2 via interactions with E4. Rep 
interferes with these pathways by (1) binding the E2F1 protein and stabilizing 
the pRb-E2F1 complexes, and, (2) binding the E2F1 promoter directly and 
mitigating adenovirus-mediated E2F1 transcription (Batchu et al., 2001). This 
serves to freeze cells in S phase and inhibit cell proliferation, and provides a 
molecular mechanism for the observed anti-oncogenic properties of AAV. 
Rep also independently achieves S-phase arrest through the binding and 
subsequent inhibition of Cdc25. 
Similar observations have been made for HSV-1 supported AAV 
replication (Bantel-Schaal and Zur Hausen, 1988; Glauser et al., 2007, 
2010). In the case of HSV-1, helper factors are all expressed with immediate 
early (IE) or early kinetics preceding viral replication, and are involved mostly 
in AAV DNA replication. Live cell covisualization experiments revealed the 
formation of separate AAV and HSV-1 RCs, with recruitment of Rep only in 
AAV RCs and HSV-1 ICP8 in both AAV and HSV-1 RCs (Glauser et al., 
2007). Formation of HSV-1 RCs was dramatically reduced in the presence of 
AAV, as well as in the presence of Rep alone. Western blotting showed that 
the HSV-1 early proteins ICP4 and ICP8, the latter of which is a helper factor 
for AAV replication, were only modestly affected, while late proteins VP16 
and gC were strongly reduced in the presence of AAV (Glauser et al., 2007). 
Although the mechanism of repression is not yet understood, it has been 
suggested that activation of the cellular DDR may in part be responsible. 
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Inhibition of HSV-1 is dependent on the ATPase and DNA binding activities 
of the Rep proteins (Glauser et al., 2010), which were also shown necessary 
to trigger DNA damage (Glauser et al., 2010; Schmidt et al., 2000). In 
addition, AAV inhibition of HSV-1 is associated with an increase in 
phosphorylation of the DNA damage marker, RPA, which has not been 
reported in the context of HSV-1 infection alone (Glauser et al., 2010).  
Although there is still much to learn about the complex triangle of 
interaction between AAV, host, and helper virus, these studies provide 
crucial insight into the mechanisms through which a genomically simple virus 
such as AAV can navigate the complexity of interactions between itself, its 
host, and its helper virus. The requirement of AAV for a helper virus 
inevitably leads to competition for cellular resources as well as for the helper 
factors themselves, which are often essential for both AAV and the helper 
virus. Understanding how AAV manages to control its environment to its 
benefit may thus provide crucial insights into AAV biology.  
 
1.4  THE COREPRESSOR KAP1 
  
1.4.1 KAP1 overview 
 KAP1 (KRIP1/TIF1β/TRIM28) was first identified as an interaction 
partner for members of the Kruppel-associated Box (KRAB)-domain 
containing ZNF transcription factors (KRAB-ZFP) in several independent 
studies during the mid-1960s (Le Douarin et al., 1996; Friedman et al., 1996; 
Kim et al., 1996; Moosmann et al., 1996). KAP1 is a member of the tripartite 
motif (TRIM) family of proteins, many of which have previously been 
implicated in antiviral immunity (Ozato et al., 2008), and is very closely 
related to three other members of this family, TIF1α, TIF1γ, and TIF1δ, which 
have little functional overlap despite sharing numerous structural features 
(Peng et al., 2002). KAP1 is ubiquitously expressed during development and 
is thought to be a critical regulator of normal development and differentiation 
(Cammas et al., 2000, 2002, 2004; Jakobsson et al., 2008). Indeed, Kap1 
deletion in mice leads to embryonic lethality (Cammas et al., 2000). 
Additionally, KAP1 is involved in maintaining pluripotency and has also been 
linked to the proliferation and differentiation of tumor cells (Beer et al., 2002; 
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Seki et al., 2010; Silva et al., 2006; Xu et al., 2015). The pleiotropic effects of 
KAP1 are thought to occur through its capacity to regulate the dynamic 
organization of higher order chromatin structure through epigenetic 
modifications. KAP1 is recruited to the genome through interactions between 
its RBCC domain and KRAB-ZFP, whereupon it serves as a scaffold for the 
recruitment of numerous histone and nucleosome modifying proteins, which 
act together to generate transcriptionally repressive heterochromatin 
(Sripathy et al., 2006).   
 
 
               
 
Figure 10. KAP1 protein interactions and mechanistic overview 
KAP1 leads to the formation of transcriptionally repressive heterochromatin through the 
recruitment of various histone and nucleosome remodeling proteins. KAP1 is recruited to the 
genome through interactions between its RBCC protein interaction domain and the KRAB 
domain of KRAB-ZFP. Upon auto-SUMOylation of its bromodomain, KAP1 then serves as a 
scaffold for the recruitment of the histone deacetylase CHD3, a component of the NuRD 
complex, and the histone methyltransferase SETDB1, leading to the deposition of H3K9me3 




1.4.2 Protein structure and interactions of KAP1 
KAP1 shares the common overall architecture of the TIF1 subfamily of 
TRIM proteins, which consists of an N-terminal tripartite motif (TRIM) – 
containing a RING (really interesting new gene) finger, two B-box zinc 
fingers, and a coiled-coil domain (RBCC) – a central TIF1 signature 
sequence (TSS), and a C-terminal plant homeodomain (PHD) and 
bromodomain (Friedman et al., 1996; Venturini et al., 1999). In addition, 
KAP1 contains a central heterochromatin protein 1 (HP1) binding domain 
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also present in TIF1α and TIF1δ, which is essential for transcriptional 
repression by KAP1 (Figure 11).  
 
 
                
Figure 11. KAP1 domains 
 Schematic representation of KAP1 (also called TIF1β and TRIM28) and the related TIF1 
family proteins, TIF1α/TRIM24 and TIF1γ/TRIM33. The RBCC domain, necessary for 
interactions between KAP1 and KRAB-ZFP, is shown in blue; the TSS site is shown in 
orange; the HP1 binding site is shown in pink; an NR box shown to bind nuclear receptors is 
shown in yellow; the C-terminal PHD and bromodomain (PB domain) are shown in green. 
 
 
The N-terminal RBCC domain (aa 65-376) of KAP1 is a high-affinity 
protein interaction domain found in an increasing number of proteins with 
important roles in cell differentiation, development, oncogenesis, and 
apoptosis, which is necessary and sufficient to mediate interactions between 
KAP1 and the KRAB repression module of KRAB-ZFPs, and is thus 
responsible for the site-specific genomic recruitment of KAP1 (Borden, 1998; 
Peng et al., 2002; Saurin et al., 1996). In the context of KAP1, the RBCC 
domain homo-oligomerizes to bind a single KRAB module as a trimer (Peng 
et al., 2000). While all TIF1 family members contain an RBCC domain, 
KRAB-binding is specific to KAP1 (Peng et al., 2002). The defining element 
of the RBCC domain is the RING finger, which is composed of two 
consensus C3HC4 zinc binding motifs, and is found in more than 200 
proteins that form macromolecular complexes with diverse functions (Borden, 
1998; Saurin et al., 1996). The two B-boxes adjacent to the RING domain are 
cysteine + histidine-rich regions that also contain CHC3H2 zinc binding 
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motifs. The third sequence is the coiled-coil motif, an amphipathic double α-
helix structure that, together with the two B-boxes, provides an extended 
hydrophobic region necessary to mediate protein interactions by the RBCC 
domain (Peng et al., 2000).  
                Adjacent to the RBCC domain is the TSS motif, a highly conserved 
25 aa sequence rich in tryptophan and phenylalanine that is specific to the 
TIF1 subfamily of proteins. The role of the TSS is not yet clear, however its 
deletion in TIF1γ results in a complete loss of repressor activity (Venturini et 
al., 1999). The central domain of KAP1 is rich in prolines and glycines, and 
as such it is difficult to make predictions about the secondary structure of this 
region (Lechner et al., 2000). The observation that virtually the entire central 
domain of KAP1 is susceptible to protease treatment and that it has little α-
helix or β-strand structure suggests that it exists in a highly extended, and 
perhaps flexible, conformation (Lechner et al., 2000), which has been 
suggested to provide KAP1 the adaptability necessary to interact with 
numerous different protein complexes (Iyengar and Farnham, 2011). While 
this central region is the least conserved domain among members of the 
TIF1 family and is in fact absent in TIF1γ, studies using recombinant GST-
tagged KAP1 containing various deletions between aa 478-516 were able to 
map the KAP1 HP1 binding domain (HP1BD) to a 5 aa stretch within the 
central domain, comprised of a conserved PxVxL HP1 binding motif (Lechner 
et al., 2000). HP1 proteins bind trimethylated histone 3 lysine 9 (H3K9me3) 
and are essential for transcriptional repression by KAP1 (Lechner et al., 
2000; Nielsen et al., 1999; Ryan et al., 1999). Each KAP1 HP1BD interacts 
with two HP1 monomers, and so a functional trimerized KAP1 corepressor 
might bring together six or more HP1 molecules (Lechner et al., 2000). 
Additionally, TIF1α and TIF1γ contain an NR box shown to bind nuclear 
receptors not present in KAP1.  
The C-terminal tandem PHD and bromodomain (PB domain) of KAP1 
(aa 628-801) form a cooperative unit that is required for transcriptional 
repression through the recruitment of chromatin modifying histone 
deacetylases and methyltransferases. Substitution of highly related PHD or 
bromodomains failed to restore KAP1 repressor activity, indicating a high 
specificity to their cooperative function and also demonstrating that both 
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domains are necessary for optimal repression (Schultz et al., 2001). The 
PHD finger is a 60 aa domain consisting of two C4HC3 zinc binding motifs 
arranged between anti-parallel β sheets, while the bromodomain is a 100 aa 
stretch consisting of a four-helical bundle (Capili et al., 2001) whose 
conserved hydrophobic core recognizes the backbone of histone tails 
(Schultz et al., 2001). The PHD domain of KAP1 functions as an 
intramolecular E3 ligase, auto-sumoylating the adjacent bromodomain 
(Ivanov et al., 2007), after which the sumoylated bromodomain can then 
recruit two chromatin-modifying enzymes via their SUMO interaction motifs 
(SIM) – (1) chromodomain-helicase-DNA-binding protein 3 (CHD3/Mi2α) 
found in the Nucleosome Remodeling and Histone Deacetylation (NuRD) 
complex, and (2) SET domain, bifurcated 1 (SETDB1), a histone 
methyltransferase specific for H3K9 (Schultz et al., 2001, 2002; Zeng et al., 
2008). Trimethylation of H3K9 by SETDB1 subsequently creates high affinity 
binding sites for HP1, stabilizing the interaction between heterochromatin 
and the KAP1 macromolecular complex.  
  
1.4.3 Recruitment of KAP1 to the genome 
 Lacking any intrinsic DNA binding activity, KAP1 is dependent on 
interactions with KRAB-ZFP for recruitment to the genome. Numerous 
studies had demonstrated that the fusion of KRAB domains to heterologous 
DNA binding domains resulted in transcriptional repression of target 
sequence-containing promoters in a dose-dependent manner and over long 
distances (Margolin et al., 1994; Witzgall et al., 1993, 1994). KRAB domains 
were first identified as a conserved sequence at the N-terminal end of 
proteins containing C2H2 zinc fingers. The C2H2 family of zinc fingers 
represents the largest class of DNA-binding transcription factors in the 
human genome, and it is now clear that approximately half of these contain 
KRAB domains (KRAB-ZFP) (Urrutia, 2003). There are ~742 structurally 
different KRAB-ZFP that have evolved through duplication events to perform 
species- and tissue-specific gene regulation, and together these proteins 
regulate essential processes during development and differentiation 
(Emerson and Thomas, 2009; Urrutia, 2003). Mammalian KRAB-ZFP contain 
up to 30 N-terminal ZNF domains (Emerson and Thomas, 2009) each of 
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which can recognize 3 nt of DNA. In this way, KRAB-ZFPs become anchored 
to specific target DNA sequences where they can then recruit KAP1 and, 
consequently, the NuRD complex, SETDB1, and HP1.  
Site-directed mutagenesis of KRAB domains demonstrated that these 
regions were responsible for the observed transcriptional repression of 
reporter constructs (Witzgall et al., 1994). Shortly thereafter, yeast two hybrid 
experiments identified KAP1 as the binding partner for two KRAB-ZFPs, 
KOX-1 and KIP-1 (Kim et al., 1996; Moosmann et al., 1996), and direct 
tethering of KAP1 to DNA demonstrated that KAP1 was in fact the mediator 
of the repression exerted by these KRAB-ZFP (Friedman et al., 1996; 
Moosmann et al., 1996). KAP1 has since been implicated as a general 
corepressor of three distinct subfamilies of KRAB-ZFP (Abrink et al., 2001), 
and indeed, 51 of 61 tested human KRAB-ZFPs interact with and mediate 
repression through KAP1 (Itokawa et al., 2009). Additionally, certain KRAB 
proteins in which alternative splicing has removed the C-terminal C2H2 zinc 
finger motifs have been shown to serve as adaptor molecules for KAP1-
mediated repression.  The KRAB only (KRAB-O) protein, a splice variant of 
Zfp748, tethers KAP1 to the sex determination transcription factor SRY, 
recruiting KAP1 to SRY binding sites (Peng et al., 2009). Similarly, the von 
Hippel-Lindau tumor suppressor (pVHL)-associated KRAB-A domain 
containing protein (VHLaK) is a splice variant of Zfp197 that recruits KAP1 to 
pVHL, resulting in the pVHL-mediated transcriptional repression of hypoxia-
inducible factor-1α (HIF-1α) (Li et al., 2003) 
 To determine the in vivo relevance of KAP1 interactions with KRAB-
ZFPs and other DNA-binding proteins, chromatin-immunoprecipation (ChIP) 
experiments were used to identify genomic KAP1 binding sites. Complete 
genomic analysis of Ntera human embryonic carcinoma cells identified over 
7000 KAP1 binding sites, mapping either to the 3’ coding regions of ZNF 
genes, or core promoter regions near transcription start sites (TSS) (O’Geen 
et al., 2007). The strongest KAP1 binding sites were at the 3’ coding regions 
of ZNF genes however, leading the authors to suggest that KRAB-ZFPs 
participate in an autoregulatory loop involving recruitment of KAP1. ChIP 
experiments using various KAP1 mutant proteins demonstrated that 
recruitment of KAP1 to the 3’ coding regions of ZNF genes was in fact 
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dependent on the KAP1 RBCC domain (Iyengar et al., 2011), and further 
studies showed that ZNF274 colocalizes with KAP1 at these regions (Frietze 
et al., 2010), supporting the notion that KAP1 is recruited to the genome via 
interactions with KRAB-ZFPs. Interestingly however, binding of KAP1 to TSS 
sites near promoter regions was independent of the KAP1 RBCC domain, 
indicating a second mechanism for KAP1 recruitment to these sites not 
involving KRAB-ZFP (Iyengar et al., 2011). Although the exact mechanism 
for this recruitment is still unclear, mutational analysis of KAP1 suggests that 
protein-protein interactions with aa 380-618 within the KAP1 central domain 
may be involved (Iyengar et al., 2011). 
 
1.4.4 Role of KAP1 in transcriptional regulation 
 Several lines of evidence suggest that KAP1 functions as a 
transcriptional repressor by coordinating the activities of nucleosome- and 
histone-modifying proteins to induce histone methylation, HP1 deposition, 
and the formation of transcriptionally repressive heterochromatin. The 
majority of data demonstrating repression by KAP1 however come from 
artificial recruitment experiments in which isolated KRAB domains fused to 
heterologous DNA binding domains were shown to mediate robust 
repression of reporter constructs containing target DNA sequences in a 
manner dependent on KAP1 binding (Margolin et al., 1994; Witzgall et al., 
1994). Several studies using inducible KRAB fusion proteins were able to 
demonstrate that KAP1-mediated repression of integrated reporter constructs 
was associated with a recruitment of SETDB1 and the HP1 family of 
proteins, as well as the deposition of the repressive mark, H3K9me3 
(Ayyanathan et al., 2003; Schultz et al., 2002; Sripathy et al., 2006).  A 
hormone inducible KOX1 KRAB domain fused to the PAX3 DNA binding 
domain was shown to repress transcription from an integrated TK-luciferase 
reporter construct containing 6 high affinity PAX3 binding sites upstream of 
the TK promoter. Importantly, a mutant KRAB domain unable to bind KAP1 
had no effect (Ayyanathan et al., 2003). Using immunofluorescence and 
ChIP experiments, the investigator further demonstrated that repressed 
reporter constructs were spatially recruited to HP1-rich nuclear regions, and 
that they physically associated with all components of the KAP1 repressive 
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complex – KAP1, SETDB1, HP1α/γ, and H3K9me3 (Ayyanathan et al., 
2003). Furthermore, repression resulting from one short exposure to the 
hormone inducer was heritable for up to 50 generations (Ayyanathan et al., 
2003). Similar results were obtained using hormone inducible GAL4-KRAB 
fusions and an integrated TK-luciferase reporter containing 5 upstream GAL4 
binding sites (Sripathy et al., 2006). Additionally, siRNA-mediated depletion 
of endogenous KAP1, HP1α/β/γ, and SETDB1 attenuated repression of the 
reporter, and direct tethering of WT KAP1, but not KAP1 with mutations in 
the HP1 binding site or PB domain, was sufficient to repress transcription 
from the integrated transgene (Sripathy et al., 2006).  
 Genomic KAP1 binding sites at the 3’ coding regions of ZNF genes 
have also been shown to be enriched for SETDB1, HP1, and H3K9me3 
(Frietze et al., 2010; Iyengar et al., 2011; Vogel et al., 2006). A systematic 
investigation of the target genes of HP1β revealed a significant enrichment 
for this heterochromatin-inducing protein at these sites (Vogel et al., 2006), 
and sequential ChIP analysis of K562 cells further demonstrated 
colocalization of SETDB1, KAP1, and H3K9me3 deposition (Frietze et al., 
2010). While these characteristics have clearly been shown to mediate 
repression in the context of artificial recruitment experiments, the in vivo 
functional relevance of KAP1-SETDB1 recruitment to ZNF genes is less 
clear. Depletion of KAP1 by siRNA had only minor effects on the 
transcriptome of HEK293 cells (Iyengar et al., 2011). Furthermore, the set of 
~90 genes that were responsive were not those bound at ZNF 3’ exons, but 
instead showed KAP1 binding only at distant intergenic sites (Iyengar et al., 
2011), suggesting either an indirect route to regulation or long-distance 
heterochromatin spreading (Groner et al., 2010). It has been suggested that, 
rather than playing a role in transcriptional regulation, KAP1 binding to ZNF 
3’ exons may play a role in stabilizing KRAB-ZNF gene clusters (Vogel et al., 
2006). KRAB-ZFP have undergone a rapid expansion in recent evolution, 
and sequence comparisons of various KRAB-ZFP gene clusters indicate that 
in situ tandem duplications play an important role in the evolution of these 
genes (Dehal et al., 2001). It is thought that the heterochromatinization of 
these regions may prevent the recombination-mediated deletion of newly 
! 71!
duplicated KRAB-ZFP, and may in fact have facilitated the incredible 
expansion of this gene family (Vogel et al., 2006).  
 In contrast to KAP1 binding sites at 3’ ZNF exons, binding sites near 
TSS are neither dependent on KRAB-ZFP for recruitment of KAP1, nor 
associated with enrichment for H3K9me3 (Frietze et al., 2010; Iyengar et al., 
2011). Rather, these binding sites may be related to the recently discovered 
role for KAP1 in promoter proximal pausing via recruitment of the 7SK small 
nuclear ribonucleoprotein (snRNP) (Bunch et al., 2015; McNamara et al., 
2016). Promoter proximal pausing of RNA polymerase II (RNA pol II) 
represents a major checkpoint for transcription. Transcription pre-initiation 
complexes (PIC) assemble at promoters to recruit RNA pol II and initiate 
transcription (Diamant and Dikstein, 2013; Hargreaves et al., 2009; Smale, 
2010), however RNA Pol II pauses ~20-63 nt downstream of TSS through 
the activity of various negative elongation factors (Adelman and Lis, 2012; 
Peterlin and Price, 2006; Yamaguchi et al., 1999). For transcription to 
continue, RNA pol II must be phosphorylated at its C-terminal domain (CTD) 
by a positive elongation factor, such as the P-TEFb kinase (Mancebo et al., 
1997; Peng et al., 1998). To prevent premature phosphorylation of RNA pol 
II, P-TEFb is held in a catalytically inactive state, reversibly bound to the 7SK 
snRNP complex (He et al., 2008; Jeronimo et al., 2007; Krueger et al., 2008).  
The role for KAP1 in this mechanism was first identified through an 
unbiased search for human proteins involved in regulating RNA pol II 
pausing using HSP70 as a model gene (Bunch et al., 2014). Genome wide 
ChIP-sequencing (ChIP-seq) analysis of WT and KAP1 depleted cells 
revealed a strong correlation between KAP1 and RNA pol II occupancy. 
Furthermore, the investigators showed that KAP1 rapidly became 
phosphorylated at serine 824 (a modification important in DNA damage 
repair, reviewed in section 1.4.5) in a DNA-PK and ATM dependent manner 
upon heat shock, and that this correlated with RNA Pol II progression and 
transcriptional elongation of HSP70 (Bunch et al., 2014). This mechanism 
was further investigated in the regulation of transcription initiation from 
primary response genes (PRGs) (McNamara et al., 2016), which utilize 
pTEFb to rapidly phosphorylate paused RNA pol II in response to danger 
stimuli. KAP1 was shown to bind directly to the 7SK snRNP complex via 
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interactions with the Larp7 component. The investigators comprehensively 
demonstrated that KAP1 is dynamically recruited to the promoters of PRGs, 
both prior to stimulation and throughout active transcription, where it tethers 
the 7SK snRNP complex and its associated pTEFb (McNamara et al., 2016). 
This functions to provide a constant source of pTEFb ready to phosphorylate 
and activate RNA pol II upon stimulation. Supporting this, KAP1 depletion 
resulted in a sharp reduction of 7SK snRNP occupancy and pTEFb 
recruitment at PRG promoters, which interestingly correlated with a decrease 
in magnitude of gene induction upon stimulation, suggesting that KAP1 is 
necessary for proper gene induction of PRGs. Furthermore, genome-wide 
studies revealed that KAP1 and 7SK snRNP co-occupy most promoter-
proximal regions containing paused RNA Pol II, also establishing a role for 
KAP1 in maintenance of efficient levels of basal transcription.  
  
1.4.5 Role of KAP1 in the cellular DDR 
Transcriptional repression by KAP1 is dependent on the attachment of 
small ubiquitin-like modifier (SUMO) proteins to its bromodomain, which 
function to recruit SETDB1 and the NuRD complex protein CHD3 via their 
SUMO-interacting motifs (SIM). SUMO family proteins are conjugated to 
target lysines via a cascade of E1, E2, or E3 ligases (Isogai and Shirakawa, 
2007), where they appear to play a key role as post-translational 
modifications involved in transcriptional repression (Gill, 2005). The KAP1 
PHD domain is highly related to the RING finger, often found in ubiquitin and 
SUMO E3 ligases (Joazeiro and Weissman, 2000), and indeed, the PHD 
domain acts as an intramolecular E3 SUMO ligase to conjugate SUMO 
moieties to the adjacent bromodomain, predominantly at lysines, 554, 770, 
and 804 (Ivanov et al., 2007; Lee et al., 2007). This activity was shown to be 
essential for KAP1 recruitment of CHD3 and SETDB1, and consequently for 
the repressor activity of KAP1 (Ivanov et al., 2007; Lee et al., 2007; Mascle 
et al., 2007)).  
KAP1 SUMOylation and repressor activity is in turn regulated through 
phosphorylation of its C-terminal domain. In response to DNA damage, the 
kinases ATM and DNA-PK mediate phosphorylation of KAP1 at serine 824 
(p-KAP1-S824), adjacent to the SUMOylated bromodomain (Tomimatsu et 
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al., 2009; White et al., 2006; Ziv et al., 2006). This has been shown to lead to 
the direct upregulation of the KAP1-regulated genes Gadd45α and p21, 
involved in cell cycle arrest, as well as to modulate expression of various 
other KAP1-targeted genes involved in the cellular DDR, including the 
proapoptotic genes Bax, Puma, and Noxa (Li et al., 2007b). KAP1 also has a 
more structural role in DNA repair. ATM activation upon the induction of 
DSBs leads to the phosphorylation of KAP1-S824 at sites of damage, which 
then spreads throughout the chromatin. This results in a wave of global 
chromatin decondensation that has been shown to increase survival after 
ionizing radiation, and, more importantly, to be essential for the repair of 
DSBs within heterochromatin by increasing access to essential repair factors 
(Goodarzi et al., 2008; Noon et al., 2010; Ziv et al., 2006).  Phosphorylated 
KAP1-S824 colocalizes at damage foci with numerous other proteins 
necessary for DNA repair, such as γH2AX, 53BP1, and ATM, and studies 
using non-phosphorylatable KAP1 (KAP1-S824A) demonstrated a 
constitutive heterochromatic DSB repair defect characterized by a loss of 
chromatin decondensation, supporting a direct role for KAP1 in this process 
(Noon et al., 2010; Ziv et al., 2006).  
The exact mechanism through which phosphorylation of KAP1 leads 
to the relaxation of chromatin and efficient DNA repair is not yet clear. 
Studies showing that the induction of DNA damage is associated with a 
decrease in levels of SUMOylated KAP1 suggest that phosphorylation of 
KAP1-S824 negatively regulates SUMOylation levels (Li et al., 2007b), which 
would in turn lead to reduced interactions between KAP1, SETDB1, and 
CHD3, and thus chromatin relaxation. Supporting this, the deSUMOylase 
SUMO/Sentrin/Smt3-specific peptidase (SENP70) interacts with KAP1 via 
HP1α to promote the removal of SUMO from KAP1, and this was shown to 
regulate the interaction between KAP1 and CHD3 (Garvin et al., 2013). 
Indeed, CHD3 dispersion from sites of DSBs upon phosphorylation of KAP1-
S824 was associated with chromatin relaxation (Goodarzi et al., 2011). 
However, the investigators in this study did not find any change in 
SUMOylation of KAP1 between phosphorylated and non-phosphorylated 
forms, and instead suggested that phosphorylation at S824 interferes with 
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the binding between SUMO bound to KAP1 and the SIM of CHD3 through 
charge repulsion (Goodarzi et al., 2011).  
KAP1 can also become phosphorylated at serine 473 (p-KAP1-S473) 
either by the ATM-Chk2 or ATR-Chk1 pathway depending on the type of 
DNA damage that occurs (Chang et al., 2008; Hu et al., 2012). Differences in 
the kinetics and nuclear localization of p-KAP1-S824 and p-KAP1-S473 
suggest that each phosphorylated form of KAP1 participates in DNA repair in 
spatially and temporally regulated way, acting synergistically to repair 
damaged DNA (Hu et al., 2012). Whereas phosphorylation of KAP1-S824 
interferes with interactions between KAP1, SETDB1, and CHD3, the 
proximity of S473 to the PxVxL motif of the HP1 binding domain leads to a 
loss of interaction between p-KAP1-S473 and HP1 (Chang et al., 2008; Hu et 
al., 2012). Studies using a phosphomimetic mutant of KAP1-S473 
demonstrated that the loss of HP1 binding resulted in the upregulation of 
various KAP1-regulated genes, including p53AIPI, Noxa, Zfp180, and 
RNApol II. Loss of HP1 binding was also associated with increased binding 
of KAP1 to the transcription factor E2F1, thus reducing the ability of E2F1 to 
induce expression of E2F1-regulated proapoptotic genes (Hu et al., 2012). 
Additionally, phosphorylation of KAP1-S473 by protein kinase C-δ (PKCδ) 
during early S phase was shown to dynamically regulate cell cycle 
progression through the induction of cell cycle genes cyclin A2, Cdc2, and 
Cdc25, leading to G2/M progression (Chang et al., 2008; Lee et al., 2012).   
Regardless of the site of KAP1 phosphorylation, basal homeostatic 
levels of phosphorylated/SUMOylated KAP1 must be restored upon 
completion of DNA repair or cell cycle progression in order to restore steady 
state gene transcription and heterochromatin formation. Protein phosphatase 
4 (PP4) was shown to interact with KAP1, and depletion of PP4 resulted in 
prolonged phosphorylation of both S824 and S473, resulting in prolonged 
G2/M checkpoint and relaxation of heterochromatin with an associated 
release of CHD3 (Lee et al., 2012). Two isoforms of PP1 were also shown to 
dephosphorylate KAP1-S824 under different stress conditions (Li et al., 
2010). PP1α interacted with KAP1 under steady state conditions, while PP1β 
interacted with KAP1 under conditions of genotoxic stress. However, based 
on experiments using the PP1 inhibitory peptide I-2, the investigators 
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concluded that PP1α could be one of the key molecules to regulate levels of 
damage-induced p-KAP1-S824. Depletion of PP1α had a similar effect on the 
expression of KAP1-regulated genes as was observed with depletion of 
KAP1, and it was subsequently found to form a constitutive functional unit 
with KAP1 at the p21 proximal promoter (Li et al., 2010).  
Finally, KAP1 has also been shown to inhibit apoptosis through the 
modulation of post-translational modifications of various transcription factors 
independently of DNA-binding. Mouse double minute 2 homolog (MDM2) is 
an E3 ubiquitin ligase that functions to promote p53 ubiquitination and 
degradation, thus playing an essential role in the regulation of apoptosis in 
response to mitogenic signals. KAP1 binds MDM2 via its coiled-coil domain, 
forming a ternary complex with p53 and cooperating with MDM2 to inhibit 
p53 acetylation through the tethering of KAP1-associated histone 
deacetylases (HDAC) and thus inhibiting p53 transcriptional and apoptosis 
functions (Wang et al., 2005). KAP1 also binds directly to the transcription 
factor E2F1 via its coiled-coil domain, stimulating the formation of E2F1-
HDAC1 complexes that inhibit E2F1 acteylation/stimulation, and preventing 
E2F1-mediated apoptosis (Wang et al., 2007). Finally, KAP1 was also found 
to act as a transcriptional regulator of the signal transducer and activator of 
the transcription 3/interleukin-6 (STAT3/IL-6) pathway by associating with 
STAT3, an interaction which prevents the accumulation of phosphorylated 
STAT3 (Tsuruma et al., 2008), although the mechanism behind this 
observation is still unclear.  
 
1.4.6 Role of KAP1 in the regulation of viral elements 
 The role for KAP1 in the regulation of viral elements was first 
discovered by Wolf and Goff (Wolf and Goff, 2007) who showed that 
recruitment of KAP1 by the mouse-specific KRAB-ZFP ZFP-809 was 
responsible for the restriction of murine leukemia virus (MLV) replication in 
mouse embryonic stem (ES) and embryonic carcinoma (EC) cells (Wolf and 
Goff, 2007; Wolf et al., 2008). It was known that MLV could successfully 
infect and integrate into the genomes of these cells, but that potent 
repression of the viral promoter in the long terminal repeat (LTR) silenced 
these genomes through a mechanism involving recruitment of a trans acting 
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DNA-binding factor (Akgün et al., 1991; Flanagan et al., 1989; Loh et al., 
1988; Tsukiyama et al., 1989) to the viral repressor binding site within the 
viral primer binding site (PBS) (Barklis et al., 1986; Feuer et al., 1989; Loh et 
al., 1987), resulting in methylation of the provirus (Niwa et al., 1983). KAP1 
was successfully purified from, and was demonstrated to be an integral 
component of, the repressive complex bound to the viral repressor binding 
site (Wolf and Goff, 2007). Reactivation of silenced MLV in differentiated EC 
cells was associated with a decrease in steady-state levels of KAP1, and 
KAP1 depletion in two EC cell lines was shown to reduce repression of an 
integrated MLV-based retroviral vector containing the WT MLV PBS. ChIP 
experiments confirmed that KAP1 was bound to MLV-based vectors 
containing a WT PBS, which are repressed, but not to vectors containing a 
mutant PBS (B2), which are not repressed (Wolf and Goff, 2007). Silencing 
of the MLV via the PBS was further shown to be dependent on HP1 
recruitment by KAP1, further supporting its role in MLV restriction (Wolf et al., 
2008). Based on this, it was suggested that KAP1 has an essential role in 
orchestrating PBS-mediated silencing of integrated MLV proviruses in EC 
and ES cells, and furthermore that this may represent a strategy evolved to 
protect the embryo from the reactivation of retrotransposons and 
endogenous retroviruses during embryogenesis (Wolf and Goff, 2007).  
Transposable elements (TE) account for more than half of the human 
and murine genomes (Lander et al., 2001; Waterston et al., 2002), and their 
ability to mediate recombination events, retrotranspose, and alter the 
transcription of neighboring genes through strong promoter/enhancer 
elements poses a threat to the developing embryo, particularly after the 
genome-wide DNA demethylation that occurs several times during 
embryogenesis (Morgan et al., 2005). It is now known that KAP1-mediated 
repression of various TE, in particular endogenous retroviruses (ERV), is 
crucial for the maintenance of genomic integrity during embryogenesis, and 
for the preservation of transcriptional dynamics, both during early 
development and in certain differentiated cells (Ecco et al., 2016; Rowe and 
Trono, 2011; Rowe et al., 2010, 2013). Depletion of KAP1 led to a marked 
increase in expression of ERVs, in particular intracisternal A-particles (IAP), 
in mouse embryonic carcinoma (EC) and embryonic stem (ES) cells, and 
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KAP1 docking at these sites triggered the deposition of repressive marks 
such as H3K9me3 and DNA methylation (Rowe and Trono, 2011; Rowe et 
al., 2010). Further studies demonstrated that KAP1- and SETDB1-mediated 
histone methylation acted cooperatively to induce de novo DNA methylation 
of flanking regions (Rowe et al., 2013), possibly through the direct 
recruitment of DNA methylases by KAP1 and SETDB1 (Li et al., 2006; 
Quenneville et al., 2011), leading to the silencing of strong neighboring 
promoters (Rowe and Trono, 2011; Rowe et al., 2013). The result was the 
establishment of stable site-specific DNA methylation signatures across the 
genome in early embryogenesis, presumably necessary to prevent 
retrotransposition as well as the illegitimate expression of neighboring genes. 
The mouse-specific KRAB-ZFP ZFP932 and its paralog Gm15446 were later 
shown to bind with KAP1 to numerous ERV (226 for ZFP932 and 448 for 
Gm15446) in mouse ES cells, and knockout of the KRAB-ZFPs led not only 
to the upregulation of their target ERV (amongst others), but also to the 
upregulation of 71 neighboring genes (Ecco et al., 2016). The investigators 
found that, although less pronounced, KAP1 knockout in certain 
differentiated mouse cells also led to an upregulation of different subsets of 
ERVs and associated neighboring genes. This effect was not systematically 
induced in all cell lines tested however, and it was suggested that the 
presence or absence of tissue-specific activators is necessary for the 
upregulation of KAP1-regulated gene expression upon ablation of repressive 
methylation (Ecco, 2016).  
More recently, KAP1 has been shown to be involved in the 
repression of human cytomegalovirus (CMV) (Rauwel et al., 2015) and 
Kaposi’s sarcoma-associated herpesvirus (KSHV) (Chang et al., 2009; Sun 
et al., 2014; Zhang et al., 2014). In the context of these latent DNA viruses 
however, KAP1 appears to act more as a regulator of latency. During KSHV 
infection, KAP1 is recruited to the genome by the viral latency associated 
nuclear antigen (LANA) protein, where its repression of lytic genes, such as 
k-bZIP and vPK, is crucial to the maintenance of latency (Sun et al., 2014). 
Induction of lytic replication through overexpression of the viral 
transcriptional regulator K-Rta results in the disassociation of KAP1 and the 
subsequent loss of HP1 and H3K9me3, and, consequently, reactivation of 
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the viral genome (Chang et al., 2009). As reactivation progresses, the newly 
expressed viral kinase vPK inactivates KAP1 corepressor activity through 
phosphorylation of KAP1 serine 824, suggesting counteraction by the virus 
is necessary for full reactivation and maintenance of lytic replication (Chang 
et al., 2009). A more recent study has also shown KAP1 to be necessary for 
both the establishment and maintenance of HCMV latency in hematopoietic 
stem cells (HSCs) (Rauwel et al., 2015). Here again, latency was shown to 
correlate with KAP1-mediated recruitment of SETDB1 and HP1, and with 
H3K9me3 deposition across the viral genome. Accordingly, depletion of 
KAP1 in HSCs resulted in the upregulation of immediate early, early, and 
late viral genes. Importantly, binding of SETDB1 and H3K9me3 were lost 
upon differentiation of HSCs to permissive dendritic cells (DCs) (Rauwel et 
al., 2015).  
Finally, in a mechanism similar to the manner in which KAP1 
modulates the post-translational modifications of certain TFs, KAP1 has 
been shown to inhibit integration of HIV by forming a complex with the viral 
integrase (IN) causing its inactivation through deacetylation by KAP1-
associated HDAC (Allouch et al., 2011). KAP1 was also suggested to 
repress adenoviral replication at early stages of infection by preventing 
efficient decondensation of incoming viral genomes, an effect which was 
counteracted by crosstalk between the Ad E1B55K protein and KAP1, 
resulting in decreased SUMOylation and increased phosphorylation of 













1.5 AIMS OF THE THESIS 
As outlined above, numerous interactions between AAV Rep and 
cellular proteins are necessary to support the complex biphasic life cycle of 
AAV. While a multitude of cellular Rep interaction partners have previously 
been described, mechanistic insights into these interactions are largely 
missing. Additionally, several aspects of AAV biology remain elusive despite 
our current knowledge of Rep protein interactions, suggesting that further 
interactions remain to be identified. One particularly intriguing feature of the 
AAV Rep proteins that remains to be fully elucidated is their capacity to 
regulate transcription from both AAV and heterologous viral and cellular 
promoters via a mechanism that is likely dependent on interactions with 
cellular transcriptional machinery. With this in mind, the aims of this thesis 
were to (1) identify new cellular interaction partners for the Rep proteins, (2) 
identify their role in the AAV life cycle, focusing on Rep-mediated 
transcriptional regulation, and (3) determine their mechanism of action. It is 
important to acknowledge here that various other aspects of basic AAV 
biology are also still poorly understood. In particular, little is yet known about 
the nature and contribution of epigenetic marks to the genome organization 
and temporal gene regulation of AAV. It is therefore that we approached the 
downstream analysis of putative Rep interaction partners with an open mind. 
In addition to enhancing our general understanding of AAV, identifying 
essential Rep-protein interactions will have implications for AAV-based gene 
therapy, as significant enhancements in AAV vector design have previously 
been derived from an enhanced understanding of basic wild type AAV2 
biology.  
 Described in Results Chapter 3 is the development and application of 
a screening method known as BioID, which was used to generate a list of 
potential interaction partners for the Rep proteins. Several candidates were 
chosen for downstream analysis based on cellular function and/or known 
interactions with viral elements, one of which was the transcriptional 
corepressor KAP1. Results Chapters 4 and 5 focus on the discovery of an 
intricate web of interactions between the Rep proteins, KAP1, the 
phosphatase PP1, and its negative regulator NIPP1. In Results chapter 4, we 
show that, while KAP1 is not involved in Rep-mediated transcriptional 
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regulation, depletion of KAP1 enhances AAV2 replication and transcription. 
We further demonstrate that KAP1 binds the latent AAV2 genome, leading to 
trimethylation of AAV2-associated H3K9. Results Chapter 5 focuses on 
defining a mechanism of PP1 antagonism through which the AAV2 Rep 
proteins counteract KAP1 repression during lytic replication. Finally, in 
Results Chapter 6, we show that infection by Ad5 and HSV-1 leads to 
depletion of KAP1 and suggest that this may represent an unknown helper 





















Chapter 2: Materials and Methods 
 
2.1 MOLECULAR CLONING  
2.1.1 Standard Polymerase Chain Reaction (PCR)  
This is the basic PCR reaction that was used for colony screening and 
other tests. The polymerase kit used was the standard goTaq® DNA 
polymerase (Promega). PCR reactions were carried out in a total volume of 
25µl containing (final concentrations): 200µM dNTPs (mix of dATP, dCTP, 
dGTP and dTTP, from NEB), 1X Colorless GoTaq Reaction Buffer, 1.25U 
GoTaq DNA polymerase, 0.4µM forward and reverse primers, ~10ng DNA, 
and ddH2O in a final volume of 25µl. 0.01µmol of unmodified oligonucleotide 
primers for PCR amplification were obtained from Eurofins MWG Operon and 
re-suspended with ddH2O to make stock solutions at 100µM. Forward 
(sense) and reverse (anti-sense, reverse complement) oligonucleotide 
primers were designed following the manufacturer’s directions: 15-30 
nucleotides in length, 40- 60% GC content, and terminating in at least one 
G/C base. PCRs were performed using an Eppendorf Mastercycler EP 
Gradient Thermal Cycler. A typical PCR reaction initiated with a 2 minute 
denaturing step at 95 ̊C followed by 25-35 cycles including a denaturing step 
of 20 seconds at 95 ̊C, an annealing step of 45 seconds at 50°C (depending 
on the primers’ melting temperature) and an extension step of 1minute/kb at 
72°C. A final 5 minutes extension at 72°C followed the cycles. Reactions 
were kept at 4°C until use. For information on all the PCR primers used in 
this thesis please see Table 1 in Appendix 1, pg. 239.  
 
2.1.2 High fidelity PCR  
The Phusion High Fidelity polymerase kit (Thermo Scientific) was 
used for all PCR reactions performed to amplify DNA fragments necessary 
for cloning. Where relevant, primers used for subcloning of DNA fragments 
into vectors were designed to include an optimal Kozak consensus sequence 
(GCC ACC) immediately upstream of the ATG, and a two-glycine linker 
(GGC GGC) between N-terminal FLAG or T7 tags and the start of the coding 
sequence. PCR reactions were carried out in a total volume of 25µl, in a 
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mixture containing (final concentrations) 10ng of DNA template, 0.5µM of 
forward and reverse primers, 200µM dNTPs (NEB), 0.5U/25µl Phusion® 
High-Fidelity DNA polymerase (Thermo Scientific), 1X Phusion® HF or GC 
Buffer and brought to the final volume with ddH2O. PCRs were performed 
using an Eppendorf Mastercycler EP Gradient Thermal Cycler. Phusion GC 
buffer was used in reactions that initially did not work with HF buffer, as it is 
indicated for GC-rich templates or those prone to forming secondary 
structures. Reaction conditions were varied depending on the size and GC 
content of the fragment to be amplified. A typical PCR reaction initiated with 
a 30 seconds denaturing step at 98°C followed by 25-35 cycles including a 
denaturing step of 10 seconds at 98°C, an annealing step of 30 seconds at 
68°C and an extension step of 30 seconds/kb at 72°C. A final 10 minutes 
extension at 72°C followed the cycles. Reactions were kept at 4°C until use. 
The annealing step temperature was adjusted to the melting temperature of 
the primers. Primers were designed and obtained from Eurofins MWG 
Operon as explained above. For some cloning strategies, primers were 
designed with external overhangs containing restriction sites matching those 
in the destination construct.  
 
2.1.3 Overlapping PCR 
 Overlapping PCR was used to fuse BirA* to the N-terminus of the Rep 
proteins for BioID. BirA* was first amplified by high fidelity PCR using a 
forward primer (primer1) containing an optimal Kozak sequence and an ApaI 
restriction site, and a reverse primer (primer 2), in which the stop codon was 
replaced with a 10X glycine linker (as reverse complement: 5X GCC TCC 
repeats). Similarly, individual Rep fragments were amplified by high fidelity 
PCR using a forward primer (primer 3) containing the complementary glycine 
linker sequence for primer 2 (5X GGC GGA repeats) and a reverse primer 
(primer 4) containing an ApaI restriction site. Amplified products were then 
purified and used in a third PCR reaction using primer 1 and primer 4. For 
this reaction, primer concentration was reduced to 0.2µM, and 10ng of each 
fragment was used. Cycling conditions were as follows: an initial 
denaturation step of 98oC, followed by 30 cycles including a denaturation 
step of 10 seconds, an annealing step of 15 seconds at 70oC, and an 
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elongation step of 1 minute at 72oC, followed by a final elongation step of 10 
minutes at 72oC.  
 
2.1.4 Site-directed mutagenesis  
To generate Rep point mutants the Stratagene site-directed 
mutagenesis kit was used. Primers were designed to contain the desired 
point mutations in the centre flanked by 10-15 base pairs on either side 
matching the template sequence to allow sufficient annealing to the template 
DNA. This technology was used to introduce the K372A mutation into Rep.  
 
2.1.5 Agarose gel electrophoresis  
Amplified DNA PCR products or DNA fragments from restriction 
enzyme (RE) digestions from PCR were diluted with 5X DNA loading dye 
(NEB). Agarose gels were prepared by dissolving agarose powder 
(UltraPureTM Agarose, Life Technologies) in 1X TAE buffer (10X: Tris-Base 
48.4g/L, Acetic acid 11.4ml/L, EDTA 3.7g/L) and heating until boiling. The 
agarose percentage varied between 0.7% and 1.5% depending on the size of 
the fragment to be observed/isolated, with higher percentages used to 
achieve better separation of smaller fragments. After allowing the dissolved 
agarose to cool down, 1µg/ml of Ethidium bromide solution (Sigma) was 
added and the mixture was poured into an electrophoresis tank (BioRad). 
Once solidified, the gel was immersed in 1X TAE buffer and DNA samples 
were loaded in the wells of the gel. Gels were run at 80-120V for about 30-90 
minutes, depending on the separation required between bands. Band sizes 
were monitored with the 100bp or the 1kb DNA ladder (NEB), which was run 
in parallel. Ethidium bromide-stained DNA fragments were visualized under a 
ultra-violet trans-illuminator using a ChemiDocTM XRS+ System (BioRad).  
 
2.1.6 Extraction and purification of DNA fragments  
DNA fragments of interest were excised from agarose gels and 
purified using a QIAGEN Gel Extraction Kit. Three volumes of solubilisation 
and binding QG buffer were added to the agarose gel slice, the mixture was 
heated to 50°C for 10 minutes and vortexed to dissolve the slice. One 
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volume of isopropanol was added to the mixture and subsequently added to 
a QIAquick spin-column. DNA was bound to the column by centrifugation at 
13,000 rpm for 1 minute, after which the flow-through was discarded and the 
column washed with 750µl of ethanol-containing PE buffer and centrifuged 
twice to completely remove the ethanol. The DNA was finally eluted into a 
sterile eppendorf tube with 30µl of ddH2O. A similar procedure was used to 
purify RE digestion products that were not run on agarose gels. The same kit 
and protocol were used, with the exception that the RE digestion mixture was 
directly mixed with the QG buffer and isopropanol before proceeding with the 
column purification.  
 
2.1.7 Restriction Enzyme Digestion of DNA  
For analytical RE digestions, 2U of RE (NEB) was used to digest 
500ng of plasmid DNA in a 1X solution of the appropriate buffer supplied by 
the manufacturer, and total reaction volume was adjusted to 20µl with 
ddH2O. For RE digestions to generate fragments for cloning, 5-10U of RE 
was used to digest 2-5µg of DNA. All reactions were performed at the 
indicated temperature for the used RE (generally at 37 ̊C) for 2 h. When 
digestions with two restriction enzymes were performed, a compatible 
reaction buffer was used as indicated by manufacturer. After single-enzyme 
digestions to generate plasmid fragments for cloning, vector DNA was 
treated with calf intestinal phosphatase (CIP, NEB) to remove the 5’ 
phosphate group from the digested vector to prevent re-circularisation 
between compatible ends. 5U of CIP were added directly to the RE digestion 
mixture and incubated at 37 ̊C for 30 minutes and further purified as 
described above.  
 
2.1.8 DNA ligations  
The purified DNA insert and vector were mixed at a 5:1 ratio using 
50ng of vector with 1µl of 10X T4 ligase buffer (NEB) and 0.5µl of T4 ligase 
enzyme (NEB), in a total reaction volume adjusted to 10µl with ddH2O. 
Reactions were incubated at room temperature for 2 hours or overnight at 
16 ̊C.  
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2.1.9 Competent bacterial cells: media and maintenance  
For DNA transformations and plasmid DNA amplification, two types of 
chemically competent cells were used. The Escherichia coli SURE 
supercompetent cells (Stratagene), that have reduced recombination 
potential, were used for transformation and amplification of plasmids 
containing AAV ITRs and grown at 30 ̊C. The Escherichia coli TOP10 
competent cells (Life Technologies) were used for all other plasmids and 
cultured at 37 ̊C. Competent cells were stored at -80 ̊. Autoclaved LB (Fisher 
Scientific, 20g/L ddH20) was used for liquid cultures. Autoclaved LB agar 
(37g/L ddH20) set in Sterilin 10cm Petri dishes was used for solid phase 
growth cultures. Antibiotics were added to autoclaved broth or autoclaved 
agar cooled to 50°C. Ampicillin (Sigma, 100µg/ml in ddH2O) or Kanamycin 
sulfate (Fisher Scientific, 50µg/ml in ddH2O) were used for selection. Stock 
preparations of transformed bacteria were kept as glycerol stocks (bacterial 
pellet resuspended in LB + 10-15% glycerol) at -80 ̊C.  
 
2.1.10 Transformation of competent bacteria  
5µl of the DNA insert-vector ligation reaction or 10-50ng of plasmid 
DNA was used for transformation into competent cells following the 
manufacturer’s protocol. For SURE competent cells, 50µl of competent 
bacteria were initially incubated with 1µl of β-mercaptoethanol for 10 minutes 
on ice. DNA was then added and incubated for 30 minutes on ice, followed 
by a heat shock at 42°C for 45 seconds and further 2 minutes on ice. For 
Top10 competent cells, 50µl of cells were mixed with DNA and incubated for 
30 minutes on ice, followed by a 30 second heat shock at 42 ̊C and a final 2 
minute incubation on ice. In both cases, reactions were then incubated with 
250µl of LB at 30 ̊C for 1 hour and plated on LB agar plates containing the 
appropriate antibiotic. Plates were incubated upside down at 30 ̊C or 37°C 
overnight.  
 
2.1.11 Plasmid DNA amplification and purification – mini preps  
Single colonies from transformed or re-streaked bacteria were picked 
and inoculated in 3ml of LB with antibiotic at the appropriate temperature 
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overnight in an incubator shaker. The following day, 2ml of the culture were 
transferred to an eppendorf tube and cells were pelleted in a bench-top 
centrifuge at 8000 rpm for 4 minutes. DNA was extracted using the QIAGEN 
mini prep kit. Briefly, cells were re-suspended in QIAGEN P1 buffer and then 
lysed in 100µl of P2 lysis buffer and mixed by inverting the tube. After a 5-
minute incubation at room temperature, chilled P3 neutralisation buffer was 
added to neutralise the mixture and samples were incubated on ice for 5 
minutes. DNA was separated from bacterial debris by centrifugation at 
13,000 rpm for 10 minutes in a bench-top centrifuge. Supernatant containing 
DNA was then transferred to a QIAprep spin column to bind DNA followed by 
washing with ethanol-containing PE buffer and elution in 40-50µl of ddH2O. 
DNA was kept at 4 ̊C for short term storage or at -20 ̊C for longer storage.  
 
2.1.12 Plasmid DNA amplification and purification – midi preps  
1ml of transformed bacteria culture or 10µl from a glycerol stock were 
inoculated overnight in 100ml (300-500ml for maxi preps) of LB with antibiotic 
selection. Cells were harvested by centrifugation at 6,000 rpm for 10 minutes 
at 4°C and DNA extraction was performed using the NucleoBond® Xtra 
Midi/Maxi kit (Macherey-Nagel), following the manufacturer’s protocol. The 
general principle behind this plasmid purification protocol is based on a 
modified alkaline lysis procedure, followed by plasmid DNA binding to a 
NucleoBond resin under appropriate low salt and pH conditions. RNA, 
proteins, dyes and low molecular– weight impurities are removed by several 
wash steps, and the plasmid DNA is finally eluted in a high-salt buffer, 
concentrated and desalted by isopropanol precipitation, and washed in 
ethanol. Finally, the clean DNA pellet was allowed to air dry before re-
suspending in 100-1,000µl ddH2O depending on the amount of purified DNA 
and the desired final concentration. DNA concentration was subsequently 
measured (see below). Preparations obtained by this method were typically 
at a concentration of 1µg/µl and stored short-term at 4 ̊C or long-term at - 





2.1.13 Determination of DNA concentration and DNA sequencing  
DNA concentration was determined using a Nanodrop ND-100 
Spectrophotometer (Labtech International). Following a blank measurement, 
1µl of undiluted DNA preparation was loaded onto the measuring pedestal. 
The Nanodrop calculates the DNA concentration measuring the sample 
absorbance at 260nm (OD260) and assuming that 1 OD260 unit corresponds 
to 50µg/ml of dsDNA. The purity of the DNA sample can be assessed by the 
OD260/OD280 ratio, which at ≈1.8 is considered ‘pure’ for DNA (i.e. free 
from protein and RNA contamination).  
DNA sequencing was performed at Eurofins MWG Operon from 1.5µg 
of plasmid DNA in 15µl ddH2O pre-mixed with 2µl of the appropriate primer 
at 10pmol/µl. Sequencing was performed using the Value Read service in 
tube format, results were returned on-line and subsequently analysed using 
the APE DNA analysis software and the NCBI Blast tool.  
 
2.1.14 Plasmids  
Here, I present the basic plasmids that were used for this thesis and 
those that have required cloning. When the cloning strategy is identical for 
several plasmids, the general strategy is described. For a list of all the 
plasmids used, please see Table 2 in Appendix 1, pg. 244.  
 
2.1.14.1 Rep-expressing constructs 
pCMV-Rep40 (pND229), pCMV-Rep52 (pND230), pCMV-Rep68 
Y156F M225G (pND226), and pCMV-Rep78 Y156F M225G (pND227) have 
been previously described (Dutheil et al., 2014). FLAG- and T7-tagged Rep 
proteins were generated by cloning of PCR amplified Rep fragments into 
either the pEGFP-C1 vector (Clontech) containing N-terminal FLAG tag or T7 
tag, respectively. Rep K372A mutants were generated by site-directed 
mutagenesis using primers SS100 and SS101. ZNF truncation mutants were 
generated by PCR amplification of aa 1-529 (Δ91/87), 1-558 (Δ63), or 1-577 
(Δ44), using either pND230 or pND227 as a template. The amplified 
fragments were then cloned into the N-terminal T7 vector described above 
using HincII and XmaI sites. 
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2.1.14.2 BirA*- Rep fusion constructs 
 Fusion of BirA* to the N-terminus of the Rep proteins was achieved by 
performing overlapping PCR between PCR-amplified BirA* and each of the 
PCR-amplified Rep proteins, with the inclusion of a 10x glycine linker. BirA* 
and each of the Rep sequences were amplified by PCR, after which 
overlapping PCR was used to fuse the BirA* fragment to the N-terminus of 
each Rep fragment. The resulting amplicons were cloned into pcDNA3.1+ 
using ApaI sites. 
 
2.1.14.3 WT AAV plasmids 
 The pDG plasmid is a tool for the production of recombinant and wt 
AAV. It contains all the adenovirus helper factors necessary for AAV 
production, as well as the AAV2 Rep and Cap ORFs (Grimm et al., 1998). 
 The mini-pDG plasmid was derived by Dr Els Henckaerts from pDG 
and contains only the AAV2 Rep and Cap ORFS. Mutagenesis to generate 
Rep-K372A for cloning into pAV2 was performed on this plasmid. 
 The pAV2 plasmid is infectious and contains the full WT AAV genome 
inserted between two BglII linkers (Laughlin et al., 1983). pAV2-RepK340H 
was derived from this plasmid (cloned by Dr. Martino Bardelli in the lab), and 
pAV2-RepK372A was cloned into this plasmid using the SfiI and HindIII 
fragment generated from the mini-pDG RepK372A variant.  
 
2.1.14.4 RUVBL1, RDBP, TCERG1, CPSF6, KAP1, PP1α, and NIPP1 
plasmids  
pC1-FLAG-wtKAP1 was a kind gift from Dr. Helen Rowe (UCL) and 
was used for the cloning of PCR-amplified wtKAP1 into untagged pcDNA3.1+ 
and the N-terminal T7-tagged vector described above. pEXN-CPSF6 was a 
kind gift from Dr. Gregory Towers (UCL). FLAG-tagged RUVBL1, RDBP, 
TCERG1, and PP1α were generated by cloning of PCR-amplified fragments 
from EST clones obtained from Genome Cube (clones IRAUp969F0818D 
{RUVBL1}; IRAUp969C0381D {RDBP}; IRCMp5012D00731D {TCERG1}; 
IRAUp969F0817D {PP1α}) into the N-terminal FLAG-vector described above. 
! 89!
GFP-NIPP1 was obtained from Dr. Angus Lamond (Trinkle-Mulcahy et al., 
2001), through Addgene (#44221).  
 
2.2 CELL CULTURE, TRANSFECTIONS, AND INFECTIONS 
2.2.1 Cell lines and viruses 
 Adherent HEK293T and HeLa cells were obtained from the America 
Tissue Culture Collection (ATCC). HeLa cells are derived from a human 
epithelial cervical adenocarcinoma (from the patient Henrieta Lacks), while 
HEK293T cells are human embryonic kidney cells immortalized with 
adenovirus E1 and E2 genes, and modified to contain the SV40 large T 
antigen.  Cells were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) (GIBCO 41966, Invitrogen) supplemented with 10% fetal bovine 
serum (FBS) (Invitrogen) plus 100 U/mL Pen/Strep (Gibco). Cells were 
cultured at 37oC and 5% CO2 in 10cm dishes (Corning). Cells were passaged 
every 2-3 days using 1ml TrypLE Express (GIBCO 12605, Invitrogen) so as 
to maintain the cells at ≤70% confluency. 
AAV2 and human adenovirus type 5 (Ad5) were produced and purified as 
previously described (Zeltner et al., 2010). 
 
2.2.2 Viral titration  
Infectious unit (IU) titer for wtAAV2 was determined by infectious 
center assay, based on similar principles as the standard plaque forming 
assay. Briefly, HeLa cells were infected with serial dilutions of wtAAV2 stock 
and coinfected with Ad5 at a multiplicity of infection (MOI) of 25 plaque-
forming units (PFU) per cell. 40h after infection, cells were harvested and 
applied to 0.45µm nylon membranes using a vacuum manifold, after which 
the membranes were denatured, UV cross-linked, and hybridized to a rep-
specific probe. The membranes were then washed at high stringency and 
exposed to a phosphoimager screen for 14-16h. For the titer calculation, 
each positive signal, corresponding to one infected cell and therefore to one 
IU, was counted, and the titer was calculated according to the volume and 
dilution of virus used for the infection. Vector genome (VG)-containing 
particle titer for wtAAV2 and rAAV was determined by quantitative real-time 
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PCR, using SYBR Green Jump Start Taq ready mix without MgCl2 (Sigma). 
Linearized pAV2 (for wtAAV2) or pTRUF11 (for rAAV) was used to set up a 
standard curve in 10-fold dilutions, ranging from 2ng to 0.002ng, and primers 
in the cap or GFP gene were used for wtAAV2 or rAAV, respectively. Plaque 
forming unit (PFU) titer for Ad5 was determined by standard plaque assay by 
Marcia Meseck at the Vector Core at Mount Sinai School of Medicine.  
 
2.2.3 Freezing and thawing of cells 
 For freezing of cells lines, at least 10ml of confluent cells were 
prepared in 10cm dishes for each desired cryovial. Cells were detached 
using 1ml of trypsin and pelleted by centrifugation at 1500 rpm for 5 minutes 
at 4oC, after which the medium was removed and the pellets placed on ice. 
Cells were then resuspended in 1ml ice-cold freezing buffer containing 50% 
FBS, 40% culture medium, and 10% DMSO (Sigma) and then immediately 
transferred to a pre-chilled 1.8ml labeled cryovial. Cryovials were initially 
stored at -80oC and after 24-48 hours the cryovials were moved to a liquid 
nitrogen tank. For thawing of cryopreserved cells, vials were thawed at 37oC, 
transferred to a 10ml tube, and 9ml of pre-warmed culture medium was 
gently added dropwise to wash the cells. Cells were pelleted at 1200 rpm for 
5 minutes and resuspended in 10ml pre-warmed DMEM with 10% FBS. Cells 
were left to recover in a 6-10cm dish for 24-48 hours.  
 
2.2.4 Transient plasmid transfections 
 For plasmid DNA transfection, 293T cells were transfected using 
polyethylenimine (PEI, Polysciences) at a density of 8 x 105 cells/ml of 
medium (e.g. 2ml medium/well of 6-well plate = 1.6 x 106 cells). For one well 
of a 6-well plate, 8µl of PEI was diluted in 40µl serum-free DMEM and 
allowed to incubate for 5 minutes at room temperature. In a separate tube, 
1µg of DNA was diluted in 40µl serum-free DMEM and then combined with 
the PEI/DMEM mixture and incubated for 20 minutes at room temperature 
before drop-wise addition to cells. Medium was replaced with fresh DMEM + 
10% FBS 6 h after transfection. For larger- and smaller-scale transfections, 





2.2.5 siRNA transfections 
In a 24-well format, 2 x 105 cells were transfected with 50nM 
(siKAP1.2 and siKAP1.4) or 60-100nM (siRDBP, siRUVBL1, siTCERG1, 
siCHD3, and siSETDB1) siRNA using 2µl DharmaFECT (Dharmacon) in 50µl 
Opti-MEM (Gibco). 6h later, medium was replaced with fresh DMEM + 10% 
FBS. 24 h after transfection, cells were re-plated into 12-well format. 36 h 
after transfection, cells were subjected to a second transfection as described 
above, using 4µl DharmaFECT in 100µl Opti-MEM and then used either in a 
p5 repression assay or AAV2 replication assay. For a list of siRNA 
sequences used in this thesis, please see Table 3, Appendix 1, pg. 248. 
 
2.2.6 Lentivector production 
The HIV-based lentiviral vector pC-SIREN, expressing either a hairpin 
targeting the 3’UTR of KAP1 (shKAP1; GATCCGCCTGGCTCTG 
TTCTCTGTCCTTTCAAGAGAAGGACAGAGAACAGAGCCAGGTTTTTTAC
GCGTG) or the corresponding empty vector (shEMPTY) were kind gifts from 
Dr. Helen Rowe (UCL). To produce virus-like particles, 2 x 107 293T cells 
were seeded in a T225 flask and transfected 24h later with 8µg of either pC-
SIREN-shKAP1 or pC-SIREN-shEMPTY, 6µg HIV Gag-Pol expression 
vector, and 6µg VSV-G expression vector using 200µl PEI in a total volume 
of 2ml serum-free DMEM. Transfection medium was replaced with fresh 
DMEM + 10% FBS 6h after transfection. Supernatants were harvested 48 
and 72 h after transfection, pooled and filtered through a 0.45µM filter, and 
frozen in 1mL aliquots at -80oC until use.  
 
2.3.7 Lentivector transductions for KAP1 depletion 
1 x 106 293T cells were transduced in a 6-well format using 1.2-1.6 mL 
of either shKAP1 or shEMPTY diluted with enough DMEM + 10% FBS to 
achieve the normal well volume of 2mL. 24h later, the transduction medium 
was removed, and cells were re-plated at a density of 5 x 105 cells/mL for 
infection with AAV2/Ad5 the next day. For larger- and smaller-scale 




2.2.8 AAV infection and transduction 
The same basic principle applied to all infections (using wtAAV2) and 
transductions (using rAAV). Briefly, cells were infected/transduced at 60-70% 
confluency in ~2/5 the normal well volume and incubated for 2h at 37oC to 
ensure maximal adsorption and infection/transduction efficiency. For rAAV 
transductions, the medium was replenished to the normal culture volume 2h 
after transduction and cells were harvested 48h after transduction for 
analysis. For wtAAV2 infections, Ad5 was added to infection medium 2h after 
AAV2 infection. 1h after Ad5 infection, the medium was replaced with the 
normal well volume of fresh DMEM + 10% FBS. Cells were harvested ~42h 
after infection, or when cells displayed optimal cytopathic effect (CPE), at 
which point all samples were harvested simultaneously. Optimal CPE is 
defined by cells that display a rounded and enlarged phenotype, as opposed 
to the normal “star-shaped” morphology of HEK293T cells, and which are 
beginning to detach but still appear bright and healthy. Cells that had 
completely lifted by the time of harvest were considered too advanced in the 
infection cycle and were excluded from analysis.  
 
2.3 DNA, RNA, AND PROTEIN EXTRACTION  
2.3.1 Total DNA extraction 
 For total/genomic DNA extraction, the QIAGEN DNeasy Blood and 
Tissue Kit was used as per manufacturer’s instructions with one additional 
step. Briefly, cells were pelleted and washed in PBS, followed by lysis and 
proteinase K digestion at 56oC to remove all proteins. An additional 10-
minute incubation at 70oC was added to ensure complete lysis of stable 
AAV2 particles. The DNA isolation/purification was performed using a silica-
based DNA purification in spin-columns using the kit buffers; DNA was eluted 





2.3.2 Total RNA extraction 
 RNA extraction was performed using the RNeasy Mini Kit (QIAGEN), 
following the manufacturer’s instruction, with some minor modifications. Cells 
were pelleted and washed in PBS, followed by lysis in 350µl of the supplied 
buffer. Lysates were homogenized using a syringe and 21G needle and 
column purified. RNA was eluted in 50µl RNAse-free water and aliquots were 
taken to determine the concentration using the Nanodrop spectrophotometer. 
For DNaseI treatment, 10µg of RNA were diluted in 85µl RNAse-free water 
and mixed with 10µl RDD buffer (supplied in kit) and 5µl DNaseI stock 
solution (QIAGEN DNAseI kit; prepared as per manufacturer’s protocol) and 
allowed to incubate for 20 minutes at room temperature. The DNaseI-treated 
RNA was then re-purified using the RNeasy kit following the RNA clean-up 
protocol. RNA was then stored at -80oC. 
 
2.3.3 Protein extraction 
 Volumes indicated are for one well of a 6 well plate. Cells were 
harvested and pelleted at 1500 rpm for 5 minutes, washed in PBS, and 
pelleted again. Cells were then lysed in ~50µl RIPA buffer (25mM Tris HCl 
pH 7.4, 150mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS, 1X 
protease inhibitor cocktail [Complete, Roche]) on ice for 10 minutes. Lysates 
were clarified by centrifugation at 13,000 rpm for 10 minutes at 4oC and then 
transferred to a clean 1.5ml tube. Proteins were either used right away or 
were stored at -80oC until use.  
 
2.4 DETECTION OF DNA AND RNA BY qPCR 
2.4.1 Quantitative PCR (qPCR) – absolute quantification 
For analysis of viral replication, total DNA was extracted using the 
Qiagen DNAeasy Blood and Tissue DNA extraction kit as described in 
section 3.3.1.  Viral DNA was quantified by qPCR using the SYBR Green 
JumpStart Taq ReadyMix for qPCR (Sigma-Aldrich) according to the 
manufacturer’s protocol using an ABI PRISM system (Applied Biosystems). 
The MgCl2 and primer concentrations were optimized previously to 4mM and 
0.25µM respectively (Zeltner et al., 2010). Linearized pDG was used to 
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prepare a standard curve for the quantification of AAV2 and Ad5, ranging 
from 1 x 102 – 1 x 108 molecules of dsDNA in 10-fold dilutions. Similarly, 
293T genomic DNA was used to prepare a standard curve of 0.2 – 5ng of 
DNA in 5-fold dilutions for the quantification of cyclophilin. Total extracted 
DNA was diluted 100-fold, and 1µl was used for quantification using primers 
specific for AAV2 cap, Ad5 100kd protein, and cyclophilin. The cycling 
parameters were the following: The cycling parameters were the following: A 
2 minute initial denaturation step at 94oC, followed by 40 cycles of a 
denaturation step at 94oC for 15 seconds, an annealing step at 58oC for 20 
seconds, and an elongation step at 72oC for 1 minute. 
 
2.4.2 Reverse transcription 
 For RNA analysis, RNA was reverse-transcribed using the High-
Capacity cDNA Reverse Transcription Kit (Applied Biosystems) following the 
manufacturer’s protocol. 1-2µg of RNA were diluted to a final volume of 10µl 
using RNAse-free water and then added to 10µl of a 2X RT master mix 
prepared by mixing the following provided reagents; 2µl 10X RT buffer, 0.8µl 
dNTP mix (100mM), 2µl 10X random primers, 1µl MultiScribeTM Reverse 
Transcriptase, and 4.2µl nuclease-free ddH2O. RT negative controls were 
prepared in parallel by excluding the 1µl MultiScribeTM Reverse Transcriptase 
and using 5.2µl nuclease-free ddH2O. Reverse transcription was performed 
using a thermal cycler with the following conditions: 10 minutes at 25oC, 2 
hours at 37oC, and 5 minutes at 85oC. cDNA was stored at 4oC for short-term 
storage or at -20oC for long-term storage, and was used for relative 
quantification by qPCR (see below).  
 
2.4.3 qPCR - relative quantification of cDNA 
 3’FAM-5’TAMRA-conjugated qPCR probes and qPCR primers 
designed to bind rep or cap were obtained from MWG Eurofins Operon (see 
table for details). cDNA was diluted 10-fold, and qPCR was performed using 
TaqMan universal PCR master mix (Life Technologies) and the custom 
primer-probe mix in a total reaction volume of 10µl. Primers were used at a 
final concentration of 900nM, and probes at 250mM. Relative expression 
levels were determined with the ΔΔCT quantification method (Schmittgen 
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and Livak, 2008), using 18S rRNA (Taqman Pre-developed assay reagents, 
human 18S rRNA, Applied Biosystems) as a housekeeping reference gene.   
 
2.5 DETECTION OF KAP1 BINDING TO THE AAV2 GENOME 
2.5.1 Chromatin immunoprecipitation (ChIP) 
Cells were cross-linked in their medium in 1% formaldehyde (10 
minutes at room temperature) and quenched with 0.125M glycine (5 minutes 
at room temperature) before being lysed in lysis buffer (1ml per 1x108 cells; 
50mM Tris-HCl, pH 8, 10mM EDTA, 1% SDS, 1x protease inhibitors) for 10 
minutes on ice. Lysates were sonicated on a Branson Sonifier 250 to obtain 
200- to 500-bp fragments (15 x 30-second cycles with 90-second intervals, 
output ~2). 10µl of the lysate was used to assess sonication efficiency by 
reverse cross-linking for 15’ at 95°C and then incubating with RNAse A for 30 
minutes at 37°C. DNA was extracted and visualized on a 1.5% agarose gel. 
The remaining lysate was clarified at 13,000 rpm for 10 minutes at 4 
degrees. The equivalent of 2x106 cells was diluted 25-fold in RIPA buffer 
(50mM Tris pH8, 150mM NaCl, 2mM EDTA, pH 8, 1% NP-40, 0.5% sodium 
deoxycholate, 0.1% SDS, 1x protease inhibitors) and pre-cleared with 80µl 
protein G agarose beads (pre-blocked in 0.1mg/mL BSA for 30 seconds) for 
2h on a rotator at 4°C. For the immunoprecipitation, primary antibodies were 
added to the lysates and incubated for 1h on a rotator at 4°C (5µg IgG 
[Abcam; ab37415], 4µg H3K9me3 [Abcam; ab8893], 10µg KAP1 [Abcam; 
ab10483]), before adding 80µl pre-blocked beads and incubating overnight 
on a rotator at 4°C. Beads were harvested and washed 4 times in RIPA 
buffer, 4 times in high salt wash (20mM Tris-HCl, pH 8, 1mM EDTA, 500mM 
NaCl, 0.5% NP-40, 1X protease inhibitors), 4 times in TE buffer (10mM Tris-
HCl, pH8, 1mM EDTA), and eluted in 160ml elution buffer (100mM HaHCO3, 
1% SDS) for 15 minutes at 30°C. Cross-links were reversed by adding NaCl 
to a final concentration of 0.2M and incubating overnight at 67°C. Eluates 
were then incubated with 2µl RNase A (10mg/mL) and 2µl proteinase K 
(20mg/mL) at 45oC for 1h. DNA was purified using a PCR purification kit 
(Qiagen) and analyzed by qPCR using primers specific for GAPDH, ZNF180, 




Purified chromatin was diluted 10-fold and quantified by real-time PCR 
using the SYBR Green JumpStart Taq ReadyMix for qPCR (Sigma-Aldrich) 
using an ABI PRISM system (Applied Biosystems). Primer sequences for 
GAPDH, ZNF180, ZNF274, and the various regions of the AAV2 genome are 
listed in Table 1, Appendix 1, pg. 239. CT values for “10% input” were 
adjusted by subtracting 3.322 cycles to correct for the 10-fold dilution factor 
(https://www.thermofisher.com/us/en/home/life-science/epigenetics-
noncoding-rna-research/chromatin-remodeling/chromatin-
immunoprecipitation-chip/chip-analysis.html). Percent input was then 
calculated as follows: 100 x 2^-(CT of adjusted 10% input - CT of ChIP-ed 
DNA). Percent input for each antibody was then normalized to values for IgG 
to calculate final fold enrichment.  
 
2.6 PROTEIN DETECTION 
2.6.1 Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) 
 2-4µl of protein extracts in RIPA buffer (in section 2.3.3) were mixed 
with 2µl of 6X Laemmli loading buffer (0.8g SDS, 5mL Tris pH 6.8, 5mL 
glycerol, 5% beta-mercaptoethanol, trace of bromophenol blue) and adjusted 
to a total volume of 12µl with ddH2O. Samples were denatured by boiling at 
95oC for 10 minutes and then separated on 6% or 12% polyacrylamide mini-
gels. The percentage was determined by altering the volume of 40% 
Acrylamide (Acrylamide:Bis-Acrylamide 29:1, Fisher Scientific) and ddH2O 
added to a solution of 1.5M Tris-HCl pH8.8, 0.4% SDS, 3.3µl/mL of 10% 
ammonium persulphate (APS, Sigma), and 0.6µl/ml of N,N,N’N’ – 
Tertramethylethylenediamine (TEMED, Sigma). Stacking gels consisted of 
4.5% Acrylamide, 0.5M Tris-HCl pH6.8, 0.4% SDS, 5µl/ml 10% APS, 1µl/mL 
TEMED, and ddH2O. Samples were loaded into gels immersed in running 
buffer (1X Tris-glycine and 1% SDS in ddH2O prepared from a 10X Tris-
glycine solution [288g glycine and 61g Tris base dissolved in 2L ddH2O]) and 
run at 80V until the samples reached the separating gel, after which the 
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voltage was increased to 120V until samples reached the bottom of the gel.  
5µl of Precision Plus Dual Color Standard (Bio-Rad) was run in parallel and 
used as a marker for molecular weights.  
 
2.6.2 Western blotting and protein detection 
 Proteins resolved in SDS-PAGE were transferred to a nitrocellulose 
0.45µM membrane (Hybond-C Extra nitrocellulose, Amersham Biosciences) 
using a BioRad Mini Trans-Blot transfer system with transfer buffer (100mL 
10X Tris-Glycine, 200mL methanol, 700mL ddH2O) at 16V overnight or at 
100V on ice for 1-2 hours. Membranes were blocked with either 5% (w/v) 
skimmed dried milk, or 2.5% (w/v) bovine serum albumine (BSA) for 
phospho-antibodies, in PBST (0.1% Tween-20, Sigma, in 1X PBS) for 45 
minutes at RT. Primary antibodies were added directly to the blocking 
medium and allowed to incubate for 2h at RT or overnight at 4oC, after which 
membranes were washed 3 x 10 minutes in PBST and incubated with HRP-
conjugated anti-mouse or anti-rabbit IgG (BioRad) for 1h at RT. After a 
further 3 x 10-minute washes in PBST, membranes were developed using 
the West Pico Enhanced Chemiluminescent Substrate (Thermo Scientific) 
prepared according to the manufacturer’s protocol. After a 5-minute 
incubation in a total volume of 2mL of substrate, membranes were placed 
between two clear plastic sheets and visualized using an Image Quant 
LAS4000 (GE Healthcare) chemiluminescence imaging system.  For a list of 
antibodies used in this thesis, please see Table 4, Appendix 1, pg. 249.  
 
2.6.3 Fluorescence-assisted cell sorting (FACS) analysis 
 GFP transfected or transduced cells were trypsinised, washed in PBS, 
passed through a cell strainer to ensure single-cell separation, and analysed 
for protein expression on a BD FACSCanto II flow cytometer using the BD 






2.7 ANALYSIS OF PROTEIN-PROTEIN INTERACTIONS 
2.7.1 Proximity-dependent biotin identification (BioID) 
Ten 10cm dishes (293T) per condition were transfected using 6µg 
DNA and 50µl PEI in 500µl SF medium per dish. 6h post-transfection, the 
medium was replaced with fresh DMEM + 10% FBS, and D-Biotin (Life 
Technologies) was added to a final concentration of 100µM. 48h post-
transfection, cells were washed twice in cold PBS to remove remaining biotin 
and lysed in 1 ml lysis buffer (50 mM Tris, pH 7.4, 500 mM NaCl, 0.4% SDS, 
5 mM EDTA, 1 mM DTT, and 1x Complete protease inhibitor). Lysates were 
sonicated for 20 seconds, on a Branson Sonifier 250, output ~2, followed by 
the addition of Triton-X-100 to a final concentration of 2%. Lysates were 
sonicated another 20 seconds after which 1ml of 50mM Tris HCL pH 7.4 was 
added before a third sonication of 20 seconds. Lysates were clarified at 
13,000 rpm for 5 minutes at 4oC, and the supernatants were incubated with 
200µl avidin-agarose beads (Fisher) for 3h at 4oC. The beads were then 
collected and washed two times by gravity filtration in 1ml wash buffer 1 (2% 
SDS). This was repeated once with wash buffer 2 (0.1% deoxycholate, 1% 
Triton X-100, 500mM NaCl, 1 mM EDTA, and 50mM Hepes, pH 7.5), once 
with wash buffer 3 (250mM NaCl, 0.5% NP-40, 0.5% deoxycholate, 1mM 
EDTA, and 10mM Tris, pH 8.1), and twice with wash buffer 4 (50mM Tris, pH 
7.4, and 50mM NaCl). Proteins were eluted from beads by boiling in 50µl 2X 
Laemmli SDS buffer saturated with biotin at 98oC for 10 minutes and sent for 
analysis by LC-MS/MS. 
 
2.7.2 Liquid chromatography mass spectrometry (LC-MS/MS) 
 Mass spectrometry was performed by Steven Lynham at the KCL 
proteomics facility at Denmark Hill. In-gel reduction, alkylation and digestion 
with trypsin were performed prior to subsequent analysis by mass 
spectrometry. Cysteine residues were reduced with dithiothreitol and 
derivatised by treatment with iodoacetamide to form stable carbamidomethyl 
derivatives. Trypsin digestion was carried out overnight at RT after initial 
incubation at 37oC for 2h. Peptides were extracted from the gel pieces by a 
series of acetonitrile and aqueous washes. The extract was pooled with the 
! 99!
initial supernatant and lyophilised. Each sample was then resuspended in 
10µL of 50mM ammonium bicarbonate and analysed by LC-MS/MS. 
Chromatographic separations were performed using an EASY NanoLC 
system (ThermoFisherScientific, UK). Peptides were resolved by reversed 
phase chromatography on a 75µm C18 column using a three step linear 
gradient of acetonitrile in 0.1% formic acid. The gradient was delivered to 
elute the peptides at a flow rate of 300 nL/min over 120 min. The eluate was 
ionised by electrospray ionisation using an Orbitrap Velos Pro 
(ThermoFisherScientific, UK) operating under Xcalibur v2.2. The instrument 
was programmed to acquire in automated data-dependent switching mode, 
selecting precursor ions based on their intensity for sequencing by collision-
induced fragmentation using a Top20 CID method. The MS/MS analyses 
were conducted using collision energy profiles that were chosen based on 
the mass-to-charge ratio (m/z) and the charge state of the peptide. Raw 
mass spectrometry data were processed into peak list files using Proteome 
Discoverer (ThermoScientific; v1.4.0.288) 
 
2.7.2 Immunoprecipitation (IP) 
 293T cells were transfected in a 6-well format with 200ng of Rep-
expressing constructs, and 250ng of FLAG-PP1α or FLAG-GFP using 8µl 
PEI in 80µl serum-free DMEM. 2 wells per condition were used for IP. 48h 
after transfection, cells were trypsinised in 200µl TrypleE and harvested 
using ice cold 1X PBS + 10% FBS. Cells were pelleted at 1500 rpm for 5 
minutes at 4oC and then lysed in RIPA buffer for 10 minutes on ice. Lysates 
were clarified at 1000 x g for 10 minutes at 4oC and transferred to clean 
1.5ml tubes. 50µl of lysate was separated at this point to use as an input 
control, and the remaining lysate was incubated with the appropriate 
antibody for 1.5h on a rotator at 4oC. 40µl of protein G agarose beads 
(Pierce) were added and incubated for a further 3h. Beads were washed 4 
times in 500µl RIPA buffer, and proteins were eluted from beads by boiling at 
95oC for 10 minutes in 60µl 2X Laemmli buffer. 50µl of 2X Laemmli buffer 





2.7.3 Cross-linked immunoprecipitation (CL-IP) 
In a 6-well format, 293T cells were transiently transfected with the 
appropriate constructs using 8µl PEI in 80ul SF medium (200ng Rep-
expressing constructs; 750ng FLAG-GFP, FLAG-KAP1, GFP-NIPP1, FLAG-
RDBP, FLAG-RUVBL1, FLAG-TCERG1, or CPSF6). 48 hours after 
transfection, cells were harvested in trypsin, washed in cold PBS + 10% FBS, 
and fixed in 350µl 0.05% formaldehyde for 10 minutes at 37oC. Cells were 
washed again in cold PBS and incubated in 350µl 0.125M glycine, pH 7, for 5 
minutes at RT in order to quench the reaction, before being lysed in 500µl 
cross-linked IP buffer (150mM NaCl, 10mM HEPES pH 7, 6mM MgCl2, 2mM 
DTT, 10% glycerol, 1X protease inhibitors, 200µM sodium orthovanadate) on 
ice for 10 minutes. Lysates were subjected to three 10-second cycles of 
sonication on a Branson Sonifier 250, output ~2, and clarified for 10 minutes 
at 4oC. 20µl of lysate was kept for an input control, and 420µl was used for 
IP.  For the IP, 40µl protein G agarose beads (Pierce) per sample were 
washed 3 times in cross-linked IP buffer and incubated with 2µg mouse anti-
FLAG (Sigma, F7425) or anti-T7 antibody, or 7µg anti-CPSF6 antibody for 
1.5h on a rotator at 4oC before being added to 420µl of cell lysate and 
incubated a further 3-4 h. Beads were harvested and washed 4 times in 500 
µl RIPA buffer, and cross-links were reversed in 25µl reverse cross-link 
buffer (10mM EDTA, 5mM DTT, 1% SDS) at 65oC for 45 minutes. Proteins 
were eluted from beads by adding 30µl of 2X Laemmli loading buffer and 
boiling at 95oC for 10 minutes before being analyzed by western blot.  
 
2.8 IMAGING 
2.8.1 Transfection and infection  
293T cells were seeded at a density of 1x105 on poly-L-lysine (Sigma) 
coated coverslips (autoclaved coverslips were placed in 24-well plate, 
incubated for 10 minutes with 400µl poly-L-lysine, and washed once with 1X 
PBS) in 24-well plates the day prior to transfection. 4h prior to transfection, 
DMSO (Sigma) or ATMi (Stratech Scientific Ltd) was added to the 
appropriate wells to a final concentration of 10µM. Cells were then 
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transfected with 20ng of empty vector or pRep78-GFP (a kind gift from Prof. 
Cornel Fraefel at the University of Zurich) using 2µl Lipofectamine 2000 in 
50µl serum-free Opti-MEM. The next day, cells were infected with Ad5 (2 
PFU/cell) in a total volume of 160µl for 1h, after which the medium was 
replaced for fresh DMEM + 10% FBS. Cells were fixed 24h after Ad5 
infection for staining and visualization (see below).  
 
2.8.2 Staining and visualization 
 Cells were fixed in 4% PFA for 10 minutes at RT, washed 3 times for 5 
minutes in PBS, permeabilized in 0.1% Triton-X-100 for 10 minutes at RT, 
and washed again 3 times for 5 minutes in PBS. Cells were then incubated 
with primary antibody (anti-p-KAP1-S824; 1:1000) diluted in PBS + 1% BSA 
for 2h at RT, washed, and then incubated with secondary antibody 
(Biolegend; rabbit IgG2b-AlexaFluor 594, 1 µg/ml (1:1000)) diluted in PBS for 
1h at RT. Cells were then washed a final time and mounted in Prolong Gold 
Antifade Reagent (Invitrogen). Images were visualized using an Eclipse Ti-E 
Inverted confocal microscope and analyzed using NIS Elements C software. 
 
2.9 ANALYSIS OF AAV2 LIFE CYCLE 
2.9.1 Analysis of WT AAV2 infection in KAP1-depleted cells 
Control or KAP1-depleted 293T cells (section 3.2.3) were infected at 
~80% confluency by adding AAV2 at the stated MOI in ~2/5 the normal well 
volume. 2h after AAV2 infection, Ad5 was added at an MOI of 2 PFU/cell, 
and medium was replaced with fresh DMEM + 10% FBS 1h after Ad5 
infection. Cells were harvested for DNA, RNA, and protein extraction ~42h 
after infection, or when they displayed optimal cytopathic effect (CPE) 
(described in section 2.2.7). 
 
2.9.2 Anlysis of AAV2-Rep-K372A infection  
8 x 106 293T cells (untreated, control, or KAP1-depleted where 
appropriate) seeded in a 10cm dish were transfected with 16µg of pAV2-
Rep-WT, pAV2-Rep-K340H, or pAV2-Rep-K372A using 90µl of PEI and 
500µl SF medium. 4h later, cells were infected with 2 PFU/cell of Ad5, and 
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the medium was replaced with fresh DMEM + 10% FBS 2h after Ad5 
infection. Cells were harvested for DNA, RNA, and protein extraction 72h 
after transfection.  
 
2.10 ANALYSIS OF PHOSPHORYLATED KAP1-S824  
Phosphorylation of KAP1-S824 was investigated in 293T cells that 
were either infected with AAV2 and/or Ad5, or transfected with various Rep-
expressing constructs using linear PEI. Where relevant, cells were pretreated 
with either DMSO or 10µM ATMi 4h prior to infection/transfection, and 
inhibitors were maintained throughout. Cells were harvested for western blot 























Chapter 3. Application of BioID for the investigation of interactions 
between the small AAV2 Rep proteins and components of the general 




The duality of the biphasic AAV life cycle requires an exceptional 
degree of complexity from what is genomically speaking a simple virus. As 
such, the simplicity of the AAV genome belies a complex strategy for 
transcriptional regulation involving the interplay of host cellular, helper virus, 
and AAV Rep proteins. In the absence of helper virus, the three AAV 
promoters are repressed through the combined efforts of the cellular factors 
YY1 and MLTF, and the large AAV Rep proteins (Beaton et al., 1989; Chang 
et al., 1989; Kyöstiö et al., 1994; Shi et al., 1991). AAV recruits YY1 and 
MLTF to binding sites in its p5 promoter where they mediate repression in 
the absence of helper virus factors; this consequently represses all three 
promoters as p19 and p40 are transactivated through p5 activity. 
Simultaneous binding of the large Rep proteins to both a repressive RBS in 
the p5 promoter and an activating RBS in the ITR (Labow et al., 1986) acts to 
balance repression such that the basal levels of rep expression necessary to 
mediate latency-associated transcriptional repression and viral integration 
are still maintained. Upon coinfection, helper virus factors such as Ad E1A 
interact with YY1 and MLTF, relieving repression of p5 (Chang et al., 1989; 
Shi et al., 1991; Tratschin et al., 1986) and leading to the transactivation of 
all three AAV promoters  (Redemann et al., 1989) in a manner that supports 
higher levels of expression from p40 than from either p5 or p19 (Mouw and 
Pintel, 2000). As infection progresses, the disproportionate accumulation of 
spliced Rep variants results in an autoregulatory feedback loop that serves to 
maintain optimal levels of gene expression (Pereira et al., 1997).  
Transcriptional repression of the AAV promoters by Rep in the 
absence of helper virus has been shown to occur via two independent 
mechanisms: (1) one mechanism present only in the large Rep proteins, 
which relies on the presence of a functional RBS within the target site 
promoter, and (2) repression by all four Rep proteins, which requires only an 
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intact NTP-binding site within the Rep proteins (Kyostio et al., 1995; Kyöstiö 
et al., 1994). Structural and biochemical studies suggest that binding of the 
RBS in the p5 promoter by the OBD-containing large Rep proteins followed 
by the assembly of Rep helicase complexes may structurally hinder either 
the start of transcription or the binding of necessary transcriptional activators 
(Chiorini et al., 1994; Dutheil et al., 2014; Zarate-Perez et al., 2012). Optimal 
repression of p5 is also dependent on a functional Rep NTP-binding motif, 
suggesting that the efficiency of helicase formation and/or its DNA affinity 
may also play a role (Dutheil et al., 2014). In contrast, repression of the p19 
promoter is dependent only on the NTP-binding site. Furthermore, the small 
Rep proteins, which do not contain an OBD and which only form transient 
helicase complexes, are also able to mediate transcriptional repression of all 
three AAV promoters, indicating the potential reliance of this pathway on 
interactions between cellular factors and the Rep ATPase domain (Dutheil et 
al., 2014; Kyöstiö et al., 1994).  
Intriguingly, Rep-mediated repression has also been observed for 
various heterologous promoters. All four of the Rep proteins were shown to 
repress transcription from the PPP1R12C promoter within the target cellular 
integration site, AAVS1, via mechanisms similar to what has been observed 
for the AAV p5 promoter (Dutheil et al., 2014). Similarly to p5, repression of 
the PPP1R12C promoter was more efficient by the large Rep proteins than 
by the small Rep proteins, which could be attributed to binding of the cellular 
RBS by the N-terminal OBD of the large Rep proteins. However, Rep40 and 
Rep52 were also shown to repress both p5 and the PPP1R12C promoter in a 
manner dependent on the NTP-binding motif. Furthermore, the PPP1R12C 
promoter displays bidirectional repression activity, and repression of the 
antisense promoter by all four Rep proteins was dependent only on the NTP-
binding motif (Dutheil et al., 2014).  
Similarly, Rep-mediated repression has been observed for various 
heterologous viral promoters. Rep78, Rep68, and Rep52 are able to repress 
transcription from the human immunodeficiency virus long terminal repeat 
(HIV LTR), the human papillomavirus type 18 upstream regulatory region 
(HPV18 URR), and the Ad major late transcription promoter (AdMLP) (Hörer 
et al., 1995; Needham et al., 2006). Repression of the HIV LTR and the 
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HPV18 URR was dependent on the NTP-binding motif, and mutational 
analysis of the HPV18 URR revealed that several cis acting sequences were 
necessary for this repression, supporting the notion that Rep protein 
interactions with cellular transcription factors are involved (Hörer et al., 
1995). Direct binding of Rep78 to the TAR element of the HIV LTR was also 
demonstrated however, suggesting that repression of HIV may occur via both 
mechanisms (Batchu and Hermonat, 1995). Repression of AdMLP was 
shown to be dependent on both the NTP-binding site as well as the direct 
interaction of the large Reps with a 55 bp sequence in the AdMLP and TBP 
bound adjacent to this site, provoking the hypothesis that Rep interferes with 
PIC formation of RNA pol II transcription (Needham et al., 2006). In addition, 
Rep78 was shown to down-regulate expression of several proto-oncogene 
promoters, such as those of c-Myc, c-Fos, H-Ras, and c-sis/platelet derived 
growth factor B (Hermonat, 1994, 1991; Wonderling and Owens, 1996).  
While a role for the Rep ATPase domain in the repression of multiple 
promoters has been clearly demonstrated, the exact mechanism through 
which this occurs has yet to be fully described. One possible candidate 
involved in repression by the Rep proteins is the human positive cofactor 4, 
or PC4.  PC4 was first identified as a transcriptional coactivator by virtue of 
its ability to activate transcription in the presence of various sequence-
specific TF (Ge and Roeder, 1994; Kretzschmar et al., 1994), however it was 
later demonstrated to also have an intrinsic repressive quality arising from its 
capacity to structurally stabilize the formation of RNA pol II PIC, thereby 
preventing the activation of elongation (Malik et al., 1998). This repression is 
subsequently reversed by phosphorylation/inactivation of PC4 in the 
presence of the general transcription factors TFIID and TFIIH. Both Rep68 
and Rep78 were shown to bind PC4 in a manner dependent on an intact 
NTP-binding site in vivo (Weger et al., 1999). The accumulation of active, 
nonphosphorylated PC4, induced through overexpression, resulted in 
downregulation of all three AAV2 promoters suggesting that PC4 is involved 
in the repression of AAV2 gene expression (Weger et al., 1999). Given the 
role for active, nonphosphorylated PC4 in PIC stabilization and the fact that 
AAV promoters contain TATA boxes, it is conceivable that repressive PC4-
mediated PIC at AAV promoters are stabilized through interactions with Rep. 
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Preliminary knockdown experiments in our lab however showed no effect of 
PC4 depletion on AAV transcription.  
Similarly, repression could be the result of interactions between Rep 
and other general components of the RNA pol II holoenzyme, including the 
general transcription factors TFIIA, -B, -D, -E, -F, and -H. For example, Rep 
interaction with TBP, a component of TFIID, has been shown to inhibit 
adenovirus major late transcription factor (Hernonat et al., 1998; Needham et 
al., 2006). Other possibilities include – (1) inhibition of gene expression 
through interference with splicing mechanisms, and (2) modulation of DNA 
structure and/or higher order chromatin structure. Several of the known Rep 
interaction partners have roles in modifying DNA structure, including PC4, 
HMG1, and SP1, and a comprehensive analysis of proteins in Rep 
complexes by Nash et al. identified numerous splicing /RNA-binding proteins.  
Additionally, this work identified several proteins involved in regulating 
transcription through the modulation of higher order chromatin structure, 
including TIF1α and RuvB-like 1. The possibility that Rep may interfere with 
such essential transcriptional processes as the formation of RNA pol II PICs 
poses the question of how AAV can remain innocuous during latency. Even 
more intriguingly, the observation that the Rep proteins can regulate 
expression from the PPP1R12C promoter suggests that AAV may have 
coevolved with its host in such a way as to maintain control of its own 
integration site (Dutheil et al., 2014). In either case, knowledge of which 
cellular proteins are involved in mediating repression by the Rep proteins will 
have broad implications for our understanding of AAV interactions with both 
host and helper virus.  
Common methods for the screening of novel protein interactions can 
be limited in their scope by an inherent dependence on both the persistence 
and strength of protein interactions. Here, we investigated interactions 
between the small Rep proteins and cellular proteins in order to identify a 
potential mechanism for Rep-mediated repression of cellular promoters using 
a screening method known as Biotin Identification (BioID) (Roux, 2012). 
BioID exploits the fusion of a promiscuous biotin ligase, BirA*, to a bait 
protein in order to trigger proximity-dependent biotinylation of neighboring 
proteins, thus allowing for the identification of a much broader scope of 
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protein associations than achievable with conventional affinity purification. 
This method was developed and validated in a study in which BirA* was 
fused to the well-characterized intermediate filament protein, lamin-A (LaA) 
(Roux et al., 2012). This study demonstrated that the BirA*-LaA fusion 
protein was correctly targeted to the nuclear lamina, where it led to the 
specific biotinylation of proteins associated with the nuclear envelope (NE), in 
contrast to the nucleoplasmic biotinylation that occurs in the presence of 
BirA* alone. The investigators were able to identify multiple known interaction 
partners of LaA, as well as an uncharacterized interaction partner later 
named SLAP75 (Roux et al., 2012). One key attribute of this approach lies in 
its detection of protein-protein interactions within their natural cellular 
environment, thus avoiding problems associated with the incorrect folding or 
post translational modification of bait/prey proteins, as can be the case in the 
commonly used yeast two hybrid (Y2H) approach. In addition, BioID 
sidesteps the issue of protein solubilization that is associated with traditional 
affinity purification methods, which may not be compatible with preserving 
weak protein interactions. As the biotinylation of vicinal proteins occurs prior 




















3.2.1 BirA*-Rep fusion proteins are stable and retain transcriptional 
regulation and biotin ligase activity.  
To generate BirA*-Rep bait proteins for BioID, we fused cMyc-tagged 
BirA* (BirA*) to the N-terminus of both Rep40 and Rep52 by overlapping 
PCR. The equivalent fusions were generated between BirA* and the 
repression-deficient NTP-binding mutants, Rep40-K340H and Rep52-K340H, 
to use as negative controls for transcriptional repression (Chejanovsky and 
Carter, 1990). By comparing results obtained from the screens using BirA*-
Rep40 and BirA*-Rep52 with their NTP-binding mutant counterparts, we 
hoped to narrow down our list of potential candidates. To ensure each fusion 
protein was stable and expressed at similar levels, 293T cells were 
transiently transfected with plasmids expressing fusion or WT Rep proteins. 
Cells were harvested 48 h after transfection and analyzed by western blotting 
using anti-Rep and anti-c-Myc antibodies for the detection of BirA* (Figure 
12A). Rep40 and BirA*-Rep40 expression was equivalent, as was that of 
Rep40-K340H and BirA*-Rep40-K340H. The higher expression levels 
displayed by the K340H mutants was expected due to the decreased 
capacity of these proteins to autoregulate. Both BirA*-Rep52 and BirA*-
Rep52-K340H expressed less efficiently than their unfused counterparts, 
however the lack of any observable degradation products suggested that the 
proteins were stable. Blotting with anti-c-Myc confirmed BirA* stability. 
Additionally, c-Myc expression levels were equivalent for all four of the fusion 
constructs.  
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Figure 12. Functional validation of Rep activity in BirA*-Rep fusion proteins 
(A) 293T cells were either mock transfected (MT) or transfected with the indicated Rep or 
BirA*-Rep fusion protein, and protein expression levels were analyzed by western blotting 
48h after transfection using anti-Rep and anti-cMyc antibodies. (B) The regulatory activity of 
the fusion proteins was determined by their ability to repress the AAV2 p5 promoter. 293T 
cells transfected with a p5-mCherry reporter construct and each of the BirA*-Rep fusion 
constructs, or each WT Rep proteins, were harvested 48h after transfection, and p5 activity 
was determined by western blotting for mCherry. Rep68 was used as an additional control 
for repression. 
 
To confirm that the fusion proteins retained their regulatory function, 
we assessed their ability to repress mCherry expression from a reporter 
construct in which mCherry is driven by the AAV2 p5 promoter. p5-mCherry 
was transiently cotransfected in 293T cells with each of the fusion proteins, 
or the respective Rep proteins for comparison. Rep68 was used as an 
additional positive control for repression. Cells were harvested 48 h after 
transfection, and p5 activity was assessed by western blot for mCherry 
(Figure 12B). Repression of p5 by BirA*-Rep40 was diminished as compared 
to Rep40 and appeared similar in efficiency to that of the repression-deficient 
Rep40-K340H mutant. However, BirA*-Rep40 repressed p5 more efficiently 
than BirA*-Rep40-K340H, suggesting that the overall activity of the Rep40 
fusion proteins was diminished rather than that the fusion proteins were not 
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functional. While repression of p5 by BirA*-Rep52 was also marginally less 
efficient than by Rep52, the effect was much less apparent than with the 
Rep40-based constructs.  
Having confirmed that the Rep proteins retained their regulatory 
function, we next sought to confirm the activity of BirA*. Each construct was 
transiently transfected into 293T cells, with or without the addition of 100µM 
free biotin, and cells were harvested 48h after transfection for protein 
extraction. Biotinylated proteins were enriched using streptavidin agarose 
beads and were visualized by western blotting using avidin-peroxidase 
(Figure 13). A clear abundance of biotinylation was evident with all four 
fusion proteins, confirming that the biotin ligase activity of BirA* remained 
intact. Surprisingly however, no clear differences were observable between 
the K340H mutant and wild-type Rep fusion proteins. The strength and 
abundance of an interaction however is not necessarily reflective of its 
biological significance, and it is possible that differences in bands not visible 
by western blot would be detected by mass spectrometry analysis.  
 
  
                   
Figure 13. BirA* activity in BirA*-Rep fusion proteins 
293T cells transfected with each of the BirA*-Rep fusion proteins, in the presence or 
absence of free biotin, were harvested 48h after transfection. Biotinylated proteins were 
enriched using avidin agarose beads and biotin ligase activity of BirA* was determined by 
western blotting using avidin peroxidase. 
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3.2.2 BioID identifies various candidates of interest as novel potential 
interaction partners for the AAV2 Rep proteins. 
 We next generated samples of biotinylated proteins for analysis by 
LC-MS/MS. 293T cells were transiently transfected with either BirA*-Rep52 
or BirA*-Rep52-K340H as described above and lysed 48h after transfection. 
Mock-transfected (MT) 293T cells were processed in parallel as a control. 
For these experiments, ten confluent 10-cm dishes were used per condition. 
Biotinylated proteins were captured using streptavidin agarose beads, 
rigorously washed, and bound proteins were analyzed by mass 
spectrometry. The efficiency of biotinylation was verified by western blotting 
as described above prior to LC-MS/MS analysis (Figure 14). A list of all the 
proteins identified by the two pull downs is shown in Table 5 in Appendix 2, 
pg. 250. As expected, virtually no proteins were identified in the MT sample, 
with the exception of trypsin and serum albumin. After applying a peptide 
identity confidence threshold of 95% and a minimum requirement for two 
identified peptides to the list of hits, proteins were categorized based on their 
cellular function (Figure 15). 
 
                                    
 
 
Figure 14. Qualitative analysis of biotinylated samples for mass spectrometry 
analysis. 





       
 
Figure 15. Proteins identified in BirA*-Rep52 and BirA*-Rep52K340H BioID screens.  
Proteins were categorized based on cellular function after applying a peptide identity 
threshold of 95% and a minimum requirement of 2 peptides. 
a Denotes candidates chosen for further downstream analysis.   
 
A multitude of factors involved in RNA metabolism and transcriptional 
regulation were identified, as well as several proteins involved in the DNA 
damage response. Surprisingly however, there was no clear difference in 
interaction profiles between BirA*-Rep52 and BirA*-Rep52-K340H; it 
appeared in fact that BirA*-Rep52-K340H supported more interactions than 
its wild-type counterpart, rendering it unusable as the control it was intended 
to be. As a result, we considered proteins identified with either BirA*-Rep52 
or BirA*-Rep52-K340H for downstream analysis. Several of our hits were in 
fact proteins previously identified as Rep interaction partners by other 
groups, such as RUVBL1, RDBP, SNW1, and MDC1 (Cervelli et al., 2008; 
Nash et al., 2009), lending support to the quality and coherence of our 
results. In the absence of our intended negative control however, we 
selected candidates on which to focus based on their cellular function in 
transcriptional regulation as well as on any previously known association with 
viral elements. RUVBL1 is thought to act as a key assembly factor for a 
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variety of biological processes, including transcriptional regulation, and is a 
known component of the ION80 complex involved in chromatin remodeling 
(Chen et al., 2011). Furthermore, it has been shown to interact with YY1 (Wu 
et al., 2007), a transcription factor known to regulate AAV2 p5. The negative 
elongation factor RDBP, one of five subunits of the NELF complex, stabilizes 
proximal-promoter pausing during transcription by RNA Pol II (Yamaguchi et 
al., 1999) and thus represents another candidate potentially involved in Rep-
mediated transcriptional regulation. TCERG1 and SF1 cooperate to 
physically couple the process of transcriptional elongation with RNA splicing; 
TCERG1 binds the CTD of RNA Pol II and recruits SF1, which then targets 
nascent transcripts for degradation (Goldstrohm et al., 2001). Both TCERG1 
and SF1 were identified in our screen. Of additional interest, TCERG1 has 
previously been linked to Tat-dependent transcriptional regulation of HIV-1 
(Coiras et al., 2013). The pre-mRNA processing factor CPSF6 also caught 
our interest, however not for its role in RNA metabolism but rather for its 
recently identified role in HIV-1 infection. During the early stages of HIV-1 
infection, CPSF6 binds the HIV-1 capsid, preventing premature release of 
viral RNA and onset of reverse transcription, thus avoiding immune detection 
by cytoplasmic pattern recognition receptors (PRRs). 
Of most interest however was the identification of the transcriptional 
corepressor KAP1, which will be discussed further in chapters 4, 5, and 6. 
These top hits were later confirmed in screens performed with BirA*-
Rep40/Rep40-K340H, BirA*-Rep68-K340H, and BirA*-Rep78-K340H. 
Complete lists of peptides identified by BioID in these screens are shown in 
Tables 6 and 7 in Appendix 2, pg. 255 and 258. 
 
3.2.3 Interactions between RUVBL1, RDBP, and TCERG1, and Rep52 are 
not essential for Rep-mediated transcriptional regulation. 
 To confirm the interaction between Rep52 and the chosen candidates 
of interest, we first repeated BioID in the context of exogenously expressed 
FLAG-tagged candidate proteins. cDNA of RUVBL1, RDBP, and TCERG1 
derived from EST clones was cloned into expression vectors containing an 
N-terminal FLAG tag, and expression of each construct was verified by 
transient transfection of 293T cells followed by western blot analysis of cell 
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lysates with anti-FLAG antibody. FLAG-tagged RDBP (expected size ~50kD) 
and RUVBL1 (expected size ~50kD) expressed efficiently and without any 
observable degradation of the tagged proteins (Figure 16, A and B). FLAG-
TCERG1 (expected size ~150kD) expression was less consistent, with all 
three clones tested showing considerable degradation (Figure 16C). 
Furthermore, two prominent bands were visible, one at ~150kD and one at 
~200kD. Given that a faint band at 150kD was also visible in the MT sample, 
the larger than expected 200kD band likely represents TCERG1. Certain 
downstream analyses were therefore not possible for TCERG1, including the 
repeat of BioID and cross-linked immunoprecipiation (CL-IP) experiments. 
For future work, it will be necessary to experiment with alternative tags as 
well as compare the amino- versus carboxy-terminal location of each tag in 
order to achieve efficient expression of TCERG1.  
 
 
              
 
 
Figure 16. Expression of FLAG-tagged RDBP, RUVBL1, and TCERG1. 
293T cells transfected with multiple clones of FLAG-tagged RDBP (A), RUVBL1 (B), or 
TCERG1 (C) were harvested 48h after transfection. Expression of FLAG-tagged proteins 





To repeat the BioID, FLAG-RUVBL1 and FLAG-RDBP were 
expressed with either BirA*-Rep52 or BirA*-Rep52-K340H in 293T cells in 
the presence of free biotin. Biotinylated proteins were purified 48 h after 
transfection and analyzed by western bloting using anti-FLAG and anti-Rep 
antibodies. FLAG-RUVBL1 and FLAG-RDBP were each readily detected 
among the purified proteins in the context of BirA*-Rep52 and BirA*-Rep52-
K340H, confirming the putative interaction between these candidates and 
Rep52 (Figure 17, A and B). We next used co-IP experiments to gain more 
insight into the nature of these interactions. Conventional co-IPs were 
unsuccessful, suggesting that the interactions identified by BioID were 
indirect, weak, and/or transient. By cross-linking cells prior to harvest 
however (CL-IP), we were able to confirm physical associations between 
Rep52 and both RDBP and RUVBL1. FLAG-RDBP, FLAG-RUVBL1, or a 
FLAG-Y14 control was coexpressed with Rep52 in 293T cells. 48 h after 
transfection, cells were cross-linked in 0.05% formaldehyde, and FLAG-
tagged proteins were immunoprecipitated from the lysates. Rep52 was 
readily detectable in both the FLAG-RDBP and FLAG-RUVBL1 pull-down 
fractions. (Figure 17, C and D). Although weak bands were visible at ~50kD 
in the FLAG-Y14 fraction, these appeared to stem from the light chain of the 
rabbit FLAG antibody used for IP still present in the lysates, as the use of 
mouse FLAG antibody for western blotting greatly diminished these bands 
without affecting the strength of bands in either FLAG-RDBP or FLAG-





Figure 17. Validation of the physical interaction of Rep52 with RDBP and RUVBL1. 
(A-B) Purified biotinylated proteins from 293T cells transfected with empty vector (EV), 
BirA*-Rep52, or BirA*-Rep52K340H and FLAG-RDBP (A) or FLAG-RUVBL1 (B) were analyzed 
for Rep and FLAG by western blotting. (C, D) Cross-linked IP for FLAG-tagged proteins from 




 To determine the potential contribution of RUVBL1 and RDBP to Rep-
mediated transcriptional regulation, we next assessed the ability of Rep52 to 
regulate expression from the AAV2 p5 promoter in the context of RUVBL1 
and RDBP depletion. Although we were unable to validate the physical 
association between Rep52 and TCERG1, we also included TCERG1 in this 
set of experiments to functionally validate this candidate. 293T cells were 
transfected with siRNAs targeting RUVBL1, RDBP, TCERG1, or luciferase 
as a control. Knockdown cells were then cotransfected with a p5-mCherry 
reporter construct, described in section 4.2.1, and increasing concentrations 
of Rep52. Activity of the p5 promoter was determined 48 h later by western 
blotting for mCherry. Repression of p5 by Rep52 appeared diminished in 
RUVBL1 knockdown cells in the presence of the lowest concentration of 
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Rep52, however repression was equally efficient at higher concentrations of 
Rep52, suggesting that RUVBL1 is not involved in Rep-mediated 
transcriptional repression (Figure 18A). TCERG1 depletion also had no effect 
on repression of p5 by Rep52, however reduced expression of mCherry in 
TCERG1 knockdown cells transfected with p5-mCherry alone suggested a 
possible role for this candidate in the positive regulation of the AAV2 p5 
promoter (Figure 18B). Despite extensive optimization efforts, we were 
unable to achieve efficient knockdown of RDBP (Figure 18C), and it is 
therefore impossible to conclude at this time what the contribution of RDBP 
might be to Rep-mediated transcriptional repression.  
 
 
       
 
 
Figure 18. Functional analysis of RUVBL1, RDBP, and TCERG1. 
To determine the role of each candidate in Rep-mediated transcriptional regulation, we 
assessed the ability of Rep52 to repress the AAV2 p5 promoter in the absence of each 
candidate. 293T cells treated with siRNAs targeting RUVBL1 (A), TCERG1 (B), RDBP (C), 
or luciferase as a control were transfected with a reporter construct in which mCherry is 
driven by the AAV2 p5 promoter, and increasing concentrations of Rep52. Cells were 






3.2.4 Potential role for interactions between CPSF6 and capsid-
associated Rep in AAV2 replication.   
During HIV-1 infection, CPSF6 has been shown to bind the incoming 
viral capsid, preventing the premature release of viral RNA and onset of 
reverse transcription, thus helping to avoid immune sensing by cytoplasmic 
pattern recognition receptors. There is also evidence to suggest that this 
interaction helps to guide the viral particle to the nuclear pore. We 
questioned whether a similar mechanism could be occurring during AAV2 
infection, and if this might account for observed differences in nuclear 
trafficking between the various AAV serotypes. We first repeated BioID in the 
context of exogenously expressed CPSF6 to validate the putative interaction 
between Rep52 and CPSF6, as described above for RDBP and RUVBL1. 
This confirmed the presence of CPSF6 in purified biotinylated proteins 
generated by both BirA*-Rep52 and BirA*-Rep52-K340H (Figure 19A). 
Conventional co-IP experiments failed to reveal a physical interaction 
between Rep52 and CPSF6, therefore we performed CL-IP experiments as 
described for RDBP and RUVBL1. CPSF6 was coexpressed with GFP, 
Rep52, or Rep52-K340H, and was immunoprecipitated from cell lysates 48h 
after transfection (Figure 19B). Interestingly, CPSF6 appeared to physically 
interact exclusively with Rep52-K340H, however input expression levels for 
Rep52-K340H were much greater than for Rep52, which may account for this 
result.  
 We then asked whether Rep could be interacting with CPSF6 at the 
viral capsid. The Rep proteins have been shown to interact with the viral 
capsid. Rep78 covalently bound to the 5’ end of viral genomes is thought to 
target viral genomes to the capsid for encapsidation by forming a complex 
with capsid proteins (Dubielzig et al., 1999; Prasad and Trempe, 1995; 
Prasad et al., 1997). In addition, all four Rep proteins have been shown to 
interact directly with capsid proteins, forming helicase complexes at the 5-
fold pore necessary for genome encapsidation (Bleker et al., 2006; King et 
al., 2001).  
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Figure 19. Validation of the Rep-CPSF6 interaction 
(A) Biotinylated proteins purified from cells expressing CPSF6 and BirA*-Rep52, BirA*-
Rep52K340H, or empty vector (EV) in the presence of free biotin were analyzed by western 
blotting for the presence of CPSF6 and Rep. (B) Co-IP for CPSF6 from lysates of 293T cells 
expressing CPSF6 with GFP, Rep52, or Rep52K340H. (C) 1 x 1011 particles of purified rAAV 
TT were analyzed by western blotting for the presence of Rep. Lysates obtained from 293T 
cells infected with AAV2 and Ad5 were run in parallel. (D) 293T cells transduced with either 
a retroviral vector expressing a shRNA targeting CPSF6 (shCPSF6), or an empty vector 
control (shEMPTY) were analyzed by western blotting 48h after transduction for efficiency of 
CPSF6 depletion. (E) Control (shEMPTY) or CPSF6 depleted (shCPSF6) 293T cells were 
infected with Ad5 at an MOI of 5 PFU/cell, AAV2 at an MOI of 10 IU/cell, or coinfected with 
Ad5 and AAV2 at the aforementioned MOIs to initiate lytic AAV2 replication. Cells were 
harvested 48h after infection for real time qPCR analysis of viral genomes.  
 
 
It is unclear however how long these interactions last, and if Rep 
proteins are still associated with capsids upon reinfection. To determine if 
Rep bound to the AAV capsid might play a role during early stages of 
infection, we first looked to see whether Rep could be detected in association 
with purified AAV particles. Proteins from 1 x 1011 particles of purified 
recombinant AAV2 (rAAV2) were subjected to SDS-PAGE and probed by 
western blotting with anti-Rep antibody. Proteins from lysates of 293T cells 
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coinfected with WT AAV2 and Ad5 were used for comparison. Surprisingly, 
all four Rep proteins were detectable with purified rAAV2 particles, and 
Rep52 was highly abundant compared to Rep40, Rep68, and Rep78 (Figure 
19C). Also of interest was the apparent shift in band size for Rep40 and 
Rep68, indicating a potential cleavage or other modification of these proteins.  
We then reasoned that if CPSF6 were involved in the trafficking of 
AAV2 to the nucleus, depletion of CPSF6 would have an observable effect 
on AAV2 replication efficiency. To explore this possibility, we performed 
genome replication experiments in cells depleted for CPSF6. 293T cells were 
transduced with retroviral vectors expressing either an shRNA targeting 
CPSF6, or the empty vector as a control (Figure 19D). 48h after transduction 
cells were infected with Ad5 alone, AAV2 alone, or coinfected to initiate 
productive replication. Cells were harvested for total DNA extraction 
approximately 42h after infection, or when cells displayed optimal cytopathic 
effect (CPE), and replication efficiency was determined by quantitative PCR 
(qPCR). In cells coinfected with Ad5 and AAV2, we observed a 4.5-fold 
enhancement in AAV2 replication in cells depleted for CPSF6 as compared 
to controls (Figure 19E). AAV2 replication efficiency in general however was 
poor. During an efficient lytic cycle, AAV2 replication should progressively 
overpower that of Ad5. While some repression of Ad5 replication was 
apparent in coinfected control cells, the effect was minimal and was not 
detectable in cells depleted for CPSF6. Furthermore, replication of Ad5 in 
coinfected cells was as efficient as that of AAV2. Future work with respect to 
CPSF6 replication experiments will require optimization in order to achieve 
the expected replication efficiency for AAV2 in control cells. This may require 
testing alternative strategies for CPSF6 depletion, such as siRNA or 
lentiviral-based shRNA vectors, as well as various multiplicities of infection 









This work was carried out in an effort to further elucidate the 
mechanism of Rep-mediated repression that has been observed for 
heterologous cellular and viral promoters (Dutheil et al., 2014; Hermonat, 
1994, 1991; Hörer et al., 1995; Needham et al., 2006; Wonderling and 
Owens, 1996). While repression of the AAV p5 promoter is dependent on 
direct binding of the large Rep proteins to the p5 RBS as well as a functional 
NTP-binding site within the Rep ATPase domain, repression of p19, p40, and 
several heterologous promoters is dependent only on the presence of a 
functional NTP-binding site (Kyostio et al., 1995; Kyöstiö et al., 1994), 
indicating the potential reliance of this pathway on interactions between Rep 
and components of the cellular transcriptional machinery. In an effort to 
identify potentially relevant cellular proteins, we used the screening method 
BioID (Roux et al., 2012) to screen for novel interaction partners of the small 
Rep proteins. The candidate proteins TCERG1, RUVBL1, RDBP, CPSF6, 
and KAP1 were chosen for downstream analysis based on their respective 
roles in transcriptional regulation and/or antiviral activity. CL-IP experiments 
confirmed the physical association of Rep52 with RUVBL1 and RDBP, 
however no role could be established for either of these proteins, or for 
TCERG1, in the negative regulation of the AAV p5 promoter by Rep52. A 
physical interaction between CPSF6 and Rep52-K340H was also confirmed 
by CL-IP, and depletion of CPSF6 led to an unexpected enhancement in 
AAV2 replication in AAV2 and Ad5-coinfected cells.  
As with any approach, there are certain limitations of BioID that must 
be kept in mind. Clearly, the success of BioID is dependent upon the fusion 
protein maintaining its correct targeting and assembly characteristics. In this 
work, we generated fusions between BirA* and the N-termini of Rep40 and 
Rep52, as well as the repression deficient NTP-binding mutants, Rep40-
K340H and Rep52-K340H. Each fusion protein displayed stable expression, 
albeit with variable efficiency of expression. As observed for the WT Rep 
proteins, the NTP-binding mutant fusion proteins expressed more efficiently 
than their WT fusion protein counterparts. It is important to consider the 
possible effect of Rep concentration on protein interactions, as Rep 
expression is normally highly regulated, both during AAV latency and lytic 
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replication. In addition, the large Rep proteins display concentration-
dependent oligomerization properties that are potentially essential for 
supporting protein interactions (Bardelli et al., 2016; Zarate-Perez et al., 
2012, 2013), and which may be adversely affected by non-physiological 
levels of Rep expression.  Although the small Rep proteins are monomeric in 
solution (Zarate-Perez et al., 2012) and have only been demonstrated to 
form transient dimers in the presence of ATP and a DNA template (Smith 
and Kotin, 1998), it is still possible that both (1) the vast difference in 
expression levels between the BirA*-Rep fusion proteins and physiological 
levels of Rep found during AAV infection, and (2) the difference in expression 
between the WT and NTP-binding mutant fusion proteins may have affected 
the results of our screen. The use of native AAV promoters might have 
proven beneficial in this respect, however the highly regulated nature of AAV 
promoters would likely result in levels of expression too low for effective 
biotinylation. 
Using a transfection-based reporter assay in which mCherry is driven 
by the AAV p5 promoter (Dutheil et al., 2014), we were able to show that the 
fusion proteins maintained their capacity to repress p5, albeit with lower 
efficiency, suggesting that their repressive activity was not compromised. 
While we felt that this method of validation was sufficient to proceed with our 
screen, it would have been prudent to more specifically assess ATPase and 
helicase activities, as well as to verify the localization of the BirA*-Rep fusion 
proteins by immunofluorescence. Indeed, confocal microscopy could have 
shed light on the observed diminished repressive activity of the fusion 
proteins by revealing any potential differences in the efficiency of nuclear 
translocation. However, as BirA* and the Rep proteins in the absence of 
helper virus coinfection display similar pan-nuclear patterns of expression, it 
would have been difficult to visually demonstrate changes in BirA*-mediated 
patterns of biotinylation resulting from the fusion of Rep to BirA*. This last 
point further provokes the question of what different protein interactions 
might have been observed either in the presence of Ad5 coinfection, or with 
the addition of AAV DNA as a template for the nucleation of protein 
interactions.  
! 123!
A second limitation of BioID arises from the mechanism of biotinylation 
itself. The efficacy of BioID is contingent upon the presence of primary 
amines, namely lysines, within the target protein. As a result, neither the 
strength nor absence of biotinylation can be directly translated to the 
importance of a particular interaction. For this reason, BioID screens should 
be used to identify candidates that can be subsequently investigated 
systematically or in a hypothesis-based manner. Furthermore, the covalent 
attachment of biotin to primary amines results in a loss of charge at these 
sites, which can adversely affect protein interactions, function, and/or 
secondary modifications. This point may explain our observation that, rather 
than act as the intended negative controls, the K340H fusion proteins in fact 
supported more interactions than their WT counterparts. It is conceivable that 
BirA* biotin ligase activity, which is lysine specific (Roux et al., 2012), 
resulted in the autobiotinylation of K340 in Rep52. This would effectively 
render Rep52 equivalent in function to Rep52-K340H, while additionally 
obstructing any potential protein interactions dependent on the structural 
integrity of this site. On the other hand, Rep52-K340H could be unaffected by 
this biotin modification and, being a catalytic mutant and not a structural one, 
would still be able to support normal protein interactions. Therefore, we 
considered proteins identified with both WT and K340H fusion proteins for 
downstream analysis. While this left us without a proper negative control, it is 
worth noting that the proteins identified in our screen varied greatly from 
those identified both by Roux et al, and from those identified by various 
groups in our department employing BioID in the context of unrelated viral 
proteins. Furthermore, several proteins previously identified as Rep 
interaction partners in other screens (Cervelli et al., 2008; Nash et al., 2009; 
Pegoraro et al., 2006) were also identified here, lending support to the quality 
and coherence of our BioID screen. Nevertheless, it would be valuable to 
repeat these experiments with the inclusion of a BirA* control. While BirA* 
would lead to high levels of nonspecific biotinylation of nuclear proteins, 
identifying enrichment over background of biotinylation in the presence of 
BirA*-Rep would likely enable the identification of true interaction partners. 
In the absence of an RBS within the target promoter, repression by 
the Rep proteins is dependent only on the presence of an intact Rep NTP-
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binding site (Kyostio et al., 1995; Kyöstiö et al., 1994), which suggests that 
the correct conformation of the ATPase domain, and its oligomerization in the 
context of the large Rep proteins, is necessary, potentially to support 
interactions between Rep and components of the cellular transcriptional 
machinery (Dutheil et al., 2014; Hörer et al., 1995; Needham et al., 2006). 
Rep is known to interact with various cellular transcription factors, such as 
E2F1, c-Jun, TBP, and PC4, in a manner shown to down-regulate promoter 
expression (Batchu et al., 2001; Hernonat et al., 1998; Needham et al., 2006; 
Prasad et al., 2003; Weger et al., 1999). Conversely, Rep-Sp1 interactions 
are necessary for the transactivation of the AAV p19 and p40 promoters 
(Hermonat et al., 1996; Pereira and Muzyczka, 1997a, 1997b). Furthermore, 
interactions between Rep, HMG1, and the TAF1/Set complex suggest that 
changes in chromatin structure may also be important for Rep-mediated 
transcriptional regulation (Costello et al., 1997; Pegoraro et al., 2006). 
Indeed, changes in higher order chromatin structure are increasingly 
recognized as being essential for both cellular and viral transcriptional 
regulation (Knipe et al., 2013; Li et al., 2007a).  
Our screen identified a multitude of factors involved in RNA 
metabolism and transcriptional regulation, as well the regulation of chromatin 
structure, including TCERG1, RUVBL1, RDBP, CPSF6, and KAP1, which 
were chosen for further downstream analysis based on their roles in 
transcriptional regulation and/or their previous association with viral 
elements. Transcription elongation regulator 1 (TCERG1/CA150) is a nuclear 
protein first identified as a component of the RNA pol II holoenzyme in a 
screen for cellular proteins involved in Tat-dependent HIV-1 transcriptional 
regulation (Sune et al., 1997), however it was later suggested to act as a 
cofactor for HIV-1 transcriptional elongation by increasing the rate of paused 
RNA pol II transcription through the phosphorylation of Ser2 in the RNA pol II 
C terminal domain (CTD) (Coiras et al., 2013). In the context of cellular gene 
regulation, the role of TCERG1 is to couple the processes of transcriptional 
elongation and mRNA processing by binding the phosphorylated CTD of 
actively transcribing RNA pol II and recruiting transcription and splicing 
factors (Carty et al., 2000; Pearson et al., 2008), such as the splicing factor 1 
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(SF1) (Goldstrohm et al., 2001). SF1 is then thought to target nascent 
transcripts, leading to the inhibition of elongation (Goldstrohm et al., 2001).  
We were unable to confirm the physical interaction between Rep and 
TCERG1 due to inefficient expression from CMV-FLAG-TCERG1, however 
repression of p5 by Rep52 in the absence of TCERG1 was unaffected, 
suggesting that the TCERG1/SF1 mechanism is not involved in Rep-
mediated repression. Alternatively, the reporter-based p5 repression assay 
does not fully recapitulate certain required physiological aspects of AAV 
infection. DNA structures such as the ITRs may be influential in facilitating 
protein interactions. Additionally, physiological levels of Rep during AAV 
infection are highly regulated, and therefore over-expression of Rep in this 
assay may also impede certain Rep functions. Finally, protein depletion by 
siRNA is not 100% effective, and it is possible that the minimal levels of 
protein remaining are sufficient to support Rep-mediated repression. 
Interestingly however, expression of mCherry was greatly diminished in the 
absence of TCERG1. Rep expression on the other hand was unaffected, 
suggesting that TCERG1 may play a role in the specific positive regulation of 
p5. It is possible that TCERG1 may play a similar role for p5 as has been 
observed for Tat-activated HIV-1 LTR transcription, where it appears to 
phosphorylate the CTD of RNA pol II, thereby releasing it from promoter 
proximally paused positions (Coiras et al., 2013; Sune and Garcia-Blanco, 
1999; Sune et al., 1997) . It would be interesting to determine RNA pol II 
occupancy on Rep-regulated promoters as well as the phosphorylation status 
of its CTD in the presence and absence of TCERG1. Alternatively, splicing of 
nascent mRNA by TCERG1/SF1 may be necessary for productive 
transcription from p5.  
RDBP is an RNA-binding component of the negative elongation factor 
(NELF) protein complex, which has a major role in regulating proximal 
promoter pausing through interactions with RNA and RNA pol II (Yamaguchi 
et al., 1999, 2002). Additionally, studies investigating the regulation of HIV-1 
transcription revealed that RDBP binding to the TAR element downstream 
from paused RNA pol II inhibits expression at the level of early elongation 
(Pagano et al., 2014). While we were able to confirm a physical association 
between RDBP and Rep52, we cannot conclude anything with respect to its 
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role in Rep-mediated repression, as we were unable to achieve efficient 
depletion of RDBP despite extensive optimization efforts. The particular 
siRNA sequences used in this set of experiments were obtained from the 
publications of other groups working on these candidates. We failed to 
consider the fact that efficiency would likely vary between cell types, which 
could explain our difficulties in depleting RDBP.  In the future, commercial 
siRNA pools will first be tested, after which the particular siRNA sequences 
mediating efficient knockdown will be experimentally derived and used for 
further analysis.  
RUVBL1, along with the closely related RUVBL2, has been associated 
with various cellular processes, including transcriptional regulation and the 
cellular DDR, through its role in facilitating the assembly of multiple 
chromatin remodeling complexes that utilize the energy of ATP hydrolysis to 
reorganize chromatin and increase access to transcription factors and DNA 
repair factors (Jha et al., 2008; Jin et al., 2005; Mizuguchi et al., 2004; Shen 
et al., 2000; Torreira et al., 2008). In particular, RUVBL1/RUVBL2 complexes 
nucleate the assembly of the INO80 complex involved in nucleosome 
remodeling, a component of which is the transcription factor YY1 (Cai et al., 
2007; Jin et al., 2005; Wu et al., 2007), also known to bind the AAV p5 
promoter and thus providing a potential link between RUVBL1 and p5 
activity. A member of the AAA+ family of helicases, RUVBL1 also bears 
striking similarities to the Rep proteins, which led us to speculate that Rep 
might interact with and inhibit RUVBL1, thereby interfering with the assembly 
of crucial activating chromatin remodeling complexes, such as the TIP60 
acetyltransferase complex. The fact that YY1 is a component of INO80 also 
presented the tempting possibility that INO80 might be necessary for YY1-
mediated activation of p5 in the presence of helper virus coinfection, and that 
Rep counteracts this activity during latency. Again however, depletion of 
RUVBL1 had no effect on Rep-mediated repression of p5. As with TCERG1 
however, expression from p5 appeared marginally less efficient with RUVBL1 
depletion, suggesting a potential role for these chromatin-remodeling 
complexes in the positive regulation of p5.  
CPSF6 is a component of the cleavage factor Im complex (CFIm) that 
plays a key role in pre-mRNA 3’-processing, including 3’-end poly(A) site 
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cleavage and poly(A) addition (Brown and Gilmartin, 2003; Kim et al., 2010; 
Rueegsegger et al., 1998). CPSF6 is thought to bind to RNA substrates and 
promote RNA looping (Yang et al., 2011), although the exact role for CPSF6 
in the CFIm complex is not clear. Interestingly however, CPSF6 has been 
shown to be necessary for infection of monocyte-derived macrophages 
(MDM) by HIV-1 (Rasaiyaah et al., 2013). It is suggested that CPSF6 binding 
to HIV-1 CA effectively cloaks reverse transcription, allowing for the evasion 
of innate immune sensors in primary human macrophages. We asked if 
CPSF6 might also bind AAV capsids and play a role in nuclear localization. 
We could only confirm an interaction between CPSF6 and Rep52-
K340H, which might be explained by the much greater abundance of Rep52-
K340H than Rep52 in cell lysates; furthermore, if the interaction between 
Rep and CPSF6 is capsid-dependent, then detecting a physical interaction in 
the absence of capsid proteins would prove difficult. We were able to show 
that Rep proteins were indeed still associated with viral particles after column 
purification, suggesting that Rep proteins bound to capsid may play a role in 
the early stages of AAV infection after entry. To test the role of CPSF6 in 
AAV infection, we performed replication experiments in CPSF6-depleted 
cells, which surprisingly revealed an increase in AAV replication in the 
context of CPSF6 knockdown. It is difficult to draw any conclusions from this 
experiment however as it was performed only once, and the general 
replication efficiency was quite poor. In addition, using replication efficiency 
as a readout for nuclear trafficking assumes that enhanced trafficking will 
necessarily and directly translate to improved replication. Given the multitude 
of events that occur after nuclear localization has already taken place, this is 
unlikely to be the case. For example, binding of CPSF6 to the capsid might 
be necessary for efficient trafficking while simultaneously slowing down the 
process of viral genome release, thereby rendering it almost impossible to 
tease these factors apart using replication as a readout. The better 
experiment would have been to analyze nuclear trafficking of the different 
AAV serotypes with and without CPSF6 using immunofluorescence.  
In this chapter, we identified numerous putative interaction partners for 
the AAV Rep proteins using the screening method BioID in an effort to further 
elucidate the mechanism of Rep-mediated repression of heterologous 
! 128!
promoters. Despite certain limitations, our screen provided us with a 
coherent list of cellular factors involved in processes such as RNA 
metabolism, transcriptional regulation, chromatin remodeling, and the cellular 
DDR. Based on their respective cellular functions, we systematically 
assessed the role of several of these candidates in the regulation of the AAV 
p5 promoter by Rep. Although we were unable to demonstrate a role for 
these various candidates in repression, there is some evidence to suggest 
that TCERG1 and RUVBL1 may be necessary for efficient transcription, a 
possibility that requires further investigation. Moving forward, it will be 
necessary not only to test further candidates, but also to widen the scope of 
our functional validation such as to include roles outside of transcriptional 
repression. One possibility is to begin by assessing the replication efficiency 
of AAV in the presence or absence of candidate proteins, as this may provide 
the best end-point readout for the functional relevance of a protein-protein 





















Chapter 4. KAP1 binds and represses latent AAV2 genomes 
 
4.1 Introduction 
Also identified in our BioID screens as an interaction partner for all 
four of the Rep proteins was the Kruppel-associated box domain-associated 
protein 1 (KAP1/TRIM28/TIF1β), a transcriptional corepressor comprised of 
an N-terminal RBCC protein-interaction domain, a central PxVxL region 
necessary for binding heterochromatin protein 1 (HP1), and a C-terminal 
plant homeodomain (PHD) and bromodomain, which recruit components of 
the NuRD histone deacetylase complex and the histone methyltransferase 
SETDB1 (Schultz et al., 2002; Schultz et al., 2001). KAP1 itself is recruited to 
the genome through interactions between its RBCC domain and KRAB-
domain containing zinc fingers (KRAB-ZNFs) (Friedman et al., 1996), after 
which its PHD, bromodomain, and PxVxL region act cooperatively to form 
transcriptionally repressive heterochromatin characterized by the deposition 
of H3K9me3. This mechanism of KAP1-mediated repression has previously 
been linked to the silencing of viral elements such as MLV and ERVs (Rowe 
et al., 2010, 2013; Wolf and Goff, 2007). Additionally, KAP1 has been shown 
to be involved in the maintenance of CMV and KSHV latency (Chang et al., 
2009; Rauwel et al., 2015; Sun et al., 2014). The observed interaction 
between Rep and KAP1 therefore provoked the question of whether KAP1 
might also regulate AAV latency through epigenetic modification of AAV 
chromatin structure. 
Both the latent and a lytic phase of the AAV life cycle require a distinct 
transcriptional program. It is already known for various other biphasic DNA 
viruses that the transition between programs is achieved through epigenetic 
modulation of chromatin dynamics (Knipe et al., 2013; Lieberman, 2008). 
Little is known however with respect to the nature and role of epigenetic 
marks in AAV infection and their contribution to viral genome organization 
and the temporal regulation of gene expression. Our understanding of AAV 
latency is further complicated by a degree of uncertainty regarding the 
relevance of integration in vivo. Although AAV sequences have been readily 
detected in a wide variety of human tissues (Chen et al., 2005; Friedman-
Einat et al., 1997; Grossman et al., 1992; Han et al., 1996; Tezak et al., 
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2000), evidence for integration comes primarily from observations in tissue 
culture, and so it is still unclear whether AAV establishes latency through 
integration or episomal persistence. There is some evidence to suggest that 
AAV assumes a chromatinized configuration shortly after infection, which 
would indicate a role for epigenetic modifications in the maintenance of 
latency and/or transcriptional regulation of AAV. An early study by CJ 
Marcus-Sekura and BJ Carter (Marcus-Sekura and Carter, 1983) used 
micrococcal nuclease digestion to demonstrate that intracellular AAV DNA 
was present in nucleosome-like structures similar to cellular nucleosomes. 
Surprisingly, this was true even in the absence of helper virus or AAV 
replication, which they hypothesized resulted from either the reassociation of 
infecting parental ssDNA, or by covalent integration into the genome. A later 
study investigating the persistence of rAAV vectors obtained from primate 
muscle up to 22 months after injection showed that rAAV also assumed a 
typical nucleosomal pattern, in this case however residing predominantly as 
monomeric and concatameric episomes that assimilated into chromatin 
(Penaud-Budloo et al., 2008). In the context of integration, genome-wide 
analysis of AAV integration sites has shown that, in addition to AAVS1, AAV 
integrates at numerous other genomic sites containing the requisite RBS with 
a preference for regions of open chromatin, further supporting a role for 
chromatin organization in AAV gene expression (Hüser et al., 2014; Petri et 
al., 2015).  
Most viruses depend on specialized viral core proteins and/or cellular 
chromatin modifying proteins for the packaging of their genomes and 
transcriptional regulation. Adenoviral genomes are packaged as highly dense 
chromatin-like structures that must first undergo decondensation during 
nuclear entry in order to become replication competent (Giberson et al., 
2012). Several cellular proteins contribute to this process, including the 
histone chaperone TAF1/Set, the ANP32A/B proteins, and the nucleolar 
protein nucleophosmin (Haruki et al., 2006; Matsumoto et al., 1993; Okuwaki 
et al., 2001). Similarly, HSV interacts with TAF1/Set to assemble an active 
chromatin structure on viral genomes (van Leeuwen et al., 2003), and the 
HSV VP16 protein recruits a wide range of histone acetyltransferases and 
chromatin-remodelling factors to regulate the temporal progression of latent 
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to lytic gene expression (Narayanan et al., 2007). These examples 
underscore the importance of chromatin dynamics, particularly in the life 
cycle of DNA viruses. It would therefore be interesting to determine if and 
what role these types of interactions might play in the regulation of AAV 
latency and lytic replication. Indeed, it has already been shown that AAV 
replication is also dependent on TAF1/Set activity (Pegoraro et al., 2006), 
which would suggest that AAV DNA can exist in a highly condensed form, 
which must be relaxed in order to replicate. Considering the influence of 
TAF1/Set on two of AAV’s most common helper viruses, Ad and HSV-1, this 
is not entirely surprising and may in fact reflect another helper function of 
these viruses.  
A better understanding of the relationship between AAV and 
epigenetic modification might also help to answer some crucial questions that 
remain regarding its biology. One phenomenon of AAV transcription that has 
yet to be mechanistically addressed is how the Rep proteins and different 
RBS can act as both activators and repressors of transcription. One 
possibility is that the formation of nucleosomes provides a scaffold upon 
which epigenetic modifications can act to rapidly “switch” a particular binding 
site from repressive to activating, and vice versa, by modifying the chromatin 
structure. Also, whether viewed as an evolutionary choice or merely as a 
replicative deficiency, helper virus dependency allows AAV to effectively 
defer gene expression until optimal conditions for replication are met, and it’s 
possible that the definition of the contributing processes would provide 
insight into a novel form of latency in which epigenetic regulation is 













4.2.1 Transcriptional repression by Rep52 is not dependent on KAP1.  
Samples from the BirA*-Rep52 screen were first analyzed by western blotting 
to confirm the presence of endogenous KAP1 among the purified proteins, 
revealing a band of approximately 110 kDa corresponding to KAP1 (Figure 
20A). A repeat of the BioID in the context of exogenous FLAG-tagged KAP1 
(FLAG-KAP1) and BirA*-Rep52 again confirmed the biotinylation of FLAG-
KAP1 (Figure 20B). To gain further insight into the nature of the interaction 
between Rep and KAP1, FLAG-tagged proteins were co-IPed from lysates of 
293T cells expressing FLAG-KAP1, or a FLAG-GFP control, with each of the 
Rep proteins. Conventional co-IPs were unsuccessful, however by using CL-
IP we were able to detect interactions between KAP1 and at least three of 
the Rep isoforms (Figure 20C). Rep40 and Rep52 were highly abundant in 
the FLAG-KAP1 pull-down fraction, and Rep78 was also detectable despite 
having low expression levels in the input. A band corresponding to Rep68 
was visible with both FLAG-KAP1 and FLAG-GFP (Figure 20C), indicating 
this may be a nonspecific interaction. This was confirmed in the reciprocal 
CL-IP, which validated KAP1 interaction with all Rep proteins except Rep68 
(Figure 20D). As Rep40 represents the only shared domain between the Rep 
proteins, these results suggest that the ATPase domain is sufficient to 
mediate a Rep-KAP1 interaction. The requirement for cross-linking however 
would indicate that this interaction is transient, weak, and/or indirect.  
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Figure 20. Validation of the physical association between Rep proteins and KAP1. 
(A) Biotinylated proteins purified from the BirA*-Rep52 BioID screen, or the empty vector 
(EV) control, were analyzed by western blotting for the presence of KAP1. (B) Biotinylated 
proteins purified from cells expressing FLAG-KAP1 and BirA*-Rep52, BirA*-Rep52K340H, or 
an empty vector (EV) control in the presence of free biotin were analyzed by western blotting 
for the presence of FLAG-KAP1 and Rep. (C) Cross-linked IP for FLAG-tagged proteins from 
lysates of 293T cells expressing FLAG-KAP1 or a FLAG-GFP control and each of the four 
Rep proteins. (D) Cross-linked IP for FLAG-tagged proteins from lysates of 293T cells 
expressing FLAG-GFP, FLAG-Rep40, FLAG-Rep52, FLAG-Rep68, or FLAG-Rep78 and 
KAP1 from transfected 293T cells. 
 
To explore the possible significance of this interaction for Rep-
mediated transcriptional regulation, we assessed the ability of Rep52 to 
repress the AAV2 p5 promoter in the context of KAP1 depletion. 293T cells 
were transduced with lentivectors targeting the 3’ UTR of KAP1 (shKAP1), or 
the empty vector as a control (shEMPTY). Untreated cells were processed in 
parallel as a further control for off-target effects of the lentivector 
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transductions. 48 h after transduction, cells were transfected with the 
previously described p5-mCherry reporter construct alone, or with increasing 
concentrations of Rep52. 48h after transfection, cells were harvested for 
protein extraction, and p5 activity was assessed by western blotting for 
mCherry (Figure 21).  As expected, expression of Rep52 in both untreated 
cells and control cells resulted in the efficient dose-dependent repression of 
p5 as demonstrated by a loss of mCherry expression. Disappointingly, Rep-
mediated p5 repression was completely unaffected by depletion of KAP1.  
Taken together, these data indicate that a consistent physical association 
exists between the Rep proteins and KAP1, but that this interaction is not 
involved in transcriptional regulation by the Rep proteins, as measured by 
this assay. This does not exclude the possibility that this interaction bears 




              
 
 
Figure 21. KAP1 is not necessary for Rep-mediated transcriptional regulation of the p5 
promoter. 
Untreated 293T cells or cells transduced with a lentiviral vector expressing a shRNA 
targeting the 3’ UTR of KAP1 (shKAP1) or an empty vector control (shEMPTY) were 
transfected with a p5-mCherry reporter construct and increasing concentrations of Rep52 to 
determine the effect of KAP1 knockdown on Rep-mediated repression of the p5 promoter. 
Cells were harvested 48h after transfection, and p5 activity was determined by western 




4.2.2 Depletion of KAP1 leads to enhanced viral transcription and 
replication 
 To explore the possible significance of the Rep-KAP1 interaction in 
the AAV2 life cycle, we performed viral genome replication experiments in 
cells depleted for KAP1, as previously described for CPSF6. To determine 
the optimal infection conditions for these experiments, 293T cells infected 
with 10 - 104 IU/cell of AAV2, with or without Ad5 coinfection (2 PFU/cell), 
were harvested ~42h after infection for qPCR analysis of AAV2 replication 
(Figure 22A). In the absence of Ad5 coinfection, we observed a progressive 
increase in viral genomes with increasing MOIs. Interestingly however, Ad5 
coinfection led to similar AAV2 replication levels in cells infected with 10, 
100, or 1000 IU/cell of AAV2, suggesting a saturation point for AAV2 
replication. Furthermore, cells infected at the highest AAV2 MOI showed 
~10-fold lower replication levels, indicating that high-number input of viral 
genomes hinders rather than enhances replication, potentially by interfering 
with Ad5 replication too early in the lytic cycle and reducing the potential for 
AAV2 replication. Replication efficiency was determined by the normalization 
of each coinfected condition to its respective AAV2 input control (AAV2/-
Ad5). This revealed that infection with 10 IU/cell of AAV2 resulted in the 
greatest dynamic range of replication (Figure 22B), providing us the best 
opportunity to detect changes in replication efficiency. Based on these 
results, we performed all subsequent infections using 10 IU/cell of AAV2 and 
2 PFU/cell of Ad5, unless otherwise stated.  Optimal concentration of Ad5 for 
293T cells was previously determined in the lab based on cytopathic effect 




                  
Figure 22. Determination of optimal infection conditions for genome replication 
experiments. 
(A-B) 293T cells infected with 10, 100, 1000, or 10,000 IU/cell of AAV2, with or without Ad5 
infection (2 PFU/cell), were harvested 48 h after infection for qPCR analysis of viral 
genomes. (A) Viral genomes per well. (B) Replication efficiency calculated by normalizing 
each coinfected condition to its respective input control (AAV2 alone). 
 
 
For the genome replication experiments, control and KAP1-depleted 
293T cells were infected with Ad5, AAV2, or Ad5+AAV2 in order to initiate 
productive replication, and were harvested for DNA, RNA, and protein 
extraction approximately 42h after infection with Ad5, or when cells began to 
display optimal cytopathic effect (CPE). Optimal CPE is defined by cells that 
display a rounded and enlarged phenotype, as opposed to the normal “star-
shaped” morphology of HEK293T cells, and which are beginning to detach but 
still appear bright and healthy. Cells that had completely lifted by the time of 
harvest were deemed too advanced in the infection cycle and were excluded 
from analysis. In the absence of Ad5, AAV2 replication was undetectable by 
qPCR in both KAP1-depleted and control cells; this was not surprising as 
AAV2 is dependent on several helper factors to initiate replication. In the 
context of coinfection however, a 6-fold enhancement in AAV2 replication was 
observed in KAP1-depleted cells as compared to control cells (Figure 23A). 
Interestingly, we also observed a 2-fold enhancement in Ad5 replication in 
KAP1-depleted cells. Supporting the genome replication data, reverse 
transciptase qPCR (RT-qPCR) analysis of rep and cap transcripts in 
coinfected cells revealed a 6-fold enhancement in transcription of both viral 
genes in KAP1-depleted cells (Figure 23B). Rep and capsid protein levels 
were also elevated, and quantification of VP3 levels revealed a 5-fold 
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enrichment (Figure 23C). Rep protein levels were not quantified as the 
temporal regulation of Rep expression throughout the replication cycle results 
in protein levels that do not necessarily mirror replication efficiency.  
 
 
Figure 23. Knockdown of KAP1 leads to enhanced AAV2 replication and transcription 
(A-C) Control (shEMPTY) or KAP1-depleted (shKAP1) 293T cells infected with either AAV2 
(10 IU/cell) alone, Ad5 (2 PFU/cell) alone, or coinfected were harvested for DNA, RNA, and 
protein extraction ~42h after infection. (A) Viral genome replication analyzed by real time 
qPCR. (B) Rep and cap expression analyzed by RT-qPCR. Expression levels were 
calculated by the ΔΔct method and represent fold changes over cells infected with AAV2 
alone. (C) Viral protein expression and KAP1 knockdown efficiency analyzed by western 
blotting using anti-Rep, anti-VP, and anti-KAP1 antibodies (upper panel). VP3 levels were 
quantified using ImageJ software (lower panel). 
Data are reported as mean±SEM, n=5, and statistical significance was determined by 
unpaired t test. 
 
 
We next repeated these experiments in HeLa cells to determine if this 
phenotype was specific to 293T cells. Efficiency of KAP1 depletion is shown 
in Figure 24A. A very modest 1.5-fold increase in AAV2 replication was 
observed in KAP1-depleted HeLa cells as compared to controls (Figure 24B). 
Ad5 replication in these cells however was vastly more efficient than in 293T 
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and completely eclipsed that of AAV2, making it difficult to conclude with any 






Figure 24. Genome replication in KAP1-depleted HeLa cells. 
(A-B) Control (shEMPTY) and KAP1-depleted (shKAP1) HeLa cells were infected with AAV2 
(10 IU/cell), Ad5 (2 PFU/cell), or coinfected with AAV and Ad5 and were harvested for DNA 
and protein extraction ~42h after infection (A) Western blot analysis of KAP1 knockdown. 
(B). Viral genome replication analysed by real time qPCR. 
Data are reported as mean±SEM, n=3. 
 
 
To ensure that our observations were specific to KAP1 depletion, we 
next sought to demonstrate a rescue of baseline AAV2 replication levels in 
KAP1-depleted cells complemented with exogenous FLAG-KAP1. This 
proved to be challenging however, and it became apparent that achieving 
physiological levels of exogenously expressed FLAG-KAP1 would be crucial. 
To this end, we assayed multiple strategies for complementation. In the first 
set of experiments, KAP1-depleted cells were transfected with different 
concentrations of a CMV-driven FLAG-KAP1 expression construct and were 
coinfected 24h later with AAV2 and Ad5. Physiological levels of KAP1 
expression were not achieved at either DNA concentration tested here. 
Instead, exceedingly high levels of exogenous KAP1 were associated with 
enhanced AAV2 replication, both in control and KAP1-depleted cells (Figure 




Figure 25. Viral replication in the context of KAP1 complementation. 
(A) Viral replication in control (shEMPTy) or KAP1-depleted (shKAP1) 293T cells 
complemented with either empty vector (EV) or CMV-KAP1 (KAP1) and coinfected with 
AAV2 (10 IU/cell) and Ad5 (2 PFU/cell). KAP1 protein levels were monitored by western 
blotting. (B) Viral replication in control (shEMPTy) or KAP1-depleted (shKAP1) 293T cells 
stably expressing KAP1 (MLV-KAP1) or an empty expression cassette (MLV-EMPTY) and 
coinfected with AAV2  (10 IU/cell) and Ad5 (2 PFU/cell). shEMPTY and shKAP1 (No MLV) 
were infected in parallel to control for the effect of transduction with the retroviral expression 
vector. (C) KAP1 protein levels in untreated, shKAP1 + MLV-EMPTY, and shKAP1 + MLV-
KAP1 293T cells.  
 
 
 using a retroviral expression vector (MLV-KAP1). These were depleted for 
endogenous KAP1 and coinfected 48h later with AAV2 and Ad5. While 
FLAG-KAP1 levels were much closer to physiological KAP1 levels here, 
AAV2 replication was elevated across all conditions (Figure 25B and C). 
Given that control cells (MLV-EMPTY + shEMPTY) also displayed greatly 
enhanced AAV2 replication as compared to cells treated with control shRNA 
alone (shEMPTY), we posited that integration of the retroviral vectors was 
affecting AAV2 replication. It is worth noting here that virtually any form of 
DNA damage has been shown to enhance AAV2 replication, and so it is 
conceivable that a cellular response to retroviral integration could be 
impeding our analysis.  
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Based on this, we returned to a transfection-based complementation 
strategy. FLAG-KAP1 was cloned into two different expression constructs in 
which truncated CMV promoters are used to achieve attenuated protein 
expression (Morita et al., 2012). These were tested for optimal expression 
levels (Figure 26A) and then used to complement KAP1-depleted cells as 
described in the first set of experiments. Levels of exogenous FLAG-KAP1 
were comparable to physiological KAP1 levels here (Figure 26B), and 
complementation of KAP1-depleted cells with FLAG-KAP1 restored AAV2 
replication levels to those observed in control cells transfected with an empty 
vector (EV) (Figure 26C). The observable rescue effect was modest however 
as transfection of the empty vector alone increased AAV2 replication in 
control cells, effectively eliminating the dynamic range of replication in which 
to demonstrate a rescue. Given that these data were not entirely conclusive, 
the replication phenotype was also recapitulated via siRNA-mediated 
knockdown of KAP1. Replication efficiency was generally lower, likely as a 
result of double siRNA transfection prior to infection, however we still 
observed a 2-fold enhancement in AAV2 replication in cells treated with 
siRNAs targeting KAP1 as compared to controls (Figure 26D). Taken 
together, these data indicate that the association between Rep and KAP1 
bears functional significance in the AAV2 life cycle, and that depletion of 
KAP1 leads to an enhancement in transcription and genome replication by 
an unknown mechanism.  
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Figure 26. Validation of replication phenotype observed in KAP1-depleted 293T cells.  
(A) KAP1-depleted (shKAP1) 293T cells transfected with increasing concentrations of either 
pWISP95-FLAG-KAP1 or pWISP96-FLAG-KAP1, in which truncated CMV promoters are 
used to achieve attenuated levels of protein expression, were harvested 48 h after 
transfection. Levels of FLAG-KAP1 were determined by western blotting using anti-KAP1 
antibody. Control cells (shEMPTY) were used for comparison. (B, C) Control and KAP1-
depleted 293T cells that had been complemented with either an empty vector control or 
pWISP95-FLAG-KAP1 were coinfected with AAV2 (10 IU/cell) and Ad5 (2 PFU/cell). Cells 
were harvested 48 h after infection for DNA and protein extraction. (B) Analysis of KAP1 
protein levels by western blotting using anti-KAP1 antibody. (C) Real time qPCR analysis of 
viral genomes. Data are normalized to replication levels in control cells (shEMPTY) and are 
reported as mean±SEM, n=3. (D) 293T cells transfected with two siRNAs targeting KAP1 
(siKAP1.2 and siKAP1.4), or a non-targeting control (siCTRL) were infected with Ad5 (2 
PFU/cell), or coinfected with AAV2 (10 IU/cell) and Ad5 (2 PFU/cell) and harvested 48 h 
after infection for qPCR analysis of viral genome, and western blot analysis to determine 




4.2.3 KAP1 binds the AAV2 genome during latency resulting in 
trimethylation of AAV2-associated H3K9. 
Given that the association of KAP1 with the genomes of CMV and 
KSHV is known to repress lytic gene expression and maintain latency, we 
next asked if KAP1 could be repressing AAV2 through the binding of its 
genome and subsequent formation of heterochromatin. We performed KAP1-
specific chromatin immunoprecipitation (ChIP) experiments on control and 
KAP1-depleted 293T cells that were infected with AAV2 alone in order to 
produce a latent infection. IgG was used as a control. Chromatin was 
isolated 48h after infection and analyzed by qPCR using primers specific for 
various regions of the AAV2 genome, as well as GAPDH as a negative 
control, and two zinc finger genes, ZNF180 and ZNF274, as positive controls 
for KAP1 binding. KAP1 binding was detected across rep, particularly at the 
5’ and middle regions, and this binding was accordingly lost in KAP1-
depleted cells confirming the observed signal was in fact KAP1-dependent 
(Figure 27A). To determine the functional significance of this binding, we also 
performed ChIP for trimethylated H3K9 (H3K9me3), a known marker for 
KAP1-mediated repression. H3K9me3 was detected across the AAV2 
genome (Figure 27B), and, importantly, histone methylation was lost in 
KAP1-depleted cells at a ratio similar to that observed for ZNF180 and 
ZNF274, supporting the notion that KAP1 not only binds the AAV2 genome 
but does so in the capacity of a repressor. Interestingly, no specific binding of 
KAP1 or enrichment for H3K9me3 was detected at the viral p5 promoter, a 
region known to be regulated by Rep and necessary for the transactivation of 
all three viral promoters. Indeed, we demonstrated earlier that the ability of 
Rep to regulate expression from a p5-mCherry reporter construct was 
completely unaffected by depletion of KAP1 (Figure 21).  




Figure 27. The latent AAV2 genome is methylated by recruitment of KAP1 to the rep 
ORF  
(A) ChIP-qPCR was performed on control (shEMPTY) and KAP1 depleted (shKAP1) 293T 
cells 48h after infection with AAV2 (100 IU/cell) alone, using anti-KAP1 antibody or IgG. 
Purified chromatin was analyzed by qPCR using primers specific for the viral p5 promoter or 
various regions of the rep and cap ORFs (right panel). GAPDH was used as a negative 
control, and the zinc finger genes ZNF180 and ZNF274 were used as positive controls (left 
panel). Values are reported as mean±SEM for 3 independent experiments.  (B) ChIP-qPCR 
was performed as described above, using anti-H3K9me3 antibody and IgG. Values are 
reported as mean±SEM for 3 independent experiments.  (C) ChIP-qPCR was performed 48h 
after infection as described above on 293T cells that were infected with AAV2 (100 IU/cell) 
alone, or coinfected with AAV2 and Ad5 (2 PFU/cell). 
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To determine whether productive AAV2 replication was associated 
with a loss in trimethylation of AAV2-associated H3K9, we performed parallel 
H3K9me3-specific ChIP in 293T cells infected either with AAV2 alone, or 
coinfected with AAV2 and Ad5 to induce lytic replication. Chromatin was 
isolated 48 h after infection and analyzed by qPCR as described above. In 
the context of latent AAV2 infection, enrichment for H3K9me3 was again 
apparent across rep (Figure 27C). In contrast to what we observed in the 
previous set of experiments however, H3K9me3 enrichment was detectable 
predominantly at the middle to 3’ region of rep, rather than the 5’ to middle 
region. Surprisingly, there was also a lack of any observable enrichment for 
H3K9me3 across cap (Figure 27C). In agreement with the previous 
experiments, the p5 promoter was again free from the repressive mark. 
Importantly, no AAV2-associated enrichment for H3K9me3 was detected in 
cells coinfected with AAV2 and Ad5 (Figure 27C), suggesting that replication 
is associated with a loss of KAP1 repressor activity. It is important to note 
however that the interpretation of these data is complicated by the presence 
of efficient AAV2 genome replication in coinfected cells. It is possible that 
high levels of AAV2 DNA in the input samples of coinfected cells could mask 
a potential signal for H3K9me3 enrichment, resulting in a false negative. For 
this reason, we performed this experiment only once. This might help to 
explain not only the difference we observed in the pattern of rep and cap 
histone methylation, but also the apparent lower degree of H3K9me3 
enrichment at the positive controls than previously observed (Figure 27B), as 
a degree of variability was inherent to these experiments.  
 
4.2.4 KAP1 recruits CHD3 and SETDB1 to mediate H3K9 methylation of 
the latent AAV2 genome. 
We then reasoned that if KAP1 represses AAV2 through the canonical 
pathway involving recruitment of SETDB1 and the NuRD complex, depletion 
of other members of the repressive complex would have a similar effect on 
AAV2 replication as depletion of KAP1. To test this, 293T cells were 
transfected with siRNAs targeting either CHD3 or SETDB1 and then infected 
as described above. AAV2 replication was monitored both by western blot for 
the VP proteins, and by qPCR. A 6-fold increase in VP expression was 
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observed in cells depleted for either CHD3 or SETDB1, and the depletion of 
both appeared to have a cumulative effect, resulting in a 10-fold increase in 
VP levels as compared to control cells (Figure 28A and B). The effect was 
less pronounced at the level of genome replication, although the trend 
remained the same. Cells depleted for either CHD3 or SETDB1 
demonstrated a 2-fold enhancement in AAV2 replication, and cells depleted 
for both a 3-fold enhancement (Figure 28C). Taken together, these data 
strongly suggest that KAP1 is repressing AAV2 through the binding of AAV2 
rep and the subsequent recruitment of histone and chromatin modifying 





Figure 28. Depletion of CHD3 and SETDB1 leads to enhanced AAV2 replication and 
protein expression. 
(A-C) 293T cells were transfected with non-targeting control siRNA or siRNA targeting CHD3 
or SETDB1, and were infected with Ad5 (2 PFU/cell) alone, or coinfected with Ad5 and 
AAV2 (10 IU/cell). Cells were harvested for DNA and protein extraction. (A) VP protein 
expression and depletion of CHD3 and SETDB1 were analysed by western blotting using 
anti-VP, anti-CHD3, and anti-SETDB1 antibodies (B) Quantification of VP3 levels using 
ImageJ software (C) Viral genome replication analyzed by real time qPCR. Values are 







It is becoming increasingly clear that the assembly, modification, and 
remodeling of viral chromatin play a crucial role in determining the outcome 
of infection. DNA viruses in particular capitalize on the formation of 
nucleosomes in order to establish a dynamic state in which transcriptional 
activity can be rapidly altered through the activity of cellular histone- and 
chromatin- modifying factors (Knipe et al., 2013; Lieberman, 2008). Indeed, 
the fates of the AAV helper viruses Ad5 and HSV-1 are inextricably linked to 
their chromatin states (Arbuckle and Kristie, 2014; Knipe and Cliffe, 2008). In 
addition to its role in the temporal regulation of viral gene expression, the 
formation of repressive chromatin on viral genomes can also be the result of 
a cellular defence strategy, as has also been observed for Ad, HSV-1, and 
hepatitis B virus (HBV) (Ducroux et al., 2014; Schreiner et al., 2013a, 2013b). 
There is still much to learn with respect to the mechanisms involved in the 
temporal regulation AAV transcription; in particular, (1) what factors are 
necessary for the establishment and maintenance of latency and what role 
do these play in supporting/suppressing reactivation, (2) what changes occur 
to allow transition from latency to lytic replication, and (3) how might these 
changes evolve throughout the course of infection. In this chapter, we first 
show that the AAV2 Rep proteins and transcriptional corepressor KAP1 
physically interact.  We also demonstrate that recruitment of KAP1 to the 
Rep ORF leads to the trimethylation of AAV2-associated H3K9, and we 
provide evidence that KAP1 achieves this through its canonical mechanism 
of repression involving the recruitment of the nucleosome- and histone-
modifying proteins, CHD3 and SETDB1. Depletion of KAP1 led to a 
significant enhancement in AAV2 replication and transcription, further 
supporting the notion that KAP1 acts as a repressor of AAV2. 
Given how intimately intertwined the fate of AAV is with that of both 
Ad5 and HSV-1, it is difficult to envision an AAV life cycle in which 
chromatin dynamics are not involved. Here, we demonstrate a role for KAP1 
in the epigenetic regulation of the AAV2 genome. Knockdown of KAP1 
resulted in a significant enhancement in viral DNA replication, transcription, 
and protein expression, suggesting that AAV2 is a target of KAP1 activity. 
Not only does this provide evidence for the chromatinization and histone 
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methylation of AAV2, it also predicts a requirement for the remodeling of 
viral chromatin in overcoming KAP1-mediated repression during the 
transition from latency to lytic replication. Several proteins pulled down in 
our original BioID screen support the idea that AAV becomes chromatinized 
upon uncoating. Interactions were detected between Rep52 and CHAF1-A, 
a core component of the CAF-1 complex thought to mediate chromatin 
assembly in DNA replication and repair (Moggs et al., 2000; Smith and 
Stillman, 1989), and which is required for chromatin assembly during SV40 
DNA replication in vitro (Stillman, 1986). Also identified were TOX4 and 
PPP1R10, two proteins that together form the PTW/PP1 complex implicated 
in the regulation of chromatin structure during mitosis (Lee et al., 2010). 
Even in the context of latency, the AAV genome must undergo some 
minimal level of replication during cellular S phase in order to generate the 
dsDNA construct necessary for long-term persistence and/or integration. It 
is thus possible that the CAF-1 and PTW/PP1 complexes mediate 
nucleosome formation during this process. The viral ITRs are also known to 
mimic DNA DSBs and could trigger DNA repair, leading to nucleosome 
formation (Moggs et al., 2000). In addition, TAF1-B/Set, nucleophosmin, 
and ANP32A were pulled down with at least one of the Rep proteins. 
Together, these three proteins comprise the cellular Template Activating 
Factor (TAF) activity necessary for the remodeling of incoming adenovirus 
DNA (Haruki et al., 2006; Xue et al., 2005), and it is tempting to speculate 
that they provide the same function for AAV.  Similarly, the cellular factor 
host cell factor 1 (HCF-1) necessary for HSV-1 reactivation (Narayanan et 
al., 2007) was also identified. These interactions strongly suggest that AAV 
undergoes a similar transformation from transcriptionally repressed 
heterochromatin to a more relaxed and active chromatin state in preparation 
for replication. Interestingly, the chromatin boundary factor CTCF was also 
found to interact with Rep52 in our screen. This protein is known to insulate 
the HSV-1 LAT promoter and enhancers from the ICP0 and other immediate 
early gene promoters (Amelio et al., 2006), and has also been implicated in 
the regulation of Epstein Barr Virus (EBV) epigenetic gene regulation (Chau 
et al., 2006). 
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The manner in which AAV2 establishes latency is still unclear. 
Evidence for integration in vitro is compelling and has led to the detailed 
molecular characterization of AAV2 integration into AAVS1 (Henckaerts and 
Linden, 2010). However, studies attempting to characterize AAV DNA from 
human tissues have found evidence mostly for episomes (Schnepp et al., 
2005). Although we cannot exclude that some of the observed binding of 
KAP1 to the AAV2 genome occurred in the context of integrated viral DNA, 
we believe that the majority of interactions occur with episomal DNA 
considering the conditions used for infection in our ChIP experiments. Cells 
were infected with 100 IU/cell of AAV2 and were harvested 48 hours after 
infection without passaging. While 30-40% of clonal cell lines have been 
shown to contain integrated viral DNA at this MOI (Hamilton et al., 2004), it 
is likely that the high level of non-integrated virus present in the input sample 
would mask any enrichment if KAP1 were predominantly bound to 
integrated viral DNA. Rather, our data are consistent with earlier studies 
showing that AAV2 adopts a nucleosomal configuration shortly after 
infection (Marcus-Sekura and Carter, 1983), and further indicate that 
heterochromatinization by KAP1 may silence the viral genome without the 
need for integration. 
In the absence of helper virus coinfection, AAV2 establishes latency 
and is silenced through the simultaneous binding of the p5 promoter region 
by the cellular factors YY1 and MLTF. To initiate lytic replication, AAV2 is 
dependent on the disruption of these repressive factors by the activity of the 
helper virus factors Ad5 E1A or HSV-1 ICP0. Here, we show that KAP1 
provides a second layer of regulation, the antagonism of which is necessary 
but not sufficient for reactivation. Depletion of KAP1 resulted in a significant 
enhancement in AAV2 genome replication, transcription, and protein 
expression in cells coinfected with AAV2 and Ad5. This effect was not 
observed in cells infected with AAV2 alone however, reflecting the 
dependency of AAV2 on various helper factors to initiate replication. These 
observations bear interesting similarities to those made for KAP1 regulation 
of KSHV. Like AAV2, KSHV replication was enhanced, but not triggered, by 
KAP1 depletion, both in the context of induced KRta expression and 
hypoxia-induced KSHV reactivation (Chang et al., 2009; Zhang et al., 2014). 
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It is also interesting to note that KSHV is an episomal virus with the ability to 
modulate KAP1 activity via its viral kinase, vPk (Chang et al., 2009). Based 
on these observations and the fact that both AAV2 and KSHV are clearly 
capable of replication without the need for KAP1 depletion, it is tempting to 
speculate that these viruses have domesticated KAP1 repression to their 
advantage. The fact that KAP1 depletion does nevertheless affect AAV2 
replication may simply reflect a difference in replication kinetics, with 
replication in KAP1-depleted cells being able to begin more rapidly. This 
would have a two-fold effect – (1) the more rapidly initiated replication would 
likely lead to better competition with Ad5, tipping the scales in favour of 
AAV, and (2) replication would simply have progressed further at the time of 
harvest. Alternatively, the presence of concurrent Ad5 replication might 
create a fixed window of opportunity for AAV replication, and a more rapid 
initiation would naturally translate to higher final numbers.  
KAP1 has been shown to regulate the latency of both CMV and 
KSHV. KAP1 recruitment to the CMV genome leads to H3K9me3 deposition 
across various lytic genes, while latency-associated genes remain free from 
repressive marks (Rauwel et al., 2015). Similarly, LANA-mediated 
recruitment of KAP1 to the KSHV genome is involved in the shutdown of lytic 
gene expression during early stages of KSHV infection (Sun et al., 2014). 
Here, we observed KAP1-dependent H3K9me3 deposition across the latent 
AAV2 genome spreading downstream from KAP1 recruitment sites in rep. 
While AAV2 does not contain a true latency-associated gene, neither KAP1-
binding nor H3K9me3 enrichment was detected at the p5 promoter, a region 
whose transactivating activity is necessary for initiation from all three viral 
promoters. It is possible that Rep and YY1 bound to p5 act not only to 
repress transcription during latency, but also to maintain the promoter free 
from repressive marks and competent for rapid reactivation. This could result 
either from direct competition between Rep and KAP1 recruitment factors for 
binding sites within p5, or, alternatively, Rep-dependent phosphorylation of 
KAP1 could promote the release of KAP1 from bound recruitment factors.  
Two types of genomic KAP1 binding sites have been identified 
(Iyengar et al., 2011). Binding sites at the 3’ ends of ZNF genes resemble 
viral KAP1 binding sites in their enrichment for H3K9me3, while binding sites 
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near transcription start sites (TSS) are free from histone methylation and may 
instead be related to the recently discovered role for KAP1 in proximal 
promoter pausing (McNamara et al., 2016). KAP1-mediated recruitment of 
the 7SK snRNP complex and its associated pTEFb to sites of paused RNA 
pol II is thought to provide a constant source of pTEFb ready to 
phosphorylate and activate RNA pol II upon stimulation.  While we show here 
that enrichment of AAV2-associated H3K9me3 is dependent on KAP1 
recruitment, the proximity of KAP1 binding to the 5’ region of rep is also 
analogous to binding sites near TSS. Further work will be necessary to fully 
elucidate the potential contribution of each mechanism. 
It is unclear at this point how KAP1 is recruited to the AAV genome. 
The most well-characterized recruitment partners for KAP1 are the KRAB-
ZFPs, although KRAB-only proteins as well as various other transcription 
factors are also known to interact with KAP1. Furthermore, mutant KAP1, in 
which the RBCC domain required for interaction with KRAB-ZFPs is 
removed, is still recruited to numerous sites in the genome (Iyengar et al., 
2011). Although we show that KAP1 and the Rep proteins physically interact 
in a manner dependent on the Rep ATPase domain, it is unlikely that KAP1 
is being recruited to the AAV2 genome by the Rep proteins themselves. The 
requirement for cross-linking of cells for detection of the Rep-KAP1 
interaction suggests that Rep and KAP1 interact only indirectly. Also, as we 
did not DNase treat lysates prior to IP, we cannot be certain that the 
observed interactions were not a result of DNA bridging, although neither 
Rep40 nor Rep52 contain specific DNA binding activity. Furthermore, if 
Rep78 recruited KAP1 to the AAV2 genome, we would expect to observe 
KAP1 binding at the p5 promoter, which we do not. While we did not identify 
any KRAB-ZFPs in our BioID screens, we did identify several zinc finger-
containing proteins, including ZNF318, a TF implicated in the transcriptional 
repression of androgen receptor (AR)-regulated genes during 
spermatogenesis (Ishizuka et al., 2005). Although very little is known about 
the function of ZNF318, it has been shown to interact with both MDM2 and 
HDAC2 (Okoro et al., 2013; Tao et al., 2006), two proteins that also interact 
closely with KAP1 (Schultz et al., 2001; Wang et al., 2005).  
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Based on the location of the primers used for ChIP-qPCR and the 
observed binding of KAP1 at the 5’ to middle region of rep, it is quite possible 
that KAP1 is in fact binding to the p19 promoter. The p19 promoter contains 
two TATA sites, which recruit TBP, two Sp1 binding sites, and a site at 
position -140 that binds an unidentified cellular AAV-activating protein (cAAP) 
(Chejanovsky and Carter, 1989; Pereira and Muzyczka, 1997b; Srivastava et 
al., 1983). Transactivation of p19 by Rep appears to require both an Sp1 site 
and the cAAP site (Pereira and Muzyczka, 1997b) and is mediated by 
interactions between Sp1 bound at p19 and Rep bound at p5, which bring 
the p5 YY1 complex into proximity to p19 (Lackner and Muzyczka, 2002). 
Interestingly, recruitment of KAP1-7SK snRNP complexes to sites of paused 
RNA pol II exactly mirrors the occupancy profiles of Sp1 and TBP 
(McNamara et al., 2016), which are components of pre-initiation complexes 
and which both interact with Rep. It is conceivable then that KAP1-7SK 
snRNP complexes are bound to the p19 promoter, where they play a role in 
the release of paused RNA pol II upon stimulation by helper virus proteins. 
Furthermore, KAP1 has been shown to bind directly to YY1 in mouse ES 
cells (Schlesinger et al., 2013). Although this interaction was lost upon 
differentiation, it is possible that KAP1 and YY1 may still interact in other 
differentiated cells where both proteins are present. Interactions between 
KAP1 bound at p19 and YY1 bound at p5 may help to form the DNA loops 
necessary for transactivation. Along these lines, Ad E1A-activated YY1 may 
directly provide the cue for release of paused RNA pol II at p19, and 
potentially p40, through interactions with KAP1-7SK snRNP complexes. 
Arguing against this possibility however is the fact that depletion of KAP1 
results in a decrease in the magnitude of induction of KAP1-7SK snRNP-
regulated promoters (McNamara et al., 2016), whereas we observed 
enhanced transcription and replication in the context of KAP1 depletion. 
Furthermore, KAP1 binding to the AAV2 genome results in downstream 
histone methylation, which is not known to be characteristic of KAP1 binding 
sites associated with proximal promoter pausing. Further analysis of p19 
transcription in the absence of helper virus coinfection will be necessary to 
determine the potential contribution of this mechanism to AAV gene 
regulation.  
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Many viral pathogens must contend with, modulate, and utilize host 
chromatin machinery during infection to promote efficient lytic replication, 
control persistent latent states, and circumvent potential cellular chromatin 
repression. In this chapter, we demonstrate for the first time a role for the 
epigenetic regulation of AAV replication and gene expression. We show that 
the latent AAV2 genome is chromatinized and repressed through KAP1-
mediated histone methylation. These data place our budding understanding 
of AAV chromatin regulation on firmer footing alongside what is already 
known for other DNA viruses, and further presents the possibility that 
observations made for other viruses, in particular Ad5 and HSV-1, might also 
be extrapolated to AAV. In the following chapter, we investigate the 
mechanisms through which AAV is able to counteract this repression so as to 





















Chapter 5. The AAV2 Rep proteins counteract KAP1 repression of latent 
viral genomes through antagonism of the protein phosphatase PP1 
 
5.1 Introduction 
In the previous chapter, we demonstrated that recruitment of KAP1 to 
the latent AAV2 genome leads to methylation of AAV2-associated H3K9. 
Given that AAV2 is capable of replication without the need for KAP1 
depletion however, we next asked how the transcriptionally repressive 
activity of KAP1 is modulated during lytic AAV2 replication such as to enable 
viral gene expression and DNA replication. One possibility lays in the 
numerous post-translational modifications of KAP1 – in particular, 
phosphorylation of KAP1 at serine 824 (p-KAP1-S824). Upon induction of 
DNA DSBs, ATM-mediated phosphorylation of KAP1-S824 interferes with the 
interactions between KAP1, CHD3, and SETDB1, leading to release of the 
repressive complex and an associated global relaxation of heterochromatin 
(Goodarzi et al., 2011; Noon et al., 2010; Ryan et al., 1999; Ziv et al., 2006). 
This has been shown to be necessary for efficient DNA repair and enhanced 
survival after ionizing radiation, an effect thought to result from the increased 
access of DNA repair factors to sites of damage (White, 2006).   
 Phosphorylation of KAP1-S824 is also associated with a secondary 
loss of KAP1 corepressor activity. Indeed, phosphorylation of KAP1-S824 
was shown to enhance p21, Gadd45α, Bax, Puma, and Noxa upregulation 
after DSB induction (Lee et al., 2007; Li et al., 2007b). Phosphorylation of 
KAP1-S824 is also linked to the transcriptional derepression of KAP1-
regulated viral elements. During KSHV infection, KAP1 is recruited to the 
genome by the viral LANA protein where its repression of lytic genes, such 
as k-bZIP and vPK, is crucial to the maintenance of latency (Sun et al., 
2014). Induction of lytic replication through the overexpression of the viral 
transcriptional regulator K-Rta results in the disassociation of KAP1 and a 
subsequent loss of HP1 and H3K9me3, and, consequently, reactivation of 
the viral genome (Chang et al., 2009). As reactivation progresses, the newly 
expressed viral kinase vPK inactivates KAP1 corepressor activity through 
phosphorylation of KAP1-S824, suggesting that counteraction by the virus is 
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necessary for full reactivation and maintenance of lytic replication (Chang et 
al., 2009). Similar results were observed for CMV, where p-KAP1-S824 was 
found to be associated with actively replicating but not latent viral DNA. The 
investigators here suggested that phosphorylation of KAP1-S824 was 
necessary to render the CMV genome permissive to transcription through the 
relaxation of viral heterochromatin, after which full viral gene expression 
became possible through NF-κB activation (Rauwel et al., 2015).  
 Upon completion of DNA repair, steady-state levels of KAP1-mediated 
heterochromatin and transcriptional repression are restored by the 
serine/threonine phosphatases PP4 and PP1 (Lee et al., 2012; Li et al., 
2010), which serve to remove the phosphate group from KAP1-S824, thereby 
restoring KAP1 interactions with CHD3 and SETDB1. The PP1 catalytic 
subunit (PP1cs) exists in several different isoforms – PP1α, PP1β, or PP1γ – 
of which PP1α/β have been shown to regulate KAP1-S824 phosphorylation 
(Li et al., 2010). PP1 is involved in regulating a vast array of cellular activities, 
including glycogen metabolism, cell progression/mitosis, the cellular DDR, 
and protein synthesis (Ceulemans and Bollen, 2004; Cohen, 2002; Tang et 
al., 2008). This is achieved through the association of the PP1cs with 
numerous PP1 regulatory subunits, such as the nuclear inhibitor of PP1 
(NIPP1), which are necessary to regulate the pleiotropic effects of PP1 
activity by correctly targeting PP1cs to its various substrates. PP1cs interacts 
with its regulatory subunits through a consensus PP1-docking motif, [KR][X]0-
1[VI]{P}[FW], the  mutation of which often abolishes the binding between 
PP1cs and its regulatory components (Hendrickx et al., 2009). 
 In this chapter, we investigated the possible relationship between the 
phosphorylation of KAP1-S824 and AAV2 replication. Given the observed 
repression of the AAV2 genome by KAP1 under latent conditions, we 
hypothesized that phosphorylation of KAP1-S824 would be necessary to 
relieve KAP1 corepressor activity and allow for the initiation of AAV2 gene 
expression and replication. We found that levels of p-KAP1-S824 are greatly 
enhanced during wtAAV2 replication, and we demonstrate a correlation 
between the observed enhanced levels of p-KAP1-S824 and interactions 
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between the AAV2 Rep52 and Rep78 proteins, the phosphatase PP1, and 
the nuclear inhibitor of PP1 (NIPP1). Furthermore, we show that Rep proteins 
unable to support the interaction with PP1 and NIPP1 are also unable to 
support AAV2 transcription and replication, demonstrating a potential role for 































5.2.1 AAV2 replication correlates with the inactivation of KAP1 
corepressor activity through phosphorylation of KAP1-S824 
Upon the induction of DNA double strand breaks (DSB), ATM-
dependent phosphorylation of KAP1 at serine 824 (S824) results in release 
of the repressive complex, relaxation of heterochromatin, and relief of 
transcriptional repression (Goodarzi et al., 2011; Li et al., 2007). We 
questioned whether AAV2 replication was associated with phosphorylation of 
KAP1-S824, which would suggest a requirement for the inactivation of KAP1 
corepressor activity. We first explored this possibility by monitoring levels of 
phosphorylated KAP1-S824 (p-KAP1-S824) in cells infected with increasing 
MOIs of either AAV2 or recombinant AAV2 (rAAV2) in the presence of Ad5. 
rAAV2 is comprised of only the viral ITRs flanking a GFP transgene cassette, 
and as such is replication defective. However the ITRs are known to recruit 
components of the Mre11/Rad50/NBS1 (MRN) complex – the principal 
mediator of ATM activation – resulting in the silencing of rAAV genomes 
(Schwartz et al., 2007). While this mechanism appears to be independent of 
the activation of downstream effectors (Lentz et al., 2015; Schwartz et al., 
2009), it has nevertheless been shown that ATM-/- cells display enhanced 
rAAV transduction (Cataldi and McCarty, 2013). We therefore used rAAV2 to 
control for the input of these structures. A clear dose-dependent increase in 
p-KAP1-S824 was observed in cells infected with AAV2, but not rAAV2 
(Figure 29A). Ad5 infection alone did not trigger any observable 
phosphorylation of KAP1-S824. As this suggested a requirement for active 
replication, we next performed a time course to determine if phosphorylation 
of KAP1-S824 could be related to replication and coinciding with Rep 
expression. 293T cells were infected with either AAV2 or rAAV2 in the 
presence of Ad5, and p-KAP1-S824 levels were monitored by western 
blotting at 4h, 18h, 28h, and 42h post infection. In cells coinfected with AAV2 
and Ad5, high levels of p-KAP1-S824 were apparent by 18 h post infection. 
Furthermore, the increase in p-KAP1-S824 levels correlated very well with 
the onset of Rep expression (Figure 29B). Phosphorylation of KAP1-S824 
was also detectable in the context of Ad5 infection alone but appeared to be 
much weaker and occurred at later time points, pointing to the potential for 
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two independent pathways to the phosphorylation of KAP1-S824 by AAV2 
and Ad5. 
 
Figure 29. AAV2 replication leads to robust phosphorylation of KAP1-S824 
(A) 293T cells infected with increasing MOIs (VG/cell) of either AAV2 or rAAV2 in the 
presence of Ad5 (2 PFU/cell)) were monitored for levels of p-KAP1-S824 42h after infection 
by western blotting. (B) 293T cells infected with Ad5 alone (2 PFU/cell), or coinfected with 
Ad5 and either AAV2 or rAAV2 (1000 VG/cell) were monitored for p-KAP1-S824 levels by 
western blot at 4h, 18h, 24h, and 42h after infection. 
 
5.2.2 The AAV2 Rep proteins Rep52 and Rep78 mediate 
phosphorylation of KAP1 independently of ATM activation 
The observed Rep-KAP1 interaction and correlation between the 
onset of Rep expression and the phosphorylation of KAP1-S824 led us to 
ask whether the Rep proteins might be directly modulating KAP1 activity. To 
address this, cells transfected with various Rep proteins were monitored for 
p-KAP1-S824 levels by western blotting 27h after transfection. The large Rep 
proteins possess endonuclease activity shown to trigger DNA damage, and 
all four Rep proteins share a helicase domain with the potential to also 
disrupt DNA. In order to minimize the possibility of DDR-dependent induction 
of p-KAP1-S824, endonuclease mutants (Y156F) of Rep68 and Rep78, and 
catalytic ATPase mutants (K340H) of all four Rep proteins were used 
(Chejanovsky and Carter, 1990; Dutheil et al., 2014). Phosphorylation of 
KAP1-S824 was evident in the presence of both Rep52 and Rep78, 
independently of either endonuclease or ATPase activity (Figure 30A). Basal 
levels of p-KAP1-S824 were also visible with Rep40 and Rep68, but were 3- 
to 6-fold lower than for Rep52 and Rep78. These data suggest that the Rep 
proteins, in particular Rep52 and Rep78, actively mediate phosphorylation of   
KAP1-S824 via an unknown, DDR-independent mechanism.         
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Figure 30. Rep 52 and Rep78 mediate phosphorylation of KAP1-S824 independently of 
ATM activation. 
(A) 293T cells transfected with the various Rep proteins were blotted for p-KAP1-S824 levels 
by western blotting 27h after transfection. Rep ATPase mutants (K340H) and endonuclease 
mutants (Y156F) were used to minimize the possibility of DDR-mediated KAP1 
phosphorylation. (B) 293T cells pretreated with either DMSO or an ATM inhibitor (ATMi) 
were transfected with and empty vector (EV), Rep52, or Rep78. Cells were harvested 48 h 
after transfection for analysis of p-KAP1-S824 levels by western blotting. Levels of 
phosphorylated Chk2 (p-Chk2) were monitored to assess efficiency of ATM inhibition. p-
KAP1-S824 levels were quantified using ImageJ software and were normalized to Rep levels 
to correct for differences in transfection efficiency as a result of pretreatment with ATMi. 
Values are reported as mean±SEM, n=4. (C) DMSO or ATMi treated 293T cells were 
infected with Ad5 (2 PFU/cell) alone, AAV2 (10 IU/cell) alone, or coinfected with Ad5 and 
AAV2. Cells were harvested 48h after infection for analysis of p-KAP1-S824 levels by 
western blotting. p-KAP1-S824 levels were quantified using ImageJ software. Values are 
reported as mean±SEM, n=4. 
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To further confirm the independence of this response from the 
conventional ATM-mediated pathway, we repeated these experiments in the 
presence of an ATM inhibitor (ATMi). 293T cells were treated with either 
DMSO or ATMi and then transfected 4 hours later with Rep52 or Rep78, and 
p-KAP1-S824 levels were monitored 27h after transfection by western 
blotting. Phosphorylated Chk2 (p-Chk2) was also monitored to control for the 
efficiency of ATM inhibition. Due to difficulties achieving similar expression 
levels of Rep in DMSO- and ATMi-treated cells (Figure 30B, lanes 2 and 5, 
lanes 3 and 6), levels of p-KAP1-S824 were normalized to Rep expression 
rather than HSP90 for the purpose of quantification. After normalization, no 
significant difference in Rep-mediated p-KAP1-S824 levels was apparent in 
ATMi treated cells as compared to controls (Figure 30B). We also performed 
this experiment in the context of AAV2 infection. 293T cells pretreated with 
either DMSO or ATMi were infected with Ad5, AAV2, or Ad5 and AAV2 and 
monitored for p-KAP1-S824 levels by western blotting 27h after infection. 
Here as well, no difference in p-KAP1-S824 levels were apparent in 
coinfected cells pretreated with ATMi as compared to controls (Figure 30C). 
Taken together, these data suggest that increased levels of phosphorylated 
KAP1-S824 during productive AAV2 infection is supported by the AAV2 
Rep52 and Rep78 proteins independently of ATM activation.  
Upon induction of DNA double strand breaks (DSB), ATM-mediated p-
KAP1-S824 rapidly localizes to sites of damage, forming foci with other 
mediators of repair such as 53-BP1 and γ-H2AX (Noon, 2010; Goodarzi, 
2008). To gain more insight into the possible mechanism through which the 
Rep proteins mediate phosphorylation of KAP1-S824, we used confocal 
microscopy to visualize the intranuclear localization of Rep78 and p-KAP1-
S824. 293T cells pretreated with ATMi or DMSO were transfected with 
Rep78-GFP, or an empty vector (EV) control. Cells were also infected with 
Ad5 in order to trigger the formation of replication centers (RC), where we 
hoped to identify colocalization of Rep78-GFP and p-KAP1-S824. Robust 
pan-nuclear phosphorylation of KAP1-S824 was apparent in the presence of 
Rep78-GFP, both in cells treated with ATMi and controls, again confirming 
our previous observation that ATM activation is not essential for Rep-
mediated p-KAP1-S824 (Figure 31). No difference in intranuclear localization 
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was observed for Rep78-GFP in cells infected with or without Ad5 however, 
indicating that Ad5 infection failed to trigger the formation of RCs by Rep78-
GFP. Equally, no difference was observed in p-KAP1-S824 localization in the 
presence of Ad5 infection. Without triggering the formation of RCs, it is 
impossible to judge the degree of colocalization between Rep and p-KAP1-
S824, as both display a pan-nuclear pattern of staining. It will be necessary 
to repeat these experiments in the context of wild type AAV2 infection as it is 
likely that the presence of actively replicating AAV2 genomes is necessary 
both to trigger the formation of RCs as well as to provide a site on which foci 
of p-KAP1-S824 are able to form. Various time points will also need to be 
tested. Localization of p-KAP1-S824 to DSB foci has been shown to occur 
within minutes of assault and to dissipate rapidly into pan-nuclear staining, as 
observed here. Interestingly, low levels of p-KAP1-S824 were also noticeable 
in cells infected with Ad5 alone, which were lost in cells treated with an ATM 
inhibitor, lending credence to the notion that the Rep proteins and Ad5 lead 




Figure 31. Immunofluorescence analysis of Rep78-GFP and p-KAP1-S824 intracellular 
localization. 
DMSO or ATMi-treated 293T cells were transfected with Rep78-GFP or an empty vector 
control (EV), with or without Ad5 (2 PFU/cell) infection (left and right, respectively). Cells 
were fixed 24h after Ad5 infection for immunofluorescence analysis of Rep78-GFP and p-
KAP1-S824 intracellular localization. 
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5.2.3 Phosphorylation of KAP1 by Rep52 and Rep78 is dependent on 
their shared zinc finger domain.  
Given that Rep52 and Rep78 share a C-term zinc finger (ZNF) domain 
not present in Rep40 or Rep68, we suspected this region might be important 
for the phosphorylation of KAP1-S824. As the Rep proteins have no kinase 
activity, it is probable that they mediate phosphorylation of KAP1-S824 
through the actions of an intermediary protein, through the coopting of a 
kinase or inhibition of a phosphatase for example. Indeed, the Rep ZNF 
domain has already been implicated in several protein interactions, including 
the recruitment of the kinase PKA. With this in mind, we generated a series 
of C-terminal truncation mutants in which the ZNF domain was progressively 
removed (Figure 32A). These were expressed in 293T cells, and p-KAP1-
S824 levels were monitored by western blotting 27h after transfection. 
Strikingly, even the smallest truncation (Δ43) completely abrogated 
phosphorylation of KAP1-S824. This was true of both Rep52 and Rep78 
(Figure 32B). As this effect was so profound, we next questioned whether the 
Rep proteins might in fact be interacting directly with KAP1 through the ZNF 
domain. We performed CL-IP for FLAG-tagged proteins in 293T cells 
coexpressing each of the Rep52 truncation mutants with either FLAG-GFP or 
FLAG-KAP1. All three of the truncations mutants readily interacted with 
FLAG-KAP1 but not with FLAG-GFP (Figure 32C), confirming that the Rep 
proteins are acting through an intermediary protein to mediate the observed 




Figure 32. Phosphorylation of KAP1-S824 by Rep52 and Rep78 is dependent on the 
shared ZNF domain. 
(A) Schematic diagram representing full length Rep52, comprising an ATPase domain 
(AAA+) shown in blue and zinc finger domain (ZNF) shown in yellow, and the C-terminal 
truncation mutants in which the ZNF domain is progressively removed. Black bars indicate a 
CXXC zinc-binding motif, and red bars a CXXH zinc-binding motif. (B) 293T cells transfected 
with Rep52, Rep78, various ZNF truncation mutants or an empty vector control (EV) were 
harvested for analysis of p-KAP1-S824 levels 48h after transfection by western blotting. (C) 
Cross-linked IP for FLAG-tagged proteins in lysates from 293T cells transfected with FLAG-
KAP1, or a FLAG-GFP control, and Rep52 or the Rep52 ZNF truncation mutants. Values are 
reported as mean±SEM, n=3.  
 
 
5.2.4 Rep52 and Rep78 interact with the phosphatase PP1 and its 
negative regulator NIPP1 to enhance levels of phosphorylated KAP1 
Potential cellular factors that could be interacting with Rep to mediate 
phosphorylation of KAP1-S824 include protein phosphatase 1 (PP1) and its 
specific inhibitors. Upon completion of DNA repair, basal levels of p-KAP1-
S824 are restored through the combined activities of PP1α, PP1β, and 
protein phosphatase 4 (Li et al., 2010; Pfeifer, 2012).  Several regulatory 
subunits of PP1 were identified as interaction partners for Rep alongside 
KAP1 in our original BioID screen, including the nuclear inhibitor of PP1 
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(NIPP1/PPP1R8), which led us to hypothesize that the Rep proteins could be 
interfering with this pathway. We postulated that Rep was inhibiting PP1 
activity by bridging the interaction between PP1 and its negative regulator 
NIPP1, thus leading to increased nuclear levels of p-KAP1-S824.   
To test this hypothesis, we first searched for potential PP1 binding 
sites within the Rep sequence. Using the conserved consensus binding 
sequence [KR][X0-1][VI]{P}[FW] as our guideline (Meiselbach et al., 2006), we 
discovered one putative binding site in the ATPase domain (K372-W376), 
partially overlapping with the Walker B motif (Figure 33A). Co-IP experiments 
in cells expressing FLAG-PP1α and Rep52 confirmed the physical interaction 
between Rep and PP1α (Figure 33B). However, as both PP1-α and –β share 
the same substrate binding domain, it is impossible to know from this 
experiment which of the isoforms Rep might interact with in a physiological 
context. In order to assess the relevance of this interaction with respect to 
the Rep-mediated phosphorylation of KAP1-S824, we introduced a lysine to 
alanine point mutation at the first lysine in the putative PP1 binding site 
(K372A). This was the only possible site in which to introduce a mutation due 
to the overlap between the consensus PP1 binding site and Walker B motif. 
Surprisingly, the PP1-binding mutant Rep52K372A also physically interacted 
with FLAG-PP1α (Figure 33C). Interestingly however, when co-IP 
experiments were repeated with the inclusion of the Rep ATPase mutant and 
PP1-binding/ATPase double mutant (Rep52K340H and Rep52K340H K372A), 
Rep52K340H again interacted with FLAG-PP1α, while the interaction between 
FLAG-PP1α and Rep52K340H K372A was lost (Figure 33C). Importantly, 
mutation of the PP1 binding site alone was sufficient to completely abrogate 













Figure 33. Rep52 binds the protein phosphatase PP1α, and mutation of the binding 
site abrogates Rep-mediated phosphorylation of KAP1-S824. 
(A) Schematic diagram depicting the putative PP1-binding site in the Rep ATPase domain. 
The Walker B motif is outlined in black, and the partially overlapping consensus binding site 
is outlined in pink. Lysine 372 in position 1 of the binding site is shown in red. (B) Co-IP for 
FLAG-tagged proteins in lysates from 293T cells transfected with Rep52 and either FLAG-
PP1α or FLAG-GFP control. (C) Co-IP for FLAG-tagged proteins in lysates from 293T cells 
transfected with either FLAG-PP1α or FLAG-GFP control, and Rep52, the PP1 binding 
mutant Rep52K372A, the ATPase mutant Rep52K340H, or the double mutant Rep52K340H K372A. 
(D) 293T cells transfected with empty vector control (EV), Rep52, or Rep52K372A were 
analyzed 27h after transfection for p-KAP1-S824 levels by western blotting. 
Values are reported as mean±SEM, n=3.  
 
 
Given the proximity of the K372A mutation to the Walker B motif, we 
deemed it necessary to ensure that the ATPase activity of Rep52K372A had 
not been compromised. Transcriptional regulation by the Rep proteins is 
dependent on a functional ATPase domain, and so we addressed this 
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concern by assessing the ability of Rep52K372A to regulate expression from 
the AAV2 p5 promoter. The previously described p5-mCherry reporter 
construct was cotransfected with either wild-type Rep52 or Rep52K372A, and 
p5 activity was determined 48 h after transfection by western blotting for 
mCherry. Repression of p5 by the PP1 binding mutant Rep52K372A was equal 
to that of wild type Rep52 (Figure 34A), confirming that the loss of KAP1-
S824 phosphorylation by Rep52K372A was not an off-target effect of having 
disrupted ATPase function. In addition, we were able to demonstrate by CL-
IP that the K372A mutation did not simply interfere with the interaction 
between Rep and KAP1 (Figure 34B), further supporting the hypothesis that 
the loss of a functional interaction between Rep and an intermediary protein, 
potentially PP1, is responsible for the reduced phosphorylation of KAP1-
S824 in the presence of Rep52K372A.   
 
      
 
Figure 34. Validation of the Rep-K372A PP1-binding mutant. 
(A) 293T cells transfected with a p5-mCherry reporter construct and Rep52, Rep52K372A, or 
empty vector control (EV) were harvested 48h after transfection. p5 activity was determined 
by western blotting for mCherry. Values are reported as mean±SEM, n=3 (B) Cross-linked IP 
for FLAG-tagged proteins from lysates of 293T cells transfected with FLAG-KAP1 and GFP 
control, Rep52, PP1 binding mutant Rep52K372A, ATPase mutant Rep52K340H, or the double 
mutant Rep52K340H K372A. 
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Based on our earlier observation that the Rep ZNF domain is also 
crucial for the phosphorylation of KAP1-S824, we next asked whether this 
domain could be recruiting NIPP1 and forming a complex with PP1 bound at 
the ATPase domain. To address this, we performed CL-IP with lysates from 
cells expressing NIPP1 with Rep52, each of the Rep52 ZNF truncation 
mutants, or the PP1-binding mutant Rep52K372A. NIPP1 readily interacted 
with both Rep52 and Rep52Δ42, while a progressive loss of interaction was 
apparent with the two larger truncations, Rep52Δ63 and Rep52Δ87 (Figure 
35). This displayed a degree of variation however, ranging from a complete 
loss of binding to only a modest decrease as compared to Rep52Δ42. 
Interestingly, the interaction with NIPP1 was consistently lost with 
Rep52K372A. Taken together, these data suggest that PP1 may in fact 
represent the main binding partner for Rep, and that NIPP1 is recruited as a 
consequence. It is conceivable that the ZNF domain acts to stabilize the 
PP1-NIPP1 holoenzyme, leading to prolonged inhibition of PP1 and 
increased levels of nuclear p-KAP1-S824.  
 
                  
Figure 35. Rep interaction with the PP1 inhibitor NIPP1 is dependent on PP1 binding 
and intact Rep ZNF domain. 
Cross-linked IP for T7-tagged proteins in lysates from 293T cells transfected with GFP-
NIPP1, and T7-GFP, T7-Rep52, T7-Rep52 ZNF truncation mutants, or the PP1 binding 





5.2.5 Inhibition of PP1 is essential for AAV2 transcription and 
replication 
To determine the functional relevance of the Rep-PP1-NIPP1 
interaction in the AAV2 life cycle, we performed replication experiments with 
an AAV2 plasmid containing the PP1 binding mutation (Rep-K372A). The 
wild-type plasmid, pAV2 (Rep-WT), was used as a positive control, and the 
NTP-binding/ATPase mutant K340H (Rep-K340H), which does not support 
AAV2 replication (Chejanovsky and Carter, 1990), was used as a negative 
control. Cells were transiently transfected with each of the infectious 
plasmids and infected with Ad5 4h after transfection. Cells were then 
harvested 72h after transfection for quantification of vector genomes, and rep 
and cap transcription levels. As expected, Rep-WT fully supported AAV2 
genome replication in the presence of Ad5, while no response was apparent 
in the presence of either Rep-K340H or Rep-K372A (Figure 36A). For the 
transcriptional analysis, primer sets targeting p5, p5 + p19, and p5 + p19 + 
p40 transcripts were used – representing respectively the large Rep proteins 
alone, all Rep proteins, and Rep and Cap proteins together – as the use of a 
single polyadenylation signal by AAV RNAs precludes the analysis of p19 
and p40 transcripts separately from p5 transcripts. We observed an increase 
in mRNA levels in response to Ad5 coinfection with all three primer sets in 
the presence of Rep-WT (Figure 36B). Base-line transcription levels were 
substantially higher with Rep-K340H than with Rep-WT due to the reduced 
capacity for transcriptional regulation of this Rep mutant (Kyostio et al., 
1995), however no response to Ad5 infection was apparent. Similarly, no 
response to Ad5 infection was observed in the presence of Rep-K372A 
(Figure 36B). Interestingly, base-line expression levels from p19 and p40, but 
not p5, were elevated for Rep-K372A, albeit at significantly lower levels than 
for Rep-K340H.  
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Figure 36. Interaction between Rep, PP1, and NIPP1 is essential for AAV2 replication 
and transcription.  
(A-B) 293T cells transfected with pAV2-WT (Rep-WT), pAV2-K340H (Rep-K340H), or pAV2-
K372A (Rep-K372A), and infected with Ad5 (4 PFU/cell) 4h after transfection were harvested 
72h after transfection for DNA and RNA extraction. (A) Real time qPCR analysis of AAV2 
replication. (B) RT-qPCR analysis of AAV2 gene transcription under the same conditions. p5 
(left panel) indicates that the data is specific for p5 transcripts; primers that bind after p19 but 
before p40 (middle panel) detect transcripts generated from both p5 and p19; p40 primers 
(right panel) detect transcripts from all three promoters. Fold change was calculated relative 
to the transcript levels in the presence of WT Rep but in the absence of Ad5.  
Values are reported as mean±SEM, n=3.  
 
To test this further, we next performed replication experiments in 293T 
cells depleted for KAP1 to determine whether replication in the presence of 
Rep-K372A could be rescued. Control (shEMPTY) and KAP1-depleted 
(shKAP1) 293T cells were transfected with either Rep-WT or Rep-K372A and 
infected with Ad5 as described above. Cells were then harvested 72h after 
transfection for quantification of vector genomes and rep and cap 
transcription levels. As shown in the first set of experiments, Rep-WT fully 
supported replication in the presence of Ad5, and while the effect was less 
pronounced under these conditions than in our original replication 
experiments, Rep-WT-supported replication was enhanced ~2-fold in KAP1-
depleted cells as compared to controls (Figure 37A). Interestingly, a very 
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modest increase in replication was also detectable in KAP1-depleted cells 
transfected with Rep-WT in the absence of Ad5 infection as compared to 
controls, although these experiments will need to be repeated to determine 
the significance of this observation. As expected, Rep-K372A was 
unresponsive to Ad5 infection in control cells. Surprisingly this was also true 
in KAP1-depleted cells, indicating that depletion of KAP1 is not sufficient to 
rescue replication by Rep-K372A (Figure 37A). This was confirmed at the 
transcriptional level, where Rep-K372A was unresponsive to Ad5 infection in 
control as well as KAP1-depleted cells with all primer sets used (Figure 37B). 
Modest disregulation of p19 and p40 was again observed in the presence of 
Rep-K372A. Transcription in the presence of Rep-WT however did not 
correlate with the genome replication data; p5 transcription in response to 
Ad5 infection appeared reduced in KAP1-depleted cells as compared to 
controls, and no significant difference between controls and KAP1-depleted 
cells was detectable for p19 and p40 transcription.  
Taken together, these data suggest that, while the interaction of Rep 
with PP1 and the associated enhancement of p-KAP1-S824 levels appear to 
play a role in AAV2 replication, the mechanism is more complex than we yet 
understand. It is possible that the minimal levels of KAP1 still present in 
KAP1-depleted cells are sufficient to maintain repression of the AAV2 
genome in the context of Rep-K372A. It is also possible that phosphorylated 
KAP1-S824 has an entirely separate function of which we are not yet aware. 
Alternatively, the observed disregulation of p19 and p40 in the presence of 
Rep-K372A suggests that additional interactions with unknown factors 
involved in the transcriptional regulation of these promoters may be 
interrupted. !
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Figure 37. KAP1 depletion does not rescue Rep-K372A-supported replication 
(A-B) Control and KAP1-depleted 293T cells transfected with pAV2-WT (Rep-WT) or pAV2-
K372A (Rep-K372A) and infected with Ad5 (4 PFU/cell) 4h after transfection were harvested 
72h after transfection as described above. (A) qPCR analysis of AAV2 replication. (B) RT-
qPCR analysis of AAV gene expression as described for Figure 36.  
















In the context of DNA damage, the ATM kinase phosphorylates KAP1-
S824, resulting in dispersion of the repressive complex, relaxation of 
heterochromatin, and relief from transcriptional repression, after which basal 
levels of p-KAP1-S824 are restored by the phosphatases PP1α/β and PP4 
(Cheng et al., 2014). Reactivation of both CMV and KSHV is characterized 
by the phosphorylation of KAP1-S824, mediated respectively by the cellular 
kinase mTOR and the viral kinase vPK (Chang et al., 2009; Rauwel et al., 
2015). Similarly, we show here that AAV2 lytic replication is associated with a 
significant increase in p-KAP1-S824 levels, suggesting that KAP1 
corepressor activity must be inactivated for replication to take place. In the 
context of CMV, the forced phosphorylation of KAP1-S824 by the ATM 
activator chloroquinine results in the reactivation of latent CMV from non-
permissive CD34+ HSCs, as demonstrated by increased levels of viral RNA 
and DNA, the presence of IE antigens, and the release of replication 
competent virus into the supernatants (Rauwel et al., 2015). The levels of 
gene expression and DNA accumulation in this context are still significantly 
lower than what is observed when CMV-harboring precursors are 
differentiated into permissive macrophages or DCs however. The 
investigators showed that treatment of cells with tumor necrosis factor α 
(TNFα) further boosted viral RNA levels and virion production by a factor of 
10 as a result of NF-κB induction, suggesting that, although necessary to 
remove repressive marks from viral chromatin, phosphorylation of KAP1-
S824 is not sufficient to fully reactivate the viral genome. It is likely that AAV2 
is subject to a similar scenario, where phosphorylation of KAP1-S824 is 
necessary to render the viral genome permissive to transcription by removing 
repressive H3K9me3, but that transcription is only initiated in the presence of 
helper virus factors. Indeed, this model is supported by our earlier 
observation that KAP1 depletion, which is equivalent to p-KAP1-S824 with 
respect to heterochromatinization, was not sufficient to initiate any 
observable AAV2 transcription or replication in the absence of Ad5. 
Another interesting observation made during the forced reactivation of 
CMV through ATM activation was that elevated levels of p-KAP1-S824 were 
only visible in cells that were also positive for CMV IE antigens (Rauwel et 
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al., 2015). The investigators interpreted this to mean that KAP1-S824 was 
phosphorylated through the combined activities of ATM and some CMV-
encoded factor. Similarly, the direct phosphorylation of KAP1-S824 by the 
KSHV kinase vPK was shown to enhance viral reactivation (Chang et al., 
2009). Interestingly, further analysis of vPK substrates revealed overlapping 
specificity between vPK and ATM kinases, suggesting that the relevance of 
vPK for viral reactivation may be dependent on the strength of ATM 
activation (Chang et al., 2009). Here, we also show that AAV2 lytic 
replication is associated with significantly enhanced levels of p-KAP1-S824. 
Furthermore, we show that this phosphorylation is correlated with 
interactions between Rep, the phosphatase PP1, and its negative regulator 
NIPP1, suggesting that Rep may act as a PP1 inhibitor to increase nuclear 
levels of p-KAP1-S824. Like KSHV vPK, the large Rep proteins have been 
shown to induce low levels of phosphorylation of the DDR factors ATM, 
H2AX, and SMC1 (Schwartz et al., 2009). It is interesting to consider what 
role this might have during AAV2 and Ad5 coinfection, where Ad5-mediated 
degradation of the MRN complex and the resulting inactivation of the DDR 
NHEJ pathway is necessary for both Ad5 and AAV2 replication (Schwartz et 
al., 2007; Stracker et al., 2002). It is conceivable that, under these 
conditions, the Rep proteins play an important role in phosphorylating 
certain downstream substrates of MRN activation that may be beneficial for 
AAV replication, such as KAP1. Indeed, while ATM activation is detrimental 
to rAAV replication, it has been shown to be necessary for efficient wtAAV 
replication (Collaco et al., 2009; Schwartz et al., 2007), supporting a role for 
a downstream effector in the efficient propagation of wtAAV.  
It is also noteworthy that KSHV, CMV, and AAV2 – three biphasic DNA 
viruses – are all targets of KAP1 while also seeming to contain 
countermeasures to KAP1 repression. This suggests that these viruses may 
in fact have domesticated KAP1 repression in order to preserve their latency 
until conditions for replication are met. Like all herpesviruses, KSHV and 
CMV establish latent infections, persisting as nuclear episomal DNA. 
Although still a matter of some debate, AAV latency can be established 
through integration into the host genome, or also through long-term 
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episomal persistence. Mounting evidence suggests that innate sensing of 
foreign DNA occurs not only in subcellular compartments in which DNA 
should not exist, but also within the nucleus itself. The interferon-inducible 
protein IFI16 is an innate DNA sensor (Unterholzner et al., 2010) that 
localizes predominantly to the nucleus in non-immune cells (Li et al., 2012; 
Orzalli et al., 2012), where it has been shown to induce responses to 
replicating CMV and KSHV (Kerur et al., 2011; Li et al., 2013). Interestingly, 
IFI16 has also been shown to mount responses in B cells containing latent 
episomal forms of KSHV or EBV (Ansari et al., 2013; Singh et al., 2013). 
IFI16 recognizes foreign DNA by tracking along stretches of exposed 
dsDNA to assemble supramolecular signaling platforms (Stratmann et al., 
2015), and nucleosome formation presents a barrier to these signaling 
complexes. Viral nucleosomes are often generated with slightly different 
conformations than normal host chromatin, (Lieberman, 2008), resulting in 
longer stretches of unprotected DNA and creating the basis for the 
distinction between self and non-self (Stratmann et al., 2015). It is therefore 
possible that heterochromatinization by KAP1 allows latent episomal AAV to 
better evade immune recognition by reducing stretches of exposed viral 
DNA. Heterochromatinization may also help to prevent deleterious 
recombination events, both intramolecularly between the ITRs, and 
intermolecularly with other viral episomes or the host genome, as well as to 
protect the latent viral genome from degradation.   
Upon the induction of lytic replication through helper virus coinfection, 
inhibition of PP1 by Rep52 and Rep78 leads to enhanced levels of p-KAP1-
S824. It is not yet entirely clear how Rep achieves this inhibition. We clearly 
show that Rep52 and PP1 physically interact, however it was necessary to 
mutate the putative PP1-binding site in the background of the additional 
NTP-binding mutation (K340H) in order to abolish this interaction. There is 
precedence to suggest that a functional interaction between PP1 and its 
regulatory subunits is based on multiple points of interaction, only one of 
which necessarily consists of the conserved binding site. It has also been 
demonstrated that mutation of only one interaction site may be sufficient to 
abolish the regulation of PP1 while being insufficient to abolish the actual 
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physical association between PP1 and its regulatory component (Beullens et 
al., 2000; O’Connell et al., 2012). Our results suggest the existence of a 
second interaction site, either defined by the Rep NTP-binding site itself or 
created by the conformational change/dimerization associated with NTP-
binding, which is sufficient to mediate a physical interaction between Rep 
and PP1 but not sufficient to inhibit PP1 activity. It is possible that direct 
binding of Rep to PP1 simply obstructs the substrate binding site necessary 
for interaction with KAP1, however the apparent role for both PP1 and the 
Rep ZNF domain in the interaction between Rep and NIPP1 suggests that 
the three proteins act as a complex, with the ZNF potentially stabilizing the 
PP1-NIPP1 holoenzyme and prolonging PP1 inhibition.  
To complicate matters further, although first identified as a potent 
inhibitor of PP1 (Beullens et al., 1992), NIPP1 does not systematically inhibit 
PP1 activity. NIPP1 is one of the evolutionarily oldest regulators of PP1, and 
more than 1/3 of the nuclear pool of PP1 forms a holoenzyme with NIPP1 
(Jagiello et al., 1995). NIPP1 contains three functional domains: (1) an N-
terminal Forkhead Associated (FHA) domain, which specifically binds 
phosphorylated threonine (p-Thr) residues followed by proline, (2) a central 
PP1-binding domain containing the consensus PP1-binding motif, and (3) a 
multifunctional C-terminal domain that binds RNA, has endoribonuclease 
activity, and inhibits PP1 activity via an unknown mechanism (Beullens et al., 
2000; Jagiello et al., 1995, 1997). Depending on (1) highly dynamic 
electrostatic interactions between NIPP1 and PP1, and (2) the recruitment of 
substrates by either the NIPP1 FHA domain or by PP1 itself, NIPP1 can 
either enhance or inhibit PP1 phosphatase activity (O’Connell et al., 2012). It 
is conceivable then that the NIPP1 FHA domain binds KAP1, effectively 
recruiting PP1 to mediate KAP1-S824 dephosphorylation, and that Rep 
binding to PP1 interferes with this activity. This is unlikely however as KAP1 
does not contain the necessary p-Thr/Pro residues for binding by the NIPP1 
FHA domain, and furthermore we could not detect an interaction between 
KAP1 and NIPP1.  
We show here that the interactions between Rep, PP1, and NIPP1 
can mediate the phosphorylation of KAP1-S824 independently from ATM 
activation, however this does not exclude a role for the activation of effectors 
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of the cellular DDR in the context of a productive infection. In fact, the nature 
of the mechanism outlined above presupposes an initial trigger for KAP1 
phosphorylation, and productive AAV2 infection is known to trigger the robust 
activation of both ATM and DNA-PK. (Schwartz et al., 2009), both of which 
are shown to mediate phosphorylation of KAP1-S824. Taken together, these 
data suggest a two-part mechanism in which the cellular DDR upon initial 
viral infection triggers the phosphorylation of KAP1-S824, a signal then 
potentiated through Rep-mediated antagonism of PP1. This hypothesis may 
also help to explain the common observation that genotoxic stress of virtually 
any form enhances AAV2 replication, as this would presumably lead to a 
DDR-dependent phosphorylation of KAP1-S824.  
Finally, we demonstrate that Rep proteins unable to interact with PP1 
are also unable to support both viral transcription and DNA replication, 
providing a potential link between Rep-mediated inhibition of PP1, 
phosphorylation of KAP1-S824, and AAV2 replication. However, the fact that 
depletion of KAP1 was not sufficient to rescue replication or induction of 
transcription in the context of the PP1-binding mutant Rep-K372A suggests 
that the mechanism involved is more complex than we yet understand. It is 
possible that low levels of KAP1 that remain after depletion are sufficient to 
mediate repression of latent AAV2. Alternatively, depletion of KAP1 may not 
be equivalent to p-KAP1-S824 in the context of AAV2; in other words, p-
KAP1-S824 may have an independent function of which we are not currently 
aware. These observations together with the apparent deregulation of 
transcription from p19 and p40 in the presence of Rep-K372A support a role 
for KAP1 in proximal promoter pausing at these promoters. Depletion of 
KAP1 results in a decrease in magnitude of induction from KAP1-7SK 
snRNP-regulated primary response genes (PRGs) upon stimulation, 
suggesting that KAP1 is necessary for the proper induction of PRGs 
(McNamara et al., 2016). One might imagine that KAP1-7SK snRNP 
complexes regulate pausing of RNA pol II at p19 and p40, maintaining these 
promoters poised for rapid activation upon stimulation by helper virus 
coinfection; this would render p19 and p40 similar to cellular PRGs and thus 
explain why KAP1 depletion would not enhance stimulation of transcription 
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from these promoters. Arguing against this possibility however is the fact that 
no reduction in stimulation from these promoters was observed in the 
presence of Rep-WT after KAP1 depletion. At the same time, PP1 has been 
shown to dephosphorylate and thus deactivate the RNA pol II CTD (Kim et 
al., 2002). Rep proteins unable to inhibit PP1 may as a consequence lead to 
more constitutively active RNA pol II at sites of proximal promoter pausing, 
potentially resulting in the observed deregulation of p19 and p40 transcription 
in the presence of Rep-K372A.  
Alternatively, it is possible that the introduction of the K372A mutation 
has altered another core function of the Rep proteins, which translates to 
deregulated transcription. Rep-K372A may not undergo the oligomerization 
necessary for normal AAV gene regulation, however this should be visible at 
the p5 promoter as well.  Although we showed that Rep52-K372A was as 
efficient as wild type Rep52 in regulating the AAV2 p5 promoter, this is an 
indirect validation of Rep52-K372A activity. It would be prudent to further 
confirm that Rep function is maintained by performing helicase and ATPase 
function assays, as the interruption of either of these activities could have 
serious implications. Finally, it is also possible that the K372A mutation 
interferes in the interaction between Rep and a cellular factor involved in an 
ATPase domain-dependent mechanism of repression by the Rep proteins, 
akin to what is thought to occur with the NTP-binding K340H mutants (Dutheil 
et al., 2014; Kyöstiö et al., 1994). This would lead to deregulation of p19 and 
p40 without necessarily affecting p5, as binding of the RBS at p5 by the Rep 
OBD mediates repression independently from the ATPase domain.   
In conclusion, in this chapter we asked how AAV2 might be released 
from KAP1-mediated repression so as to allow for replication to occur. We 
showed that AAV2 lytic replication is associated with a strong 
phosphorylation of KAP1-S824, suggesting the KAP1 corepressor activity is 
inactivated during replication. We presented evidence to suggest that this 
modulation of KAP1 activity is mediated through complex interactions 
between AAV2 Rep52 (and presumably Rep78 through the shared ATPase 
and ZNF domains) with the phosphatase PP1 and its regulator NIPP1, which 
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lead to enhanced levels of nuclear p-KAP1-S824, and importantly that these 
interactions were necessary for normal AAV2 transcription and replication 
upon helper virus coinfection. While these data establish an active role for 
AAV2 in the regulation of its epigenetic landscape and transcriptional 
competence, there still remains the question of how AAV2 transitions from 
being repressed by KAP1 to actively counteracting KAP1 via the Rep 
proteins. Evidently, basal levels of Rep expression during latency are not 
sufficient to lift KAP1 repression, which implies the need for some biological 
switch. In the next chapter, we investigate the role of the AAV2 helper viruses 




















Chapter 6. KAP1 targeting by the AAV2 helper viruses Ad5 and HSV-1 
as a novel helper function for AAV2 replication with the potential for 
improving recombinant AAV vector production.  
 
6.1 Introduction 
In the previous chapters, we demonstrated that latent AAV2 genomes 
are bound by the corepressor KAP1, leading to the transcriptionally 
repressive methylation of AAV2-associated histones. We were also able to 
show that KAP1 corepressor activity is inactivated through phosphorylation of 
KAP1-S824 during AAV2 lytic replication through interactions between 
Rep52/Rep78, PP1, and NIPP1. This suggests that KAP1 repression must 
be inactivated for AAV2 replication to take place and that the AAV2 Rep 
proteins play an active role in counteracting this repression. The question 
remains however of how latent AAV2 transitions from being bound and 
repressed by KAP1 to actively counteracting this repressor, as the basal 
levels of Rep expression during latency are clearly not sufficient to mediate 
this effect. This implies the existence of a biological switch necessary to 
allow for the upregulation of rep expression prior to the onset of p-KAP1-
S824 accumulation. As AAV2 is a dependovirus, we hypothesized that helper 
viruses could potentially fulfill this role. 
The minimal set of adenovirus helper proteins for AAV replication is 
comprised of E1A, E1B55K, E2A, E4orf6, and VA RNA, which act together to 
directly support viral replication as well as alter the cellular milieu such that it 
becomes conducive to viral replication. E1A directly interacts with the cellar 
factor YY1 to relieve repression of the AAV p5 promoter (Chang et al., 1989; 
Lewis et al., 1995; Shi et al., 1991; Weitzman et al., 1996), the E2A gene 
product is a ssDNA binding protein necessary for the efficient replication of 
ssDNA AAV genomes (Ward et al., 1998), and VA RNA binds the kinase 
PKR to overcome the shutdown of protein translation that is often associated 
with viral infection (Nayak and Pintel, 2007). Of particular relevance to this 
study, E1B55K and E4orf6 act in complex as cullin-based E3 ubiquitin 
ligases to facilitate infection by inducing the degradation of cellular proteins 
that adversely affect viral replication (Harada et al., 2002; Querido et al., 
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2001). E4orf6 forms the core complex with elongins B and C, either Cul5 or 
Cul2, and Rbx1, after which E1B55K binds to the complex and recruits 
substrates for ubiquitination (Blanchette et al., 2004; Cheng et al., 2013; 
Querido et al., 2001). The particular cellular proteins targeted are serotype-
specific (Forrester et al., 2011); in the context of Ad5, a Cul5-based complex 
leads to the degradation of Mre11, DNA ligase IV, Bloom helicase (BLM), 
p53, MDM2, and Tip60 (Baker et al., 2007; Gupta et al., 2013; Orazio et al., 
2011; Querido et al., 2001; Stracker et al., 2002). Degradation of Mre11, DNA 
ligase IV, and BLM serves to inactive the cellular DDR and NHEJ pathway, 
while degradation of p53 and MDM2 prevents apoptosis. Tip60 is a lysine 
acetyltransferase shown to repress transcription from the adenovirus E1A 
promoter (Gupta et al., 2013). Based on this, we asked whether Ad5 infection 
might also lead to the degradation of KAP1 via this pathway. 
Another adenovirus protein that plays an essential role during infection 
is E4orf3. This protein associates with the cellular promyelocytic leukemia 
(PML) protein, the key organizer of PML nuclear bodies (NB) (Carvalho et al., 
1995). PML NBs are functionally complex nuclear domains that recruit an 
astonishing variety of proteins involved in central cellular processes such as 
DNA replication, transcription, epigenetic silencing, and host defense 
mechanisms against viral infection (Lallemand-Breitenbach and de Thé, 
2010; Mao et al., 2011). Through its interaction with PML, E4orf3 reorganizes 
PML NBs into distinctive track-like structures where it sequesters numerous 
cellular proteins involved in DDR and repair pathways (Carson et al., 2009; 
Doucas et al., 1996; Evans and Hearing, 2005). E4orf3 also binds and 
reorganizes to these PML tracks the TIF1 family members TIF1α and TIF1γ, 
which are closely related to KAP1 (TIF1β) (Vink et al., 2012; Yondola and 
Hearing, 2007). In addition, E4orf3 leads to the degradation of TIF1γ 
independently of E1B55K or E4orf6 (Forrester et al., 2012). Interestingly, 
E1B55K was shown to bind all three TIF1 family members, however no 
reorganization or degradation of KAP1 has previously been observed 
(Forrester et al., 2012; Vink et al., 2012; Yondola and Hearing, 2007).   
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Recently however, binding of E1B55K to KAP1 has been suggested to 
play a role during the early stages of adenovirus infection (Bürck et al., 
2015). Adenovirus replication can be restricted at early stages of infection by 
factors that affect the initial decondensation of the viral genome upon entry, 
such as the histone deacetylatse Daxx, which is also targeted for degradation 
by the E1B55K/E4orf6 ubiquitin ligase complex (Schreiner et al., 2010). The 
protein SPOC-1 (survival time-associated PHD protein in ovarian cancer) is 
another cellular factor involved in DNA repair that acts via the selective 
modulation of and cooperation with transcriptionally repressive chromatin 
modifiers, and which has been suggested to inhibit adenovirus 
decondensation through an association with KAP1 (Bürck et al., 2015; 
Schreiner et al., 2013a). Significantly reduced levels of E1B and E4orf6 were 
apparent in adenovirus-infected cells overexpressing KAP1, suggesting 
KAP1 can inhibit adenovirus gene expression, however depletion of KAP1 
had no effect on gene expression or progeny production (Bürck et al., 2015). 
Nevertheless, the investigators showed that KAP1 was efficiently 
deSUMOylated, and thus inactivated as a repressor, during adenovirus 
infection seemingly through interactions with E1B55K (Bürck et al., 2015).  
Based on these observations, we asked whether interactions between 
Ad5 proteins and KAP1 might provide the molecular switch necessary to 
initially release AAV from KAP1-mediated repression by targeting KAP1 for 
degradation, sequestration, or deSUMOylation, for example. To investigate 
this further, we monitored KAP1 protein levels in cells infected with 
increasing concentrations of either Ad5 or HSV-1, which revealed a dose-
dependent degradation of KAP1 in the presence of either helper virus. Based 
on this observation, we propose that KAP1 targeting by Ad5 and HSV-1 
represents an unidentified helper function for AAV replication necessary to 
relieve the viral genome from its latent state. These results then provoked the 
question of whether the modulation of KAP1 protein levels might be used to 
enhance recombinant AAV (rAAV) transduction or replication, as there is 
currently a strong drive to establish methods for the scaling-up of vector 
production and the design of vectors with greater bioactivity. Transduction 
and replication efficiency of various rAAV serotypes and vectors was 
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analyzed in the context of KAP1 depletion, revealing a 2-fold increase in 

































6.2.1 Ad5 and HSV-1 infection leads to the degradation of KAP1 
Since basal levels of Rep expression under latent conditions are not 
sufficient to counteract KAP1, and depletion of KAP1 alone is not sufficient to 
trigger AAV2 transcription and replication, it is conceivable that a biological 
switch is necessary to allow for the upregulation of rep expression prior to the 
onset of p-KAP1-S824 accumulation. As AAV2 is a dependovirus, we 
hypothesized that helper viruses could potentially fulfill this role. Previous 
studies have shown that Ad5 interacts with the very close KAP1 (TIF1-β) 
relatives TIF1-α and TIF1-γ, resulting in the proteasome-mediated 
degradation of TIF1-γ as well as the reorganization of both TIF1-α and TIF1-γ 
to promyelocytic leukemia body tracks (Forrester et al., 2012; Yondola and 
Hearing, 2007). To investigate whether Ad5 targets KAP1 for degradation, 
we infected 293T and HeLa cells with increasing MOIs of Ad5 and monitored 
KAP1 levels by western blot. We observed a clear, dose-dependent 
depletion of KAP1, with almost complete loss at the highest MOI (Figure 
38A). The reduction in KAP1 levels was not apparent in previous replication 
experiments as the low Ad5 MOI used in these experiments (2 PFU/cell) only 
resulted in minimal depletion of KAP1. In HeLa cells, we observed almost 
complete loss of KAP1 at an MOI of 5 PFU/cell (Figure 38B). KAP1 levels 
were rescued in the presence of 5µM MG132 in HeLa cells, suggesting that 
Ad5 targets KAP1 for proteasome-mediated degradation (Figure 38C). We 
next infected 293T cells with 10 PFU/cell of Ad5 and harvested at various 
time points to determine the kinetics of KAP1 degradation. At this MOI, 
degradation only became apparent at 48h post infection (38D). To determine 
whether this observation extended to other AAV2 helper viruses, we 
repeated these infection experiments using HSV-1. While the effect was less 
pronounced, HSV-1 infection also resulted in a 60% depletion of KAP1 over 
the range of MOIs tested for both 293T and HeLa cells (Figure 38E and F).  
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Figure 38. Ad5 and HSV-1 target KAP1 for degradation. 
(A-B) Analysis of KAP1 levels by western blotting in 293T (A) and HeLa (B) cells 48h after 
infection with increasing concentrations (PFU/cell) of Ad5. (C) 293T cells pretreated with 
increasing concentration of the proteasome inhibitor MG132 were infected with 10 PFU/cell 
of Ad5. Cells were harvested 48h after infection for analysis of KAP1 levels by western 
blotting. (D) 293T cells infected with 10 PFU/cell Ad5 were harvested at the indicated time 
points for analysis of KAP1 levels by western blotting (E-F) Analysis of KAP1 levels by 
western blotting in 293T (E) and HeLa (F) cells 48h after infection with increasing 
concentrations (PFU/cell) of HSV-1.  
Values are reported as mean±SEM, n=3.  
 
 
6.2.2 KAP1 depletion does not enhance recombinant AAV transduction. 
 Recombinant AAV vectors (rAAV) have demonstrated great success 
as vectors for gene therapy in numerous clinical trials. However various 
challenges remain in bringing rAAV vectors more widely into the clinics. In 
particular, exceedingly high doses of rAAV are currently necessary to 
effectively target large human organs or the musculoskeletal system. This 
presents a real challenge at the level of vector production, and also 
increases the ordinarily low risk of complications related to vector 
immunogenicity. As a result, there is a strong drive to establish methods both 
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for the scaling-up of vector production, as well as for the design of vectors 
with greater bioactivity. We wondered if the manipulation of cellular KAP1 
levels might be used to enhance either rAAV transduction or 
replication/production. This work suggests that KAP1-mediated repression of 
AAV2 is dependent on the presence of binding sites within the rep gene, 
which is not present in rAAV. However it is possible that further binding sites 
exist, within the viral ITRs for example, which could affect transduction 
efficiency. To address this, control and KAP1-depleted 293T cells were 
transduced with increasing MOIs of rAAV2, rAAV6, or rAAV9 expressing a 
CMV-GFP transgene cassette and were analyzed for GFP expression by 
FACS 48h post transduction. No difference in transduction efficiency was 
detectable between control and KAP1-depleted cells for any of the three 
serotypes tested (Figure 39A, B, and C). These results support the idea that 
the interaction between KAP1 and AAV2 is dependent on the presence of the 
rep gene.  
 
 
             
 
Figure 39. Depletion of KAP1 has no effect on recombinant AAV vector transduction.  
(A-C) 293T cells transduced with increasing concentrations (VG/cell) of (A) rAAV2-GFP, (B) 
rAAV6, or (C) rAAV9 were analyzed by FACS 48h after transduction for GFP expression. 




6.2.3 KAP1 depletion leads to modest enhancement in rAAV replication 
in the context of Ad5 infection. 
We next considered whether rAAV production could be affected by 
KAP1 repression. Although provided in trans, helper plasmids containing the 
rep gene might be subject to KAP1-mediated transcriptional repression.  To 
test this, control and KAP1-depleted cells were cotransfected with either a 
single-stranded (ss) or a self-complementary (sc) rAAV2-GFP vector, and the 
helper plasmid pDG, which contains rep, cap, and the minimal Ad5 helper 
functions necessary for AAV replication. Cells were harvested 72h post 
transfection for qPCR analysis of vector genomes. No difference was 
observed between control and KAP1-depleted cells transfected with either 
single-stranded or self-complementary rAAV2 (Figure 40A). We next 
performed replication experiments using Ad5 and mini-pDG, which contains 
only rep and cap, in place of the helper plasmid pDG. Control and KAP1-
depleted 293T cells were transfected with a single-stranded rAAV2-GFP 
vector and mini-pDG and infected with Ad5 4h after transfection. Cells were 
harvested as described above. Replication in control cells was ~10-fold less 
efficient in the context of Ad5 infection than previously observed with pDG 
transfection (Figure 40B). Interestingly however, there was a 2-fold 
enhancement in rAAV2-GFP replication in KAP1-depleted cells as compared 
to controls in the presence of Ad5. These results suggest that KAP1 inhibits 
a helper function of Ad5 not present in pDG. While replication in the 
presence of pDG is clearly more efficient than with Ad5, it is possible that 
identifying and introducing this unknown helper function into pDG may further 













     
 
Figure 40. Recombinant AAV2 replication is modestly enhanced in KAP1-depleted 
cells in the presence of Ad5, but not when replication is supported by the helper 
plasmid pDG. 
(A) Control (shEMPTY) or KAP1-depleted (shKAP1) 293T cells transfected with either a self-
complementary (sc) or single-stranded (ss) rAAV2 vector and the helper plasmid pDG were 
harvested 72h after transfection for qPCR analysis of vector genomes. (B) Control 
(shEMPTY) or KAP1-depleted (shKAP1) 293T cells transfected with a single-stranded (ss) 
rAAV2 vector and the helper plasmid mini-pDG, containing only rep and cap, and infected 
with Ad5 (4 PFU/cell) 4h after transfection were harvested 72h after transfection for qPCR 
analysis of vector genomes. 


















DNA viruses that replicate in the nucleus face the challenge of host 
cell chromatin modulation machinery, which controls access to the viral 
genome for the processes of transcription and DNA replication. The 
formation of nucleosomes on incoming viral genomes is necessary to create 
transcriptionally competent DNA, however it also provides a scaffold for the 
activity of cellular nucleosome- and histone-modifying proteins that can 
rapidly alter transcriptional activity from permissive to non-permissive, and 
vice versa.  
The dynamic chromatin regulation of the HSV-1 genome is a critical 
regulatory determinant of both the latent and lytic phases. Upon nuclear 
release, the non-nucleosomal HSV-1 genome (Pignattii and Cassai, 1980) is 
rapidly assembled into chromatin (Conn and Schang, 2013; Lacasse and 
Schang, 2012) by one of two possible classes of histone chaperone 
complexes – the heterochromatin-associated Daxx/ATRX complex 
(Lukashchuk and Everett, 2010), or the euchromatin-associated HIRA/ASF1a 
complex (Oh et al., 2012) – and enrichment for either of these complexes in 
the particular subnuclear microenvironment into which the viral genome is 
released likely determines the progression of infection (Knipe and Cliffe, 
2008). In the context of latency, the HSV-1 genome is quiescent, and 
nucleosomes associated with lytic genes bear repressive histone marks. For 
reactivation to take place, this repression is countered by the recruitment of 
various activating proteins – including TAF1-B/Set and the cellular 
coactivator complex, comprised of HCF-1 coupled to the histone 
demethylases LSD1 and JMJD2 – to viral IE promoters where they act 
together to shift the epigenetic balance to one of transcriptionally active 
euchromatin (Knipe and Cliffe, 2008). 
Interestingly, the KAP1-interacting protein CHD3 was shown to be 
necessary for the initial repression of HSV-1 genomes (Arbuckle and Kristie, 
2014). Repression of IE and E genes by CHD3 was observed as early as 30 
minutes post infection, and the inhibition of HSV-1 gene expression that is 
associated with inhibition of the histone demethylase LSD1 was partially 
compensated for by CHD3 depletion. This suggests that CHD3 acts during 
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the initial repression of incoming viral genomes, a process that is normally 
circumvented by the HCF-1/LSD1 coactivator. The investigators in this study 
did not address how CHD3 is recruited to the HSV-1 genome however. It is 
well documented that KAP1 mediates the formation of repressive 
heterochromatin through the recruitment of CHD3 and the histone 
methyltransferase SETDB1, and so it is conceivable that HSV-1 targets 
KAP1 through an unknown mechanism in order to counteract the repressive 
effects of CHD3.  
Alternatively, HSV-1 infection has been observed to result in the broad 
suppression of cellular protein synthesis through viral host shutoff 
mechanisms (Smiley, 2004). Host shutoff essentially stems from two distinct 
inhibitory pathways – (1) destabilization of existing mRNA during early 
infection by the HSV-1 virion host shutoff protein (vhs), a ribonuclease which 
enters the cell as a component of the viral tegument (Kwong and Frenkel, 
1987), and (2) suppression of host mRNA synthesis by the multifunction IE 
protein ICP27 (Hardwick and Sandri-Goldin, 1994). This global suppression 
of cellular gene expression combined with HSV-1 manipulation of RNA pol II 
functions to optimize viral protein synthesis. Further analysis of the temporal 
changes in KAP1 transcription will be necessary to determine what 
contribution these processes make to the observed depletion of KAP1.  
The adenovirus genome on the other hand enters the host nucleus 
already as a highly condensed nucleoprotein complex, which must be 
remodeled in order for transcription and replication to take place (Giberson et 
al., 2012). Similarly to HSV-1, the cellular proteins TAFI-B/Set, 
nucleophosmin, and the pp32 proteins work together to remodel the tightly 
compacted viral genome (Haruki et al., 2006; Spector, 2007; Xue et al., 
2005), increasing accessibility of the viral DNA to transcriptional activators. 
KAP1 has been suggested to repress adenovirus replication at this initial 
stage by preventing the decondensation of the incoming viral genome (Bürck 
et al., 2015). Supporting this, we also observed a 2-fold enhancement in Ad5 
replication in the context of KAP1 depletion (Chapter 4, Figure 23). It is 
possible then that Ad5 targets KAP1 for degradation to counteract this 
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repression, however the fact that we only observe degradation at late time 
points during infection makes this unlikely. One study has shown that KAP1 
repressor activity is inhibited during adenovirus infection through interactions 
between Ad E1B55K and KAP1, which stimulate the deSUMOylation of 
KAP1 (Bürck et al., 2015). KAP1 has six lysine residues that are putative 
sites for SUMOylation (Lee et al., 2007). K554, K779, and K804 are the 
major sites shown to be necessary to support interactions with CHD3, and 
thus to mediate KAP1 repressive activity (Goodarzi et al., 2011; Lee et al., 
2007). However, K767 SUMOylation in combination with S824 
phosphorylation provides a signal for the targeted degradation of KAP1 by 
the SUMO-targeted E3 ubiquitin ligase, ring finger protein 4 (RNF4) (Kuo et 
al., 2014). It is possible that E1B55K leads to the selective deSUMOylation of 
K554, K779, and K804 to counteract KAP1 repression, but that SUMO-K767 
combined with the phosphorylation of KAP1-S824 that we observed at ~42h 
post infection with Ad5 results in the observed degradation of KAP1 via 
RNF4. In other words, E1B55K-mediated deSUMOylation is sufficient to 
inhibit KAP1 with respect to adenovirus decondensation, and degradation is 
simply a secondary consequence of the altered state of KAP1 post-
translational modifications. However, this provokes the question of why Rep-
mediated accumulation of p-KAP1-S824 does not lead to a similar 
degradation. It will be interesting to dissect the particular SUMOylation states 
of KAP1 during Ad5, AAV2, and Ad5 + AAV2 infection.  Equally, identifying 
the particular Ad5 proteins necessary to mediate this effect on KAP1 protein 
levels will be crucial to characterizing a mechanism. Supporting the 
mechanism outlined above, preliminary work in the lab suggests that 
transfection of E1B55K alone is sufficient to mediate KAP1 depletion.  
In addition, we predict that during the early stages of coinfection – 
when helper virus replication is already ongoing but AAV2 remains latent – 
targeting of KAP1 by helper viruses is exploited by AAV2 for the release of its 
own genome from the latent state. In HeLa cells for example, considerable 
degradation of KAP1 was apparent even at the low MOIs equivalent to those 
used in previous replication experiments. This may help to explain why we 
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did not observe a strong effect of KAP1 depletion on AAV2 replication in 
HeLa cells, as Ad5-mediated degradation of KAP1 would have effectively 
rendered control and KAP1-depleted cells equivalent. Equally, E1B55K-
mediated deSUMOylation of KAP1 in combination with E1A-mediated relief 
from YY1 repression of p5 may be sufficient for efficient rep expression 
without the need for KAP1 degradation. Why it is then necessary for AAV to 
also target KAP1 through phosphorylation might be explained by the complex 
interactions that take place between adenovirus and AAV during coinfection, 
which result in the inhibition of adenovirus gene expression by AAV 
(reviewed in section 1.3.3). As AAV replication progressively overpowers that 
of its helper virus, lytic replication is sustained through Rep-mediated 
phosphorylation of KAP1-S824.  
 These observations highlight the possibility that, although the minimal 
set of helper proteins for AAV replication have been identified for both Ad5 
and HSV-1, the multiple roles of these factors in supporting AAV replication 
may be only partially understood. This provokes the question of whether 
there remain unknown cellular targets of helper virus factors, which might be 
modulated for the purpose of improving rAAV vector transduction and 
production. The observed 2-fold enhancement in rAAV replication in the 
presence of Ad5 suggests that KAP1 targets an adenovirus function that is 
irrelevant in the context of helper plasmid transfection, and furthermore that 
this function is beneficial to rAAV replication. For example, the process of 
efficient Ad5 decondensation might recruit factors involved in supporting 
AAV/rAAV replication, such as TAF1-B/Set and the ANP32 proteins, which 
have also been shown to be necessary for efficient AAV replication 
(Pegoraro et al., 2006). In addition, these factors may play a more important 
role under conditions in which AAV/rAAV replication is not optimally efficient, 
as observed in rAAV + Ad5 cells.  
That no effect on rAAV replication was apparent in the presence of 
pDG alone despite the presence of a rep gene suggests that KAP1 is not 
being recruited to helper plasmids. Helper plasmids lack certain viral 
elements, such as the ITRs and the p5 promoter, which may be necessary 
for the recruitment of KAP1 through the formation of complex DNA 
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structures. For example, the chromatin-modifying protein HMG1 has been 
shown to promote the formation of Rep-DNA complexes (Costello et al., 
1997); it is thought that HMG1-induced DNA bending produces allosteric 
transition structures that promote the recognition and binding of other 
proteins to form protein:DNA complexes. Additionally, HMG1 binds with high 
affinity to already distorted DNA structures (Pil and Lippard, 1992), such as 
ITRs.  It is conceivable then that higher order DNA structures dependent on 
interactions between HMG1 and the viral ITRs are necessary for KAP1 
recruitment. Alternatively, it is possible that the formation of DNA loops 
through interactions between KAP1-7SK snRNP complexes bound to p19 
with YY1 bound to p5, which is not present in helper plasmids, are necessary 
to support the KAP1-rep interaction.  
 In conclusion, we show in this chapter that the AAV2 helper viruses 
Ad5 and HSV-1 both target KAP1, leading to its depletion apparently through 
proteasome-dependent degradation, although this will have to be further 
confirmed for both Ad5- and HSV-1-supported replication. This suggests the 
possibility that interference with KAP1 represents an unidentified helper 
function for AAV2 replication, and furthermore that KAP1 targeting is a 
conserved requirement for the efficient replication of DNA viruses. This led us 
to ask whether KAP1 might have a role in rAAV transduction or replication. 
While we were unable to demonstrate a role for KAP1 in rAAV transduction 
or replication in the presence of the helper plasmid pDG, a 2-fold 
enhancement in rAAV replication in the presence of Ad5 coinfection suggests 
that the interplay between Ad5, KAP1, and AAV/rAAV is more complex than 
anticipated. Importantly, it will be necessary to determine whether this 
observed enhancement in replication necessarily translates to increased 
rAAV particle production. Nevertheless, a more detailed understanding of the 
interactions involved may yet serve to further enhance rAAV replication and 





CHAPTER 7: GENERAL DISCUSSION AND FUTURE PERSPECTIVES 
 
7.1 Introduction 
AAV is remarkable in that it has evolved a unique, biphasic life cycle in 
which productive replication is dependent on both cellular host factors and 
coinfection by a helper virus, such as Ad5 or HSV-1. Unable to replicate 
autonomously however, infection by AAV alone leads to the establishment of 
latency either through long-term episomal persistence, or through preferential 
integration of the viral genome into specific sites in the human genome. 
These unique characteristics – the dependence on an unrelated virus for 
reactivation coupled with low immunogenicity and a capacity to establish 
latency through integration – are in notable contrast to what is known for 
other biphasic DNA viruses and have long fostered a view of AAV as 
somewhat of an anomaly.  
The duality of the AAV lifestyle also necessitates an exceptional 
degree of complexity and flexibility from what is fundamentally a simple virus. 
AAV must be able to camouflage itself effectively against cellular defenses in 
order to persist during latency, while simultaneously remaining poised for 
rapid reactivation upon helper virus coinfection. Upon coinfection, AAV must 
regulate both its own replication and that of its helper virus such that optimal 
conditions for propagation are maintained. An interesting consequence of 
AAV’s helper virus dependency is that both virus and host appear to benefit. 
It has been proposed that AAV has a protective effect on its host through the 
selective killing of cells infected with potentially pathogenic viruses, while 
remaining apparently innocuous in healthy cells. AAV may also benefit as the 
extra level of regulation imposed by helper dependency prevents its efficient 
replication from causing any deleterious effect to the host. In this respect, 
AAV might arguably represent a highly evolved virus – one that has 
successfully minimized any harmful effects on its host while simultaneously 
maximizing its pervasiveness – and thus presents a unique platform from 
which to study a novel class of host/pathogen/pathogen interactions.    
The importance and breadth of the host/pathogen interactions 
necessary for completion of the complex AAV lifecycle are highlighted by the 
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striking simplicity of its genome. Having a limited repertoire of viral proteins, 
AAV must interact with an array of cellular factors to complete its life cycle. 
Indeed, a multitude of factors involved in transcription, RNA splicing, and the 
cellular DDR pathway have been shown to colocalize with AAV replication 
centers, as well as to copurify with Rep (Vogel et al., 2013). Although our 
understanding of the significance of such protein interactions in the AAV life 
cycle is constantly growing, there are still many roles of the astonishingly 
multifunctional Rep proteins that have yet to be fully explored. 
The work presented in this thesis was intended to identify novel 
potential interaction partners for the AAV Rep proteins with the purpose of 
illuminating the processes involved in the regulation of AAV gene expression, 
and, furthermore, to define the mechanism of interaction. We initially set out 
to identify cellular factors involved in a mechanism of transcriptional 
repression by the Rep proteins that is dependent only on an intact NTP-
binding site within Rep, and which has been observed for the AAV p5 
promoter as well as various heterologous cellular and viral promoters (Dutheil 
et al., 2014; Kyöstiö et al., 1994). We performed BioID screens using each of 
the four Rep isoforms, which led to the identification of several interesting 
candidates involved in transcriptional regulation, including RDBP, RUVBL1, 
TCERG1, and KAP1. Physical interactions between Rep52, RDBP, RUVBL1, 
and KAP1 were confirmed by cross-linking IP, however no role for these 
candidates, or for TCERG1, could be demonstrated in the regulation of p5.  
A role for KAP1 in the AAV2 lifecycle was discovered however when 
depletion of KAP1 led to a significant enhancement in AAV2 genome 
replication and transcription. Upon further analysis, we were able to 
demonstrate that KAP1 recruitment to the latent AAV2 genome triggers H3K9 
trimethylation across the viral genome. Conversely, we show that the 
repressor activity of KAP1 is inactivated during lytic replication through 
phosphorylation of KAP1-S824 in a manner potentially dependent upon 
interactions between the Rep proteins, the phosphatase PP1, and its 
negative regulator NIPP1, and that these interactions may play a role in both 
AAV2 transcription and genome replication. Finally, based on the observation 
that Ad5 and HSV-1 both lead to the depletion of KAP1, we propose a model 
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in which latent AAV2 genomes are maintained in a repressed state by KAP1 
until its partial degradation or manipulation by helper virus triggers the initial 
upregulation of rep. We envision that, during latency, KAP1 bound to the rep 
ORF serves to silence the downstream viral genome through histone 
methylation, while Rep proteins bound to AAV2 p5 maintain this essential 
early promoter free from repressive marks and thus competent for rapid 
reactivation (Figure 41A). Upon helper virus coinfection, previously described 
interactions between helper virus factors and cellular proteins bound to p5 
upregulate rep, while interference with KAP1 by helper virus renders the 
genome permissive to transcription (Figure 41B and C). Newly expressed 
Rep proteins then form a complex with PP1 and NIPP1 and through these 
interactions inhibit the dephosphorylation of KAP1, leading to increased 
levels of p-KAP1-S824 and full reactivation of AAV2 (Figure 41D). It is also 
possible that modulation of KAP1 by Rep is necessary for the initiation of 













Figure 41. Model for release of AAV2 from KAP1-mediated latency. 
(A) Incoming AAV2 genomes undergo second-strand synthesis, concatamerization, and 
chromatinization upon nuclear entry. KAP1 is recruited to the rep ORF via an unknown 
binding partner where it forms a scaffold for the recruitment of SETDB1 and CHD3, leading 
to the methylation of AAV2-associated histones. Rep bound to the p5 promoter both 
represses p5 activity while maintaining the promoter free from repressive marks. (B) Upon 
helper virus superinfection, repression of p5 is relieved through previously described 
interactions between helper virus proteins and cellular factors while interference with KAP1 
by helper virus allows for (C) the initial upregulation of Rep. (D) Binding of Rep to PP1 and 








7.2 Paving the way for a potential new field of AAV epigenetics  
While all biphasic DNA viruses establish and maintain latency in a 
unique way, there still exist common themes that govern all persistent viral 
infections. Importantly, factors that restrict productive infection often 
positively and essentially affect the establishment of latency (Lieberman, 
2016, 2008). For example, cellular sensing of incoming naked viral DNA 
leads to the formation of chromatin, which can repress the viral genome, but 
which is also necessary to protect the latent viral genome from DNA damage 
signaling and nucleolytic attack. Chromatinization of viral DNA also provides 
the scaffold required for the establishment of a dynamic transcriptional state, 
in which activating and repressive histone modifications are absolutely 
necessary for the correct temporal regulation of gene expression during the 
different stages of the biphasic viral life cycle.  The rapidly expanding field of 
viral epigenetics has revealed an intricate web of interactions between viral 
and host cellular machinery where intrinsic cellular defense mechanisms are 
effectively coopted by the virus to promote viral latency. Various virally-
encoded proteins can also modulate these repressive mechanisms – through 
the targeting of repressive chromatin assembly factors such as Daxx or 
ATRX, or through the recruitment of the histone demethylases JMJD2s and 
LSD1, for example – to regulate lytic and latent gene expression programs 
through the conversion of repressive heterochromatin to active euchromatin 
(Lieberman, 2016).  
In line with its long-standing view as an outsider amongst DNA 
viruses, little is yet known about the nature and contribution of epigenetic 
marks to the genome organization and temporal gene regulation of AAV. 
Being a nuclear DNA virus however, it seems unlikely that AAV does not also 
encounter and interact with similar cellular defenses as do other DNA 
viruses, thus becoming subject to the epigenetic control of its genome. Given 
the importance of these interactions in the life cycles of DNA viruses such as 
HSV, Ad, EBV, HPV, CMV, and KSHV, it feels imperative that we develop a 
deeper understanding of these phenomena for AAV, not only to understand 
how AAV is affected by epigenetic modifications to its genome, but also how 
it may counteract these effects itself, or hijack other viral proteins to do so. 
! 197!
The findings presented in this work may thus open the door to a new field of 
AAV study focused on epigenetics. We show here that the latent AAV2 
genome, with the exception of the p5 promoter, is enriched for the repressive 
mark H3K9me3. There is an ever-expanding list of possible histone 
modifications however, each involved in a considerable degree of crosstalk 
with one another (Bannister and Kouzarides, 2011), which could have a 
profound effect on the overall transcriptional state of the viral genome. It will 
therefore be necessary to determine the global epigenetic landscape of the 
AAV genome throughout latency and lytic replication and to relate changes in 
gene expression to changes in chromatin states. Identifying the particular 
modifications involved may also lead to the identification of new cellular 
proteins involved in the modification of AAV chromatin, and furthermore may 
reveal novel potential targets of the Rep proteins for the counteraction, or 
domestication, of these activities.  
These findings also highlight the possibility that AAV is not so 
fundamentally dissimilar from other DNA viruses and that certain phenomena 
observed for other viruses might be extrapolated to AAV. Equally, the 
absence of such phenomena in AAV might represent a key factor in the 
difference between autonomy and helper dependency. One question that 
remains to be answered is whether AAV establishes latency through 
integration or episomal persistence in vivo. Viruses that establish latency in 
proliferating cells must have a mechanism in place to maintain their 
genomes. For viruses that do not integrate, this involves tethering of the viral 
DNA to metaphase chromosomes by virally encoded DNA-binding proteins, 
an activity that has never been demonstrated for the Rep proteins. 
Interestingly, one of the proteins identified in our BioID screen, BRD4, is a 
chromatin-associated factor involved in the E2-mediated chromosome 
tethering of HPV (Abbate et al., 2006) and the targeting of MLV integration 
through tethering of viral genomes to regions of polyacetylated histones 
(DeRijck et al., 2013), suggesting that the possibility of AAV tethering may 
require further investigation. Alternatively, a lack of tethering activity for AAV 
would certainly explain the need to evolve a mechanism for integration, 
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particularly in proliferating tissues. The ability to establish latency by two 
different mechanisms may be yet another example of how AAV is able to be 
so promiscuous in its tissue tropism. As mentioned previously, both HSV-1 
and Ad5 play highly active roles in the modulation of their chromatin states 
upon entry and reactivation. It will be interesting therefore to determine which 
chromatin-modifying functions, if any, of Ad5 and HSV-1 proteins might be 
necessary for AAV replication. It is also tempting to speculate that the loss of 
some autonomous chromatin-modifying activity by AAV might have rendered 
it helper-dependent.   
To date, the only tissue found to have high frequencies of AAV DNA is 
muscle, where 17% of random biopsies tested positive (Tezak et al., 2000). 
Most viruses establish latency only in specialized cell types where conditions 
are ideal for enabling viral latency. For example, predominant latent forms of 
EBV are found in CD19+ memory B cells, and CMV in CD34+ HSCs. In the 
case of CMV, CD34+ HSCs in effect force viral latency through the concerted 
effect of a lack of viral activators and the presence of latency-associated 
repressors, such as KAP1, which act together to establish a repressive 
heterochromatin state on the viral genome (reviewed in Poole and Sinclair 
2015). Following differentiation into macrophages or dendritic cells, changes 
in the nuclear environment, including the loss of KAP1 expression, lead to 
the chromatin-mediated reactivation of lytic CMV replication. In this scenario, 
viral latency appears to be almost completely at the mercy of the nuclear 
microenvironment and its influence on chromatin states. It is conceivable 
then that defining the particular set of chromatin-modifying proteins involved 
in establishing AAV latency will help to guide our search for the latent 
reservoir and possibly illuminate the deciding factors in the choice between 
integration and episomal persistence. It would be interesting, for example, to 
make the distinction of whether AAV sequences detected in muscle biopsies 
are derived only from terminally differentiated muscle cells, from tissue-
resident muscle stem cells (satellite cells), or from both, and to relate these 
differences to changes in nuclear microenvironment, epigenetic 
programming, and proliferative potential.  
! 199!
 
7.3 PP1 targeting as a novel mechanism for the inactivation of KAP1 
corepressor activity 
One characteristic of KSHV reactivation is the vPK-mediated 
inactivation of KAP1 through phosphorylation of serine 824 (Chang et al., 
2009), presumably necessary to fully relieve the viral genome from KAP1-
mediated repression. Here, we show that lytic replication of AAV in the 
presence of Ad5 is also strongly associated with a phosphorylation of KAP1. 
Furthermore, we show that this phosphorylation is the direct result of an AAV 
countermeasure to KAP1 through the Rep-mediated inhibition of PP1. 
Interestingly, several viruses have already been shown to target PP1 for a 
variety of reasons. Upon viral infection, the protein kinase PKR is activated 
and leads to the phosphorylation of the initiation factor eIF2α, resulting in the 
global inhibition of protein synthesis and halting viral replication. In order to 
counteract this, viruses have found ways to prevent the accumulation of 
phosphorylated eIF2α. The HSV-1 protein ICP34.5 leads to the specific 
dephosphorylation of eIF2α by forming a bridge between it and PP1, 
effectively bypassing infection-mediated ribosomal shutdown (Li et al., 2011). 
The HPV E6 protein achieves the same goal by interacting with the 
GADD34/PP1 complex (Kazemi et al., 2004). PP1 is also involved in the 
regulation of CREB signaling through the dephosphorylation and inactivation 
of CREB proteins, which consequently results in a down-regulation of CRE-
regulated elements (Bito et al., 1996; Hagiwara et al., 1992). Both EBV and 
HBV have been shown to target PP1 for this reason. One of the key proteins 
in EBV-mediated immortalization is the CRE-regulated latent membrane 
protein 1 (LMP1), and it is thought that the viral protein EBNA2 inhibits PP1 
in order to increase expression of this essential factor (Fahraeus et al., 
1994). Similarly, inhibition of PP1 by the HBV regulatory protein HBx leads to 
enhanced CRE-regulated viral transcription (Cougot et al., 2012). Finally, the 
V proteins of the measles virus and the related paramyxovirus Nipah virus 
interact with PP1, preventing PP1-mediated dephosphorylation of the RNA 
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sensor MDA5 and allowing for evasion of innate immune recognition (Davis 
et al., 2014).  
Here, we show that the AAV Rep52 and Rep78 proteins also inhibit 
PP1 activity, possibly by bridging the interaction between PP1 and the 
negative regulator NIPP1, and that this inhibition leads to increased levels of 
phosphorylated, inactive KAP1. Importantly, we demonstrate that Rep 
proteins unable to interact with PP1 are also unable to support both viral 
transcription and DNA replication, providing an essential link between Rep-
mediated inhibition of PP1, phosphorylation of KAP1, and AAV replication. 
This is not only the first example of PP1 targeting by a parvovirus, but also 
of PP1 targeting for the purpose of regulating KAP1 activity. Additionally, the 
hypothesis that Rep manipulates PP1 activity by bridging its interaction with 
a negative regulator represents a novel mechanism of viral PP1 targeting. 
Alternatively, Rep might behave in a similar manner to HPV E6, selectively 
interacting with and recruiting NIPP1/PP1 complexes to KAP1 and 
effectively competing out the binding of active PP1.   
While KSHV has been shown to target KAP1 directly via the viral 
kinase vPK, there is evidence to suggest that an as yet unidentified CMV-
encoded protein also targets KAP1 for phosphorylation (Rauwel et al., 
2015). It will be interesting to determine if either KSHV or CMV uses a 
similar mechanism to AAV in the relief of their genomes from KAP1-
mediated repression. Furthermore, it would be interesting to determine 
whether this mechanism extends to other members of the parvovirus family. 
Initial analysis of the sequences of both B19 and MVM NS1 proteins 
revealed potential PP1 consensus binding sites. Although it is not fully 
understood whether the parvovirus B19 establishes latency as a rule, 
reactivation of latent virus in immunocompromised patients can lead to 
persistent and relapsing viremia, suggesting the presence of a latent 





7.4 Significance for AAV gene therapy 
AAV gene therapy is demonstrating great success in multiple ongoing 
clinical trials, highlighting the enormous potential for this new experimental 
therapy in the treatment of debilitating monogenic diseases. Various 
challenges remain in bringing rAAV vectors into the clinics however. In 
particular, high doses of rAAV are currently necessary to effectively target 
large human organ systems. This presents a real challenge at the level of 
vector production, and also increases the ordinarily low risk of complications 
related to vector immunogenicity. As a result, there is a strong drive to 
establish methods both for the scaling-up of vector production, as well as for 
the design of vectors with greater bioactivity. Significant enhancements in 
AAV vector design have previously been derived from an enhanced 
understanding of wild type AAV2 biology. Given that the biology of rAAV 
vectors likely mimics that of latent viral genomes, the findings presented here 
have particular relevance for gene therapy with strong implications for the 
improvement of AAV vector design. 
Although we were unable to demonstrate a role for KAP1 in rAAV 
transduction or replication in the presence of the helper plasmid pDG, the 
moderate effect observed in the presence of minipDG and Ad5 coinfection 
highlights the need to further investigate the possibility that KAP1 depletion 
may improve vector production. It is possible that proteins recruited during 
the process of Ad decondensation may be beneficial for the initial 
reactivation of AAV, and that the activating properties of such proteins are 
effectively counteracted by KAP1. In defining the potential role for Ad5-
recruited chromatin-modifying proteins in AAV replication, we may uncover 
new targets, as well as new host factors, that might be manipulated for the 
purposes of vector production. Preliminary data in the lab have revealed that 
Ad5 E1B55K may be necessary for the degradation of KAP1. Given that 
293T cells have been immortalized with Ad E1/E2 genes, these observations 
also provoke the more practical question of whether 293T cells truly 
represent the ideal cell line in which to produce rAAV. We show that KAP1 
degradation by Ad5 is significantly more pronounced in HeLa cells than in 
293T cells. This might be representative of the development in 293T cells of 
(1) compensatory mechanisms to combat E1B55K-mediated degradation of 
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KAP1, and (2) redundant mechanisms to compensate for KAP1 depletion.  
Both possibilities would have implications for rAAV replication in 293T cells.  
Interestingly, rAAV-expressed transgene expression has not yet been 
shown to be affected by either DNA or histone methylation (Dupont et al., 
2015; Léger et al., 2011; Penaud-Budloo et al., 2008). Instead, diminished 
transgene persistence has been related to such factors as a progressive loss 
of therapeutic vector genomes over time, and increased levels of transgene 
mRNA oxidation (Dupont et al., 2015; Le Hir et al., 2013; Manno et al., 2006). 
These studies were carried out on a limited number of transgenes and target 
tissues however. Given the rapid expansion of AAV gene therapy and its 
application for an ever-growing number of diseases, it may still prove 
beneficial to screen new desired transgenes and promoters for sites of KAP1 
or KRAB-ZFP binding, the modification of which would avoid unwanted 
transcriptional silencing.  
Another challenge in gene therapy is balancing efficient in vivo 
transduction in susceptible tissues while exclusively targeting a desired 
organ. Current strategies for achieving this include the use of tissue-specific 
promoters and enhancers to drive expression of the transgene in question, 
and packaging of the recombinant vector genome within an AAV serotype 
having the desired tissue tropism. The various AAV serotypes are not 
specific for one target tissue however, and instead target different subsets of 
tissues; similarly, strong promoter/enhancer elements have the potential to 
generate leaky expression in undesired tissues.  One elegant strategy to 
achieve specific transgene expression involves the exploitation of post-
transcriptional regulation mechanisms to degrade transgene mRNA through 
the use of endogenous tissue-specific microRNA (miRNA) systems. 
Specifically, the incorporation of target sequences for the liver-specific miR-
122T into the 3’-UTR of an AAV vector cassette was successful in inhibiting 
AAV9-mediated gene expression in the liver (Qiao et al., 2011). In situations 
where a suitable tissue-specific miRNA does not exist, the incorporation of 
target sites for tissue-specific KRAB-ZFPs might represent another 




7.5 Future Perspectives 
Bearing in mind the layers of complexity that are created through the 
amalgamation of AAV’s helper dependency and its susceptibility to 
epigenetic mechanisms, it is clear that the work presented here represents 
merely the tip of the iceberg. There are still many questions left to answer in 
order to fully define the mechanism and consequence of KAP1 activity on 
AAV. One of the first will be to identify the recruitment factor for KAP1. One 
possibility is that KAP1 is recruited by YY1, as the two proteins have been 
shown to interact with each other in mouse ES cells. This can be verified 
using KAP1-specific ChIP experiments in latently infected control and YY1-
depleted cells to determine whether KAP1 is still recruited in the absence of 
YY1. In the event that YY1 is not the factor responsible, potential proteins 
involved might be purified using a combination of EMSA followed by mass 
spectrometry analysis. By comparing shift patterns of latent AAV2 
fractionated from control or KAP1-depleted cells, it may be possible to 
specifically purify a band representing AAV2 genomes bound by the KAP1 
repressive complex. Purification of this band followed by mass spectrometry 
analysis of bound proteins would potentially identify new candidate proteins 
necessary for KAP1 recruitment. Alternatively, lysates from a KAP1-specific 
cross-linked IP might be separated by EMSA and probed for AAV sequences 
to the same end. Answering this question will not only be instrumental in 
further defining the mechanism of KAP1 action, but will also have 
implications for tissue-specific changes in AAV behavior, as KAP1 
recruitment factors often have tissue-specific expression profiles.  
KAP1 recruitment factors are generally considered to be KRAB-ZFPs, 
which interact with KAP1 via its RBCC domain. However, KAP1 deleted for 
this domain is still recruited to numerous sites in the human genome. Our 
cross-linked IP experiments demonstrate that the minimal Rep ATPase 
domain is sufficient to mediate interactions between Rep and KAP1, however 
we have yet to identify which domains of KAP1 are involved. This can be 
determined by CL-IP using mutants of KAP1 deleted for the various domains. 
Additionally, it may be possible to determine which domains are necessary 
for recruitment of KAP1 to the AAV2 genome by performing KAP1-specific 
ChIP in cells depleted for endogenous KAP1 and reconstituted with the 
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various deletion mutants. These results might be very helpful not only in 
identifying a recruitment factor for KAP1, but also in understanding the role 
for KAP1 in binding AAV2. For example, while binding of KAP1 to 3’ coding 
exons of ZNF genes and H3K9me3 deposition are associated with RBCC-
dependent recruitment, binding of KAP1 to TSS and associated proximal 
promoter pausing of RNA pol II is not.  In parallel to these experiments, it will 
be interesting to analyze the effect of Rep expression on KAP1 protein 
interactions, or during latent versus lytic replication, as this could help to 
detect any potential changes in function of KAP1 in the context of AAV. 
Furthermore, it will also be necessary to fully characterize the 
dynamics of epigenetic changes that take place on the AAV genome 
throughout the lifecycle. ChIP experiments for the various activating and 
repressive histone modifications will be assessed under latent conditions. It 
may be possible to circumvent the problems that we encountered previously 
when attempting to perform H3K9me3-specific ChIP on actively replicating 
AAV2 by harvesting cells at much earlier time points, which would avoid the 
presence of high levels of AAV2 DNA. The challenge will be in determining 
the ideal time-point at which changes in AAV2-associated H3K9 methylation 
have taken place, but DNA replication has not yet begun in earnest. 
Alternatively, it might be possible to generate replication defective AAV2 
particles bearing the Rep-K340H mutation by providing Rep in trans, which 
could then be used to compare +/- Ad5 conditions without any active 
replication. The risk in this approach would lie in the fact that WT Rep may 
be necessary for the recruitment of KAP1 to the AAV genome. In addition to 
histone modifications, it will be interesting to further analyze the involvement 
of other members of the KAP1 repressive complex, such as HP1. Taking a 
broader view, interactions between Rep and components of several other 
chromatin-modifying complexes were detected in our screen – including the 
CAF1-A, PTW/PP1, and HCF-1 complexes – which will require further 
investigation.  
The studies described above will not only provide us with an 
understanding of the dynamic AAV epigenetic landscape, but will also 
complement a deeper analysis of the effect of KAP1 on base-line AAV 
transcription. Up to this point, we have yet to directly demonstrate an effect of 
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KAP1 depletion on AAV transcription. The requirement for helper factors to 
initiate transcription is once more a complicating factor; without them, 
transcription is very inefficient, while in their presence, transcription is so 
efficient as to mask any early differences. It may again be beneficial to try 
much earlier time points – within 30 minutes to an hour after infection for 
example – when AAV2 in KAP1-depleted cells may still have an advantage. 
In parallel to these and the above outlined work, it will be interesting to 
analyze RNA pol II occupancy across the viral genome in the presence and 
absence of KAP1 and to correlate these changes with KAP1 occupancy, 
histone modifications, and changes in promoter transcriptional activity.  
In conclusion, we demonstrate for the first time that AAV2 latency is 
regulated through the epigenetic modification of its genome by the 
corepressor KAP1. This challenges the long-standing model whereby latent 
AAV2 is silenced solely through the binding of its genome by the cellular 
factors YY1 and MLTF, and the viral Rep proteins. We provide evidence that 
the helper viruses Ad5 and HSV-1 target KAP1 for degradation and suggest 
that this not only represents an unknown helper function for AAV2 replication, 
but also a conserved requirement for the efficient replication of DNA viruses. 
Furthermore, we characterize a novel mechanism of PP1 antagonism 
through which the AAV2 Rep proteins further counteract KAP1-mediated 
repression, thus establishing an active role for AAV2 in the regulation of its 
epigenetic landscape. This work provides the first steps towards the 
development of a new field of AAV biology focused on the inevitable 
contribution of chromatin dynamics, with the potential for significant 
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APPENDIX 1: SUPPLEMENTARY INFORMATION 
 
 
Table 1. Primers 
 










Rv –  
CCAAGGGCCCTCAGAGAGAGTGTCCTC 
GAGCCAAT 














BirA* from pMycBirA* 




























RUVBL1 from IMAGE clone 
SS57 Rv - ccaactcgagagaattattttgttgatcgtctcgtgggctccgatgct TCERG1 from IMAGE clone 
SS59 
Fw -  
ccaactcgagagaattacttgtcatcgtcatccttgtaatctcctcctccttt
tgttgatcgtctcgtgggctccgatgctgtgggaggtggg 
TCERG1 from IMAGE clone 
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SS62 
Fw -  
ccaaTCTAGAGCCGTGAGCAAGGGCGAGGAGCT
GTTC 










FLAG-KAP1 from pKerppola 
SS82 Rv – RV primer for TRIM28 containing XhoI site FLAG-KAP1 from pKerppola 
SS93 Fw – ccaaTCTAGAGCCtccgacagcgagaagctcaacctggac PP1 from IMAGE clone 





Mutagenesis on mini-pDG 





Mutagenesis on mini-pDG 















Rep52 and Rep52 from 





Rep52 and Rep78 from 





Rep68 and Rep78 from 





Rep40 and Rep68 from 










KAP1 from pKerppola 
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SS119 FW – ccaaGTCGACAAGATGGTGATCTGG 
Rep52 and Rep78 from 





Rep52 and Rep78 from 





Rep52 and Rep78 from 





Rep52 and Rep78 from 





KAP1 from pKerppola 
 qPCR primers  
Cap1 TTCTCAGATGCTGCGTACCGGAAA WT AAV quantification 
Cap2 TCTGCCATTGAGGTGGTACTTGGT WT AAV quantification 
Ad5 
100K_FW TCATTACCCAGGGCCACATT Ad5 quantification 
Ad5 100k_RV CCTCGTCCAAAACCTCCTCT Ad5 quantification 
Cyclo_FW TGCTGGACCCAACACAAATG Housekeeping control 
Cyclo_RV TGCCATCCAACCACTCAGTCT Housekeeping control 
GAPDH_FW CACCGTCAAGGCTGAGAACG ChIP-qPCR 
GAPDH_RV ATACCCAAGGGAGCCACACC ChIP-qPCR 
ZNF180_FW TGATGCACAATAAGTCGAGCA ChIP-qPCR 
ZNF180_RV TGCAGTCAATGTGGGAAGTC ChIP-qPCR 
ZNF274_FW GGAGAAATCCCATGAGGGTAA ChIP-qPCR 
ZNF274_RV GGCTTTTGTGAGAATGTTTTCC ChIP-qPCR 
p5_FW CTGTATTAGAGGTCACGTGAGTG ChIP-qPCR 
p5_RV TCAAACCTCCCGCTTCAAA ChIP-qPCR 
Rep5’_FW CCGAGAAGGAATGGGAGTT ChIP-qPCR 
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Rep5’_RV CCATTCCGTCAGAAAGTCG ChIP-qPCR 
Rep 
middle_FW GCCTTGGACAATGCGGGAAAGATT ChIP-qPCR 
Rep 
middle_RV TGTCGACACAGTCGTTGAAGGGAA ChIP-qPCR 
Rep3’_FW TTCCCGTGTCAGAATCTCAA ChIP-qPCR 
Rep3’_RV CCAAATCCACATTGACCAGA ChIP-qPCR 
Cap5’_FW GACAGTGGTGGAAGCTCAAA ChIP-qPCR 
Cap5’_RV TTGTACCCAGGAAGCACAAG ChIP-qPCR 
Cap 
middle_FW TTCTCAGATGCTGCGTACCGGAAA ChIP-qPCR 
Cap 
middle_RV TCTGCCATTGAGGTGGTACTTGGT ChIP-qPCR 
Cap3’_FW GTCAGCGTGGAGATCGAGT ChIP-qPCR 
Cap3’_RV AGGCTCTGAATACACGCCAT ChIP-qPCR 
MB85_p5fw AACAAGGTGGTGGATGAGT taqman qPCR on AAV cDNA 
MB86_p5rv CGTTTACGCTCCGTGAGATT taqman qPCR on AAV cDNA 
MB87_p19fw TCACCAAGCAGGAAGTCAAAG taqman qPCR on AAV cDNA 
MB88_p19rv CCCGTTTGGGCTCACTTATATC taqman qPCR on AAV cDNA 
MB89_p40fw GGAAGCAAGGCTCAGAGAAA taqman qPCR on AAV cDNA 
MB90_p40rv CCTCTCTGGAGGTTGGTAGATA taqman qPCR on AAV cDNA 
Primers for mutagenesis 
SS100_FW CTTTCCCTTCAACGACTGTGTCGACgcgATGGTGATCTGGTGGGAGGAGGGG 
K372A mutagenesis on 
Rep52 and Rep78 
SS101_RV CCCCTCCTCCCACCAGATCACCATcgcGTCGACACAGTCGTTGAAGGGAAAG 
K372A mutagenesis on 
Rep52 and Rep78 
qPCR probes  
Probe p5 FAM-ACTGTTCCATATTAGTCCACGCCCAC-TAM FAM-TAMRA probe to b used with MB85 and MB86 
Probe p19 FAM-ACGTGGTTGAGGTGGAGCATGAAT-TAM FAM-TAMRA probe to b used with MB87 and MB88 
Probe p40 FAM-AGGAAATCAGGACAACCAATCCCGT-TAM FAM-TAMRA probe to b used with MB89 and MB90 
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Table 2. Plasmids   
    







pND229 CMV-Rep40 Cloned by Nathalie Dutheil Kana 
pND230 CMV-Rep52 Cloned by Nathalie Dutheil Kana 
pND226 CMV-Rep68 Y156 M225G Cloned by Nathalie Dutheil Kana 
pND227 CMV-Rep78 Y156 M225G Cloned by Nathalie Dutheil Kana 
pND234 CMV-Rep40 K340H Cloned by Nathalie Dutheil Kana 
pND233 CMV-Rep52 K340H Cloned by Nathalie Dutheil Kana 
pND232 CMV-Rep68 Y156 M225G K340H Cloned by Nathalie Dutheil Kana 
pND231 CMV-Rep78 Y156 M225G K340H Cloned by Nathalie Dutheil Kana 
pSS003 CMV-BirA*-Rep40 
Fragment amplified from mycBirA* and 
pND229 using SS23/22 (BirA*), 
SS13/14 (Rep40), and SS23/14 (BirA*-
Rep40); cloned into pcDNA3.1+ vector 
using ApaI 
Amp 
pSS004 CMV-BirA*-Rep40 K340H 
Fragment amplified from mycBirA* and 
pND234 using SS23/22 (BirA*), 
SS13/14 (Rep40), and SS23/14 (BirA*-




Fragment amplified from mycBirA* and 
pND230 using SS23/22 (BirA*), 
SS13/16 (Rep52), and SS23/16 (BirA*-
Rep52); cloned into pcDNA3.1+ vector 
using ApaI 
Amp 
pSS006 CMV-BirA*-Rep52 K340H 
Fragment amplified from mycBirA* and 
pND233 using SS23/22 (BirA*), 
SS13/16 (Rep52), and SS23/16 (BirA*-
Rep52); cloned into pcDNA3.1+ vector 
using ApaI 
Amp 
pSS009 CMV-BirA*-Rep68 Y156 M225G 
Fragment amplified from mycBirA* and 
pND226 using SS23/22 (BirA*), 
SS40/14 (Rep68), and SS23/14 (BirA*-
Rep68); cloned into pcDNA3.1+ vector 
using ApaI 
Amp 
pSS010 CMV-BirA*-Rep68 Y156 M225G K340H 
Fragment amplified from mycBirA* and 
pND232 using SS23/22 (BirA*), 
SS40/14 (Rep68), and SS23/14 (BirA*-
Rep68); cloned into pcDNA3.1+ vector 
using ApaI 
Amp 
pSS011 CMV-BirA*-Rep78 Y156 M225G 
Fragment amplified from mycBirA* and 
pND227 using SS23/22 (BirA*), 
SS40/16 (Rep78), and SS23/16 (BirA*-
Rep78); cloned into pcDNA3.1+ vector 
using ApaI 
Amp 
pSS012 CMV-BirA*-Rep78 Y156 M225G K340H 
Fragment amplified from mycBirA* and 
pND231 using SS23/22 (BirA*), 
SS40/16 (Rep78), and SS23/16 (BirA*-





Rep amplified from pND229 using 




Rep amplified from pND230 using 
SS85/88; cloned into T7-tagged vector 
using XbaI/SmaI 
Amp 
pSS026 CMV-T7-Rep68 Y156 M225G 
Rep amplified from pND226 using 
SS86/87; cloned into T7-tagged vector 
using XbaI/SmaI 
Amp 
pSS027 CMV-T7-Rep78 Y156 M225G 
Rep amplified from pND227 using 
SS86/88; cloned into T7-tagged vector 
using XbaI/SmaI 
Amp 
pSS033 CMV-T7-Rep40 K340H 
Rep amplified from pND234 using 
SS85/87; cloned into T7-tagged vector 
using XbaI/SmaI 
Amp 
pSS034 CMV-T7-Rep52 K340H 
Rep amplified from pND233 using 
SS85/88; cloned into T7-tagged vector 
using XbaI/SmaI 
Amp 
pSS036 CMV-T7-Rep68 Y156 M225G K340H 
Rep amplified from pND232 using 
SS86/87; cloned into T7-tagged vector 
using XbaI/SmaI 
Amp 
pSS037 CMV-T7-Rep78 Y156 M225G K340H 
Rep amplified from pND231 using 
SS86/88; cloned into T7-tagged vector 
using XbaI/SmaI 
Amp 
pSS040 CMV-T7-Rep52 K372A Mutagenesis on pSS025 using SS100/101 Amp 
pSS041 CMV-T7-Rep78 Y156 M225G K372A 
Mutagenesis on pSS027 using 
SS100/101 Amp 
pSS042 CMV-T7-Rep52 K340H K372A Mutagenesis on pSS034 using SS100/101 Amp 
pSS043 CMV-T7-Rep78 Y156 M225G K340H K372A 
Mutagenesis on pSS037 using 
SS100/101 Amp 
pSS047 CMV-Rep52 K372A Rep amplified from pSS025 and cloned into pcDNA3.1+ using SmaI Amp 
pSS048 CMV-Rep78 Y156 M225G K372A Rep amplified from pSS027 and cloned into pcDNA3.1+ using SmaI Amp 
pSS058 CMV-T7-Rep52Δ87 
Truncated Rep amplified from pSS025 
using SS119/123 and cloned in T7-
tagged vector using HincII/SmaI 
Amp 
pSS059 CMV-T7-Rep52Δ62 
Truncated Rep amplified from pSS025 
using SS119/124 and cloned in T7-




Truncated Rep amplified from pSS025 
using SS119/126 and cloned in T7-
tagged vector using HincII/SmaI 
Amp 
pSS061 CMV-T7-Rep78 Y156 M225G Δ91 
Truncated Rep amplified from pSS027 
using SS119/123 and cloned in T7-
tagged vector using HincII/SmaI 
Amp 
pSS062 CMV-T7-Rep78 Y156 M225G Δ62 
Truncated Rep amplified from pSS027 
using SS119/124 and cloned in T7-
tagged vector using HincII/SmaI 
Amp 
pSS063 CMV-T7-Rep78 Y156 M225G Δ43 
Truncated Rep amplified from pSS027 
usingSS119/126 and cloned in T7-
tagged vector using HincII/SmaI 
Amp 
KAP1 
pKerppola CMV-FLAG-KAP1 (full length KAP1) Obtained from Helen Rowe Kana 
pSS037 CMVΔ5-FLAG-KAP1 
FLAG-KAP1 amplified from pKerppola 
using SS81/82 and cloned into 
pWISP12-96 vector using XhoI 
Amp 
pSS038 CMVΔ6-FLAG-KAP1 
FLAG-KAP1 amplified from pKerppola 
using SS81/82 and cloned into 
pWISP12-97 vector using XhoI 
Amp 
pSS064 CMV-T7-KAP1 
KAP1 amplified from pKerppola using 
SS117/118 and cloned into T7 vector 
using XbaI/BglII digest on fragment and 
XbaI/BamHI digest on vector 
Amp 
pSS074 CMV-KAP1 
KAP1 amplified from pKerppola using 
SS129/SS82 and cloned into 




FLAG-TCERG1 amplified from IMAGE 
clone using SS59/57 and cloned into 
pCDNA3.1+ using XhoI 
Amp 
pIN001 FLAG-RDBP 
FLAG-RDBP amplified from IMAGE 
clone using SS52/53 and cloned into 
pCDNA3.1+ using EcoRI/XhoI 
Amp 
pIN002 FLAG-RUVBL1 
FLAG-RUVBL1 amplified from IMAGE 
clone using SS54/55 and cloned into 
pCDNA3.1+ using NotI/XhoI 
Amp 
pSS015 FLAG-GFP 
GFP amplified from pND104 using 
SS62/63 and cloned into pKerppola 




PP1 amplified from IMAGE clone using 





GFP amplified from pSS015 using 
SS102/103 and cloned into T7 vector 
using XbaI/BglII digest on fragment and 
XbaI/BamHI digest on vector 
Amp 
pEXN-
CPSF6 CMV-CPSF6 Obtained from Greg Towers Amp 
pC1-
NIPP1 GFP-NIPP1 
Obtained from Angus Lammond via 
Addgene Amp 
AAV/rAAV/Helpers 
pAV2 Infectious AAV plasmid  Amp 
pMB32 pMB2 based, Rep mutation to K340H Cloned by Martino Bardelli Amp 
pSS078 pAV2 based, Rep mutation to K372A 
Mutagenesis on mini-pDG using 
SS100/101 then cloned into pAV2 using 
SfiI/HindIII 
Amp 
pDG Rep and Cap, and Ad helper functions  Amp 
Mini-pDG Rep and Cap only Cloned by Els Henckaerts Amp 













































































siRNA Target Sequence Source 
siTCERG1 GGAGUUGCACAAGAUAGUU Sune et al. 2012 
siRUVB1 UAAAGGAGACCCAAGGAAGU Dutta et al. 2008 
siRDBP GGCAUUGCUGGCUCUGAAG Li et al. 2004 
siKAP1 
(Smartpool) 
siKAP1.1 - GAAAUGUGAGCGUGUACUG 
siKAP1.2 - GCGAUCUGGUUAUGUGCAA 
siKAP1.3 - AGACAGCACUGGCGUGGUG 




















Table 4. List of antibodies 
 
 
Antibody Source Conditions Application 
α-HSP90 Santa-Cruz Sc-69703 
1:10,000 
5% milk in PBST WB 
α-KAP1 Chemicon MAB3662 
1:1,000 






2.5% BSA inPBST 
WB 
IF 
α-VP ARP 03-61058 
1:500 
5% milk in PBST WB 
α-Rep Progen 61069 
1:100 
5% milk in PBST WB 
α-dsRed Clontech 632496 
1:2,000 
5% milk in PBST WB 
α-CHD3 Bethyl A301-219A 
1:4,000 
5% milk in PBST WB 
α-SETDB1 Abcam Ab12317 
1:1,000 










5% milk in PBST WB 
α-T7 Merck Millipore 69522-3 
WB: 1:10,000 
PBST 
IP: 1µl/500µl lysate 
WB 
IP 
α-p-Chk2 NEB 2661S 
1:1000 
2.5% BSA in PBST WB 
α-GFP Roche 11814460001 
1:5,000 
5% milk in PBST WB 
α-rabbit IgG BioRad 1:10,000 5% milk in PBST WB 
α-mouse IgG BioRad 1:10,000 5% milk in PBST WB 
α-TCERG1 Bethyl A300-360A 
1:5,000 
5% milk in PBST WB 
α-RUVB1 Serum obtained from  Dr Anindya Dutta 
1:1,000 
5% milk in PBST WB 
α-RDBP Serum obtained from  Dr Rong Li 
1:200 
5% milk in PBST WB 
α-CPSF6 Abcam 99347 
WB: 1:4,000 
5% milk in PBST  
IP: 2µg/mL lysate 
WB 
IP 
α-KAP1 Abcam ab10483 10mg/IP ChIP 
α-H3K9me3 Abcam ab8893 4mg/IP ChIP 
IgG Abcam ab37415 5mg/IP ChIP 
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APPENDIX 2: BioID PULL-DOWN DATA 
 
 
Table 5. Unique peptides identified by BioID using bait proteins BirA*-









Cationic!trypsin!OS=Bos!taurus!! P00760! 10! 9! 4!
HNRNPK!! P61978! 13! 18! 0!
NASP! P49321! 8! 12! 0!
!BirA!OS=Escherichia!coli! P06709! 19! 24! 0!
NCL! P19338! 3! 13! 0!
REP=AdenoGassociated!virus!2! P03132! 15! 20! 0!
SF3B1! O75533! 5! 11! 0!
FLNA! P21333! 2! 14! 0!
RBM26! Q5T8P6! 4! 7! 0!
SF3B2! Q13435! 3! 11! 0!
NUDC! Q9Y266! 2! 11! 0!
CCT8! P50990! 4! 8! 0!
SNW1! Q13573! 4! 9! 0!
SF3A1! Q15459! 4! 9! 0!
TCERG1! O14776! 2! 9! 0!
TMPO! P42167! 4! 8! 0!
SF1! Q15637! 3! 7! 0!
YLMP1! P49750! 0! 10! 0!
SFPQ! P23246! 5! 6! 0!
HNRNPU! Q00839! 3! 8! 0!
TAGLN2! P37802! 1! 9! 0!
TOX4! O94842! 5! 5! 0!
DACH1! Q9UI36! 5! 5! 0!
TRIM28! Q13263! 4! 4! 0!
HSPA1A! P08107! 4! 5! 0!
MRE11A! P49959! 0! 8! 0!
CPSF6! Q16630! 3! 6! 0!
TCOF1! Q13428! 3! 4! 0!
RUVBL1! Q9Y265! 4! 5! 0!
BCLAF1! Q9NYF8! 3! 5! 0!
DNAJC8! O75937! 3! 4! 0!
THRAP3! Q9Y2W1! 2! 5! 0!
SERBP1! Q8NC51! 1! 7! 0!
HNRNPA1! P09651! 0! 8! 0!
! 251!
CFDP1! Q9UEE9! 2! 5! 0!
U2SURP! O15042! 0! 7! 0!
FGA! P02671! 3! 4! 0!
PCNP! Q8WW12! 2! 5! 0!
HSP90AB1! P08238! 0! 7! 0!
WDR70! Q9NW82! 0! 7! 0!
CNN3! Q15417! 1! 5! 0!
SSB! P05455! 0! 6! 0!
HCHC1! P51610! 0! 6! 0!
USP15! Q9Y4E8! 0! 5! 0!
UBB! P0CG47! 2! 3! 0!
HIST1H4A! P62805! 3! 2! 0!
PDLIM1! O00151! 0! 5! 0!
PPIL4! Q8WUA2! 0! 6! 0!
Avidin!OS=Gallus!gallus!! P02701! 3! 8! 0!
ZRANB2! O95218! 2! 3! 0!
MDC1! Q14676! 1! 4! 0!
SPDL1! Q96EA4! 0! 5! 0!
PHAX! Q9H814! 0! 5! 0!
BRD4! O60885! 0! 3! 0!
NONO! Q15233! 0! 4! 0!
HIST1H2AB! P04908! 1! 3! 0!
HNRNPD! Q14103! 1! 3! 0!
VBP1! P61758! 0! 4! 0!
SUGT1! Q9Y2Z0! 0! 4! 0!
SART1! O43290! 0! 4! 0!
ACIN1! Q9UKV3! 0! 4! 0!
NUP50! Q9UKX7! 0! 4! 0!
NPM1! P06748! 1! 2! 0!
FAM50A! Q14320! 0! 3! 0!
ORC2! Q13416! 0! 3! 0!
TrypsinG1!OS=Homo!sapiens!! P07477! 1! 1! 1!
GTF2A1! P52655! 1! 2! 0!
CRKL! P46109! 1! 2! 0!
NUCKS1! Q9H1E3! 1! 2! 0!
HNRNPA2B1!! P22626! 0! 3! 0!
SPAG7!! O75391! 0! 3! 0!
API5!! Q9BZZ5! 0! 3! 0!
ENO1!! P06733! 0! 3! 0!
NUDT5! Q9UKK9! 0! 3! 0!
KHSRP! Q92945! 0! 3! 0!
PPP1R10! Q96QC0! 0! 3! 0!
CDC5L!! Q99459! 0! 3! 0!
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GMEB2! Q9UKD1! 0! 2! 0!
SNRPA1! P09661! 0! 3! 0!
RPRD2!! Q5VT52! 0! 2! 0!
PUS7!! Q96PZ0! 0! 3! 0!
CHERP!! Q8IWX8! 0! 3! 0!
EEF1A1!! P68104! 1! 1! 0!
HIST1H2BK! O60814! 0! 2! 0!
SNRNP200! O75643! 0! 2! 0!
WAC!! Q9BTA9! 0! 2! 0!
RNF113A!! O15541! 0! 2! 0!
C3!! P01024! 1! 1! 0!
ARID3B!! Q8IVW6! 1! 1! 0!
MAP4! P27816! 0! 2! 0!
RBM10! P98175! 0! 2! 0!
NACA! Q13765! 0! 2! 0!
SAMHD1!! Q9Y3Z3! 0! 2! 0!
GTF2E2!! P29084! 0! 2! 0!
PPM1G!! O15355! 0! 2! 0!
DNAJB1! P25685! 0! 2! 0!
IK!! Q13123! 0! 2! 0!
HNRNPL!! P14866! 0! 2! 0!
SAFB2!! Q14151! 0! 2! 0!
ZMYND8! Q9ULU4! 0! 2! 0!
PKM! P14618! 0! 2! 0!
TLE1!! Q04724! 0! 2! 0!
RDBP!! P18615! 0! 2! 0!
SMEK1! Q6IN85! 0! 2! 0!
SPEN! Q96T58! 0! 2! 0!
CCDC174!! Q6PII3! 0! 2! 0!
RFC4!! P35249! 0! 2! 0!
NUMA1!! Q14980! 0! 2! 0!
ZNF318!! Q5VUA4! 0! 2! 0!
TPX2! Q9ULW0! 1! 1! 0!
KRIT1!! O00522! 1! 0! 0!
EIF4B!! P23588! 0! 1! 0!
RBM17!! Q96I25! 0! 1! 0!
MKI67!! P46013! 0! 1! 0!
SUMO3!! P55854! 1! 0! 0!
AKAP8! O43823! 0! 1! 0!
PC!! P11498! 0! 1! 0!
PIP!! P12273! 0! 1! 0!
TAF1!! P21675! 0! 1! 0!
TKT!! P29401! 0! 1! 0!
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FUS!! P35637! 0! 1! 0!
CBX5!! P45973! 0! 1! 0!
CTCF!! P49711! 0! 1! 0!
PAPOLA! P51003! 0! 1! 0!
MNAT1! P51948! 0! 1! 0!
PSME3!! P61289! 0! 1! 0!
SNRPE!! P62304! 0! 1! 0!
CHAF1A!! Q13111! 0! 1! 0!
RIF1!! Q5UIP0! 0! 1! 0!
CIAPIN1! Q6FI81! 0! 1! 0!
!RAI1!! Q7Z5J4! 0! 1! 0!
WAPAL!! Q7Z5K2! 0! 1! 0!
C15orf38!! Q7Z6K5! 0! 1! 0!
BOD1L1! Q8NFC6! 0! 1! 0!
DGCR8! Q8WYQ5! 0! 1! 0!
CCDC104!! Q96G28! 0! 1! 0!
!FTO!! Q9C0B1! 0! 1! 0!
LUC7L! Q9NQ29! 0! 1! 0!
COPS7A!! Q9UBW8! 0! 1! 0!
FAM208A!! Q9UK61! 0! 1! 0!
LARP1!! Q6PKG0! 0! 1! 0!
SMAP!! O00193! 0! 1! 0!
NOL11! Q9H8H0! 0! 1! 0!
CD2AP!! Q9Y5K6! 0! 1! 0!
EIF2A! Q9BY44! 0! 1! 0!
MATR3!! P43243! 0! 1! 0!
NSRP1!! Q9H0G5! 0! 1! 0!
EIF5A! P63241! 0! 1! 0!
EIF5! P55010! 0! 1! 0!
PYGL!! P06737! 0! 1! 0!
DLGAP5!! Q15398! 0! 1! 0!
HNRNPH1! P31943! 0! 1! 0!
PRCC!! Q92733! 0! 1! 0!
USP5!! P45974! 0! 1! 0!
ARID1A!! O14497! 0! 1! 0!
ILKAP!! Q9H0C8! 0! 1! 0!
CCT6A!! P40227! 0! 1! 0!
NCOR1!! O75376! 0! 1! 0!
MED1!! Q15648! 0! 1! 0!
ANP32E!! Q9BTT0! 0! 1! 0!
DUT!! P33316! 0! 1! 0!
RBBP6!! Q7Z6E9! 0! 1! 0!
HNRNPR!! O43390! 0! 1! 0!
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GCFC2!! P16383! 0! 1! 0!
CRK!! P46108! 0! 1! 0!
RBM12!! Q9NTZ6! 0! 0! 0!






































Table 6. Unique peptides identified by BioID using bait proteins BirA*-






( ! ! !
BirA=Escherichia(coli(( P06709! 11! 19!
REP=Adeno5associated(virus(2(( P03132! 7! 9!
TAGLN2(( P37802! 4! 7!
HNRNPK(( P61978! 5! 8!
SF1(( Q15637! 2! 6!
SNW1(( Q13573! 2! 5!
PDLIM1(( O00151! 1! 5!
NASP(( P49321! 2! 4!
NPM1(( P06748! 3! 2!
GTF2E2(( P29084! 1! 2!
TMPO( P42167! 1! 2!
PUS7(( Q96PZ0! 1! 2!
HNRNPU( Q00839! 1! 3!
SF3A1(( A2VDN6! ! 5!
FLNA(( P21333! ! 5!
CHMP5( Q5RBR3! ! 4!
DNAJB1(( P25685! ! 4!
DUT(( P33316! ! 3!
PCMT1(( P22061! ! 2!
SPAG7(( O75391! 1! 1!
SLC4A1AP(( Q9BWU0! ! 4!
TPX2(( Q9ULW0! ! 4!
HDGF(( P51858! ! 2!
TRIM28(( Q13263! ! 3!
ENO1( P06733! 1! 2!
EIF5A(( P10160! 1! 2!
CLIC1(( O00299! ! 3!
TCERG1( O14776! ! 3!
TOX4(( O94842! ! 3!
YLPM1( P49750! ! 3!
USP15(( Q2HJE4! ! 3!
SPDL1(( Q96EA4! ! 3!
SF3B2( Q13435! ! 3!
CWC15(( Q2KJD3! 1! 1!
HSPA1A( P08107! ! 2!
RDBP(( P18615! ! 2!
SFPQ(( P23246! ! 2!
CPSF6( Q0P5D2! ! 2!
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CTTN( Q14247! ! 2!
MDC1( Q14676! ! 2!
GPKOW( Q92917! ! 2!
MCCC1( Q96RQ3! ! 2!
PHAX( Q9H814! ! 2!
DNAJC8( O75937! ! 2!
HNRNPA1( A5A6H4! ! 2!
RUVBL1( P60122! ! 2!
PPIL4( Q8WUA2! ! 2!
KRT4( P19013! 1! !
SMNDC1( O75940! ! 2!
SAP30B( Q02614! ! 2!
NUP50( Q9UKX7! ! 2!
CHAMP1( Q96JM3! ! 2!
ZC3H4( Q9UPT8! ! 2!
CRKL( P46109! ! 2!
STMN1( A9YWH3! ! 1!
SF3B1( O57683! ! 1!
ZC3H14( Q4R6F6! ! 1!
SERBP1( Q6AXS5! ! 1!
C15orf38( Q7Z6K5! ! 1!
FAM192A( Q91WE2! ! 1!
PIPSL( A2A3N6! ! 1!
EFHD2( A5D7A0! ! 1!
ALYREF( B5FXN8! ! 1!
SMAP( O00193! ! 1!
DFFA( O00273! ! 1!
PDCD5( O14737! ! 1!
PPMIG( O15355! ! 1!
RNF113A( O15541! ! 1!
NUDC( O35685! ! 1!
API5( O35841! ! 1!
TXNL1( O43396! ! 1!
HTATSF1( O43719! ! 1!
EDF1( O60869! ! 1!
ZC3H11A( O75152! ! 1!
CFDP1( O88271! ! 1!
NCL( P08199! ! 1!
PGAM1( P18669! ! 1!
ARHGDIA( P19803! ! 1!
S100A7(( P31151! ! 1!
PTPN11( P35235! ! 1!
FUS( P35637! ! 1!
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FASN( P49327! ! 1!
MRE11A( P49959! ! 1!
CCT8( P50990! ! 1!
ADAR( P55265! ! 1!
VBP1( P61758! ! 1!
SET( Q01105! ! 1!
WDR70( Q0VA16! ! 1!
PPP1R8( Q12972! ! 1!
IK( Q13123! ! 1!
ORC2( Q13416! ! 1!
NT5DC1( Q2TBU5! ! 1!
PCNP( Q32PF3! ! 1!
HN1( Q3T0T5! ! 1!
THRAP3( Q569Z6! ! 1!
NUDT5( Q5RCY2! ! 1!
CHMP4B( Q5XGW6! ! 1!
PRCC( Q92733! ! 1!
NANS( Q9NR45! ! 1!
SIX4( Q9UIU6! ! 1!
KRT16(( P08779! 1! !
SNRPA1( P09661! ! 1!
SNRNP40( Q5RF51! ! 1!
GTF2E1(PE=2(SV=1( A6QLI8! ! 1!
TAF9( Q16594! ! 1!
HNRPDL(( O14979! ! 1!
BCLAF1( Q9NYF8! ! 1!
HNRNPL(( P14866! ! 1!
















Table 7. Unique peptides identified by BioID using bait proteins BirA*-







TAGLN2( P37802! 23! 18!
FLNA( P21333! 21! 10!
Trypsin51(OS=Homo(sapiens(( P07477! 15! 15!
PCNP(( Q8WW12! 14! 9!
NCL(( P19338! 15! 4!
Serum(albumin(OS=Homo(sapiens(( P02768! 9! 14!
SERBP1( Q8NC51! 12! 4!
NASP( P49321! 9! 5!
ACTB(( P60709! 6! 4!
HNRNPK( P61978! 11! 4!
DSG1( Q02413! 4! 4!
HSP90AB1( P08238! 9! 2!
DNAJC8( O75937! 4! 2!
HN1L( Q9H910! 5! 3!
FUS(( P35637! 5! 3!
CNN3( Q15417! 6! 4!
CWC15(( Q9P013! 2! 3!
VIM(( P08670! 4! !
SF1(( Q15637! 4! 2!
NPM1( P06748! 5! 2!
SET( Q01105! 4! 1!
AMY1A(( P04745! 3! 2!
ANXA2(( P07355! 2! 2!
GAPDH( P04406! 3! 1!
SERPINB3( P29508! 1! 2!
PDLIM1(( O00151! 5! 2!
DSP( P15924! 1! 2!
DCD(( P81605! 3! 3!
PRDX1( Q06830! 3! 1!
SMAP( O00193! 3! 4!
TMPO(( P42166! 5! 2!
TRIM28(( Q13263! 3! 1!
AZGP1(( P25311! 2! 3!
UBB(( P0CG47! 3! 1!
CTTN(( Q14247! 2! 1!
S100A9(( P06702! ! 4!
HMGB1(( P09429! 5! !
S100A8(( P05109! 1! 3!
! 259!
HSPA8(( P11142! 2! 1!
SAP30BP( Q9UHR5! 1! 2!
C1orf52(( Q8N6N3! 2! 2!
TAF9(( Q16594! 4! 2!
HDGF(( P51858! 3! 1!
KIAA1704(( Q8IXQ4! 2! 2!
SPAG7(( O75391! 3! 2!
EDF1(( O60869! 3! 2!
TOX4(( O94842! 2! 2!
NUCKS1(( Q9H1E3! 4! 2!
CFDP1( Q9UEE9! 2! 2!
NACA(( Q13765! 4! 1!
GTF2E2(( P29084! 2! 1!
C15orf38(( Q7Z6K5! 5! !
GGCT(( O75223! 1! 1!
FUBP1(( Q96AE4! 4! !
HNRNPD(( Q14103! 4! 2!
FAM192A(( Q9GZU8! 2! 2!
SNW1(( Q13573! 1! 2!
KHSRP(( Q92945! 3! 1!
PDAP1(( Q13442! 3! 1!
TUBA1B(( P68363! 2! !
HSP90AA1( P07900! 8! !
JUP( P14923! 2! !
RDBP( P18615! 4! !
EPRS(( P07814! 2! 2!
DSC1(( Q08554! 1! 2!
SERPINB12(( Q96P63! 1! 1!
HBB(( P68871! 1! 2!
HIST1H2AB(( P04908! 2! 1!
YWHAE( P62258! 2! !
STMN1(( P16949! 2! !
TCOF1( Q13428! 3! !
CIAPIN1(( Q6FI81! 3! !
PIP( P12273! 1! 1!
ARG1( P05089! 1! 1!
PHAX( Q9H814! 2! 1!
ZRANB2(( O95218! 2! 1!
EIF4H(( Q15056! 2! 1!
HSPA5(( P11021! 2! !
FABP5( Q01469! 1! !
KPRP( Q5T749! ! 1!
CASP14(( P31944! 1! !
! 260!
EEF1A1(( P68104! 1! !
NUDT5(( Q9UKK9! 3! !
HIST1H4A( P62805! 2! !
PRSS2(( P07478! 2! 2!
CALD1( Q05682! 1! 1!
ARID3B(( Q8IVW6! 1! 2!
VBP1(( P61758! 1! 1!
CFL1( P23528! 1! !
RNF113A(( O15541! 1! !
DMD(( P11532! ! 1!
IGHG1(( P01857! ! 1!
SPRR2E(( P22531! ! 1!
RBBP4(( Q09028! 2! !
HMGB3( O15347! 1! 1!
JUN(( P05412! 1! 1!
SUB1( P53999! 1! 1!
DACH1(( Q9UI36! 1! 1!
RUVBL1( Q9Y265! 1! 1!
GSDMA(( Q96QA5! 1! 1!
HNRNPA2B1( P22626! 1! !
FLYWCH2(( Q96CP2! 1! 1!
ALDOA( P04075! 2! !
MDC1(( Q14676! 1! !
C19orf43( Q9BQ61! 1! !
CHMP2B(( Q9UQN3! 1! !
PPM1G(( O15355! 1! !
FAM50A(( Q14320! 1! !
IREB2(( P48200! ! 1!
FLG2(( Q5D862! ! 1!
SSBP1( Q04837! 1! !
SPDL1(( Q96EA4! ! 1!
HSPA1A( P08107! 2! !
HSPD1(( P10809! 1! !
GTF2A1( P52655! ! 1!
BRD4(( O60885! ! 1!
RFC4(( P35249! ! 1!
DFFA(( O00273! 1! !
SMNDC1(( O75940! 1! !
SSB(( P05455! 1! !
CPA1( P15085! 1! !
EIF4B( P23588! 1! !
PSME3( P61289! 1! !
YBX1(( P67809! 1! !
! 261!
ERH(( P84090! 1! !
EWSR1(( Q01844! 1! !
ALYREF(( Q86V81! 1! !
CCDC43(( Q96MW1! 1! !
PUS7(( Q96PZ0! 1! !
ANP32E(( Q9BTT0! 1! !
API5( Q9BZZ5! 1! !
TCERG1(( O14776! 1! !
PEBP1(( P30086! 1! !
ORC2(( Q13416! 1! !
IMPDH2(( P12268! 1! !
HNRNPA1(( P09651! 1! !
ANP32A(( P39687! 1! !
CDSN( Q15517! ! 1!
SUGP1(( Q8IWZ8! ! 1!
CDV3(( Q9UKY7! 1! !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
! 262!
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Adeno-Associated Virus Rep Represses the Human Integration Site
Promoter by Two Pathways That Are Similar to Those Required for
the Regulation of the Viral p5 Promoter
Nathalie Dutheil,* Sarah C. Smith, Leticia Agúndez, Zoé I. Vincent-Mistiaen, Carlos R. Escalante,* R. Michael Linden, Els Henckaerts
Department of Infectious Diseases, King’s College London School of Medicine, London, United Kingdom
ABSTRACT
Adeno-associated virus serotype 2 (AAV2) can efficiently replicate in cells that have been infected with helper viruses, such as
adenovirus or herpesvirus. However, in the absence of helper virus infection, AAV2 establishes latency by integrating its genome
site specifically into PPP1R12C, a gene located on chromosome 19. This integration target site falls into one of the most gene-
dense regions of the human genome, thus inviting the question as to whether the virus has evolved mechanisms to control this
complex transcriptional environment in order to facilitate integration, maintain an apparently innocuous latency, and/or estab-
lish conditions that are conducive to the rescue of the integrated viral genome. The viral replication (Rep) proteins control and
direct every known aspect of the viral life cycle and have been shown to tightly control all AAV2 promoters. In addition, a num-
ber of heterologous promoters are repressed by the AAV2 Rep proteins. Here, we demonstrate that Rep proteins efficiently re-
press expression from the target site PPP1R12C promoter. We find evidence that this repression employs mechanisms similar to
those described for Rep-mediated AAV2 p5 promoter regulation. Furthermore, we show that the repression of the cellular target
site promoter is based on two distinct mechanisms, one relying on the presence of a functional Rep binding motif within the 5=
untranslated region (UTR) of PPP1R12C, whereas the second pathway requires only an intact nucleoside triphosphate (NTP)
binding site within the Rep proteins, indicating the possible reliance of this pathway on interactions of the Rep proteins with
cellular proteins that mediate or regulate cellular transcription.
IMPORTANCE
The observation that repression of transcription from the adeno-associated virus serotype 2 (AAV2) p5 and integration target
site promoters is mediated by shared mechanisms highlights the possible coevolution of virus and host and could lead to the
identification of host factors that the virus exploits to navigate its life cycle.
Adeno-associated virus serotype 2 (AAV2) is a human DNAvirus that is dependent upon a number of factors provided by
helper viruses in order to replicate efficiently (1–4). In the absence
of helper factors, AAV2 has the ability to establish latency by site-
specifically integrating its genome into chromosome 19 (5, 6). A
complex interplay between host cellular, AAV2, and helper virus
proteins leads to the tight regulation of a life cycle that is unique
among eukaryotic viruses. The nonstructural proteins Rep78,
Rep68, Rep52, and Rep40, encoded by the AAV2 rep genes, play a
major role in orchestrating the different aspects of the AAV2 life
cycle. The large Rep proteins, Rep78 and Rep68, transcribed from
the p5 promoter, aremultifunctional proteins with DNA binding,
endonuclease, and helicase activities that control replication, in-
tegration, and transcription (reviewed in reference 7). The small
Rep proteins, transcribed from the p19 promoter, share the nu-
cleoside triphosphatase (NTPase) and helicase activity with the
large Rep proteins and are required for efficient packaging of the
viral particles (8). The Rep proteins have a distinctive autoregula-
tory role in that they control p5 and p19 transcription as well as
p40-controlled transcription of the structural proteins. In the
presence of helper virus, repression of the p5 promoter byRep and
cellular factors YY1 and MLTF is lifted (9–11), which leads to
transactivation of transcription from all three promoters (12) but
is regulated so that p40 transcript levels are higher than the p5 and
p19 transcript levels (13). Sequences within, as well as outside, the
viral promoter regions have been shown to be involved in Rep
activation (14). Interestingly, during productive infection, the
Rep proteins can mediate both activation and repression of tran-
scription (15). More specifically, the large Rep proteins activate
transcription from the p5 promoter through binding to the Rep
binding site (RBS) present in the inverted terminal repeat (ITR)
and mediate p5 repression by binding to the RBS in the p5 pro-
moter. This repression can be partially lifted by the small Rep
proteins and contributes to an autoregulatory loop, which main-
tains constant ratios of the p5 and p19 transcripts (16).
In the absence of helper virus, p5, p19, and p40 transcription is
significantly reduced, leading to minute levels of Rep protein ex-
pression (17–19). Rep-mediated repression of p5 transcripts ap-
pears to be dependent on the NTP-binding motif present in the
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central domain of the Rep proteins, as well as the presence of an
intact RBS motif in the p5 promoter (20). In contrast, Rep-medi-
ated repression of the p19 promoter requires only the NTP-bind-
ing motif of Rep (19). Transcriptional repression by Rep is not
exclusive to AAV2 promoters but has also been observed for het-
erologous promoters, such as theHIV long terminal repeat (LTR),
the human papillomavirus 18 (HPV18) upstream regulatory re-
gion (URR), and the major late transcription promoter of adeno-
virus (AdMLP), and is dependent on the Rep NTP-binding do-
main (21, 22). Rep also affects the expression of cellular genes,
such as those encoding c-myc and c-sis/platelet-derived growth
factor B (23–25); however, the significance of Rep-mediated reg-
ulation of these promoters in the context of AAV2’s life cycle has
yet to be established.
AAV2 has the ability to site-specifically integrate its genome
into a gene,PPP1R12C, that encodes a protein that is thought to be
a component of the regulatory subunit of myosin light chain
phosphatase (26). Analysis of the 5= untranslated region (UTR) of
this gene led to the observation that the minimal promoter region
of PPP1R12C and the p5 promoter have two important cis-regu-
latory elements in common, namely, the RBS and YY1 sites (27).
This observation, together with the fact that AAV2 establishes
latency by integrating into a ubiquitously transcribed locus, pro-
voked the question of whether AAV2 has evolved the ability to
control transcription of theAAV2 integration target locus in order
to aid the establishment of latency and secure viral rescue.
We demonstrate here that Rep proteins efficiently repress ex-
pression from the target site PPP1R12C promoter, employing
mechanisms similar to those described for Rep-mediated viral p5
promoter regulation. We provide evidence that the observed re-
pression is based on two distinct mechanisms: one relies on the
presence of a functional Rep binding motif within the 5= UTR of
PPP1R12C, whereas the second pathway requires only an intact
NTP-binding site within the Rep proteins, possibly indicating the
reliance of this pathway on interactions of the Rep proteins with
factors of or associated with the cellular transcription machinery.
We propose that the p5 promoter has coevolved with the host
PPP1R12C promoter, thereby ensuring the possibility that Rep
can control the expression at the viral integration site.
MATERIALS AND METHODS
Cell lines and viruses. HEK-293T/17 human embryonic kidney cells
(ATCC CRL-11268) and HeLa human cervical epithelial cells (ATCC
CCL-2) were cultured in Dulbecco’s modified Eagle’s medium (DMEM)
(Invitrogen) supplemented with 10% fetal bovine serum (FBS) (Invitro-
gen).
AAV2 and human adenovirus type 5 (Ad5) were produced and puri-
fied as previously described (28).
Infections. Cells were infected in 60-mm plates at 70% confluence by
adding increasing amounts of wild-type (wt) AAV2 (multiplicity of infec-
tion [MOI], 1 to 104 infectious units per cell) to 1 ml of DMEM and 10%
FBS. After 2 h of incubation at 37°C, 293T and HeLa cells were coinfected
with adenovirus type 5 at an MOI of 5 and 10 PFU, respectively. After 1 h
of incubation at 37°C, the inoculum was removed, and 3 ml of fresh
medium was added to the cells.
Reporter constructs. To increase the sensitivity of the reporter con-
struct, we replaced DsRed2.1 with mCherry in the previously used!332/
"94 plasmid (pND26). The plasmid contains the PPP1R12C promoter
region from nucleotides (nt) !332 to "94 relative to the transcription
start site (27).
The PPP1R12Cp-mCherry (pND203) reporter construct was cloned
in two steps. The mCherry open reading frame (ORF) was first amplified
by PCR using ND381 (5=GGATCCCACAACCATGGTGAGCAAGGGC-
3=) andND382 (5=-GCGGCCGCTACTTGTACAGCT-3=) as primers and
pTW149 as the template (28). The resulting PCR product was cloned into
pCR2.1 (Invitrogen) to create pND202. To generate the PPP1R12Cp-
mCherry (pND203) and p5-mCherry (pND208) reporter constructs, the
mCherry sequence linked to a BamHI/NotI fragment from pND202 was
subcloned into the BamHI/NotI-digested pND26 and p5 vectors
(pND85), respectively (27). The p5-mCherry construct contains the p5
promoter region (nt 190 to nt 310 relative to the AAV2 sequence) de-
scribed by Cheung et al. (29).
Mutations within the PPP1R12C RBS were introduced by inserting
annealed primers into the BamHI/SmaI sites of the pND23 plasmid (the
PPP1R12Cpromoter region fromnt!332 to"20 cloned into pBluescript
II SK [Fermentas]) (27). The resulting plasmid, pND31 (the PPP1R12C
promoter region from nt !332 to "94), was digested with BamHI and
HindIII, and the PPP1R12C promoter fragment containing the mutated
RBS motif was blunt ended prior to ligation into the SmaI site of the
pDsRed2.1 vector (Clontech) to create plasmid pND34 (PPP1R12Cp-
RBS*-DsRed2.1). To generate the PPP1R12Cp-RBS*-mCherry reporter
construct (pND212), the mCherry-containing BamHI/NotI fragment
from pND202 was subcloned into the BamHI/NotI sites of the pND34
plasmid. The same mutation was introduced into the p5 RBS by site-
directed mutagenesis on the pND84 (p5-pCR2.1) template (27) to create
pND235. To generate the p5-RBS*-mCherry construct (pND236), the
SmaI fragment containing the p5 promoter region from pND235 was
inserted into the SmaI sites of pND208.
To generate the pEGFP-PPP1R12Cp-mcherry bidirectional promoter
construct (pND238), the blunt-endedAflII/MscI enhanced green fluores-
cent protein (EGFP)-encoding fragment of pIRES2-EGFP (Clontech) was
subcloned into the blunt-ended EcoRI site of pND203.
Rep-expressing constructs. All Rep-expressing constructs were
cloned into the pIRES2-EGFP vector. To generate the Rep78-expressing
plasmid (pR78-IRES2-EGFP), the Rep78-encoding DraI/SphI fragment
from plasmid pHis-Rep78 (30) was first ligated to annealed adaptors and
inserted between the SmaI and NheI sites of the pIRES2-EGFP vector. To
generate pR78Y156F-IRES2-EGFP, the SacII/SalI fragment containing
the Y156F mutation from plasmid pHis-Rep68Y156F (30) was cloned
into the SacII/SalI-digested pR78-IRES2-EGFP vector. To generate
pRep68Y156F-IRES2-EGFP (pND21), the BamHI fragment of pHis-
Rep68 (31) containing the C-terminal region of Rep68 was inserted be-
tween the BamHI sites of pR78Y156F-IRES2-EGFP. The initiationmethi-
onine of Rep52 and Rep40 was mutated to a glycine (M225G) by site-
directed mutagenesis. The resulting PCR fragment was cloned into the
pCR2.1 vector to generate pND102. The SacI/SalI fragment containing
the M225G mutation from pND102 was inserted into the corresponding
SacI/SalI fragment of pRep78Y156F-IRES2-EGFP and pND21 to generate
pR78Y156F/M225G-IRES2-EGFP (pND105) and pR68Y156F/M225G-
IRES2-EGFP (pND104), respectively.
The 5= ends of Rep52 and Rep40 were generated by PCR on a pAV2
template with primers ND144 (5=-GATATCGCACAACATGGAGCTGG
TCGGG-3=) and ND67 (5=-CATCCGGTCTTGCAACGGCTGC-3=), and
the resulting PCR product was subcloned into the pCR2.1 cloning vector
to create pND20. pRep52-IRES2-EGFP (pND22) was constructed by in-
serting the 5= end of Rep52 containing the EcoRV/SalI fragment from
pND20 into the EcoRV/SalI sites of pRep78Y156F-IRES2-EGFP. To gen-
erate pRep40-IRES2-EGFP (pND56), the Rep40 3=-end BamHI fragment
from pND21 was inserted into the BamHI sites of pND22.
One, two, or three copies of the simian virus 40 (SV40) large T antigen
nuclear localization signal (NLS), PKKKRKV, were added in frame to the
3= end of the N208 open reading frame. PCR fragments amplified on
pRep78Y156F-IRES2-EGFP with primers containing the NLS sequences
were subcloned into pCR2.1 to generate pND59 (pN208Y156F-NLS1)
and pND75 (pN208Y156F-NLS2). pND81 (pN208Y156F-NLS3) was
generated by PCRon a pND75 template. To generate pN208Y156F-NLS1-
IRES2-EGFP (pND62), pN208Y156F-NLS2-IRES2-EGFP (pND82#2),
Dutheil et al.
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and pN208Y156F-NLS3-IRES2-EGFP (pND82#3), the PstI/BamHI frag-
ment containing the 3= end of N208 from pND59, pND75, and pND81
was inserted into the corresponding PstI/BamHI sites of pRep78Y156F-
IRES2-EGFP.
To generate pRep68Y156F/K340H-IRES2-EGFP (pND25), the SacI/
AccI fragment of pHis-Rep68K340H (32, 33), containing the K340Hmu-
tation, was inserted between the SacI/AccI sites of pND21. pRep68Y156F/
M225G/K340H-IRES2-EGFP (pND140) and pRep40/K116H-IRES2-
EGFP (pND80) were generated by inserting the BamHI fragment from
pND25, containing the K340Hmutation, into the corresponding BamHI
fragments from pND104 and pND56. pRep78Y156F/M225G/K340H-
IRES2-EGFP (pND146) and pRep52K116H-IRES2-EGFP (pND143)
were generated by inserting a fragment containing the K340H mutation
frompND140 (SacI/AccI) and pND80 (EcoRV/SalI) into the correspond-
ing sites of pRep78Y156F-IRES2-EGFP.
Todelete the internal ribosomeentry site 2 (IRES2)-EGFP sequence from
Rep-expressing vectors andgeneratep!IRES2-EGFP(pND216), theplasmid
pIRES2-EGFP was digested with BamHI and NotI, and the overhangs were
blunt endedwith theKlenowDNApolymeraseprior to religation.TheRep78
and Rep68 ORFs were amplified by PCR from the pND105 and pND104
plasmids using the SmaI-containing primers ND387 (5=-CCCGGGATATC
GCACAACATGCCGGGG-3=) and ND388 (5=-CCCGGGTTATTGTTCAA
AGATGCAGTCATCCAAATC-3=), andND387andND389(5-CCCGGGT-
CAGAGAGAGTGTCCTCGAGC-3=), respectively. The resulting PCR
fragments were subcloned into the PCR2.1 cloning vector to generate
pND221 (Rep78Y156F/M225G-pCR2.1) and pND220 (Rep68Y156F/
M225G-pCR2.1). pRep78Y156F/M225G-!EGFP (pND227) and pRep
68Y156F/M225G-!EGFP (pND226) were generated by subcloning the Rep-
encoding SmaI fragment from pND221 and pND220 into the SmaI site of
pND216. pRep52-!EGFP (pND230) and pRep40-!EGFP (pND229) were
generated by inserting the 5= ends of the Rep52 and Rep40 EcoRV/BstEII
fragments from pND22 and pND56 into the EcoRV/BstEII sites from
pND227 and pND226, respectively. Plasmids pRep78Y156F/M225G/
K340H-!EGFP (pND231), pRep68Y156F/M225G/K340H-!EGFP
(pND232), pRep52K116H-!EGFP (pND233), and pRep40K116H-!EGFP
(pND234)were generated by inserting the EcoRV/BstEII fragments contain-
ing the K340H mutation from plasmids pND146, pND140, pND143, and
pND80 into the corresponding EcoRV/BstEII sites of plasmids pND227,
pND226, pND230, and pND229. All the vectors were sequenced.
Transient transfections. Transient transfections were performed in
60-mm plates using Lipofectamine 2000 according to the manufacturer’s
instructions (Invitrogen). At 70% confluence, 293T cells were transfected
with 4.5"g of reporter plasmid and 9"g of Rep-expressing plasmid. Cells
were harvested 48 h posttransfection and assayed for plasmidDNAuptake
and RNA and protein levels.
Plasmid uptake determination.The transfected cells were lysed in 0.2
M NaOH and 10 mM EDTA, boiled for 15 min at 90°C, and loaded onto
a Hybond nitrocellulose membrane (Amersham) using a slot blot mani-
fold (Bio-Rad). The membranes were hybridized to mCherry or EGFP
probes to estimate the amount of reporter plasmid taken up by the cells.
The probes were generated by PCR using 5=-GGATCCCACAACCATGG
TGAGCAAGGGC-3= and 5=-GCGGCCGCTACTTGTACAGCT-3= for
mCherry and 5=-GCTAGCCACAACCATGGTGAGCAAGGGC-3= and
5=-GCTAGCTTACTTGTACAGCTCGTCCATGCCG-3= for EGFP.
Transfection efficiencies were normalized to plasmid reporter uptake.
Real-time qRT-PCR. Total RNA was extracted with the RNeasy kit
(Qiagen) and reverse transcribed using SuperScriptIII reverse transcrip-
tase (RT) (Life Technologies). Real-time quantitative RT-PCR (qRT-
PCR) was performed on 50 to 100 ng cDNA using TaqMan Gene Expres-
sion Assays for ACTB (Hs99999903_m1) and PPP1R12C (Hs01085952_
m1) andTaqManUniversal PCRmastermix (Life Technologies). Relative
expression levels were determined by the comparative threshold cycle (Ct)
method (34).
Northern blot analysis. Total RNA was extracted with the RNeasy kit
(Qiagen). Tenmicrograms (infected cells) or 2"g (transiently transfected
cells) of RNA was separated on a 1.2% formaldehyde-agarose gel and
transferred onto a nitrocellulose membrane. The membranes were first
hybridized to [#-32P]dCTP-labeled mCherry, PPP1R12C (exons 18 to
22), rep, or GFP probes; stripped at 65°C in 50% formamide, 2$ SSC (1$
SSC is 0.15 M NaCl plus 0.015 M sodium citrate); and rehybridized to a
%-actin cDNA probe. The PPP1R12C and %-actin cDNA probes were
generated as described byDutheil et al. (27). ThemCherry andGFP cDNA
probes were generated by PCR using the primers mentioned above. The
rep probe was generated by PCR on a plasmid containing a 315-bp PstI/
SacI fragment from pAV2 using 5=-GGATCCTCAATTCTGATTCTCTT
TG-3= and 5=-CCCGGGGGTCCTGTATTAGAGGTCACGTG-3=. All
Northern blots were analyzed with a Typhoon PhosphorImager (Molec-
ular Dynamics) and then exposed to an X-ray film to generate high-qual-
ity images. ImageQuant TL software was used to calculate fold repression.
Each average repression level is represented as the mean and standard
error of the mean (SEM).
Western blot analysis. Forty-eight hours after transfection, cells were
lysed in RIPA buffer (50 mMTris-HCl [pH 8], 150 mMNaCl, 0.1% SDS,
1% Nonidet P-40, 0.5% sodium deoxycholate, 1$ Complete protease
inhibitor cocktail [Roche Applied Science]), and proteins were quantified
by the bicinchoninic acid (BCA) protein assay (Pierce). For each condi-
tion, the same amount of protein (10 "g) was separated on a 15% SDS-
polyacrylamide gel and transferred to a nitrocellulose membrane (Hy-
bond-C Extra nitrocellulose; Amersham Biosciences). The membranes
were blocked with 5% nonfat dry milk in Tris-buffered saline (TBS) (100
mM Tris-Cl, pH 7.5, 150 mMNaCl) containing 0.5% Tween 20 (TBS-T)
for 1 h at room temperature and incubated with primary antibody over-
night at 4°C. Themembranes were washed in TBS-T buffer (three 15-min
washes) and then incubated with secondary antibody conjugated to
horseradish peroxidase for 1 h at room temperature. After three washes in
TBS-T buffer, the membranes were developed using enhanced-chemilu-
minescence (ECL) substrate (Pico detection kit; Pierce). Using an Im-
ageQuant LAS 4000 Biomolecular Imager and ImageQuant software (GE
Healthcare Life Sciences), band densitometry was performed, and the
result was normalized against the value of actin protein expression. After
visualization of the desired protein, the membranes were stripped in Re-
store Western blot stripping buffer (Pierce) for 30 min at room tempera-
ture. The membranes were washed four times in TBS-T buffer, blocked
with 5% nonfat dry milk, and then hybridized with specific antibody.
The primary antibodies used in the study were antibodies against
mCherry (1:16,000 dilution in 1% bovine serum albumin [BSA] in
TBS-T; Clontech; rabbit polyclonal red fluorescent protein [RFP] anti-
body; catalog no. 632397); GFP (1:5,000 dilution in 5% milk in TBS-T;
Roche Applied Science; mouse monoclonal GFP antibody; catalog no. 11
814 460 001); AAV2Rep proteins Rep78, Rep68, Rep52, andRep40 (1:100
dilution in 5% nonfat dry milk–PBS-T for monoclonal antibody clone
303.9 [Progen Biotechnik catalog no. 61069] or 1:500 dilution in 1%
BSA–PBS-T for monoclonal antibody clone 226-7 [Acris Antibodies cat-
alog no. BM5012SU]); AAV-2 Rep proteins Rep78, Rep68, and Rep78-
!N208 (1:200,000 dilution in 5% nonfat dry milk–PBS-T; rabbit poly-
clonal anti-N208 antibody); and actin proteins (1:10,000 dilution in 5%
nonfat dry milk in PBS-T; BD Biosciences; mouse monoclonal actin an-
tibody; catalog no. 612656). Polyclonal anti-N208 antibodywas produced
in rabbits immunizedwith the truncated Rep protein Rep78-!N208, con-
taining the first N-terminal 208 amino acids of Rep78 and Rep68 (Co-
calico Biologicals Inc.).
Goat anti-mouse (Jackson ImmunoResearch Laboratories; catalog no.
115-035-003) or anti-rabbit (Jackson ImmunoResearch Laboratories;
catalog no. 111-036-003) secondary antibody conjugated to horseradish
peroxidase was used at a dilution of 1:10,000 in 5% nonfat dry milk in
PBS-T.
Each average repression level is represented as the mean and SEM.
Immunofluorescence. HeLa cells were grown in 24-well plates on
coverslips coated with poly-L-lysine. At 50% confluence, the HeLa cells
were transfected with 0.75 "g of DNA using the Lipofectamine Plus re-
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agents (Invitrogen). The cells were fixed 48 h posttransfection in cold
acetone, permeabilized with 0.1% Triton X-100 for 5 min, and blocked in
5%normal goat serumovernight. The slides were incubated with primary
rabbit anti-N208 antibody (1:1,000 dilution in PBS) for 1 h at room tem-
perature, washed in PBS, and incubated with a Cy3 goat anti-rabbit anti-
body (1:1,000 dilution in PBS; Jackson ImmunoResearch; catalog no. 711-
165-152) for 1 h at room temperature. The slides were subsequently
washed in PBS and mounted in Vectashield Mounting Medium contain-
ing DAPI (4=,6-diamidino-2-phenylindole; Vector Laboratories). Images
were acquired at!100 magnification using a Leica DMRA2 fluorescence
microscope with a Hamamatsu charge-coupled-device (CCD) digital
camera and analyzed with Openlab software (Improvision).
Fluorescence-activated cell sorting.Todetermine the effect ofRepon
endogenous PPP1R12C expression, 293T cells transfected with the differ-
ent Rep-IRES-GFP expression constructs were harvested 48 h posttrans-
fection and sorted for GFP expression using the BD FACSAria II (Becton
Dickinson) prior to RNA isolation.
RESULTS
Under permissive conditions, AAV2 infection leads to down-
regulation of PPP1R12C expression. To determine if AAV2 in-
fection leads to changes in the expression levels of the target site
PPP1R12C promoter, 293T and HeLa cells were infected with wt
AAV2 using increasing MOIs in the presence and absence of
adenovirus (wt Ad5). Coinfection with adenovirus leads to
permissive conditions, which support efficient AAV2 replication,
whereas infection with AAV2 alone represents nonpermissive
conditions under which the virus can establish latency. Total RNA
was extracted 48 h postinfection (p.i.), and the expression of
PPP1R12Cwas analyzed byNorthern blotting and real-time qRT-
PCR. In the absence of adenovirus infection, expression levels of
PPP1R12C were similar in control and wt AAV2-infected HeLa
cells at all MOIs tested (Fig. 1A, top right). In 293T cells, the same
tendency was observed; however, at higher MOIs, slightly lower
levels of PPP1R12C expression were observed than in control cells
(Fig. 1A, top left). In contrast to nonpermissive conditions,
PPP1R12C expression is clearly repressed in wt AAV2- and ade-
novirus-coinfected cells compared to control cells, and this was
observed for both cell lines (Fig. 1A, top row). Importantly, this
effect does not appear to be mediated by adenovirus alone, as
PPP1R12C expression levels were similar in control and adeno-
virus-infected cells. Note that the actin expression levels re-
mained unaltered upon productive AAV2 infection. The ob-
served repression of PPP1R12C expression under permissive
conditions was confirmed by real-time qRT-PCR (Fig. 1B).
As the large Rep proteins, Rep78 and Rep68, are highly ex-
pressed under permissive conditions, we determined whether
downregulation of PPP1R12C expression might be related to the
presence of Rep78 or Rep68 (Rep78/Rep68) transcripts (12). As
expected, the AAV2 p5 transcripts can be detected in AAV2- and
adenovirus-coinfected cells, whereas Rep78/Rep68 expression
cannot be detected in AAV2- or adenovirus-infected or control
cells (Fig. 1A, middle row). These data indicate that a decrease in
PPP1R12C expression might be correlated with an increase in p5
FIG 1 PPP1R12C and rep expression levels in AAV2-infected cells. (A) Representative example of Northern blot analysis of 293T (left) and HeLa (right) cells
infected with wt AAV2 at increasing MOIs (1 to 10,000) in the absence ("Ad) and presence (#Ad) of adenovirus 48 h postinfection. Northern blots were
hybridized with PPP1R12C (top), p5-Rep (middle), and $-actin (bottom) cDNA probes. Relative fold repression of PPP1R12C expression is indicated at the
bottom. (B) Determination of PPP1R12C expression levels by real-time qRT-PCR in the samples shown in panel A confirms downregulation of PPP1R12C
expression during productive AAV2 infection in two different cell lines.
Dutheil et al.
8230 jvi.asm.org Journal of Virology
transcript levels, suggesting that the AAV2 Rep proteins canmod-
ulate PPP1R12C expression within its genomic locus. It is inter-
esting that in 293T cells, despite the decrease of Rep transcript
levels at higher MOIs, PPP1R12C expression levels remain
strongly repressed.
A potential link between downregulation of expression from
theAAV2 integration target site promoter andRep expressionwas
further supported by a time course experiment of AAV2 and ad-
enovirus infection in 293T cells, for which PPP1R12C and Rep
expression levels were determined by real-time qRT-PCR. The
presence of Rep proteins in AAV2- and adenovirus-coinfected
cells was confirmed byWestern blotting. Twenty-four hours after
infection, we could observe a modest decrease in relative
PPP1R12C expression levels in cells coinfected at a highMOI (Fig.
2A, left), which became more pronounced at later time points
(Fig. 2A and B, left). At 48 h postinfection, we could also observe
downregulation of expression in the absence of adenovirus. Inter-
estingly, Rep transcripts were detected under all conditions but
increased strongly when adenovirus was added to the cultures. In
general, Rep transcript levels decreased as the infection pro-
gressed. Western blot analysis of the samples showed strong ex-
pression of the large Rep proteins 24 h after coinfection, increas-
ing expression of the small Rep proteins at 30 h postinfection, and
decreasing Rep protein levels at 48 h postinfection (Fig. 2A, B, and
C, right).
Both large and small Rep proteins repress PPP1R12C pro-
moter activity. In order to test whether the observed repression is
directly mediated by the viral Rep proteins, we transfected 293T
cells with different Rep expression constructs. Since the chromo-
somal RBS and terminal resolution site (TRS) are located in the 5=
UTR of the PPP1R12C gene (27), it is conceivable that Rep78 and
Rep68 can interfere with the PPP1R12C promoter activity by in-
troducing a site-specific nick in the 5=UTR (35, 36). Therefore, all
experiments were executed using the Rep mutant RepY156F,
which lacks nicking enzymatic activity (37) (Fig. 3A). Since the
Rep52 and Rep40 proteins are the N-terminally truncated forms
of Rep78 and Rep68, respectively, the initial methionine of Rep52
and Rep40 was mutated to a glycine to accomplish expression of
the large Rep proteins only (20, 21) (Fig. 3A). We also examined
whether the truncated protein containing only the first N-termi-
nal 208 amino acids of Rep, Rep78-Y156F-!N208, could affect
PPP1R12C promoter activity. The rationale for using the Rep78-
Y156F-!N208protein is that this truncated protein has previously
been shown to be the minimal domain that can efficiently bind to
both AAV2 and PPP1R12C RBS sequences in vitrowhile retaining
its TRS endonuclease activity (30). Because Rep78-Y156F-!N208
lacks the bipartite NLS, which is localized in the C-terminal do-
main of Rep78/Rep68 (38), the C-terminal region of Rep78-
Y156F-!N208 was fused to either one, two, or three tandem re-
peats of the NLS of SV40 large T antigen. In order to assess
whether Rep78-Y156F-!N208 is effectively translocated to the
nucleus, we performed immunofluorescence microscopy on cells
transfectedwith the differentNLS constructs. As shown in Fig. 3B,
Rep78-Y156F-!N208 containing three copies of the SV40 large T
antigen NLS is, like wild-type Rep78, mainly located in the nu-
cleus. Rep78-Y156F-!N208 containing only one or two copies of
the SV40 large T antigen NLS is predominantly located in the
cytoplasm and in the perinuclear region (data not shown). All Rep
variants were cloned into an IRES-GFP vector. The transfected
cells were sorted forGFP expression to ensure the presence of Rep.
As shown in Fig. 3C, all Rep proteins except Rep78-Y156F-!N208
had the ability to strongly repress endogenous PPP1R12C expres-
sion levels in GFP-positive cells (Fig. 3C). Western blot analysis
confirmed expression of the different Rep proteins in the trans-
fected cells (Fig. 3D).
In order to obtain better insight into potential mechanisms
responsible for the observed Rep-mediated repression of
PPP1R12C expression, we cotransfected Rep constructs (Fig. 3A)
with reporter constructs containing the mCherry gene under the
control of the PPP1R12C or AAV2 p5 promoter (Fig. 4A). Since
Rep proteins can modulate the expression of a number of cellular
and viral genes, including the cytomegalovirus (CMV) promoter
(23, 24, 39), it is not possible to correct for variations in transfec-
tion efficiency by normalization to the activity of a cotransfected
plasmid expressing a marker gene under the control of a viral or
eukaryotic promoter. Therefore, transfection efficiencies were
normalized to plasmid DNA uptake, as described previously (39).
Figure 4B shows a representative example of the Northern and
Western blot analyses performed. Transcript and protein levels
from three independent experiments are shown in Fig. 4C. Rep78
and Rep68 strongly inhibit PPP1R12C promoter-driven expres-
sion at both the RNA and protein levels. In contrast to the large
Rep proteins, Rep52 and Rep40 reproducibly inhibit PPP1R12C
promoter activity, but at lower levels. Changes in RNA levels par-
allel those observed for protein levels. These data demonstrate that
all Rep proteins have the ability to mediate repression of the
PPP1R12C promoter despite significant differences in the levels of
inhibition between Rep78/Rep68 and Rep52/Rep40. The differ-
ence in ability to repress PPP1R12C expression between the small
and large Rep proteins was not as evident with the endogenous
gene, which can be explained by a lower gene copy number than in
the overexpression system. Similarly to what is shown in Fig. 3C,
the level of PPP1R12C expression in the presence of Rep78-
Y156F-!N208 is comparable to that detected in the absence of
Rep (Fig. 4B and C). These data indicate that Rep78-Y156F-
!N208 does not have the ability to regulate PPP1R12C promoter
activity, suggesting that the DNA binding domain is not sufficient
to inhibit PPP1R12C expression.
As the AAV2 p5 promoter shares common regulatory elements
with the PPP1R12C promoter (27), the question arises as to
whether the viral Rep proteins might regulate the two promoter
activities by similar mechanisms. Therefore, we compared Rep’s
effects on the p5 and PPP1R12C promoters. Interestingly, all Rep
proteins downregulate the AAV2 p5 promoter similarly to what
we observed for the PPP1R12C promoter (Fig. 4B andC, right). In
agreement with previously published data (19), the large Rep pro-
teins completely repress p5 promoter activity, whereas the small
Rep proteins inhibit the p5 promoter to a lesser extent. Of note,
Rep78-Y156F-!N208moderately represses p5 transcriptional ac-
tivity, whereas the PPP1R12C promoter activity remains relatively
unchanged in the presence of this truncated Rep protein.
The NTP-binding motif is required for Rep52- and Rep40-
mediated repression of the p5 andPPP1R12C promoters. Previ-
ous studies established that a residue within the NTP-binding do-
main of Rep78 (K340) is critical for the negative regulation of the
p19, HIV LTR, and HPV18 URR promoters (21), raising the hy-
pothesis that the same residue might be required for PPP1R12C
promoter repression. As Rep52 and Rep40 mainly consist of an
NTP-binding domain with ATPase and helicase activities (Fig.
5A), we used the smaller Rep proteins to determine whether mu-
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tations in the NTP-binding motif would have an effect on
PPP1R12C and p5 promoter activities. To address this, wild-type
or mutant Rep proteins were cotransfected with the PPP1R12C or
p5 reporter construct. Northern and Western blot analyses were
performed to determine RNA and protein expression levels, re-
spectively (Fig. 5B). Transcript and protein levels from 3 indepen-
dent experiments are shown in Fig. 5C. Similar to the data pre-
sented in Fig. 4B and C, wt Rep52 and wt Rep40 moderately
inhibit the PPP1R12C and p5 promoter activity, as seen for RNA
and protein levels (Fig. 5B and C). In contrast to the wt Rep pro-
FIG 2 Time course of PPP1R12C and rep expression levels in AAV2-infected 293T cells. (A to C, left) Determination of PPP1R12C expression levels by real-time
qRT-PCR in 293T cells 24 (A), 30 (B), and 48 (C) hours after AAV2 infection (at increasing MOIs in the absence and presence of adenovirus). Relative fold
repression of PPP1R12C expression is indicated at the bottom. (A to C, top right) Determination of rep expression levels by real-time qRT-PCR in 293T cells 24
(A), 30 (B), and 48 (C) hours after AAV2 infection (at increasing MOIs in the absence and presence of adenovirus). Relative expression levels were determined
in 2 independent infection experiments at each time point. (A toC, bottom right) Representative example ofWestern blot analysis of Rep expression in 293T cells
24 (A), 30 (B), and 48 (C) hours after AAV2 infection.
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teins, the mutant Rep52-K116H and Rep40-K116H proteins,
which harbor a mutation that corresponds to the K340H muta-
tion in the large Rep proteins, have no clear effect on PPP1R12C
and p5 promoter activity (Fig. 5B and C). The relief of repression
by the NTP-binding mutants is not due to differences in protein
expression levels, as they are similar for all Rep constructs, or even
slightly higher for the Rep40-K116H mutant than for the corre-
sponding wt protein, as indicated by Western blotting. In sum,
these data demonstrate that Rep52 and Rep40 inhibit the
PPP1R12C and p5 promoter activities in a similar manner and
that this repression requires the consensus NTP-binding motif.
The RBS and the NTP-binding motif are both required for
Rep78/Rep68-mediated repression of the p5 and PPP1R12C
promoters.We next investigated the mechanism by which Rep78
and Rep68 mediate PPP1R12C repression. Since the AAV2 Rep78
and Rep68 proteins have the ability to bind to the RBS located
within the 5= UTR of the PPP1R12C gene (36), we hypothesized
that, as observed for the repression of the p5 promoter (20), direct
interaction of Rep with the RBS might also be involved in the
inhibition of PPP1R12C. To address this, we used a reporter con-
struct containing a mutation within the RBS that abolishes Rep
binding to the RBS in the PPP1R12C promoter (36). We intro-
duced the same mutation in the p5 RBS. Transcript and protein
levels from 3 independent experiments were quantitated (Fig.
6C), and a representative example is shown in Fig. 6B. Similarly to
what is shown in Fig. 4, Rep78- and Rep68-expressing plasmids
strongly repress PPP1R12C and p5 promoter activities (Fig. 6B
and C). Compared to the wt promoters, the mutation within the
RBS motif reduces the ability of Rep78 and Rep68 to decrease the
levels of PPP1R12C and p5 promoter transcripts (Fig. 6B and C).
Although Rep’s repressive effect on the mutant promoter is par-
tially relieved, it is still clearly present. These data indicate that a
direct interaction of Rep with the RBS is not sufficient to direct
Rep-mediated repression of the PPP1R12C promoter, suggesting
the existence of at least one additional mechanism at the basis of
the observed phenomenon. It has previously been shown that
Rep78 and Rep68 inhibit transcription from the p5 promoter by
two different mechanisms. The first mechanism requires direct
interaction of Rep with the RBS, while the second mechanism
depends on the presence of a functional NTP-binding motif (20).
We therefore tested the effects of the Rep78 and Rep68 nicking-
and NTP-binding-negative mutant proteins (Rep78-Y156F-
FIG 3 Endogenous PPP1R12C expression levels in Rep-transfected cells. (A) Schematic representations of the large (Rep78/Rep68), small (Rep52/Rep40), and
truncated (N208) Rep proteins used for overexpression in 293T cells. At the top are shown the different functional domains present in Rep78. Nucleotide
positions indicating the beginning and end of each domain are indicated above. The black bar shows the position of the NLS. Below are shown the large Rep
proteins, Rep78 and Rep68, used for the analysis. Mutations were introduced to avoid endonuclease activity (Y156F) and simultaneous expression of the small
Rep proteins (M225G). At the bottom are depicted the small Rep proteins (Rep52 and Rep40) and the N-terminally truncated Rep protein fused to 3 tandem
repeats of the SV40 large T antigen NLS (N208-NLS3). The different Rep proteins were expressed from CMV promoter-IRES-GFP vectors. (B) Epifluorescence
microscopy images of cells transfected with plasmids expressing Rep78-Y156F-N208! containing three copies of the SV40 large T antigen NLS and stained with
DAPI and anti-Rep ("-Rep) (N208) antibody. The positive control consisted of cells transfected with a plasmid expressing full-length Rep78-Y156F; the negative
control consisted of cells transfected with the CMVpromoter-IRES-GFP vector. The images were taken at#100magnification. (C)Determination of PPP1R12C
expression levels by real-time qRT-PCR in cells transfected with the different Rep constructs and sorted by fluorescence-activated cell sorter (FACS) for GFP
expression. Relative expression levels were determined in 3 independent transfection experiments. The error bars indicate SEM. (D) Western blot analysis
confirmed the presence of the respective Rep proteins in the transfected cells.
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K340H and Rep68-Y156F-K340H) (Fig. 6A) on the wt and mu-
tated PPP1R12C and p5 promoters. As shown in Fig. 6B and C
(left), in the presence of an unaltered RBS, mutant Rep78/Rep68
proteins have a moderate repressive effect on the PPP1R12C pro-
moter activity. This effect can also be observed for protein levels.
Interestingly, the introduction of a mutation in the NTP-binding
motif did not affect the repression of p5 transcription levels, as
previously observed (19); however, a change in p5 repression was
clear at the protein level (Fig. 6B and C, right). These results indi-
cate that the activity of the NTP-binding motif in Rep78/Rep68 is
FIG 4 Analysis of the effects of the four AAV2 Rep proteins on PPP1R12C promoter (PPP1R12C p)- and AAV2 p5-directed gene expression. (A) Schematic
representations of the AAV2 p5 and PPP1R12CmCherry reporter plasmids. The genomic structures of the Rep and PPP1R12C genes are depicted at the top. The
bent arrowsmark the p5 and PPP1R12C transcription start sites (TSS). The white boxes indicate the positions of the p5 RBS and PPP1R12CTRS-RBSmotifs. (B)
Northern blot analysis shows PPP1R12C (left) and p5 (right) transcription levels in 293T cells cotransfected with an mCherry reporter plasmid and the
Rep-expressing plasmids shown in Fig. 3A. The blots were stripped and hybridized with a!-actin cDNAprobe (lower blots). Relative fold repression ofmCherry
expression is indicated below the blots. Western blot analysis shows the corresponding mCherry protein levels resulting from PPP1R12C (left) and p5 (right)
promoter activity. Rep expression was confirmed by Western blotting using the 226-7 and N208 antibodies. The blots were also incubated with a !-actin
antibody, and relative fold repression was determined (indicated below the blots). Slot blot membranes hybridized to an mCherry probe show similar plasmid
uptake for all experimental conditions. (C) Determination of average mCherry expression levels from the PPP1R12C (left) and p5 (right) promoters from 3
independent experiments by Northern andWestern blot analyses. Average fold repression of mCherry expression is indicated at the bottom of each graph. The
error bars indicate SEM.
FIG 5 Analysis of the effects of the Rep52/Rep40 proteins and corresponding NTP-binding mutants on gene expression from the PPP1R12C and p5 promoters.
(A) At the top are shown the different functional domains present in Rep78. Nucleotide positions indicating the beginning and end of each domain are indicated
above. The black bar shows the position of theNLS. Below are shown schematic representations of the various small Rep proteins coexpressedwith thePPP1R12C
and p5 mCherry reporter plasmids. The NTP-binding mutants harbor a mutation at amino acid position 116 (K116H). (B) Northern blot analysis shows
PPP1R12C (left) and p5 (right) transcription levels in 293T cells cotransfectedwith anmCherry reporter plasmid and various Rep-expressing plasmids. The blots
were stripped and hybridized with a !-actin cDNA probe (lower blots). Relative fold repression of the mCherry transcription levels is indicated at the bottom of
the blots. Western blot analysis shows the corresponding mCherry protein levels resulting from PPP1R12C (left) and p5 (right) promoter activity (top).
Expression of the small Rep proteins and NTP-binding mutants was determined by hybridization with the 226-7 antibody. The blots were also incubated with
a !-actin antibody, and relative fold repression was determined (indicated below the blots). Slot blot membranes hybridized to an mCherry probe show similar
plasmid uptake for all experimental conditions. (C) Determination of average mCherry expression levels from the PPP1R12C (left) and p5 (right) promoters
from 3 independent experiments by Northern and Western blot analyses. Average fold mCherry repression is indicated at the bottom of each graph. The error
bars indicate SEM.
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FIG 6 Analysis of the effects of the Rep78/Rep68 proteins and corresponding NTP-binding mutants on gene expression from wild-type and RBS mutant
PPP1R12C and p5 promoters. (A) At the top are shown the different functional domains present in Rep78.Nucleotide positions indicating the beginning and end
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not sufficient to accomplish complete PPP1R12C and p5 pro-
moter repression. Therefore, we investigated whether the Rep78/
Rep68 NTP-binding mutant proteins in the context of the mu-
tated PPP1R12C and p5 promoters would lead to the complete
abolishment of Rep78/Rep68’s repressive effects. In contrast to
the Rep78/Rep68-expressing plasmid, the NTP-binding-negative
mutant was unable to repress transcription from the PPP1R12C
and p5 promoters containingmutations in the RBSmotif (Fig. 6B
and C). Our data are in agreement with previously published re-
sults on Rep68-mediated repression of the p5 promoter (20).
Taken together, our data provide strong evidence that Rep78/
Rep68 exerts its negative regulatory effect on the PPP1R12C and
p5 promoters by identical mechanisms. Rep-mediated repression
of the p5 and PPP1R12C transcriptional activities requires, in ad-
dition to the NTP-binding motif, direct binding of Rep78/Rep68
to the RBS located within the promoter.
Rep-mediated repression of the antisense promoter requires
only a functional NTP-binding motif. We have previously re-
ported that the PPP1R12C promoter displays bidirectional pro-
moter activities (27). The ability of Rep to regulate PPP1R12C
transcription raises the question as to whether Rep is also able to
regulate the transcriptional activity of the antisense PPP1R12C
promoter. To address this question, the wt PPP1R12C promoter
fragment used in the PPP1R12Cp-mCherry reporter construct,
which exhibits both sense and antisense promoter activities (27),
was cloned into a dual-reporter construct carrying the mCherry
and EGFP genes in opposite directions. The PPP1R12C promoter
drives the expression of mCherry, while the antisense promoter
drives the expression of the EGFP cDNA. In order to simultane-
ously compare the effects of Rep on PPP1R12C sense and anti-
sense promoter activities, the EGFP cDNA was deleted from all
Rep-expressing constructs.
293T cells were transiently cotransfected with the PPP1R12C
bidirectional reporter vector and various Rep-expressing con-
structs. In the first set of experiments, we investigated the effects of
wt and NTP-binding mutant proteins on PPP1R12C promoter
activity in the context of the bidirectional construct (Fig. 7A).
Similarly to what is shown in Fig. 4, Rep78 and Rep68 strongly
repress PPP1R12C transcription from the bidirectional promoter,
whereas Rep52 and Rep40 moderately repress the levels of
PPP1R12C transcripts (Fig. 7B andC,mCherry). In contrast to the
wt Rep proteins, Rep78/Rep68 and Rep52/Rep40 NTP-binding
mutants exert different effects on the regulation of PPP1R12C
promoter activity. Rep78 and Rep68 mutant proteins moder-
ately repress the level of transcription, while the Rep52/Rep40
mutant proteins do not exhibit any negative regulatory effect
on PPP1R12C promoter activity (Fig. 7B and C, mCherry).
Similar observations were made for protein levels (Fig. 7B and
C, mCherry).
Having validated that the mechanism by which Rep represses
PPP1R12C transcription from the bidirectional promoter was
similar to what we observed with the PPP1R12Cp-mCherry re-
porter construct, we next investigated the effects of Rep on the
antisense promoter activity. Rep78 and Rep68 inhibit the anti-
sense transcriptional activity by 5- and 7-fold, respectively, while
Rep52 and Rep40 repress the antisense promoter by 2- and 3-fold,
respectively (Fig. 7B and C, EGFP). Western blot analysis showed
strong repression of the antisense promoter by all Rep proteins
(Fig. 7B and C, EGFP). In contrast to the wt Rep proteins, all Rep
NTP-binding mutants were unable to repress transcription from
the antisense promoter (Fig. 7B and C, EGFP). This observation
was also made for protein levels (Fig. 7B and C, EGFP).
Altogether, these results highlight the fact that, even though all
four Rep proteins inhibit transcription from both promoters,
there is a major difference in Rep78/Rep68-mediated transcrip-
tional repression of the sense and antisense promoters. While re-
pression of the PPP1R12C promoter requires the NTP-binding
motif in the central domain of the Rep proteins, as well as direct
interaction with the RBS, only the NTP-binding motif appears to
be required for Rep78/Rep68-mediated inhibition of the antisense
promoter. With regard to the small Rep proteins, our results sug-
gest that a similar mechanism is involved in Rep52/Rep40-medi-
ated repression of both PPP1R12C and antisense promoter activ-
ities and that this repression is dependent on the presence of a
functional NTP-binding motif.
DISCUSSION
The AAV Rep proteins are multifunctional proteins with the abil-
ity to regulate expression from cellular and viral promoters, in-
cluding the three AAV promoters p5, p19, and p40 (7). The rep-
lication phase of the AAV life cycle is strongly dependent on
controlled expression of AAV, as well as helper virus proteins, and
Rep’s role in this regulation has been well characterized (40).
However, much less is known about a potential role for Rep in the
regulation of cellular proteins that are involved in the different
aspects of the AAV life cycle. In particular, it is not known if Rep
has the ability to control the expression of the gene in which it
integrates to establish latency. In order to gain insight into a po-
tential additional regulatory role for Rep, we investigated if AAV2
infection and Rep expression influence the PPP1R12C promoter
activity and compared the effect to Rep-mediated repression of
the p5 promoter.
We have shown that AAV2 and adenovirus coinfection and the
associated increase in Rep expression lead to a decrease in
of each domain are shown above. The black bar shows the position of the NLS. Below are shown schematic representations of the various large Rep proteins
coexpressed with the PPP1R12Cp and p5 mCherry reporter plasmids. All Rep proteins lack endonuclease activity and contain mutations that avoid expression
of the small Rep proteins (M225G). The NTP-binding mutants harbor a mutation at amino acid position 340 (K340H). (B) Northern blot analysis shows
PPP1R12C (left) and p5 (right) transcription levels in 293T cells cotransfected with an mCherry reporter plasmid and various Rep-expressing plasmids.
Rep-mediated repressionwas analyzed on PPP1R12Cp and p5 reporter plasmids with unaltered, as well asmutated, RBS sequences that abolish Rep binding. The
blots were stripped and hybridized with a !-actin cDNA probe (lower blots). Relative fold repression of mCherry expression is indicated at the bottom of the
blots. Western blot analysis shows the corresponding mCherry protein levels resulting from PPP1R12C (left) and p5 (right) promoter activity (top). Expression
of the large Rep proteins and correspondingNTP-bindingmutants was determined by hybridization with theN208 antibody. The blots were also incubated with
a !-actin antibody, and relative fold repression was determined (indicated below the blots). Slot blot membranes hybridized to an mCherry probe show similar
plasmid uptake for all experimental conditions. (C) Determination of average mCherry expression levels from the PPP1R12C (left) and p5 (right) promoters
from3 independent experiments byNorthern andWestern blot analyses. Average fold repression ofmCherry expression is indicated at the bottomof each graph.
The error bars indicate SEM.
AAV2 Modulates Expression of Its Integration Site
August 2014 Volume 88 Number 15 jvi.asm.org 8237
PPP1R12C expression levels. The observed infection-induced
PPP1R12C repression appears to be different in 293T and HeLa
cells in that the observed repression can be seen in 293T cells
infected with AAV2 at high MOIs, a condition under which Rep
transcripts cannot be detected byNorthern blotting.However, the
presence of E1A and E1B in 293T cells leads to Rep levels that are
sufficient to support limited replication in the absence of helper
virus (17, 41) and is thus expected to also have an effect on
PPP1R12C transcription. An additional observation we made in
293T cells is that the level of repression in the presence of adeno-
virus appears to go upwith increasingMOIs despite declining Rep
transcripts. This decrease in Rep expression was not observed in
HeLa cells and could be due to differences in AAV replication
levels and autoregulatory feedback loops (41). The presence of
Rep transcripts in the absence of adenovirus infection and down-
regulation of Rep expression over timewere confirmed in the time
FIG 7 Analysis of the effects of the four Rep proteins and corresponding NTP-binding mutants on gene expression from the PPP1R12C sense and antisense
promoters. (A) Schematic representation of the PPP1R12Cp mCherry-GFP reporter plasmid. The Rep proteins that are coexpressed with the reporter plasmid
are depicted in Fig. 5 and 6. (B) Northern blot analysis shows mCherry (top) and GFP (bottom) transcripts driven by the sense and antisense promoters,
respectively. The blots were stripped and hybridized with a !-actin cDNA probe, and the relative fold repression was calculated (indicated at the bottoms of the
mCherry and GFP blots). Western blot analysis shows the corresponding mCherry and GFP protein levels resulting from PPP1R12C (top) and antisense
promoter activity (second panel from top). Expression of the Rep proteins and corresponding NTP-binding mutants was determined by hybridization with the
226-7 antibody. The blots were also incubatedwith a!-actin antibody, and the relative fold repressionwas determined (indicated below the blots). Slot blots were
hybridized to an mCherry and a GFP probe to determine cellular uptake of plasmid DNA. ND, not detected. (C) Determination of average EGFP and mCherry
expression levels from the PPP1R12C promoter from 3 independent experiments by Northern and Western blot analyses. Average fold repression of mCherry
and EGFP expression is indicated at the bottom of each graph. The error bars indicate SEM.
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course infection experiments in 293T cells. In summary, we ob-
served that under permissive conditions AAV2 infection causes
downregulation of PPP1R12C expression, which is potentially
mediated by Rep but not necessarily dependent on high levels of
Rep transcription.
Transfection-based experiments directly showed that the ob-
served effect is indeed mediated by Rep. In fact, we could show
that all four Rep proteins mediate repression of the endogenous
gene, as well as the PPP1R12C reporter construct, and that this
activity is directed by mechanisms similar to those employed by
the Rep proteins for the downregulation of the p5 promoter. As
was seen for repression of p5 transcription (19, 21), the large Rep
proteins display a stronger repressive effect on the PPP1R12C pro-
moter reporter constructs than the small Rep proteins (19, 21).
This difference could be attributed to the N-terminal DNA bind-
ing domain present in Rep78 and Rep68; however, this domain by
itself showed a decreased ability to suppress the PPP1R12C pro-
moter compared to the full-length large Rep proteins. It is likely
that the Rep78/Rep68-induced repression is dependent on the
final Rep78/Rep68 oligomeric complex that assembles on the p5
and PPP1R12C promoter sites. This event is mediated through
specific DNA binding dependent on the presence of the origin
binding domain (OBD), interdomain linker, and helicase domain
(42). Evidence from structural and biochemical experiments sug-
gests that the assembly of Rep78/Rep68 complexes on RBS-con-
taining DNA sites is both directional and highly cooperative (un-
published data). The X-ray structure of the OBD-RBS complex
shows that the Rep molecules bind to the RBS positions in such a
way that the C-terminal helicase domain is oriented upstream of
the 5=-GCTC-3= repeats, where it interacts with DNA nonspecifi-
cally (43). This model is supported by biochemical data showing
that the affinity of Rep68 for DNAwith only the minimal RBS site
is significantly lower than for sites that also include upstream se-
quences (32). In addition, footprinting experiments have shown
that Rep68 protects regions upstream of the RBS sequence (32).
Taken together, it appears that binding of Rep78/Rep68 to RBS
DNA sites is a highly cooperative event that requires the partici-
pation of all structural domains. Our model proposes that the
repression mechanism is a direct effect of Rep78/Rep68 either
blocking the start of transcription and/or binding of transcrip-
tional activators in both the p5 and thePPP1R12C promoters (Fig.
8). The different directionality of the 5=-GCTC-3= repeats in the
RBS of the p5 versus PPP1R12C promoter allows physical inter-
ference with the initiation of transcription despite their different
positions with respect to the transcriptional start site (Fig. 8). We
hypothesize that the K340Hmutationmay have an effect on DNA
affinity or complex formation, explaining the observed lower level
of repression in the context of the large Rep proteins and the p5
and sense PPP1R12C promoter. However, we cannot exclude the
possibility that an additional mechanism that is independent of
binding to the RBS but requires interactions with the NTPase
domain and cellular proteins also plays a role in Rep78/Rep68-
mediated repression.
Our data suggest that this mechanism is likely also responsible
for Rep78/Rep68-mediated repression of the antisense promoter,
which lacks the RBS and, similar to what was observed for other
heterologous promoters (21), requires only an intact NTP-bind-
ing motif. The small Rep proteins, which lack the OBD, might
exploit the aforementioned interactions with host cell proteins in
order to mediate repression of the p5 and PPP1R12C sense and
antisense promoters (Fig. 5 and 7). In addition, nonspecific DNA
binding activities of these proteins may also interfere with the
binding activities of proteins from the transcriptionmachinery by
masking binding sites; however, further studies need to be per-
formed to answer this question.
In summary, in addition to direct interactions with the pro-
moter site, transcriptional repression of both viral p5 and cellular
target site promoters may rely on interactions of Rep with factors
of the transcriptionmachinery. In fact, DNA-protein interactions,
as well as protein-protein interactions, have also been described
for Rep-mediated repression of the AdMLP (22). The close prox-
imity of the Rep binding site to the TATA element in AdMLP and
the observed interactions of Rep with TATA-binding protein
(TBP) have provoked the hypothesis that Rep could repress gene
expression by interferingwith the formation of the RNApolymer-
ase II preinitiation complex (22).
It could be hypothesized that Rep recruits factors that directly
act on RNA polymerase II or exert their function bymanipulating
the chromatin environment (44). Indeed, several Rep-interacting
partners have been identified, among which several proteins are
involved in transcriptional regulation: Sp1 (45, 46), high-mobility
group 1 (HMG1) nonhistone proteins (47), putative protein ki-
nase PKX and protein kinase A (48, 49), and transcriptional co-
activator PC4 (50, 51). The last is an ideal candidate, as Rep-PC4
interactions have been shown to be dependent on Rep’s NTPase
domain; however, preliminary knockdown experiments in our
FIG 8 Model of Rep-mediated repression of p5 and integration target site
promoters as mediated through OBD-RBS interactions. (Top) Rep78-Rep68-
mediated transcriptional repression of the p5 promoter. (Bottom) Rep78-
Rep68-mediated transcriptional repression of the PPP1R12C sense promoter.
The light-blue arrowheads depict transcription factor binding. The red arrows
indicate the positions of the transcriptional start sites. The black arrows indi-
cate the directions of the 5=-GCTC-3= repeats in the RBS. Ribbon representa-
tions of the Rep68 OBD (green), interdomain linkers (black), and NTPase
domains (blue) depict RBS binding and upstream positioning of the C-termi-
nal SF3 helicase domain, which interferes with the start of transcription and/or
binding of transcriptional activators to the promoter.
AAV2 Modulates Expression of Its Integration Site
August 2014 Volume 88 Number 15 jvi.asm.org 8239
laboratory did not affect Rep-mediated repression of the
PPP1R12C promoter (data not shown).
It is interesting to speculate that AAV2 has adapted to integrate
into a chromosomal site, which appears to be regulated by protein
complexes that also direct viral gene expression. In fact, once in-
tegrated, the virus may exploit these regulatory mechanisms in
order to silence the integration site and associated provirus to
maintain latency. Furthermore, the observation that the 5= end of
the provirus, containing the promoter region of recombinant or
wt AAV2, is usually found in the 5=-3= transcriptional direction of
the PPP1R12C gene (52) indicates that these transcriptional pro-
tein complexes may also be involved in the formation and posi-
tioning of the preintegration complex. Future work directed at
identifying Rep’s binding partners involved in transcriptional reg-
ulation might therefore also shed light on the intricacies of a
unique viral integration mechanism.
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Epigenetic regulation of adeno-associated virus latency  1!
 2!
S. Smith-Moore1, S. Neil1, C. Fraefel2, R.M. Linden1, 3, H. M. Rowe4, and E. Henckaerts1 3!
 4!
Adeno-associated virus (AAV) is a human dependovirus whose low 5!
immunogenicity and capacity for long term persistence have led to its widespread use 6!
as a vector for gene therapy1. Despite great recent successes in AAV-based gene 7!
therapy2–4, further improvements are hindered by an inadequate understanding of 8!
various aspects of AAV biology. Of particular importance for the design and safety of 9!
AAV vectors, which mimic the latent phase of the viral life cycle, are the mechanisms 10!
involved in the regulation of AAV latency. These are poorly understood however. Here 11!
we show that recruitment of the corepressor KAP1 to the latent AAV2 genome leads to 12!
trimethylation of AAV2-associated histone 3 lysine 9 (H3K9me3). We show that 13!
infection by the AAV helper viruses adenovirus type 5 (Ad5) and herpes simplex virus 14!
type 1 (HSV-1) leads to KAP1 degradation, and we demonstrate that antagonism of 15!
protein phosphatase 1 (PP1) by the AAV Rep52 and Rep78 proteins further counteracts 16!
KAP1-mediated repression by enhancing nuclear levels of phosphorylated KAP1-S824. 17!
Moreover, we show that this interaction is essential for AAV transcription and 18!
replication. This work challenges the currently held model for AAV latency, and 19!
introduces not only a new viral mechanism for the counteraction of KAP1 repression, 20!
but also the notion that KAP1 targeting may represent a conserved requirement for 21!
replication among DNA viruses.  22!
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! 2!
The rapidly expanding field of viral epigenetics has revealed an intricate web 23!
of interactions between viral and host cellular machinery necessary in the establishment 24!
of viral latency5. In line with the long-standing view of AAV as an anomaly amongst 25!
DNA viruses, little is yet known about the nature and contribution of epigenetic marks 26!
to the genome organization and temporal gene regulation of AAV. Being a nuclear 27!
DNA virus however, it seems unlikely that AAV does not also encounter and interact 28!
with similar cellular defenses as other DNA viruses. In this study, we sought to gain 29!
insight into the potential role for chromatin structure in the regulation of AAV2 latency 30!
by using the screening method BioID6 to identify new interaction partners for the 31!
AAV2 Rep proteins. This led to the identification of Krüppel-associated box domain-32!
associated protein 1 (KAP1/TRIM28/ TIF1-β) (Extended Data Table 1,), a corepressor 33!
which acts to form transcriptionally repressive heterochromatin through the recruitment 34!
of chromatin-modifying proteins, such as the NuRD histone deacetylase complex and 35!
the histone methyltransferase SETDB17,8, and which has been linked to the regulation 36!
of several viral elements9–12. Physical interaction of KAP1 with Rep40, Rep52, and 37!
Rep78 was confirmed by biotinylation and immunoprecipitation assays (Extended Data 38!
Fig. 1a, b, c, d). To explore the possible significance of the Rep-KAP1 interaction in 39!
the AAV life cycle, we performed replication experiments in cells depleted for KAP1. 40!
AAV2 genome replication, transcription, and protein expression were enhanced in 41!
KAP1-depleted cells coinfected with AAV2 and the helper virus Ad5, but not in cells 42!
infected with AAV2 alone (Fig. 1a, b, Extended Data Fig. 2a, b), reflecting AAV2’s 43!
dependency on helper virus factors to initiate replication and suggesting that KAP1 44!
provides a second layer of regulation, the antagonism of which is necessary but not 45!
sufficient for reactivation.  46!
! 3!
We next asked if KAP1 could be repressing AAV2 through binding of the 47!
viral genome and subsequent formation of heterochromatin. We performed KAP1-48!
specific chromatin immunoprecipitation (ChIP) on AAV2-infected 293T cells and 49!
analyzed the purified chromatin 2 days after infection by qPCR using primers specific 50!
for various areas of the AAV2 genome, as well as GAPDH as a negative control, and 51!
two zinc finger genes, ZNF180 and ZNF274, as positive controls. KAP1 binding was 52!
detected across the rep gene, particularly at the 5’ and middle regions (Fig. 1c). To 53!
determine the functional significance of this binding, we performed ChIP-qPCR for 54!
trimethylated H3K9 (H3K9me3), a known marker for KAP1-mediated repression. 55!
H3K9me3 was detected across the AAV2 genome (Fig. 1d), and, importantly, histone 56!
methylation was lost in KAP1-depleted cells at a ratio similar to that observed for 57!
ZNF180 and ZNF274, supporting the notion that KAP1 not only binds the AAV2 58!
genome but also does so in the capacity of a repressor. Importantly, depletion of CHD3 59!
and SETDB1, two members of the KAP1 repressive complex7,8, also led to an 60!
enhancement in AAV2 replication and protein expression (Extended data Fig. 3a, b, c). 61!
Upon DNA damage, ATM-dependent phosphorylation of KAP1 at serine 824 (p-62!
KAP1-S824) results in release of the repressive complex, relaxation of 63!
heterochromatin, and relief of transcriptional repression13,14. We questioned whether 64!
AAV2 replication was associated with the phosphorylation of KAP1-S824, which 65!
would suggest a requirement for the inactivation of KAP1 corepressor activity. A dose-66!
dependent increase in p-KAP1-S824 was observed in 293T cells coinfected with Ad5 67!
and increasing concentrations of AAV2, but not a recombinant AAV2 vector (Fig. 2a), 68!
suggesting that active replication is necessary to trigger phosphorylation. We next 69!
performed a time course to determine if phosphorylation of KAP1-S824 could be 70!
related to replication and coinciding with Rep expression (Fig. 2b). In cells coinfected 71!
! 4!
with Ad5 and AAV2, high levels of p-KAP1-S824 were apparent by 18h post infection, 72!
correlating well with the onset of Rep expression and suggesting that the Rep proteins 73!
could be directly modulating KAP1 activity.  74!
The large Rep proteins possess endonuclease activity shown to trigger DNA 75!
damage15,16, and all four Rep proteins share a helicase domain with the potential to also 76!
disrupt DNA. To determine whether Rep might modulate KAP1 independently from 77!
DNA damage, 293T cells expressing various Rep proteins, including endonuclease 78!
mutants (Y156F) of Rep68 and Rep78, and catalytic ATPase mutants (K340H) of all 79!
four Rep proteins17,18, were monitored for p-KAP1-S824 levels. Elevated levels of p-80!
KAP1-S824 were apparent in the presence of both Rep52 and Rep78, independently 81!
from either endonuclease or ATPase activity (Fig. 2c), suggesting that the Rep proteins 82!
mediate phosphorylation of KAP1-S824 via an unknown, DDR-independent pathway. 83!
This idea was further supported by transfection and infection experiments performed in 84!
the presence of an ATM inhibitor (ATMi), which showed that ATM-activation is not 85!
necessary for Rep-mediated phosphorylation of KAP1-S824 (Extended Data Fig. 4a, b, 86!
c).  Furthermore, expression of a series of C-terminal truncation mutants, in which the 87!
C-terminal ZNF domain shared by Rep52 and Rep78 was progressively removed, 88!
completely abrogated phosphorylation of KAP1-S824 (Fig. 2d) while having no effect 89!
on the Rep-KAP1 interaction (Extended data Fig. 5), suggesting that the Rep proteins 90!
act through an intermediary protein(s).  91!
Potential cellular factors that could be interacting with Rep to control the 92!
phosphorylation state of KAP1-S824 include protein phosphatase 1 (PP1) and its 93!
specific inhibitors. Upon completion of DNA repair, basal levels of p-KAP1-S824 are 94!
restored through the combined activities of PP1α/β and protein phosphatase 4 19,20.  95!
Several regulatory subunits of PP1 were identified as interaction partners for Rep 96!
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alongside KAP1 in our original BioID screen, including the nuclear inhibitor of PP1 97!
(NIPP1/PPP1R8), leading us to hypothesize that the Rep proteins could be interfering 98!
with this pathway. Using the conserved PP1 consensus binding sequence [KR][X0-99!
1][VI]{P}[FW] as our guideline21, we discovered one putative binding site in the Rep 100!
ATPase domain (K372-W376), partially overlapping with the Walker B motif 101!
(Extended data Fig. 6a). Co-IP experiments in cells expressing FLAG-PP1α and 102!
Rep52K340H confirmed the physical interaction between Rep and PP1 (Fig. 3a). Use of 103!
the repression-deficient ATPase mutant Rep52K340H was necessary to successfully 104!
coexpress both proteins at acceptable levels for co-IP. We have shown however that 105!
Rep52K340H efficiently phosphorylates KAP1-S824 (Figure 2c). Importantly, mutation 106!
of the first lysine in the putative binding site (K372A) impaired this interaction (Fig. 107!
3a) and completely abrogated phosphorylation of KAP1-S824 (Fig. 3b) without 108!
affecting Rep ATPase activity (Extended Data Fig. 6b)18 or interaction with KAP1 109!
(Extended Data Fig. 6c).   110!
Based on our earlier observation that the Rep ZNF domain is also crucial for 111!
the phosphorylation of KAP1-S824 (Fig. 2d), we next asked whether this domain could 112!
be recruiting the PP1 inhibitor NIPP1, forming a complex with PP1 bound at the 113!
ATPase domain. Cross-linked co-IP (CL-IP) experiments between NIPP1 and the 114!
various Rep52 ZNF truncation mutants demonstrated that, while NIPP1 readily 115!
interacted with Rep52 and Rep52Δ43, this interaction was progressively lost with the 116!
two larger truncations, Rep52Δ62 and Rep52Δ87 (Fig. 3c). This displayed a degree of 117!
variability however, ranging from a complete loss of binding with both to only a 118!
modest decrease as compared to Rep52Δ43. Interestingly, the interaction with NIPP1 119!
was consistently lost with Rep52K372A (Fig. 3c), suggesting that PP1 may in fact 120!
represent the main binding partner for Rep and that the Rep ZNF domain acts to 121!
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stabilize the PP1-NIPP1 holoenzyme, leading to prolonged inhibition of PP1 and 122!
increased levels of nuclear p-KAP1-S824. To determine the functional relevance of this 123!
interaction in the AAV2 life cycle, we performed replication experiments with an 124!
infectious AAV2 plasmid containing the PP1 binding mutation (Rep-K372A). The 125!
wild-type plasmid, pAV2 (Rep-WT), was used as a positive control, and the NTP-126!
binding/ATPase mutant K340H (Rep-K340H), which does not support AAV2 127!
replication17, was used as a negative control. While Rep-WT fully supported both 128!
replication and transcription in the presence of Ad5, no response was detectable by 129!
Rep-K372A (Fig. 3d, e), supporting a model in which Rep-mediated inhibition of PP1 130!
is necessary for both DNA replication and transcription, likely through the associated 131!
increased levels of p-KAP1-S824. 132!
Given that basal levels of Rep expression during latency are not sufficient to 133!
counteract KAP1 and that depletion of KAP1 alone is not sufficient to trigger AAV2 134!
transcription and replication, we hypothesized that AAV2 helper viruses might act as a 135!
biological switch necessary to allow for the upregulation of rep expression prior to the 136!
onset of KAP1 phosphorylation. KAP1 protein levels were significantly depleted in 137!
293T and HeLa cells infected with increasing concentrations of Ad5 (Fig. 4a, b) and 138!
were restored in the presence of 5µM of the proteasome inhibitor MG132 (Fig. 4c), 139!
suggesting that Ad5 targets KAP1 for degradation. To determine whether this 140!
observation extended to other AAV2 helper viruses, we repeated these infection 141!
experiments using HSV-1. While the effect was less pronounced, HSV-1 infection also 142!
resulted in a 60% depletion of KAP1 over the range of MOIs tested for both 293T and 143!
HeLa cells (Fig. 4d, e), suggesting that KAP1 targeting may represent an unknown 144!
helper function for AAV2 replication necessary to release the viral genome from its 145!
latent state (Extended Data Fig. 7). 146!
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This work demonstrates for the first time that AAV2 latency is regulated 147!
through the epigenetic modification of its genome, which challenges the long-standing 148!
model for AAV latency, whereby AAV is silenced alone through binding of the p5 149!
promoter by cellular factors YY1 and MLTF, and the Rep proteins22,23. Given that the 150!
biology of AAV vectors likely mimics that of latent viral genomes, the findings 151!
presented here have additional relevance for gene therapy. Our data highlight that 152!
current production helper plasmids may lack helper genes that may be critical for 153!
navigating host responses. Understanding the epigenetic control of AAV may also shed 154!
light on the intriguing and unexplained resistance of AAV gene therapy vectors to host 155!
shut off, and will undoubtedly contribute to understanding the consequences of 156!
integrating wild type and recombinant viruses. In addition, the recent controversial 157!
discovery of AAV2 sequences in human liver tumors24 has caused some to call into 158!
question the safety of rAAV vectors and has highlighted the need to further explore 159!
AAV2 regulation of latency. These findings may thus provide key insights into the 160!





Cell lines and viruses 165!
293T human embryonic kidney cells and HeLa human cervical epithelial cells were 166!
obtained from the American Tissue Culture Collection (ATCC). Cells were cultured in 167!
Dulbecco’s modified Eagle’s (DMEM) (Invitrogen) supplemented with 10% fetal bovine 168!
serum (FBS) (Invitrogen) plus 1% Pen/Strep (Sigma) and were tested for mycoplasma 169!
once per month. 170!




pcDNA-mycBirAR118G, pCMV-Rep40 (pND229), pCMV-Rep52 (pND230), pCMV-175!
Rep68 Y156F M225G (pND226), and pCMV-Rep78 Y156F M225G (pND227) have 176!
been previously described18. BirA* and each of the Rep sequences were amplified by 177!
PCR, after which overlapping PCR was used to fuse the BirA* fragment to the N-178!
terminus of each Rep fragment. The resulting amplicons were cloned into pcDNA3.1+. 179!
FLAG- and T7-tagged Rep proteins were generated by cloning of Rep PCR products into 180!
either the pEGFP-C1 vector (Clontech) containing N-terminal FLAG tag or T7 tag, 181!
respectively. K372A mutants were generated by site-directed mutagenesis. ZNF 182!
truncation mutants were generated by PCR amplification of aa 1-529 (Δ91/87), 1-558 183!
(Δ63), or 1-577 (Δ44), using either pND230 or pND227 as a template. The amplified 184!
fragments were then cloned into the N-terminal T7 vector described above. FLAG-PP1α 185!
was generated by cloning of PCR-amplified PP1α from an EST clone obtained from 186!
Genome Cube (Clone IRAUp969F0817D) into the N-terminal FLAG-vector described 187!
above. GFP-NIPP1 was obtained from Angus Lamond 26, through Addgene (#44221). 188!
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pC1-FLAG-wtKAP1 was a provided by Helen Rowe and was used for cloning of PCR-189!
amplified wtKAP1 into untagged pcDNA3.1+. 190!
 191!
BioID Screening  192!
Ten 10cm dishes of 293T cells per BirA*-Rep construct were transfected using 6µg DNA 193!
and 50µl PEI in 500µl serum-free (SF) medium per dish. 6h post-transfection, the 194!
medium was replaced with fresh DMEM + 10% FBS, and D-Biotin (Life Technologies) 195!
was added to a final concentration of 100µM. 48h post-transfection, cells were harvested 196!
for LC-MS/MS analysis as previously described6. Mass spectrometry was performed by 197!
the KCL proteomics facility at Denmark Hill. 198!
 199!
Immunoprecipitation 200!
 293T cells were transfected in a 6-well format with 200ng of Rep-expressing constructs, 201!
and 250ng of FLAG-PP1α or FAG-GFP using 8ul PEI in 80µl serum free (SF) medium. 202!
48h after transfection, cells were lysed in RIPA buffer, and lysates were incubated with 203!
2µg anti-FLAG (Sigma, F7425) for 1.5h on a rotator at 4°C. 40µl of protein G agarose 204!
beads (Pierce) were added and incubated a further 3h. Beads were washed 4 times in 205!
RIPA buffer, and proteins were eluted from beads by boiling at 95oC for 10 minutes in 206!
60µl 2X Laemmli buffer. 207!
 208!
Cross-linking Immunoprecipitation 209!
  293T cells were transfected in a 6-well format with 200ng of Rep-expressing constructs, 210!
and 750ng of FLAG-GFP, FLAG-KAP1, or GFP-NIPP1 using using 8ul PEI in 80µl SF 211!
medium. 48 hours after transfection cells were fixed in 350ul 0.05% formaldehyde for 10 212!
minutes at 37°C and then quenched in 350ul 0.125M glycine, pH 7, for 5 minutes at room 213!
! 10!
temperature before being lysed in 500µl cross-linking IP buffer (150mM NaCl, 10mM 214!
HEPES pH 7, 6mM MgCl2, 2mM DTT, 10% glycerol, 1X protease inhibitors, 200uM 215!
sodium orthovanadate) on ice for 10 minutes. Lysates were subjected to three 10-second 216!
cycles of sonication, output ~2, and clarified at 1000 x g for 10 minutes at 4°C. 40ml 217!
protein G agarose beads (Pierce) per sample were incubated with 2µg FLAG antibody 218!
(Sigma, F7425) for 1.5h on a rotator at 4°C before being added to the cell lysates and 219!
incubated a further 3-4 hours. Beads were harvested and washed 4 times in RIPA buffer, 220!
and cross-links were reversed in 25 µl reverse cross-link buffer (10mM EDTA, 5mM 221!
DTT, 1% SDS) at 65°C for 45 minutes. Proteins were eluted from beads by adding 3µl of 222!
2X Laemmli SDS buffer and boiling at 95oC for 10 minutes. 223!
 224!
Western Blot Analysis 225!
 Cells were lysed in RIPA buffer, and proteins were separated on a 6-12% SDS-PAGE 226!
gel and transferred to a nitrocellulose membrane (Hybond-C Extra nitrocellulose, 227!
Amersham Biosciences). Membranes were blocked with either 5% nonfat dry milk or 228!
2.5% BSA (for phospho-antibodies) in PBS containing 0.5% Tween-20 (PBST) for 45 229!
minutes at RT and then incubated with primary antibody for 2h at room temperature. The 230!
membranes were then washed 3x10’ in PBST and incubated with HRP-conjugated anti-231!
mouse or anti-rabbit IgG (BioRad) for 1h at RT. After 3x10’ washes in PBST, 232!
membranes were developed using West Pico ECL reagent (Thermo Scientific). The 233!
following primary antibodies were used: HSP90 (Santa Cruz, sc-69703; 1:10,000), KAP1 234!
(Chemicon, MAB3662; 1:000), p-KAP1-S824 (Bethyl, A300-767A; 1:2000), VP (ARP, 235!
03-61058; 1:500), Rep (Progen, 61069; 1:100), dsRed (Clontech, 632496; 1:2000), 236!
CHD3 (Bethyl, A301-219A; 1:4000), SETDB1 (Abcam, ab12317; 1:1000), FLAG 237!
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(Sigma, F1804; 1:1000), T7 (Merck Millipore, 69522-3; 1:10,000), pChk2 (NEB, 2661S; 238!
1:1000), GFP (Roche, 11814460001; 1;5000) and avidin peroxidase (Sigma; 1:8000). 239!
 240!
Lentiviral transductions 241!
 pC-SIREN-based lentiviral vectors expressing either a hairpin targeting the 3’UTR of 242!
KAP1(shKAP1; GATCCGCCTGGCTCTGTTCTCTGTCCTTTCAAGAGAAGGA 243!
CAGAGAACAGAG CCAGGTTTTTTACGCGTG) or the corresponding empty vector 244!
(shEMPTY) were provided by Helen Rowe. Lentiviral vector-containing supernatants 245!
were produced by the common triple transfection method using VSV-G, HIV-Gag, and 246!
the lentiviral vector in a 3:2:1 molar ratio. Supernatants were harvested 48 and 72 hours 247!
after transfection, pooled, filtered, and frozen at -80oC until use. For knockdown, 1 x 106 248!
293T cells were transduced in a 6-well format using 1.2-1.6 mL of either shKAP1 or 249!
shEMPTY diluted with the appropriate amount of DMEM + 10% FBS. 24h after 250!
transduction, cells were re-plated at a density of 5 x 105 cells/mL for infection with 251!
AAV2/Ad5 the next day.  252!
 253!
siRNA transfections. In a 24-well format, 2 x 105 cells were transfected with 50nM 254!
(siKAP1.2 and siKAP1.4) or 100nM (siCHD3 and siSETDB1) siRNA using 2ul 255!
Dharmafect (Dharmacon) in 50ul Optim-mem (Gibco). 6h later, medium was replaced 256!
with fresh DMEM + 10% FBS. 24h after transfection, cells were re-plated into 12-well 257!
format. 36h after transfection, cells were subjected to a second transfection as described 258!
above, using 4ul Dharmafect in 100ul Opti-mem. 4h after the second transfection, cells 259!
were infected with 10 IU/cell AAV2 and 2 PFU/cell of Ad5 as described for the viral 260!




 For KAP1 depletion, 293T cells were transduced with a lentiviral vector expressing 264!
either a hairpin targeting the 3’UTR of KAP1, or the corresponding empty vector, 48h 265!
before infection with AAV2/Ad5. Cells were infected at ~80% confluency by adding 266!
AAV2 at the stated MOI in ~2/5 the normal well volume. 2h after AAV2 infection, Ad5 267!
was added at an MOI of 2 PFU/cell, and medium was replaced with fresh DMEM + 10% 268!
FBS 1h after Ad5 infection. Cells were harvested for qPCR, RT-qPCR, or western blot 269!
~42h after infection, or when they displayed optimal cytopathic effect (CPE). Optimal 270!
CPE is defined by cells that display a rounded and enlarged phenotype, as opposed to the 271!
normal “star-shaped” morphology of HEK293T cells, and which are beginning to detach 272!
but still appear bright and healthy. Cells that had completely lifted by the time of harvest 273!
were deemed too advanced in the infection cycle and were excluded from analysis.  274!
 275!
ChIP-qPCR 276!
 Cells were cross-linked in their medium in 1% formaldehyde (10’ at room temperature) 277!
and quenched with 0.125M glycine (5’ at room temperature) before being lysed in 278!
1mL/1x108 cells lysis buffer (50mM Tris-HCl, pH 8, 10mM EDTA, 1% SDS, 1x 279!
protease inhibitors) for 10’ on ice. Lysates were sonicated to obtain 200- to 500-bp 280!
fragments (15 x 30” cycles with 90” intervals, output ~2). 10ml of lysates were used to 281!
assess sonication efficiency by reverse cross-linking for 15’ at 95°C and then incubating 282!
with RNAse A for 30’ at 37 degrees. DNA was extracted and visualized on a 1.5% 283!
agarose gel. The remaining lysates were clarified at 13,000 rpm for 10’ at 4 degrees. The 284!
equivalent of 2x106 cells was diluted 25-fold in RIPA buffer (50mM Tris pH8, 150mM 285!
NaCl, 2mM EDTA, pH 8, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 1x protease 286!
inhibitors) and pre-cleared with 80ml protein G agarose beads (pre-blocked in 0.1mg/mL 287!
! 13!
BSA for 30’) for 2h on a rotator at 4°C. For the immunoprecipitation, antibodies were 288!
added to lysates and incubated with antibody for 1h on a rotator at 4°C (5mg IgG 289!
[Abcam; ab37415], 4mg H3K9me3 [Abcam; ab8893], 1mg KAP1 [Abcam; ab10483]), 290!
before adding 80ml pre-blocked beads and incubating overnight as above. Beads were 291!
harvested and washed 4 times in RIPA buffer, 4 times in high salt wash (20mM Tris-HCl, 292!
pH 8, 1mM EDTA, 500mM NaCl, 0.5% NP-40, 1x protease inhibitors), 4 times in TE 293!
buffer (10mM Tris-HCl, pH8, 1mM EDTA), and eluted in 160ml elution buffer (100mM 294!
HaHCO3, 1% SDS) for 15’ at 30°C. Cross-links were reversed by adding NaCl to a final 295!
concentration of 0.2M and incubating overnight at 67°C. Eluates were then incubated 296!
with 2ml RNase A (10mg/mL) and 2ml proteinase K (20mg/mL) at 45 degrees for 1h. 297!
DNA was extracted using a PCR purification kit (Qiagen) and analyzed by qPCR using 298!
primers specific for GAPDH, ZNF180, ZNF274, or various regions of the AAV2 299!
genome.  Purified chromatin was diluted 10-fold and quantified by real-time PCR using 300!
the SYBR Green JumpStart Taq ReadyMix for QPCR (Sigma-Aldrich) using an ABI 301!
PRISM system (Applied Biosystems). Primer sequences are listed in the Extended Data 302!
Table 2. CT values for “10% input” were adjusted by subtracting 3.322 cycles to correct 303!
for the 10-fold dilution factor (https://www.thermofisher.com/uk/en/home/life-304!
science/epigenetics-noncoding-rna-research/chromatin-remodeling/chromatin-305!
immunoprecipitation-chip/chip-analysis.html). Percent input was then calculated as 306!
follows: 100 x 2^-(CT of adjusted 10% input - CT of ChIP-ed DNA). Percent input for 307!
each antibody was then normalized to values for IgG to calculate final fold enrichment.  308!
 309!
Real-time PCR 310!
For analysis of viral replication, total DNA was extracted using the Qiagen DNAeasy 311!
Blood and Tissue DNA extraction kit.  Viral DNA was quantified by real-time PCR using 312!
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the SYBR Green JumpStart Taq ReadyMix for qPCR (Sigma-Aldrich) using an ABI 313!
PRISM system (Applied Biosystems). Cap and Ad5 100kd-specific primers and a pDG-314!
based27 standard curve were used for absolute quantification; the signal was normalised 315!
to cyclophilin. Primers: Cap FW (5’ – TTCTCAGATGCTGC GTACCGGAAA – 3’), 316!
Cap RV (5’ – TCTGCCATTGAGGTGGTACTTGGT – 3’), Ad5 100kd FW (5’- 317!
TCATTACCCAGGGCCACATT – 3’), Ad5 100kd RV (5’ – 318!
CCTCGTCCAAAACCTCCTCT – 3’), cyclophilin FW (5’ – TGCTGGACCCAAC 319!
ACAAATG – 3’), cyclophilin RV (5’ – TGCCATCCAACCACTCAGTCT – 3’). 320!
 321!
qRT-PCR 322!
 Total RNA was extracted using the RNeasy kit (Qiagen) after DNAseI (Qiagen) 323!
treatment for 15 minutes at 37˚C. Reverse transcription was performed using the High 324!
Capacity Reverse Transcription kit (Applied Biosystems). cDNA was quantified by real-325!
time qPCR on an ABI PRISM system (Applied Biosystems) using the TaqMan Universal 326!
PCR master mix (Life Technologies and custom designed primer-probe mixes (Eurofins). 327!
Primers: p5 FW (5’- AACAAGGTGGTGGATGAGT - 3’), p5 RV (5’ – 328!
CGTTTACGCTCCGTGAGATT - 3’), p40 FW (5’ – GGAAGCAAGGCTCAGAGAAA 329!
-3’) and p40 RV (5’ – CCTCTCTGGAGGTTGGTAGATA - 3’). Probes: p5 (5’ - FAM-330!
ACGTGGTTGAGGTGGAGCATGAT-TAM - 3’), and p40 (5’ - FAM-331!
AGGAAATCAGGACAA CCAATCCCGT-TAM - 3’). Relative expression levels were 332!
determined with the ∆∆Ct quantification method using 18s ribosomal RNA (Taqman Pre-333!





Analysis of p-KAP1-S824 levels 338!
 Phosphorylation of KAP1-S824 was investigated in 293T cells that were either infected 339!
with AAV2/Ad5, or transfected with various Rep-expressing constructs using linear PEI. 340!
Where relevant, cells were pretreated with either DMSO or 10µM ATMi 4h prior to 341!
infection/trasnsfection, and inhibitors were maintained throughout. Infections were 342!
performed as described above, and transfections were performed at ~70% confluency 343!
using 1µg DNA/8x105 cells and 4 µl PEI/1µg DNA. Medium was changed 6h after 344!
transfection, and cells were harvested for western blot 27h after infection/transfection.  345!
 346!
Immunofluorescence 347!
293T cells were seeded at a density of 1x105 on poly-L-lysine (Sigma) coated coverslips 348!
in 24-well plates the day prior to transfection. 4h prior to transfection, DMSO or ATMi 349!
was added to the appropriate wells to a final concentration of 10µM. Cells were then 350!
transfected with 20ng of empty vector or pRep78-GFP using 2µl Lipofectamine 2000 in 351!
50µl serum-free Opti-mem. The next day, cells were infected with Ad5 (2 PFU/cell) in a 352!
total volume of 160µl for 1 h, after which the medium was replaced for fresh DMEM + 353!
10% FBS. Cells were fixed 24h after Ad5 infection in 4% PFA for 10’ at room 354!
temperature, washed in PBS, permeabilized in 0.1% Triton-X-100 for 10’ at room 355!
temperature, and washed again in PBS. Cells were then incubated with primary antibody 356!
(α-p-KAP1-S824 antibody; 1:1000) diluted in PBS + 1% BSA for 2h at room 357!
temperature, washed, and then incubated with secondary antibody (Biolegend; rabbit 358!
IgG2b-AlexaFluor 594, 1 µg/ml (1:1000) diluted in PBS for 1h at room temperature. 359!
Cells were then washed a final time and mounted in Prolong Gold Antifade Reagent 360!
(Invitrogen). Images were visualized using an Eclipse Ti-E Inverted confocal microscope 361!
and analyzed with NIS Elements C software. 362!
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 363!
Analysis of Rep-K372A replication efficiency. 8 x 106 293T cells in a 10 cm dish were 364!
transfected with 16ug of pAV2-Rep-WT, pAV2-Rep-K340H, or pAV2-Rep-K372A 365!
using 90µl of PEI and 500µl SF medium. 4h later, cells were infected with 2 PFU/cell of 366!
Ad5, and the medium was replaced 2h after infection. Cells were harvested for DNA, 367!
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Figure 1. The latent AAV2 genome is methylated by recruitment of KAP1 to the Rep ORF  457!
a-b, AAV2 replication in control (shEMPTY) or KAP1-depleted (shKAP1) 293T cells. a, Viral genome 458!
replication. b, Rep and cap expression. Expression levels represent fold changes over control cells infected 459!
with AAV2 + Ad5. Data are reported as mean±SEM, n=5, and statistical significance was determined by 460!
unpaired t-test. c, ChIP-qPCR performed on AAV2-infected shEMPTY or shKAP1 293T cells using anti-461!
KAP1 antibody or IgG. Purified chromatin was analyzed by qPCR using primers for the viral p5 promoter 462!
or various regions of the rep and cap ORFs (right panel). GAPDH was used as a negative control, and the 463!
zinc finger genes ZNF180 and ZNF274 were used as positive controls (left panel). d, ChIP-qPCR 464!
performed as described above, using anti-H3K9me3 antibody. Values are reported as mean±SEM for 3 465!





   470!
Figure 2. Rep52 and Rep78 lead to phosphorylation of KAP1 in a ZFN domain-dependent manner.  471!
a, p-KAP1-S824 in 293T cells infected with increasing MOIs of either AAV2 or rAAV2 in the presence of 472!
Ad5. b, p-KAP1-S824 in 293T cells infected with Ad5 alone, or coinfected with Ad5 and either AAV2 or 473!
rAAV2 (MOI = 103) monitored at 4, 18, 24, and 42 h post infection. c, p-KAP1-S824 in 293T cells 474!
expressing various Rep proteins. d, p-KAP1-S824 in 293T cells transfected with full length Rep52 and 475!
Rep78, or truncation mutants in which the C-terminal ZNF domain is progressively removed. Values are 476!




Figure 3. Binding of PP1α and its negative regulator NIPP1 by Rep is necessary for phosphorylation 480!
of KAP1 and is required for AAV2 genome replication and transcription.  481!
a, Co-IP of FLAG-tagged proteins from 293T cells expressing FLAG-PP1α or a FLAG-GFP control and 482!
the indicated Rep proteins. b, Immunoblot of p-KAP1-S824 in 293T cells transfected with either wild-type 483!
Rep52, or Rep52-K372A. Protein levels were quantified using ImageJ software. Values are reported as 484!
mean±SEM, n=3. c, CL-IP of T7-tagged proteins from 293T cells expressing T7-GFP, or the indicated T7-485!
Rep proteins and GFP-NIPP1. All immunoblots are representative of at least 3 independent experiments. d-486!
e, 293T cells transfected with pAV2-WT, pAV2-K340H, or pAV2-K372A and then infected with Ad5 487!
were analyzed for AAV2 genome replication by qPCR, d, and rep and cap transcription by RT-qPCR, e. 488!




Figure 4. Ad5 and HSV-1 infection leads to KAP1 degradation. 492!
a-b, Immunoblot of KAP1 in 293T cells a and Hela cells b infected with Ad5 at the stated MOI (PFU/cell). 493!
Values are reported as mean±SEM, n=3. c, Immunoblot of KAP1 in HeLa cells treated with MG132 at the 494!
stated concentrations and infected with 10 PFU/cell of Ad5. d-e, Immunoblot of endogenous KAP1 in 495!












Extended Data Table 1. Peptides identified by BioID for KAP1 and various known 508!














BirA*-Rep40 2 3.1% 100% 
BirA*-Rep52 8 12.9% 100% 
BirA*-Rep68 3 6.0% 100% 
BirA*-Rep78 1 1.3% 100% 
RUVBL1 Q9Y265 
BirA*-Rep40 2 7.2% 100% 
BirA*-Rep52 7 22.1% 100% 
BirA*-Rep68 1 2.9% 99% 
BirA*-Rep78 1 2.9% 99% 
MRE11 P49959 
BirA*-Rep40 1 2.0% 99% 
BirA*-Rep52 8 19% 100% 
SNW1 Q5R7R9 
BirA*-Rep40 5 23.7% 100% 
BirA*-Rep52 9 24.1% 100% 
BirA*-Rep68 1 2.8% 100% 
BirA*-Rep78 2 4.3% 100% 
MDC1 Q14676 
BirA*-Rep40 2 2.0% 100% 
BirA*-Rep52 4 3.3% 100% 
BirA*-Rep68 1 0.5% 100% 
TAF1/SET Q01105 
BirA*-Rep40 1 4.8% 100% 
BirA*-Rep68 1 4.8% 100% 
NUCLEOLIN P19338 
BirA*-Rep40 1 2% 99% 
BirA*-Rep52 10 16.2% 100% 
BirA*-Rep68 13 18% 100% 
BirA*-Rep78 4 6.2% 100% 
 510!
      511!
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 512!
Extended Data Table 2. ChIP-qPCR primers 513! !514!
Gene FW RV 
GAPDH CACCGTCAAGGCTGAGAACG ATACCCAAGGGAGCCACACC 
ZNF180 TGATGCACAATAAGTCGAGCA TGCAGTCAATGTGGGAAGTC 
ZNF274 GGAGAAATCCCATGAGGGTAA GGCTTTTGTGAGAATGTTTTCC 
p5 CTGTATTAGAGGTCACGTGAGTG TCAAACCTCCCGCTTCAAA 
Rep 5’ CCGAGAAGGAATGGGAGTT CCATTCCGTCAGAAAGTCG 
Rep middle GCCTTGGACAATGCGGGAAAGATT TGTCGACACAGTCGTTGAAGGGAA 
Rep 3’ TTCCCGTGTCAGAATCTCAA CCAAATCCACATTGACCAGA 
Cap 5’ GACAGTGGTGGAAGCTCAAA TTGTACCCAGGAAGCACAAG 
Cap middle TTCTCAGATGCTGCGTACCGGAAA TCTGCCATTGAGGTGGTACTTGGT 
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Extended Data Figure 1. The AAV2 Rep Proteins Physically Interact with KAP1 518!
a, Immunoblot of biotinylated proteins purified from BirA*-Rep52 BioID screen using anti-519!
KAP1. b, Verification of BioID using exogenous FLAG-KAP1; purified biotinylated proteins 520!
from 293T cells expressing FLAG-KAP1 with either empty vector (EV) or BirA*-Rep52 were 521!
analyzed for Rep and KAP1 by western blot. c, Cross-linked co-IP for FLAG-tagged proteins 522!
from 293T cells expressing FLAG-KAP1 or a FLAG-GFP control and each of the four Rep 523!
proteins. d, Cross-linked co-IP for FLAG-tagged proteins from lysates of 293T cells expressing 524!
FLAG-GFP, FLAG-Rep40, FLAG-Rep52, FLAG-Rep68, or FLAG-Rep78 and KAP1 from 525!








Extended Data Figure 2. AAV2 replication and protein expression in KAP1-depleted cells. 533!
a, viral protein (VP) expression and KAP1 knockdown efficiency in AAV2 and Ad5 infected 534!
control (shEMPTY) and KAP1-depleted (shKAP1) 293T cells. Data are reported as mean±SEM, 535!
n=3 b, AAV2 replication in control (siCTRL) or KAP1-depleted (siKAP1.2/siKAP1.4) cells. 536!
Viral genome replication was analyzed by qPCR, and KAP1 knockdown efficiency was analyzed 537!













Extended Data Figure 3. Knockdown of CHD3 and SETDB1 leads to enhanced AAV2 550!
replication and protein expression 551!
a-c, AAV2 replication and protein expression in 293T cells depleted for CHD3 (siCHD3) and/or 552!
SETDB1 (siSETDB1). a, VP protein expression and depletion of CHD3 and SETDB1 analyzed 553!
by western blotting. b, Quantification of VP3 levels using ImageJ software. c, Viral genome 554!
replication analyzed by real time qPCR. Values are reported as mean±SEM, n=4. 555!
! 28!
 556!
Extended Data Figure 4. Phosphorylation of KAP1-S824 by the Rep proteins is independent 557!
from ATM activation 558!
a, p-KAP1-S824 localization in 293T cells pretreated with ATMi and expressing Rep78-GFP 559!
with and without Ad5 infection (left and right panel, respectively). b-c, p-KAP1-S824 levels 560!
analyzed in 293T cells pretreated with ATMi. b, cells were transfected with EV, Rep52, or 561!
Rep78. p-Chk2 was monitored to assess efficiency of ATM inhibition. p-KAP-S824 levels were 562!
normalized to Rep levels to correct for differences in transfection efficiency as a result of 563!
pretreatment with ATMi. c, Cells were infected with AAV2 and Ad5 as in Extended Data Figure 564!
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 571!
Extended Data Figure 5. Truncation of Rep C-terminal zinc finger domain does not affect 572!
Rep-KAP1 physical interaction. 573!
Cross-linked co-IP for FLAG-tagged proteins from 293T cells expressing FLAG-KAP1, or a 574!
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 581!
 582!
Extended Data Figure 6. Validation of Rep-K372A PP1-binding mutant.  583!
a, Depiction of the PP1-binding site in the Rep ATPase domain. The Walker B motif is outlined 584!
in black, and the partially overlapping consensus binding site is outlined in pink. b, Rep-mediated 585!
repression of AAV2 p5 is dependent on a functional ATPase/helicase domain28. To verify 586!
ATPase activity of Rep52K372A, 293T cells expressing a p5-mCherry reporter construct with 587!
Rep52 or Rep52K372A were analyzed for p5 activity by western blotting for mCherry18. Protein 588!
levels were quantified using Image J software. Values are reported as mean±SEM, n=3. c, Cross-589!
linked co-IP for FLAG-tagged proteins from 293T cells expressing FLAG-KAP1, or a FLAG-590!






Extended Data Figure 7. Model for release of AAV2 from KAP1-mediated latency. 596!
a, Incoming AAV2 genomes undergo second-strand synthesis, concatamerization, and 597!
chromatinization upon nuclear entry. KAP1 is recruited to the rep ORF via an unknown binding 598!
partner where it forms a scaffold for the recruitment of SETDB1 and CHD3, leading to the 599!
methylation of AAV2-associated histones. b, Partial degradation of KAP1 upon Ad5 600!
superinfection triggers the initial upregulation of Rep. c, Binding of Rep to PP1 and NIPP1 leads 601!
to enhanced levels of phosphorylated KAP1 and release of the repressive complex. 602!
